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Abstract 
This thesis is concerned with how previously neglected issues, in this instance tropical 
diseases, gain prominence on policy agendas, and shows how advocacy and measurement are 
used to bring issues to the attention of policymakers.  The term 'neglected tropical diseases' 
(NTDs) was coined in the early 2000s to describe lesser-known diseases that existed in the 
shadow of the high-profile and well-funded “big three” – HIV/AIDS, tuberculosis (TB), and 
malaria.  The case of NTDs demonstrates how a policy problem can be understood amidst 
connections being drawn or not drawn between issues, and the forms of intervention taken to 
address neglect in policy.  Thus, the central question of this thesis is: How did a re-labeled 
disease category within a decade result in billions of funding being directed towards a previously 
'neglected' issue, with global commitments for control, elimination, and eradication?  
The analysis is presented in two parts and shows how NTDs have gained acknowledgement 
and care through the concept of neglect.  The first part involves the conceptualization of 
common characteristics and methods of standardizing a disease grouping, which is far from a 
straightforward process as various lists of NTDs attest.  The second part, through a socio-
historical analysis of the origins and policy development of NTDs, demonstrates how policy 
appeal is created through the use of both advocacy and measurement, more usually treated as 
distinct areas within global health policy.  
It draws on interviews with 55 actors from scientists, to policy officials, NGO workers, and 
academics, and also undertakes a documentary analysis, which includes historical sources.  
Using theoretical perspectives from Science and Technology Studies, Public Policy, and 
Political Economy, this thesis demonstrates what the concept of neglect brings to understanding 
policy problems.  It concludes that both the perception and responses to neglect in policy can be 
understood in four distinct and overlapping ways, through: information, action, feeling and 
thought. 
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Chapter 1. Introduction  
1.1 Caring about neglected narratives 
Postcolonial and feminist literature has had a long-held concern with 'the other'.  Jean Rhys’s 
'Wide Sargasso Sea' (1966) is an example of adopting the neglected character's perspective.  
Rhys takes on a 19th century classic novel 'Jane Eyre' by Charlotte Brontë, through a 
questioning of where our moral sensibilities and support should lie.  As a prequel, 'Wide 
Sargasso Sea' tells the story of the 'madwoman in the attic' giving voice to Antoinette (later 
known as Bertha) who is the first wife of one of the main characters Mr. Rochester.  In 'Jane 
Eyre' Bertha is simply mad: "...it grovelled, seemingly, on all fours; it snatched and growled like 
some strange wild animal" (Brontë, 1847, p. 370).  She is a marginalized character, originally 
devoid of empathy or concern, who is elevated through Rhys's direct attention.  A host of other 
novelists have followed a similar path of enquiry.  As Hephzibah Anderson explains, these 
subversive points of view have produced: 
"...intriguing new insights into classic works of fiction ... By giving voice to the marginalised and 
the maligned ... parallel tales appeal to our egalitarian worldview. It’s a kind of cultural 
revisionism, yet even as these works challenge the canon, they’re simultaneously reinforcing it" 
(2016).   
Through this thesis it is not my intention to 'give voice' to the marginalized and maligned.1  This 
is the job of others, particularly anthropologists.  However, as with literary theory, neglected 
aspects of texts are being revisited and critics are appraising what this means for literary study.  
In this thesis I am studying the nature of neglect in policy through the case of neglected tropical 
diseases (NTDs). 
I believe that observing how the phenomenon of neglect is perceived and enacted within policy 
has a similar value, to reveal aspects of policymaking within the context of competition and 
congruity.  It is only more recently that we have begun to care about what policy problems are 
not currently being addressed but should be, due to being unaware, ignorant, having poor 
information or other uncertainties (Frickel, 2014; Harman, 2012; Rappert & Balmer, 2016).  
Exploring why some issues and topics are not on policy agendas,2 provides insight into how we 
																																																								
1 To a lesser degree I have given voice to the marginalized and maligned through scientists in endemic 
countries, neglected in media and academic accounts.  However the truly marginalized and maligned are 
the patients whose voices are rarely heard, apart from in sound-bites of advocacy campaigns or more 
comprehensively through anthropological study. 
2 I use a standard, succinct definition of policy agendas supplied by Cobb and Elder for the, "...range of 
legitimate concerns meriting the attention of the polity" (Cobb & Elder, 1971, p. 905), although I expand the 
conception from polity and to policy, as outlined in the next chapter. 
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identify and select problems for policy, with competition between issues but also congruity in the 
overlapping threads that connect issues to one another.   
This remit and the challenges that researching neglect poses, confronted me midway into this 
PhD.  I was presenting my research aims and objectives at a workshop about the 'Changing 
Political Economy of Research and Innovation' (CPERI), in San Diego.  As I was going over how 
I was interested in the concept of 'neglect' in policy, one of the other participants made the 
statement: "It's fine looking at the meaning of words, but there are children dying".  I have been 
acutely aware of this point throughout the research project and have been keen for it not to be 
an esoteric, impractical exploration of a group of diseases that cause immense suffering and 
death to huge swathes of humanity.   
I have been fortunate to observe the admirable efforts of scientists, NGO workers and policy 
makers in trying to make a difference to this state of affairs.  Although it is not the full story 
about NTDs, I believe their story is worth telling and from a critical perspective that goes beyond 
the biomedical or journalistic accounts that have been written thus far.  More than this I think it 
important to understand why we characterize policy problems through the lens of neglect, and 
how, as a result, these policy problems rise in prominence.  Names matter and calling diseases 
'neglected' has a meaning and an effect, as Rosenberg eloquently describes: "In some ways 
disease does not exist until we have agreed that it does, by perceiving, naming and responding 
to it..." (in Rosenberg & Golden, 1992, pp. xiii–xxi).  
Specifically the "...choice of the word 'neglect' is pointed and loaded, forcing us to reflect on our 
social obligations" (Allotey, Reidpath, & Pokhrel, 2010, p. 5).  Calling something 'neglected' is a 
way of determining and asserting importance and priority.  In a competitive global health 
environment, where donors want to differentiate themselves, the 'neglected' terminology carries 
a weight of urgency, and of making a difference.  It is a paradox that an assertion of importance 
has the effect of spreading recognition of diseases that had not been considered important 
enough before.  The 'packaging' diseases as an object of neglect, through language and 
associated ideas is what I am interested in exploring further.  Therefore, this thesis does not 
present a practical framework or model to better fund or incentivize research into NTDs, but 
aims for a deeper understanding about the policy world in which they originate.     
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1.2 Summary 
'Neglected tropical diseases' (NTDs for short) are a collection of diseases, coined in the early 
2000s that have received growing policy attention within global health.  As Koplan, 
Bond,!Merson, Reddy, Rodriguez, Sewankambo and!Wasserheit describe, "(G)lobal health is 
derived from public health and international health, which, in turn, evolved from hygiene and 
tropical medicine" (2009, p. 1993).  NTDs have gone full circle, originally being largely diseases 
of hygiene and tropical medicine, to be sidelined on many levels (scientifically, financially, 
socially and politically), and now they are of central interest within global health.  These 17 
diseases are listed by the World Health Organization (WHO) as the following in alphabetical 
order:3 
 
• Buruli ulcer 
• Chagas disease 
• Dengue and chikungunya 
• Dracunculiasis (guinea-worm disease) 
• Echinococcosis 
• Foodborne trematodiases 
• Human African trypanosomiasis (sleeping sickness) 
• Leishmaniasis 
• Leprosy (Hansen's disease) 
• Lymphatic filariasis (elephantiasis) 
• Onchocerciasis (river blindness) 
• Rabies 
• Schistosomiasis 
• Soil-transmitted helminthiases 
• Taeniasis/Cysticercosis 
• Trachoma 
• Yaws (Endemic treponematoses) 
Table 1 WHO list of NTDs 
The WHO groups NTDs on the basis of agreed common characteristics – just as was done for 
tropical diseases in former times, but the methods behind the standardizing this grouping are far 
from straightforward.  The various lists of NTDs attest to this difficulty and I will go into more 
detail about lists and the politics of categorization in Chapter 5.  For now it is worth remarking 
that the 17 NTDs listed by the WHO tend to be the most well acknowledged and other 
organizations draw a shorter selection from this list.  This is the case for organizations running 																																																								
3 WHO, 2016a, http://www.who.int/neglected_diseases/diseases/en/, Accessed 2/4/16  
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programs that require direct interventions.4  Only the PLOS journal on NTDs has a longer list.  
Being an academic endeavor there is more reason to encompass a larger number of diseases 
to have a wide research scope. 
Returning to the 17 WHO list, the diseases listed form a mixed bag of not very pronounceable 
diseases, some of which may be familiar to 'western' audiences.  Leprosy and rabies are 
ancient diseases of the poor (Little, 2007).  While travelers can vaccinate against rabies, they 
may have come across dengue and chikungunya, for which there is no vaccine.  Still others 
may pick up one of the other non-descript 'tropical diseases' from a hot country.  Indeed the 
NTD group derives from a larger grouping of tropical diseases, although some tropical diseases 
never were especially tropical and have not been (or never were) common.  I will discuss this 
point of why some tropical diseases cannot be only seen as tropical in Chapter 5.   
Rather than being rare and exotic, NTDs are in fact a common affliction, not only a threat to 
travellers.  They are often debilitating and sometimes deadly for the majority of the world's 
poorest people.  The scale of NTDs for the global poor is large, with one or more NTD affecting 
over a billion people in 149 countries (WHO, 2015a).  Therefore, despite the label of neglect, 
and perhaps unfamiliarity in the western world, these diseases are widespread and pervasive.   
Progress is being made to tackle NTDs, with 'big pharma' mostly behind the over $5 billion in 
anti-parasitic drugs donated (ibid.) and global health commitments made through 'The London 
Declaration' in 2012 and Sustainable Development Goals (SDGs) in 2015, with national NTD 
master plans coordinated by the WHO.  As of 2015, 27 countries have 75% coverage of Mass 
Drug Administration (MDA), where drugs are provided for at-risk populations5 and there have 
been some strong achievements in elimination (WHO, 2015a). For example, Colombia 
eliminated onchocerciasis in 2011, followed by elimination by Ecuador in 2014 (ibid.).  These 
are significant successes in the space of approximately 10 to 15 years, seeing as the term 
NTDs was only coined in the early 2000s.  While much more is still to be done, it is remarkable 
progress.  Considering these diseases have been labeled 'neglected', especially in terms of 
global public health awareness and commitments, what were the events and milestones that 
lead to such an outcome?  
																																																								
4 Organizations with direct NTD interventions are: US Agency for International Development (USAID), 
Centers for Disease Control and Prevention (CDC), the Department for International Development (DFID), 
The Global Network for Neglected Tropical Diseases, Uniting to Combat NTDs and Drugs for Neglected 
Diseases Initiative (DNDi). 
5 Drug provided for at-risk populations are primarily for Soil-transmitted helminthiases (STHs). 
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1.3 Research questions 
To explain how progress has been made with NTDs on policy agendas, means first pursuing a 
more fundamental question, as to where the new disease grouping arose.  NTDs as a group 
reflect how the relative neglect or non-neglect of one issue over another is negotiated through 
the use of advocacy and measurement.  NTDs stand apart from other diseases deemed not 
neglected – the so-called 'big three' HIV/AIDS, tuberculosis (TB), and malaria (Elliott, 2013), 
given the name by their advocates as "...three of the deadliest infectious diseases the world has 
ever known".6  
In 2000 the big three were causing more than 4 million deaths per year and the UN's Millennium 
Development Goals set HIV/AIDS and malaria as a priority (ibid.).  In 2002 the Global Fund was 
set up to tackle these diseases along with TB, channeling US$4 billion a year in funding (ibid.).  
Since then the big three have received the lions' share of attention in policy, media and 
academic spheres for being high mortality diseases on a global scale.  However, malaria was 
once a tropical disease, as Kelly and Beisel (2011) note the term ‘all except malaria’ is 
shorthand for NTDs.  How did unfold that malaria became a tropical disease that is not 
neglected?   
The argument of Kelly and Beisel is that political concerns and technical capacities have, 
"...transformed malaria into a global enemy” (2011, p. 71, emphasis added), despite it being a 
disease 'exclusive to the tropics' (Hamoudi & Sachs, 1999, p. 1).  Therefore, malaria in being a 
killer disease that has eluded eradication campaigns, is made a global enemy through a 
particular 'vision' of a disease as a common concern, requiring global mapping and capital.7  
HIV/AIDS joins malaria, as a newly emergent disease but another global killer, with high death 
tolls in both the developed and developing world, and similarly TB has historically been a largely 
global disease affecting all regions (Daniel, 2006).8   
Competition between diseases is a feature of global health, from the 'big three' competing for 
attention, followed by NTDs.  However, sign of connections across issues is evident at the 
WHO: the NTD group has grown, expanding from an original grouping of 13 to 17; TB joined the 
HIV/AIDS and malaria group to form the big three; and now TB, HIV/AIDS, malaria, NTDs and 
hepatitis form a larger cluster.  The WHO created this new cluster (that individual disease 
departments sit under for reporting) in 2015, with the acronym 'HTM' for HIV, tuberculosis, 
malaria, hepatitis and NTDs' (WHO, 2016a).  Since NTDs have risen up policy agendas, they 																																																								
6 Global Fund, http://www.theglobalfund.org/en/overview/, Accessed 2/4/16.   
7 The main weapon against malaria from the 1950s onwards was aerial DDT spraying, and as a result, 
"…epidemiological models came to replace detailed entomological reports, malaria shifted further from a 
situated illness to a global pandemic" (ibid., p. 76). 
8 Due to advancements of treatment and control TB is now mainly a disease of the global poor, in 
developing countries, with some signs of resurgence in poor communities residing in richer countries 
(Elliott & Arora, 2011). 
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are increasingly referred to along with HIV/AIDs, TB and malaria as 'The gang of four' in the 
global health community (Elliott, 2013).  
The question remains as to how NTDs reached a similar status as the big three.  Through the 
course of this thesis, by charting the policy development for NTDs I intend to show that the use 
of the term 'neglect' matters in how NTDs gained attention.  Pinpointing how neglect has been 
used, involves exploring the conceptual history of NTDs in how neglect has been deployed as a 
policy rationale, through forms of advocacy and measurement.   
Assumptions about the conceptual origin of NTDs as a disease grouping initially point to the 
World Health Organization (WHO).  The WHO positions itself as the strategic authority on global 
health policy, to standardize disease groupings through their authority and expertise (Ng & 
Ruger, 2011).  However, the socio-historical analysis of this thesis reveals an alternative 
institutional heritage and organizational agency.  This analysis opens the way for an 
understanding of the positioning and evolution of global health institutions and the struggle for 
prominence amongst health issues.  The aim of this thesis is thus to explore how the coining of 
the term 'NTDs' has resulted in a group of diseases gaining prominence in policy agendas, at a 
time then when competition but also connection is a feature of policy.  To pursue this aim leads 
me to the following key questions:  
1) In charting the policy development of NTDs, what does the concept of neglect bring to 
understanding policy problems?   
In posing this question I mean: how has neglect been used by policy actors to advocate and 
measure why NTDs should be addressed?  But also as an analyst I am interested in: how can 
neglect help us better understand policy problems, particularly in how they compete and are 
prioritized?  During the course of this research I identified two defining characteristics that 
respond to neglect and utilize the concept in policy.  One is the advocacy for NTDs to move up 
policy agendas, specifically through activism by scientists.  The other is the use of 
measurement in providing evidence to determine neglectedness 9  and make persuasive 
arguments for action, leading to the next question of: 
2) How is advocacy and measurement used in pushing an issue up policy agendas? 
The use of advocacy in bringing attention to NTDs has already been noted (Maio, 2014; 
Manderson et al., 2009).  However, through 55 interviews with key actors – including scientists, 
policy officials, NGO workers, and academics, it became evident to me that measurement also 
played a central role in bringing policy attention to NTDs.  This role was not only in putting 
measurement to use through advocacy but measurement forming a type of advocacy in the 
metrics of global health.   																																																								
9 Neglectedness refers to measuring the degree of neglect, discussed in Chapter 7. 
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Advocacy and measurement tend to be treated as distinct areas of research within global health 
and public policy more widely.  Indeed, a number of studies attest to this separation (see 
Majone, 1989; Obermeyer, 2003).  Research on social movements, action, and activism lean 
towards questions of emotion, politics and advocacy.   
On one hand advocacy is the support or recommendation for a particular cause, the mode of 
which is argumentative, to make a case in order to spur action.  I use the concept in a more 
narrow sense, referring more to activity to influence decisions.    The activity I concentrate on is 
activism, a stronger version of advocacy involving, "vigorous campaigning to bring about 
political or social change" (Oxford Dictionaries).  On the other hand measurement research 
often covers the role of metrics and provision of evidence.  In this thesis the type of 
measurement relied on for NTD advocacy by activist scientists and NGOs is shown through 
metrics and what metrics are able to do beyond direct measurement.  The type of measurement 
I am interested in is that which is described as objective, scientific, and quantitative, dominating 
the metrics used in global health.     
It is not often that advocacy and measurement go hand-in-hand as a research topic, rather 
features of tension or instrumentality are highlighted.  For example Kapilashrami et al. (2015) 
examine the tensions between public health evidence collected through various measures and 
advocacy.  They question whether practitioners and researchers who belong to the traditional 
'evidence-based public health paradigm’ can, “...improve and protect the public's health” by 
being more involved in politics and advocacy" (Kapilashrami et al., 2015, p. 1).  To produce 
evidence through measurement has a legitimizing authority, leading to an overemphasis in 
public health in the, “...reassuring sense of objectivity and corporeality" (Smith, 2013, p. 71).  
Furthermore, evidence is thought of as sit outside of political maneuvering through advocacy or 
other means, and viewed in a neutral fashion.  Neutrality is at the heart of the distinction – that 
advocacy cannot be neutral as it is arguing for one side over another.  
The case is also made for the instrumental use of advocacy and evidence.  Tillman et al. (2014) 
argue for the advocacy of “…evidence-based measures to improve the health of society”, 
observing that there should be a “bolder analysis of public health issues” by public health 
institutions.  The pursuit of evidence can also be led by advocacy as seen with the work of AIDS 
activists.  Epstein has demonstrated that AIDS advocacy groups required a mastering of the 
science to form 'an alternative basis of expertise' in which to acquire and use evidence for 
advocacy (Epstein, 1996).  The use of evidence for advocacy has been coined as ‘evidence-
based advocacy’ (EBA), a term that rapidly emerged in the early 2000s onward.  As Storeng 
and Béhague put it: “This term was used to highlight the importance of persuading the broader 
global health community to invest in maternal health not by making explicit moral claims, but by 
using quantitative objective evidence” (2014, p. 261).   
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EBA has been used by maternal health advocates to ‘bolster authority’ in public health, but can 
also lead to a technocratic narrowing of policy agendas in borrowing from an ‘audit-and 
business-orientated ethos' (ibid.).  In the global maternal health campaigning, EBA signaled a 
shift from advocacy relying on principled arguments – for example through a human rights 
approach that emphasized social justice.  Evidence is applied to instrumentally, through 
'creative epidemiology', in modifying the presentation of statistical data10 depending on the 
stakeholder audience (Storeng & Béhague, 2014, p. 268).  The use of evidence is explained, 
but not discussed is where the evidence is from and why some types of evidence is produced 
and others not.  
Science and Technology Studies (STS) has shown how both concepts are contested.  Evidence 
as described by Helga Nowotny intends to bring, "...to the fore what is there to be seen. But not 
everything that can be made to be seen is admitted as evidence" (2007, p. 481).  This 
description of evidence speaks to the availability and presentation of information and 
knowledge, with a hierarchy of evidence from the more scientific, measurable and objective at 
the top, moving to anecdotal, opinion-based and subjective at the bottom (Moore & Stilgoe, 
2009).  Lambert calls the legitimacy instilled by statistical evidence the 'new regime of truth' 
(2009, p. 17).  Evidence acts as proof and justification for why we should care, while advocacy 
is thought to rely more on moral and ideological argument.   
How does advocacy and measurement in the production of argument and evidence relate to 
neglect?  Arguments pertain for the lack of advocacy and measurement as being a cause of 
neglect.  If measurement is of poor quality and scope can lead to what is referred as an 
'evidence trap' in a self-reinforcing circle of neglect through low resource allocation (Storeng & 
Béhague, 2014).  Advocacy can be a moral obligation, with some scholars arguing that the lack 
of advocacy is a type of neglect in itself (Kapilashrami et al., 2015, p. 1).  Others have argued 
that advocacy for NTDs is legitimized by a moral characterization of neglect: 
 
"A pragmatic consequence of this moral sense of ‘neglect’ is that it legitimises the prominent 
use of advocacy as a key strategy to address NTDs, thus legitimising non-governmental 
organisations’ (NGOs) and other actors’ (from civil society to philanthropic entities) participation 
in the political field" (Jackson & Stephenson, 2014, p. 998).   
 
I intend to go beyond the view that advocacy is a source of tension in using measurement and 
that measurement in the production of evidence is used ‘for’ advocacy, as described by Storeng 
and Béhague (2014), or in other words the view that advocacy is needed to ‘present evidence’.  
I will argue that measurement can be a form of advocacy in itself.  The act of measuring and 																																																								
10 An example of modifying the presentation of statistical data is presenting to a public audience the 
number of deaths in pregnancy and childbirth in a developing country, compared to developed countries 
(ibid.).  Global level policy actors may view these deaths as too low compared with other issues, so (as 
with NTDs) the focus needs to be turned from mortality to morbidity and the combined burden of mothers, 
children and newborns.     
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provision of metrics can act as advocacy for a cause.  I will draw upon the literature on social 
movements, social policy, evidence-based policy and health metrics to support this argument.   
1.4 Research relevance 
This brings me to four points I want to make on the relevance of this research concerning: (1) 
the lack of social science research on NTDs; (2) the research approach that has dominated in 
researching NTDs (and why this has been the case); (3) what approaches could be beneficial to 
the study of NTDs, and; (4) situating the study of these diseases in a policy context by 
addressing the meaning of 'policy' used in this thesis.  I also briefly discuss the adoption of the 
NTD term in the medical and health care literature. 
Firstly, social science (and in particular policy) research on NTDs has been lacking.  There have 
been a number of review articles (Allotey et al., 2010b; Manderson et al., 2009), an introductory 
thematic series (of four papers) on NTDs (Allotey et al., 2010) and a series applying a biosocial 
approach to NTDs focusing on individual NTDs (Parker, Polman, & Allen, 2016a).  Even though 
the number and range of NTD research is rising, there has yet to be an in-depth enquiry on 
NTDs from a social science and policy perspective (Barry, 2014; De Maio, Llovet, & Dinardi, 
2014; Mantilla, 2011).  Mantilla even charges that "...it appears that social science has colluded 
in the low priority and invisibility of NTDs" (2011, p. 118).   
I would argue that this charge is only partly true.  There has been an enormous amount of 
research on tropical diseases and only fledging research on NTDs, but these two literatures 
need to be combined.  For example, two historical books of interest are by Farley, on 'Bilharzia: 
A history of imperial tropical medicine' (Farley, 2003) and 'To cast out disease: A history of the 
International Health Division of the Rockefeller Foundation (1913-1951)' (Farley, 2004).  His 
exploration of the connection between health, the economy and philanthropy, bringing in socio-
political accounts, has wider implications for the study of NTDs.   
NTDs form a research topic identified to potentially benefit from 'social science' and 
'interdisciplinary research' in reaction to a predominately biomedical lens.  As described by 
Reidpath, Allotey, and Subhash:  
"These diseases represent a rich and dynamic interplay between vector, host, and pathogen 
which occurs within social, physical and biological contexts.  The overwhelming sense, 
however, is that neglected tropical diseases research is a biomedical endeavour largely 
excluding the social sciences" (2011, p. 1).   
Particularly the 'intense' advocacy that has brought attention to NTDs is noted as a point to 
explore further, "...a systematic analysis of this process would make an important contribution to 
our understanding of advocacy and the dynamic research-policy-practice nexus in public health" 
(Manderson et al., 2009).  Therefore, advocacy has been presented as a key aspect for why 
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NTDs have gained policy attention but through the course of this research I also found that 
measurement played a similarly important role. Advocacy and measurement could both fall 
under a policy understanding of NTDs. 
Secondly, the type of theoretical gaps caused by a lack of social science, especially 
investigator-driven11 and interdisciplinary research on NTDs have been highlighted by Reidpath 
et al. (2011), using bibliometric analysis.  They argue that the social science research that has 
tended to accompany NTD research is either a misclassification of pure clinical research or 
'handmaiden' research to support the implementation of biomedical solutions (2011, p. 1).  What 
this dominance has resulted in is a lack of interdisciplinary focus on the, "...complex social, 
cultural, biological, and environmental dynamic involved in human pathogenesis" (ibid.).9  
Reidpath et al. locate a systemic basis to this situation in funding that requires:  
"...more sophisticated funders and priority setters who are not beguiled by uncritical biomedical 
promises...designed to support (and never challenge) the curative activities of biomedical 
research. If one of the core ideas underpinning scientific research is that it should challenge and 
confront existing dogma, then this kind of adjuvant research, though utilitarian, does not 
contribute to the advancement of science because it is intended to support the activities of a 
dominant paradigm" (Reidpath et al., pp. 1-8).   
De Maio, Llovet, and Dinardi are not very optimistic of any change, because of a funding bias 
that, "...may continue to prohibit the social sciences from playing anything but a marginal role in 
interdisciplinary teams" (2014, p. 373).   
Thirdly, De Maio (2014) in reiterating that more needs to be done from the perspective of social 
science, points toward the scarcity of sociological or anthropological accounts of NTDs beyond 
two classic works concentrating on one NTD – Chagas disease: Roberto Briceño-León (1990) 
'La Casa Enferma: Sociologica de la Enfermedad de Chagas [The Sick House: Sociology of 
Chagas Disease]' and Joseph Bastien (1998) 'The Kiss of Death: Chagas Disease in the 
Americas' . 
He particularly encourages engagement by sociologists, contending that they have not been 
involved with the scholarly discussion surrounding NTDs, such that:  "...the framing of NTDs has 
been overly narrow, and a situation that is perhaps best understood as a manifestation of 
structural violence has instead been seen through a technical rather than socio-political lens" 
(ibid.).   
These accounts encouraged me to pursue NTDs from a predominantly STS and public policy 
perspective.  The social science critiques of the current NTD literature that I have touched upon 																																																								
11 Investigator-driven research is a science policy term where the investigator is the one who designs and 
implements the study as opposed to being given instructions by someone else (Horizon 2020, 
https://ec.europa.eu/programmes/horizon2020/en/h2020-section/excellent-science, Accessed 2/4/14). 
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have tended to focus on a dichotomy between the socio-political structural aspect of NTDs, and 
technical medical interventions.  This dichotomy has been overemphasized in my view.  I adopt 
a broadly constructivist theoretical approach to view this global health problem, but recognize 
that it arises from an ideational and material basis (Ruggie, 1998), an approach could be 
described more specifically as coproductionist, in which natural and social orders produce one 
another (Jasanoff, 2004).   
The notable exception in considering ideational and material factors is De Maio, who sees the 
progress for NTDs, of advocacy and success in resources being redirected, as falling across 
three areas: "...epidemiological indicators, research activity and policy attention" (2014, p. 97).  I 
have followed similar themes in this thesis, but have taken more encompassing outlook through 
a concentration on advocacy (through activism), measurement (through metrics), and the 
concept of neglect in policy.  I intend to ascertain what advocacy and measurement mean, as 
modes of positioning NTDs as a new disease grouping characterized by neglect.  I also believe 
both aspects of the technical and socio-political are important in understanding neglect.  
Therefore through this thesis I aim to produce an interdisciplinary enquiry that involves making 
the connection with colonial tropical diseases and the policy development of NTDs.  
Lastly, it is worth noting early on the use of 'policy' in this thesis is described as a directed 
activity of a diverse group of actors toward a perceived problem.  Policy is directed by a group of 
actors extending further than government but it still means a rationale is driving the activity, 
revealed through dominant discourses and narratives.  Such a discussion is part of a theoretical 
and practical shift from government to governance, where a wider range of actors participate in 
what was once a more exclusive process of government (Hill & Hupe, 2014, p. 1).  I will go into 
more detail about this in Chapter 3.  
This is a broader conception of policy used by Colebatch in policy being an activity that is 
"...deliberate and purposeful rather than erratic or random" (1998, pp. 6-72).  Policy is more than 
a set of objectives or guiding principles but standardizes and articulates practice, in how action 
is framed rather than simply described.  It is in this sense that I use policy throughout this thesis, 
to mean the activity directed to the problem of NTDs and the activity I am most concerned with 
is acknowledgement, attention, and most importantly care as opposites of neglect in policy.12   
																																																								
12	Characteristics of ‘attention, and care’ are the opposite to neglect if defined as the failure to give 
attention or care (Cambridge Dictionary) and I argue that acknowledgment of the need to care is also 
required. 
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1.4 Thesis structure 
The next chapter explains how I approach NTDs as a policy problem through a discussion of the 
methods and methodology.  The research for this thesis was qualitative, based on 55 interviews 
and I cover the procedures employed to carry out this data collection.  I also provide an 
overview of the documentary sources and key terms I used throughout the thesis, as well as 
introducing new terms. 
Chapter 3 explores theoretical underpinnings to thinking about policy problems from the 
perspective of a number of disciplines.  I review a diverse literature to provide a theoretical 
grounding on which to ask questions about how a policy problem is formed, raised in profile, 
and the types of solutions that are offered.  NTDs present a policy problem that involves a 
tropical disease history, followed by a reconceptualization and branding, which I call a 
'repackaging' of the neglected aspect of NTDs.  I discuss how problematization has been 
understood for policy and how 'critical global health' has attempted to problematize global health 
policy.  I then draw attention to the ways innovation has been directed toward policy solutions 
and the disciplinary lens taken through economics, history, and interdisciplinary approaches to 
policy problems.  By the end of the chapter I begin to consider policy problems related to global 
health, with how the concept of neglect is positioned within this landscape. 
Chapter 4 covers the most important milestones for the construction of NTDs, with the central 
contribution being how the present system of global health governance is disaggregated, from 
the WHO once dominating policy to a situation of numerous important stakeholders (Patrick, 
2014).  Throughout the chapter I further explore what it means to have a global health 
landscape of multiple stakeholders.   I concentrate on how two early initiatives for NTDs by the 
Rockefeller Foundation and WHO were both illustrative of the general trends in global health 
governance and the later conceptualization of NTDs. 
In Chapter 5 I consider the common characteristics for what constitutes an NTD and how the 
criteria or methods of standardizing the grouping are not clear-cut, as seen in the different lists 
of NTDs that exist.  While there is instability in the category boundaries, the reasons and 
consequences for why we categorize some diseases as being part of one group and others a 
part of another is important.  It matters for attention of the global community, the policy 
approaches employed, and funding and resources applied.  A utilitarian approach to 
classification, in which systematic classification serves practical needs, has played a large and 
ongoing role in how we classify the natural world (Stepan, 2001, p. 17).  However, classification 
is a, "...social and uncertain process" (Freeman & Frisina, 2010).  In medicine, diseases are 
also classified in terms of the people they afflict, rather than only seeking distinctions based on 
the intrinsic nature of the disease (Bowker & Star, 1999).  It is this element of subjective 
interpretation that I want to expand on in the characterization of one group of people given by 
another.  
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Chapter 6 charts the branding of NTDs by UK and US scientists, who became activists and how 
this formed part of an elite policy movement of advocacy.  I also wanted to ensure endemic 
countries were included, with ‘endemic’ referring to the, "...constant presence and/or usual 
prevalence of a disease or infectious agent in a population within a geographic area".13  
Therefore it was important that this thesis reflected the countries where NTDs are prevalent.  
As stated already NTDs affect some 149 countries, so I needed to narrow down my focus to a 
manageable number to draw insight from individual countries.  I began with the idea of the so-
called 'BRIC' countries, Brazil, Russia, India, and China.14  They present a novel angle as 
countries with the potential to contribute scientifically and strategically to the NTD problem, and 
represent a move away from western dominance (ibid.).  I narrowed this choice to Brazil and 
China to concentrate on (and will elaborate on the reasons why in the next chapter).  
For Chapter 7, I take stock of how NTD policy development is reflected in public discourse.  I 
chose two leading measurement discourses related to NTDs, to demonstrate the role that 
measurement has had in conceptualizing the NTD problem.  I argue that measurement is a way 
of caring in global health, and evidence (presented through measurement), has acted as a form 
of advocacy for raising the profile of NTDs.  
The final chapter, Chapter 8 revisits the initial questions posed by the introduction and 
discusses the ways that advocacy and measurement showcase neglect.  I argue that neglect is 
present in policy across typologies of action, emotion, thought, and information.  Such an 
understanding of neglect in policy has implications for whom have responsibility and how the 
concept is used as a resource in global health.  I finish this thesis by presenting what might be 
fruitful next avenues for research on NTDs as a fledging area of social science research. 
																																																								
13 CDC http://www.cdc.gov/globalhealth/ntd/, Accessed 2/4/16.  
14 The group acronym ‘BRIC’ was coined by the former chairman of Goldman Sachs, Jim O'Neill, to 
represent these countries as being at a similar stage of 'newly advanced' economic development as 
'emerging markets' (Tett, 2010). 
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Chapter 2. Methods and methodology  
2.1 Introduction and overview 
 
The methodological approach of this thesis has been guided by an intention to draw out the 
relationship between NTDs and policy.  There could have been a number of ways in which to 
explore the topic but this study has been shaped by three central methodological research aims, 
to (1) connect the understanding of NTDs with tropical diseases and their colonial origins; (2) 
explore the policy development of NTDs in how these diseases have been moved up policy 
agendas through advocacy and measurement; (3) provide examples – with endemic countries – 
in which to view the enactment of global policies.  This approach is grounded in gaining an 
account of the policies for NTDs over time, across countries, and through relevant discourses.   
 
At the outset of this research project I began with wanting to know more specifically about the 
role of innovation in NTD policy, but this quickly moved to becoming a broad concern with the 
policy process and development of policies for NTDs.  Following a series of initial pilot 
interviews, I widened the research inquiry toward understanding the nature of NTDs and how 
they are treated in policy.  Thus I embarked on a speculative approach rather than following a 
rigid research design, which helped me become acquainted with a large topic area without 
becoming fixed upon preconceived themes.  I was inspired mostly by a grounded theory   
approach, in developing working hypotheses as the research progressed and appling theories 
of others.  As Locke, Silverman and Spirduso put it:  
 
"...grounded theory studies do not start with a theory – they end with one... Also, because 
theories pronounced tend to be very specific to the content studied, they often have strong 
implications for the design of effective practice. What they lack in terms of grand generalization 
they gain in terms of applicability" (2010, p. 192).   
 
I will elaborate on how this worked in practice later, in the manner in which I treated my object of 
enquiry.  Through the course of the research certain themes did emerge and were likely 
influenced by my disciplinary leaning and I chose to emphasize to tighten the scope and 
argument.  These were the role of measurement in making policy arguments shown through 
discourses, and advocacy through activist scientists constituting a policy movement.  I qualify 
this subject matter later in the chapter but these themes demonstrate coverage of the individual, 
collective, and discursive in policy. 
 
This chapter will describe how the thesis methodology has evolved and my rationale for 
decisions taken.  I have drawn upon a wide range of disciplines including: public policy, history, 
medical anthropology, sociology, and political economy.  Science and Technology Studies 
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(STS) remains my main disciplinary basis, with encompassment of the other disciplines 
mentioned.  I found that my subject of focus being on scientists and the interaction between 
science, medicine and policy lent itself to an STS treatment.  If STS scholars are concerned with 
the nature and practices of science and technology, it follows that scientists will be a central 
subject of study as actors involved with decision-making, priority-setting, and future planning 
with ramifications for politics, policy and ethics.  
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2.2 Research aims 
2.2.1 Connecting NTDs with tropical diseases 
 
I have undertaken a socio-historical analysis of NTD policy change to understand the treatment 
of NTDs.  Here critical policy historiography was a useful technique toward documentary 
evidence to observe changes, including posing questions about complexity in the account of the 
policy and who is advantaged or disadvantaged by the arrangements (Gale, 2001, p. 385).  As 
noted in the introduction, I use a wide definition of policy to not only include stated intentions by 
government but also interventions and activities, as well as governance of NTDs directed by 
various actors.  Policy is sometimes narrowly understood as being constrained to politics as the 
prospective policy of a future government or decisions taken by political leaders to bring state 
power to bear on particular problems (Colebatch, 1998, p. 2).  A wide definition encompasses a 
number of interpretations of policy problems, which might be more expressed than others 
through values, systematic activities, routine practice, and goals, all of which manifest as 
organized action or inaction (ibid.). 
 
Within the document analysis, the majority of my sources were journals and books.  See 
Appendix 1 for an overview of my most cited source types, by number of different individual 
documents I referred to.  The journals contained a mix of health and social science topics, with 
the PLOS Neglected Tropical Diseases journal being my most cited source (with the 
acknowledgement that PLOS is an open-access platform, attracting different types of papers to 
a traditional peer-reviewed journal).  I also referred to the high-profile science journals the 
Lancet, Nature, and Science.  The books included those of an overview nature for scientists or 
medical professionals produced by scientists, with a mix of scientist and general reader in mind, 
including tropical medicine histories.  More recently there have been books by activist scientists 
about NTDs ('Forgotten People, Forgotten Diseases' by Peter Hotez, 2013).  In a latter section 
of this chapter I go into more detail about a series of popular science books by Robert S. 
Desowitz aimed at a public lay audience interested in the human stories of tropical disease.  
One other medium has been documentary film, which I provide an overview of later in this 
chapter.  
 
Other sources included media reports (e.g. magazine articles, commentaries) or reports by 
government, NGOs and governance institutions (most referenced being the WHO followed by 
the CDC).  I outline the main reports I drew upon further on in this chapter.  I paid special 
attention to grey literature generated by NGOs and research institutes, including through 
webpages, blog posts, news sites and press releases (e.g. The Nobel Assembly, Fiocruz).  
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2.2.2 Policy development of NTDs – through advocacy and measurement 
 
I employed a further level of analysis through ‘policy archaeology’ and ‘policy genealogy’ to 
understand the conditions for why policy problems15 can be viewed as constructions and to 
uncover the reasons for change (Gale, 2001, p. 387-9).  Originally outlined by Scheurich 
drawing on the post-structuralist work of Foucault, policy archaeology is interested in the social 
construction of problems to question what constitutes a legitimate problem and solution 
(Scheurich, 1994).  Gale adapted this approach to concentrate on 'policy formation': how 
constitutive rules are established and the conditions of their realization (Olssen, Codd, & O’Neill, 
2004, p. 57).  As a method, policy archaeology is sociologically inspired, requiring interviews in 
order to address the ‘who, what, and why’.   
 
Policy genealogy is used to uncover a number of legitimizing strategies for policy agendas, to 
understand policy production (Gale, 2001, pp. 387-9).  Gale has a broader conception of 'critical' 
policy genealogy than Scheurich, to mean what policy makers license for the items on policy 
agendas, the actors involved and conditions that regulate the patterns of interaction (Olssen, 
Codd, & O’Neill, 2004, p. 57).  Both of these approaches have proven insightful to understand 
NTD policy development, in the construction of NTDs as an idea and the resulting policy agenda 
change. 
2.2.3 Examples of neglect  
 
'Endemic' is a term used in epidemiology to describe those countries or populations where a 
disease is prevalent in a steady state, compared with an epidemic where disease instance is 
rising rapidly (See Beaglehole, Bonita, & Kjellstrom, 1993, p. 121).  I undertook fieldwork 
interviews in endemic countries Brazil and China for three weeks each, at research institutes 
and universities, totaling 21 interviews (which included two group interviews).  I visited China in 
2013 for seven interviews in Shanghai at the National Institute of Parasitic Diseases and The 
Drug Discovery Centre for Tuberculosis, as well as an interview in Beijing at Tsinghua 
University where I presented my work at the Institute for Science, Technology and Society.  I 
went to Brazil in 2014, conducting six interviews in São Paolo at the Virology Lab of the Institute 
of Tropical Medicine and Instituto de Medicina Tropical de São Paulo and Departamento de 
Parasitologia and two at the Universidade de Sao Paulo.  I then went to Rio de Janeiro to 
conduct two further interviews, one at the Center for Technological Development in Health 
(CDTS) and another at Fundação Oswaldo Cruz (translated as Oswaldo Cruz Foundation, 
known as Fiocruz, attached to the Brazilian Ministry of Health).  My intention was to explore 
																																																								
15 Further detail on connections to the social problem literature is discussed in Chapter 3. 
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Brazil and China as ‘innovative developing countries’ (IDCs)16 adopting strategies that differ 
from traditional donor-recipient relationships in funding and resource arrangements for global 
health.    
 
Brazil and China are part of a larger cross-national group, the 'BRICS' also including Russia, 
India and more recently South Africa.  They have received attention in their potential to address 
NTDs – with the exception of Russia, as it is not endemic for NTDs and to a lesser extent South 
Africa where HIV/AIDS and TB dominate as the big killers.  The WHO has described the BRICS 
as being, "...uniquely positioned – as a group and as individual countries – to ensure that 
neglected tropical diseases receive the international attention they deserve" (Cashwell et al., 
2014, p. 461).  This potential arises from their positioning as emerging economies with growing 
innovation capacity (See Hotez, 2014b).  However, in looking at two BRIC countries, it is 
important to keep in mind that these countries lack a common vision but share, "...confidence 
born of economic dynamism and resentment over a global economy they perceived as stacked 
to favor the West" (Patrick, 2014).  Therefore, the BRICS are not a coherent grouping but have 
in common a positioning to differentiate themselves from other developing countries.  
 
A more useful categorization for this inquiry could very well be 'innovative developing countries' 
(IDCs) characterized by an advancing R&D capacity, to establish a 'new geography' for NTD 
research (Adams et al., 2012, p. 3).  The number of papers published on NTDs in 2011 from 
Brazil and China, matched that of Japan, Spain, Switzerland, and Australia, respectively (ibid, 
pp. 4–5). NTD research forms a significant part of the research base for developing and 
emergent economies because it has direct economic and social relevance: "Brazil is evidently a 
global research leader, with a substantial volume of NTD papers in its portfolio" (ibid, p. 5).  
What drew me to Brazil and China is their heavy investment in science and a historical 
connection with NTD scientific discovery.   
 
The intention to include Brazil and China was not to produce endemic country case studies but 
contribute to a more global story, by conducting fieldwork across multiple sites.  What this thesis 
does not include is an explicit and systematic compare-and-contrast between countries.  My 
guiding imperative was to follow the action through the term 'NTDs'.  Still it is not enough only to 
reflect NTD policy through how endemic countries have been involved.  This is the reason why I 
explore 'public discourses of measurement' in Chapter 7 to understand how discourses have 
implicated NTDs.  As these diseases have not been in the public arena I want to pinpoint where 
they have entered more mainstream public discussions and have found this through wider 
debates and controversy about measurement. 
																																																								
16 The IDC group often also encompasses a wider list of Taiwan, Ukraine, Malaysia, Belarus, Argentina, 
Mexico, Turkey, Chile and Indonesia. 
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2.3 Qualitative Interviews 
 
In total I conducted 55 semi-structured interviews (including the 21 fieldwork interviews) to 
better understand views and collect anecdotal evidence (Appendix 2 outlines the interviews in 
more detail).  I started with an initial set of informants that I chose to study 'innovation 
approaches to NTDs'.  However, during the course of the interviews it became apparent that a 
different story was emerging. These first interviews constituted an early fact-finding and 
overview of the NTD community.  In keeping with a 'grounded theory' approach to theoretical 
sampling I conducted an NVivo analysis and a new set of conceptual cores emerged around 
'measurement' and 'advocacy'.  These cores guided my selection of further informants, whose 
current institutional affiliations spanned across academic, policy and charitable fields. 
 
The next set of interviewees were sampled using an element of 'snowballing' and 'chain-
referring' to choose interviewees once I had made contact with a key actor in the field or 
completed an interview.  The strengths of such an approach were to find interviewees within 
networks that were not so obvious through an outside search.  The limitation was being 
constrained to those original networks and so not including more oppositional viewpoints.  As 
Ruane points out, relying completely on snowballing may risk omitting individuals who are not 
well 'networked' (2005, p. 118).  Therefore, snowballing was in complement to a purposeful 
sample of interviewees, generally following the criteria of policy awareness or engagement.   
 
The NTD community itself is small and could be regarded as an elite, with high-profile scientists 
and politicians as policy influencers and participants in policy change.  To clarify elite 
interviewing, I adopted Hochschild's definition of "...discussions with people who are chosen 
because of who they are or what position they occupy... the term indicates a person who is 
chosen by name or position for a particular reason, rather than randomly or anonymously" 
(2009, p. 124).  By the end I had interviewed a mixture of policy actors through semi-structured 
qualitative interviews.  As Clifford et al. describe this type of verbal interchange allows the 
interviewer to elicit information through prepared questions but it is done so in a conversational 
manner, with the chance for participants to "...explore issues they feel are important" (2016, p. 
143).  Therefore, it is a more of a two-way process as opposed to survey or structured interview.  
These interviews were predominantly with research institutes and universities in Europe, the US 
and Australia, as well as my fieldwork countries Brazil and China (totaling 35).  I also identified 
five 'activist scientists' in the US, UK, and Australia as instrumental in developing policy for 
NTDs.  Finally for a rounded policy picture, the remaining 15 actors I interviewed were from 
governance institutions (the WHO being especially important), NGOs, and Pharma companies.  
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In addition, five of the interviews formed part of a podcast series with colleague Erman 
Sozudogru at UCL.  This was an online podcast and workshop series on NTDs called 
'Challenging Neglect'.  We interviewed five high-profile academics about their work on NTDs in 
different disciplines ranging from history, philosophy, and the biomedical sciences and held 
workshops to discuss disciplinary perspectives.17   
 
For the fieldwork interviews, where I wanted to meet actors in their work settings, I did not 
employ a formal translator.  I found that as most of my interviewees were engaged in global 
policy-making and forums for NTDs, English was the modus operandi.  When I did need 
assistance with translation this was provided on several occasions at Tsinghua University and 
the National Institute for Parasitic Diseases by the colleagues of the interviewee.  Translation by 
colleagues aided the conversation, which can sometime be stifled and formalized by the 
presence of an outside translator.  Still, there was is a restriction in using English searches of 
the literature and for interviewees, which means I may not have included some non-English 
sources of information and insight. 
 
The typical interview time varied from forty-five minutes at the minimum to up to two hours in 
some cases.  Most interviews were held in the participant’s office but in cases where this was 
not possible a Skype or telephone interview was conducted instead.  As well as taking detailed 
notes, I recorded all interviews and transcribed them.  The exceptions to recording, included 
once when the interviewee did not agree and another when the setting was particularly noisy.    
 
The interview questions were centred on six main lines of questioning: 
1. Reason for involvement in NTDs: Can you tell me about your background, what led you to the 
topic? 
2. Problem and solution understanding and framings: What are the causes of NTDs and what 
are the proposed ways of solving them? 
3. Approach being taken to address NTDs: Which particular strategies are being pursued and 
why? 
4. Reflections on the change of term: What is your opinion of the use of the term 'NTDs'? 
5. What is the relationship between actors: Who are the main partners you work with?  
6. Positioning of Brazil and China within global policies for NTDs: What is being done differently 
in these countries, what are the challenges, what are the strategies being deployed? (The 
last question I tweaked the most depending on the interviewee). 
(See Appendix 3 for a more detailed list of interview questions). 
 
As the interviews progressed I did aim at greater specificity or directness, although it struck me 
that interviewees still will want to say what they want, rather than what you want, and this is as it 
should be.  I avoided steering the conversation too heavily, only moving to next questions when 																																																								
17 See www.challengingneglect.com. 
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ground was repeated or asking qualifying questions when answers were unclear, rather than 
due to my being 'unsatisfied' with answers.  It may have been because of the type of 
interviewees, most of whom were senior scientists engaged in policy and public roles, that 
opinions and accounts of events had already been formed in their minds and some experienced 
difficulty in looking at these from a new light.  When I did ask questions prompting reflexivity, I 
often had the response of "you tell me" or "I hadn't thought about that before" or a deflecting 
answer in order to avoid going into too much detail.   
 
These hurdles may be generally reflective of the realities of interviewing as a research method, 
disciplinary differences, and the type of interviewee.  However what I did find surprising was the 
level of openness interviewees had about airing disputes and being very frank about dislike for 
individuals, organizations, and activities, even though many did not want to have anonymity.  I 
have not included all of these references as they were not always relevant to the research but 
they certainly assisted me in navigating and gaining an understanding of the NTD community.  
 
I gave a varied level of anonymity to all the participants ranging from full disclosure to full 
anonymity, depending on their preference.  After the interviews I transcribed the text and coded 
the field notes to be classified according to themes, topics, and other relevant categories with 
the aid of the software package NVivo (See Appendix 4 for node listing).  Therefore, my data 
analysis was supported through creating distinctive categories, which allowed linkages to be 
made between concepts, and comparisons between cases and events.  I then analyzed the 
coded text and other data inspired by a ‘grounded theory approach’ in order to concentrate on 
developing theory related to concepts, relationships and explaining actions to identify the 
perspectives of groups of actors, reflecting on my interpretative role as researcher.  Thus 
following the general steps typical for grounded theorizing, I did not strictly apply grounded 
theory, concentrating instead on a close and exploratory-oriented reading of the data.  I began 
with the early stage of data collection and continued up until the writing-up stage with the focus 
of enquiry clarified over the course of the research.   
 
I developed analytical categories to make sense of the data by coding at the level of theoretical 
codes.  The codes were derived from the data rather than being pre-determined and these 
involved not only substantive codes but the gathering data from various interviews or 
documentary sources under the same relevant category (Sapsford & Jupp, 2006, p. 251).  It is 
the segmenting and comparison of data from different parts of the data record that 
"...distinguishes grounded theorizing from other forms of qualitative data analysis" (ibid.). 
 
I also undertook a small amount of participant observation – described as the observation and 
participation of the social action being documented (Hume & Mulcock, 2004) – at a number of 
technical (and semi-technical) conferences and events listed in Appendix 5.  
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2.3.1 Ethical considerations 
 
The departmental ethics board approved my research plan and I gained informed consent for all 
my interviews according to the criteria listed by UCL Research Ethics Committee 
(ethics.grad.ucl.ac.uk) on qualitative research.  Interviewees were given an information sheet 
with a consent form and a copy for them to keep.  The sheet covered the following aspects of 
the research: 
 
• Research background 
• Project aims and objectives 
• Information about who is interviewing 
• What the interview will be used for and how 
• How information is stored and protected 
Table 2 Overview of ethics sheet 
 
As mentioned earlier, interviewees were asked if they wanted to be anonymous, what level of 
anonymity and if not whether they wanted to be informed of which quotes were used, with the 
possibility to change anonymity after circulation.   
2.3.2 Qualitative secondary analysis 
 
For a subset of interviews in this thesis I undertook a qualitative secondary analysis.  I reused 
qualitative research data in the form of interviews with individuals who, for various reasons, I 
was not able to interview.  Some key figures who were instrumental at the beginning of NTDs 
developing as a concept were deceased, from both the 'Great Neglected Diseases of Mankind' 
Program' (GND) and the WHO Special Programme for Research and Training in Tropical 
Diseases (TDR).   
 
Kenneth Warren (1929 – 1996) was the director of health services the GND.  I interviewed 
historian Conrad Keating who will publish a biography on Warren in 2017 and interviewed 
Warren's contemporaries.18  At the WHO, Lee Jong-wook (1945 – 2006) was director general in 
2003, when he initiated changes in the organization for the control and elimination of NTDs 
(which have been called a 'paradigm shift').  In addition I used secondary research through 
interviews with Lee published in policy documentation.  There were a number of other interviews 
that I refer to of directors of the TDR WHO, published on policy websites (the WHO and Genève 
Internationale) of: John Reeder: (2012 – present); Robert Ridley: (2004 – 2012); and 
Adetokunbo Lucas: (1976 – 1986). 
 																																																								
18 Nick White is Professor of Tropical Medicine Mahidol Oxford Research Unit and David Weatherall is the 
founding Director of the Weatherall Institute of Molecular Medicine. 
 33 
Other high profile individuals whom I did not interview but relied on newspaper interviews 
included Bill and Melinda Gates the founders of the Gates Foundation, and Nobel Prize winner 
Tu Youyou.  A second reason why I relied on secondary qualitative research was because I was 
interested in the public-facing representation of NTDs.  I acknowledge there are limitations in 
using this type of data source.  Sarah Irwin defines qualitative secondary analysis as: "...the use 
of already produced data to develop new social scientific and/or methodological 
understandings" (Irwin, 2013).  Irwin with Mandy Winterton state that the distance from primary 
data production and the related knowledge of "...proximate contexts of data production" can 
present methodological, ethical, and practical concerns (2011, p. 2).   
 
The focus of my analysis was on the representation of arguments and ideas, therefore the 
context where the sources were generated is less important.  Contextual and situatedness of 
the sources are points that I address when quoting the interviews, addressing the ‘problem of 
data fit’ by providing detail on the nature of the source (Heaton, 2010, p. 4).  Irwin and Winterton 
support this view that: "So long as data analysis is fit for purpose then secondary analysis is no 
poor relation to primary analysis" (2011, p. 2).  
2.4 Documentary analysis 
 
The documentary analysis involved collating and comparing how NTDs were listed and 
portrayed in various policy documents, meaning that I often produced tables to order 
information.  Overall the analysis was pursued with an interest in the broad ideas portrayed 
rather than a detailed description of the institutional and political workings (of organizations such 
as the WHO), which I felt would bring me out of scope.  
 
Policy documents have been an important source from which to view changing understandings 
of policy.  There are clear limits to documentary analysis in that the conversations, viewpoints 
and other material are not included in a formal and official text.  Shaw et al. (2004) list a number 
of practical reasons for using documentary analysis, including a limited availability of other 
sources at an early stage of policy innovation but see negatives in partiality, superficiality, and 
being aspirational.  I have followed this advice in using these sources, by noting intentions and 
planned strategies along with their justifications.  I have been wary not to take the meanings of 
texts at face value, and with a degree of skepticism, looking for alternative explanations and 
meanings held with underlying assumptions and ideologies.  The limitation of policy documents 
is also why I have conducted qualitative interviews in order to gain an understanding of policy 
that goes beyond the official lines. 
 
The key documents that I analyzed from the WHO begin with the first important report following 
an international workshop in Berlin, 18–20 April 2005 (the second of two held in Berlin, with the 
first in 2003).  The workshop was co-hosted by WHO with the German government who 
provided funding (the German Ministry for Economic Cooperation and Development, the 
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German Ministry of Health, and the Agency for Technical Cooperation and the Development 
Bank respectively).19  Present were, "experts from public health, economics, human rights, 
research, and other fields" (WHO, 2005, p. ii) who deliberated on steps to translate the NTD 
agenda into action.   
 
I refer to this pivotal 2005 meeting as the 'Berlin Meeting' and the corresponding first report was 
called 'Neglected Tropical Diseases: Hidden Successes, Emerging Opportunities' (2006b).  This 
report was followed by three more WHO reports (until 2015) on NTDs, which defined the 
strategy taken by the organization.  See Table 3 below. 
 
 
2010 
 
2012  
 
2015  
First WHO report on neglected tropical diseases: Working to overcome the global 
impact of neglected tropical diseases  
 Accelerating work to overcome the global impact of neglected tropical diseases: a 
roadmap for implementation  
 'Investing to overcome the global impact of neglected tropical diseases: Third WHO 
report on neglected tropical diseases'  
Table 3 WHO NTD reports 
 
The first report set out the state of play, the second was a roadmap of goals and the third 
concentrated on the investment and financing needed.  Other key WHO reports are listed in 
Appendix 6.  Important non-WHO reports included the Global Research Report on Neglected 
Tropical Diseases (Adams et al., 2012) published by Thomson Reuters, looking at the research 
environment for NTDs; Delivering on Promises and Driving Progress: The Second Report on 
Uniting to Combat NTDs (Uniting to Combat NTDs, 2014) covered in the next chapter about the 
'London Declaration' and Neglected Tropical Diseases: Background, Responses, and Issues for 
Congress (Salaam-blyther, 2011) informing US policy.   
 
There were also a number of other institutional reports by international organizations that I 
reviewed.20  Country-specific reports included the 'OECD Reviews of Innovation Policy: China 
Synthesis Report' (OECD, 2007).  G-Finder is an annual report by the NGO Policy Cures as a 
comprehensive source of data looking at global investments in tropical disease R&D (G-
FINDER, http://policycures.org/gfinder.html, Accessed 2/4/16).  Some of these reports were 
historical documents (e.g. 'The Rockefeller Foundation Annual Report', 1978).  Using the 
reference manager 'Mendeley' helped me order and keep track of sources.   
 
Secondary sources consisted of news articles and video clips.  I made use of the BBC online 
archives on the documentary series Horizon, which explores health and other public interest 
																																																								
19 Gesellschaft für Technische Zusammenarbeit (GTZ), Kreditanstalt für Wiederaufbau (KFW).  
20 The World Bank World Development Report 'Investing in Health' (1993).   
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topics.21  The benefit of such documentaries is in how the cultural currency of the BBC allowed 
for interviews with top scientists and officials at crucial moments in time.  Although there are 
also caveats in using documentaries, as with any source.  They are produced for specific 
purposes, for example they may need to follow a script or narrative (requiring a narrator who is 
a voice of authority), and so can be less exploratory in nature, relying on sound-bites rather than 
description.  The NIH US National Library of Medicine has produced a 'Guide to Tropical 
Disease Motion Pictures and Audiovisuals', comprehensively listing documentaries on tropical 
diseases (NIH U.S National Library of Medicine, 2014).22  Arguably the neglected, lesser-
known, but impactful nature of these diseases make them attractive to documentary film.  The 
promise of eradication also is a powerful narrative for storytelling – with a conclusion in sight 
through heroic efforts and breakthroughs.  A number of films are produced by the WHO, and 
appear to be part of their health education and advocacy work. 
2.4.1 The tropical tales of Robert S. Desowitz 
 
An unexpectedly rich source has been one popular science writer, Robert S. Desowitz.  As 
Donohoe (2012) notes: "Literature, medicine, and public health share a fundamental concern 
with the human condition. Through literature, readers can vicariously experience new situations, 
explore diverse philosophies, and develop empathy with and respect for others whose place in 
society may be very different from their own".  This reader placement is true of the writing by 
Desowitz (1926-2008) who through his books brings to life tales of tropical diseases.  He has 
been described as: "A veritable Sherlock Holmes of parasites and pathogen" reflecting the 
intrigue, a fast pace and curiosity of his works (Desowitz, 1991).  Tropical medicine is viewed 
through a portrayal of the scientists involved and policy ideas employed.  While his writings did 
not win a major award nor were they sell-out successes, he was praised for his writing style23 
and the topics he brought to life in the science writing community, (including a highly 
commended prize from The Medical Writers Group24 and supportive reviews from the New York 
Times).  
 
Of course there are limitations of using a single-authored resource and it is used in conjunction 
with a wide variety of other sources, outlined earlier.  I also must acknowledge the particular 																																																								
21 Horizon films relevant to NTDs (The TVDB, http://thetvdb.com, Accessed 2/4/14) are: The New Face of 
Leprosy (1986); Mosquito! (1998); Malaria: Defeating the Curse (2005); and Guide to a Pandemic (2009) 
22 Influential films on NTDs have included: Chagas: A Silent Killer, 2005, Ricardo Preve for Al Jezeera 
(said to be influential to Argentinian footballer Lionel Messi who then did another documentary); Malaria: 
Fever Wars (2005) by PBS; The virus hunters (2007) by Steven Jones, WHO; Yoro, the empty granary, 
(1995) by WHO; and the Compassionate exile (1999) by Bob Madey and Larry Thomas. 
23 A quote by two of Desowitz's mentees sums up his writing style: "Bob’s rich anecdotes that tropical 
medicine was a noble discipline of vast importance to human health and also an adventure involving 
outsized or odd personalities, hilarious incidents, and great failures and successes" (Miller & Duffy, 2008).  
Another reviewer said of his books: “the life complexities of the microbial agents of disease are more than 
matched by that of human behaviour” (Wilkinson, 2004).  
24 The Medical Writers Group or the book prize was given for 'Federal Bodysnatchers and the New Guinea 
Virus' (2004) (Wilkinson, 2004). 
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lens that he looks through.  While culturally sensitive and having spent years in the field, 
Desowitz is from the US and identifies with an American outlook.  For example, at one point he 
asks why the Mexicans were not grateful for being relieved of yellow fever and speaks from and 
to an American perspective when reluctantly conceded: "We see only ingratitude where we 
should, instead, have empathy for the hurt national pride of the beneficiary countries, which may 
also have antipathy for the donor countries that they too often perceive as economic and 
political aggressors" (Desowitz, 1991, p. 174). 25   He is not a trained anthropologist, historian or 
social scientist, he is a doctor and epidemiologist first and foremost.   
 
However, it is also worth highlighting the benefits in exploring one perspective of how tropical 
disease is communicated to a public and lay audience, which he does exceptionally clearly as a 
medical specialist.  Like other doctors who have written medical histories he is interested in the 
doctors or scientists and their stories of scientific discovery but does also engage to an extent in 
the policy and politics of disease.  His books spanned the 1980s to early 2000s and he was able 
to capture the changing story of tropical disease.  Desowitz was not active in writing when these 
diseases made their final iteration as NTDs (and indeed it would have been interesting to see 
his perspective on them).  He had already charted a vividly descriptive evolution of tropical 
medicine, encapsulated in six books.26  The book series was compiled from field stories, 
interviews and many years of experience in tropical medicine as an epidemiologist, official at the 
WHO and academic, with a career spanning over 60 years, the last 20 of which he spent 
producing popular science works.  These books are shown below in table 4. 
 
Date Title 
1987 
1988 
1991 
1993 
1997 
2004 
New Guinea Tape Worms & Jewish Grandmothers 
The Thorn in the Starfish 
Tropical Diseases: From 50,000 BC to 2500 AD4 
The Malaria Capers 
'Who Brought Pinta to the Santa Maria 
Federal Body Snatchers & the New Guinea Virus: Tales of Parasites, People &  Politics 
Table 4 Books by Robert Desowitz shown by date 
 
It is the title of his last book that sums up most tidily his contribution in: 'Parasites, People and 
Politics'.  His focus of interest lay in parasites, the people they inhabit, the pursuit of cures and 
the political treatment that pursuit involves.  'Malaria Capers' was most probably his most 
famous book, shown through the media coverage at the time.  It is his most journalistic and also 																																																								
25 The critique of the Rockefeller Foundation as a cultural imperialist is also overlooked, in underlying: 
"...cultural imposition of American culture and values abroad; favouring elitism rather than equity; 
ideologically trying to vindicate capitalism; and investing in health to make the tropics safe for commerce" 
(Chen, 2014, p. 718). 
26 Desowitz began writing for the public in 1976 writing for the public with an article for the Natural History 
Magazine (Miller & Duffy, 2008).  The article was entitled 'How the wise men brought malaria to Africa' and 
sparked a life-long interest in popular science writing.  
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his most critical with the second half of the book dedicated to exposing corruption in malaria 
research, most specifically the illegal mishandling and misuse of USAID funding by scientists 
(and an administrator).  In his other writings this policy gaze was also evident when he took on 
patents in 'Federal Body Snatchers and in the New Guinea Virus: Tales of Parasites, People 
and Politics'.  Insights taken from Desowitz's body of work will be referred to throughout this 
thesis. 
 
Desowitz also undertook a self-reflection of his own involvement with tropical diseases.  When 
he began his career in the 1950s he was told: “Malaria is about to be totally eradicated, and you 
will never make a career, let alone a living, from it” (Desowitz, 1987, p. 12).  The supposed near 
eradication of malaria was why he switched to trypanosomiasis research but “(B)y the 1970s, 
malaria was more of a threat than ever, at the expense of interest in the trypanosomiases” 
(Wilkinson, 2004).  Such a snippet is emblematic of a group of diseases that are closely 
connected to the promise of eradication, to varying degrees, where at least the possibility often 
appears in near sight.  It is a constant movement for which diseases require attention.  The 
quote extends to Desowitz's very premise about the category of tropical disease in challenging 
preconceived ideas: "Well, these diseases that we call "typically tropical" have been as 
American as the heart attack" (Killheffer, 1997).  He held a deeply informed and open outlook on 
these diseases in time and space.  As well as touching upon the related politics of science and 
medical practice, he was aware of the effect the term had on how the diseases were viewed.   
 
Terminology forms a topic that I am concerned with throughout this thesis.  My disciplinary 
background in development economics has led me to have a preference for the terms 
'developing' and 'developed'.  I also see the disciplinary preference in STS to use 'global north' 
and 'global south', which I do use occasionally but my contention is that these terms send 
across a false geographic message, even if implicitly, in an imagined or constructed south and 
north.  'The West' as ideological positioning and political hegemony is a term I use occasionally.   
 
Tariq Khokhar a data editor at the World Bank and colleague economist-statistician Umar 
Serajuddin reflected on the use of the terms at their institution: 
 
"Humans, by their nature, categorize. Economists are no different. For many years, the World 
Bank has produced and used income classifications to group countries.  The low, lower-middle, 
upper-middle and high income groups are each associated with an annually updated threshold 
level of Gross National Income (GNI) per-capita, and the low and middle income groups taken 
together are referred to in the World Bank (and elsewhere) as the “developing world.” This term 
is used in our publications (such as the World Development Indicators and the Global 
Monitoring Report) and we also publish aggregate estimates for important indicators like poverty 
rates for both developing countries as a group and for the whole world.  But the terms 
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“developing world” and “developing country” are tricky: even we use them cautiously, trying to 
make it clear that we're not judging the development status of any country" (2015). 
 
This is an interesting consideration of terms, especially as some scholars, such as William 
Easterly charge that the World Bank means something 'lesser' in referring to ‘the Third World' or 
'less-developed countries’ as places devoid of "liberty, freedom, equality, rights, or democracy" 
(2014, p. 5).  Easterly believed this characterization of countries is shown by the limited role 
these concepts play in their reports, a linguistic omission to avoid the consideration of 
government in development.  He had the following extraordinary response when querying:  
 
"Questioned about the remarkably consistent omission of the word democracy from World Bank 
official reports and speeches, for example, the World Bank Press Office explained to this author 
that the World Bank is legally not allowed by its own charter to use the word democracy" (ibid.).   
 
Economist Branko Milanović similarly talks of how the World Bank has preferred not to use the 
word inequality but the 'watered down' version 'inequity' (see his 2011 book 'The haves and the 
have-nots') instead, looking for more technical rather than political reasons for poverty: "Every 
study on inequality, of course, challenges the structures not only of the economy but also of the 
world we live in, and these questions are not always welcome... it was very, very difficult to get 
any type of grants for research on inequality..." (Milanović, 2016). 
 
There are evidently problems in using the terms 'developing' and 'developed', not least the 
question of when does development happen, when does development stop and where is all of 
this development leading to?  It immediately gives the impression that certain countries are 
done, they have achieved an ahistorical state, while others lag behind, they are lesser, always 
catching up and always sub-par.  At the time of my training 'developing' and 'developed' were 
deemed better than using 'First world' and 'Third world', which were seen as particularly 
derogatory.  Also commonly used were high-income, middle-income, and low-income.  These 
are more neutral in some ways, although have the drawback of being three groups, that can 
begin to get messy, especially as more subcategories are used such as 'higher middle income' 
and 'lower middle income'.  I also think that the perceived neutrality of these terms is a 
misnomer because there remains of politics of categorization, in why some countries belong to 
one group and some to the other – it is an organization that cannot be done in an objective way.   
 
I have even less preference for the terms 'highly industrialized' and 'unindustrialized' as it is very 
difficult to say where the cut off is and it sounds especially old fashioned to claim that countries 
need to have an industrial revolution to develop.  To me 'developed' and 'developing' accepts 
that we have perceptions of some countries being in one group and others in another, 
dependent on country types, their histories, when they have 'developed', their relationship with 
other countries, and their aspirations for the future.  It is not perfect but they are the terms I find 
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most agreeable and as long as limitations are acknowledged, especially in providing detail, 
contradictions, and tracking changing circumstances, they serve an adequate function in this 
thesis.   
 
The dividing lines and distinctions run deep in understandings between the 'developed', 'global 
north', 'the West', 'industrialized', 'high-income' and 'the rest', 'subaltern' (in reference to colonial 
relations) or the 'other'.  The status is of inside or outside, with other terms such as the 'centre' 
and the 'periphery' demarcating that there is somewhere that countries want to be and 
somewhere else, where they want to move away from.  Anthropologists have often considered 
this positioning between one and another.  The ethnographic 'other' according to Rapport and 
Overing has been the anthropological object, "...reified, homogenized and exoticized" but as 
objects they are silenced (2000, p. 98).  The 'other' has "negative properties in Western thought, 
for they cannot speak, think, or know" and these descriptions apply to people or peoples, but 
could very well be applied to countries as well (ibid. p. 99).   
 
One of the central dividing lines, apart from wealth and industry, is science 27  and the 
epistemological privilege it provides: "...the idea of the superiority of Western culture, particularly 
its spectacular scientific success, became the potent and decidedly unliberal yardstick through 
which anthropologists assessed the accomplishments of other cultures" (ibid.).  The very 
analytical categories that we use such as scientific and unscientific, cause unhelpful binaries 
and ignorance to cultural relativism, as "...the other's local was to be understood within the 
context of our local, which in the end became a universal standard, not only of judgment, but for 
description as well" (ibid., pp. 99 - 100).  These are important methodological considerations in 
the use of terminologies and distinction made with the 'other', to take forward throughout the 
rest of this thesis. 
 
2.5 Introducing new terms 
 
I want to introduce some new terms I use that have arisen as out of this research.  This was not 
for want of inventing new jargon but because I did not have the language to adequately describe 
the NTD story.  These are: 
1. Activist scientists 
2. Policy repackaging 
3. Elite policy movement  
 
																																																								
27 in addition to the dividing lines between ’western’ and ‘other’ are associated values of democracy, 
economic growth or competiveness, power, military might, culture and education, secularism and so on. 
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2.5.1 Activist scientists  
 
My intention initially was not to follow scientists.  However during the course of this research I 
found it was scientists who were precisely the ones most active in generating policy for NTDs 
and a more limited activity of other groups.  This point may appear to be an obvious if these 
diseases are 'neglected'.  Still it is a common focus of researchers studying other diseases or 
disease groups to look at how patients have brought attention to diseases, but with NTDs this 
type of patient activism is not happening (Epstein, 1996; Klawiter, 2008; Macq, Torfoss, & 
Getahun, 2007; Rabeharisoa, 2003).  I found instead that a dozen core scientists have been 
actively involved in promoting the NTD cause along with a handful of other personalities that 
span from the economist Jeffery Sachs (see Sachs, 2007) to politicians such as Baroness 
Hayman in the UK, whose involvement can often be tied back to the core scientists (Interview 
with author, Hayman, 2013).  I will explore activist scientists in Chapter 5. 
 
In addition, student medics have typically been a group concerned with NTDs such as the non-
profit organization Universities Allied For Essential Medicines (UAFEM).  Pharma companies 
have varying levels of dedicated involvement from research groups to drug donation programs –
including Merck & Co., GlaxoSmithKline, Johnson & Johnson, Pfizer, Novartis and Sanofi-
Pasteur.  As do governments, with the biggest example being USAID's Neglected Tropical 
Disease Program launched in 2006 (streamlined under President Obama's Global Health 
Initiative in 2009).  However, the driving actors are the activist scientists, who have defined the 
terms, influenced policy agendas and created networks of interested parties, establishing their 
own lobbying governments and NGOs.  I show how scientists became politically engaged to 
transform tropical diseases into NTDs through a policy repackaging.  
2.5.2 Policy packaging  
 
A term that encompasses both advocacy and measurement is a policy packaging.  NTDs are a 
conceptual packaging – more accurately a repackaging – of what is essentially the same 
(narrowed-down) collection of tropical diseases.  I call this a policy repackaging because it is 
through policy that tropical diseases have been reconceptualized and is more than a simple 
renaming.28  Nor is it turning an issue into a problem by a categorization in different ways as 
Zahariadis (2016) describes, drawing on Schattschneider's idea of 'redefinition' of issues, 
although categorization does play a role.   
 
In fact a number of authors use the term repackaging in book and article titles but do not always 
offer an explanation for what they mean by the term or make explicit relation to policy; it appears 																																																								
28 Chapter 5 outlines the change of type of diseases listed as tropical diseases to the NTDs and what 
rebranding in health policy means. 
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to be taken for granted that the meaning is obvious.29  Joan Fujimura used a notion of 
packaging in her paper 'Constructing `Do-able' Problems in Cancer Research: Articulating 
Alignment' (Fujimura, 1987).  Here she referred to 'standardised packages of tasks' in the need 
to package the work of scientists through modularization and standardization as a strategy to 
make dissemination easier.  Through Fujimura's use of the term, packaging articulates the way 
science is done through a technique, procedure, or task.  Likewise the 'packaging' approach can 
also be applied in the realm of policy, with the aim of simplifying, regularizing, and providing 
distinctive boundaries.  When I refer to the term policy repackaging this is in relation to the 
policy treatment of a new way of viewing a policy problem.  Other scholars have explored 
conceptual packaging in policy along similar lines, to refer to how a policy is conceptualized as a 
representative and coherent whole, but tend not to relate to the means of repackaging as being 
through policy (see Ferrero-Waldner, 2006; Rusi, 2007). 
 
I use packaging in a similar vein to framing, where to construct meaning through 'frames', is to 
apply a definition or interpretation to the social world, as I will discuss more in the next chapter.  
Communications theorist Van Gorp considers 'frame packages' as a way of grouping frames of 
reasoning about an issue of an event into a coherent collection of for, "...definition, an 
explanation, a problematization and an evaluation" (Van Gorp, 2007, p. 65).  The reason I use 
the term packaging is the stronger connotations with commodification and marketing.  A policy 
problem is packaged in such a way to compete with other policy ideas and is especially the 
case in the 'global health marketplace', where diseases vie for their place on policy agendas, to 
move along priorities and hierarchies of importance and urgency.  Chatterjee describes how 
packaging for a commodity is intended to be visually differentiate in order to attract a particular 
group (2007, p. 293).  As I will discuss in Chapters 5 and 6, repackaging is what the NTD term 
does in differentiating tropical disease from what it had previously been understood to be.30  
Although as Mata and Louca argue, drawing on the work of George Stigler in the 1960s, the 
worlds of business and of intellect are not so disconnected in that, “...both fields pay a fair 
amount of attention to packaging and advertising, and both fields place an absurdly high value 
on originality” (2009, p. 13). 
 
2.5.3 Elite policy movement  
 
Endemic countries may have a different perception of policy repackaging.  Indeed when I 
presented my research to an audience of international researchers, one Brazilian researcher 																																																								
29 Titles referring to ‘repackaging’ relating to policy include: Repackaging exemptions under National 
Health Insurance in Ghana: How can access to care for the poor be improved? (Derbile & van der Geest, 
2013).  Or a repackaging of a policy problem through renaming, as Measham and Brain (2005) give the 
example of 'lager louts' to 'binge' drinkers in “Binge” drinking, British alcohol policy and the new culture of 
intoxication.   
30 Malaria would be later excluded from the NTD grouping as well as the multitude of less serious or well-
treated tropical diseases that would not be included under the 'neglected' banner. 
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remarked: "We do not call these neglected tropical diseases, to us these are diseases" (STS 
Fellows meeting, Harvard University, 2014).  He described NTDs as diseases he had grown up 
knowing, so in a way it was bemusing that an outside community would give them this label.  
Indeed NTDs are 'common afflictions' to the world's poorest people.31  NTDs are heterogeneous 
diseases, and commonality is not found in pathology or etiology but through labeling based in 
socio-political grounds.  Presented to a donor audience, the diseases cannot be ordinary and it 
takes a directed form of policy action to construct the idea of why NTDs need to be cared about.  
The construction of caring has happened through a policy movement.   
 
The idea of a policy movement opens up the discussion to encompass activism on a much 
broader level, to locate action on a scale and not only radical change within the public sphere, 
social groups or civil society.  However it is elite in being directed by a small group of scientists 
based in the UK and US to create the NTD repackaging and may not reflect local 
understandings.  I go into more detail about what I mean by this in Chapter 6.  It is a privileged 
group by their permanent contact with key global health organizations, wealthy philanthropists 
and prestigious academic institutions. 
 
There are inherent problems of globalized policy making, which is universalist in scope, 
contrasting with statist limitations and contradictions in localized strategies or approaches.  
Scale considerations go beyond local and global, the division lines of size, reach and expanse 
of policy making are not clear-cut.  Measuring the scale of neglect is an interrelated issue and 
as a discourse became a prominent theme in this thesis as a form of evidence, to complement 
how advocacy has been applied through activist scientists.  
 
I have discussed the new terms that I have introduced but at the heart of those conceptions is 
the methodological question: how can an analyst observe neglect?  Neglect is what activist 
scientists are trying to overcome through their agency and through the means of a policy 
repackaging, policy movement, and reflected in public discourses of measurement.  But how is 
best to study something that is said not to be known or cared about? 
																																																								
31 Global Network, http://www.globalnetwork.org/, Accessed 2/4/16.  
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2.6 Exploring neglect 
 
To explore neglect in how it can be analyzed and theorized, I drew insight from a body of work 
within sociology about the study of absence.  Balmer and Rappert in their book 'Absence in 
Science, Security and Policy: From Research Agendas to Global Strategy' (2016) raise a 
number of points related to causality between absence and presence, and the production of 
absence.  The presence of certain activities and events such as the Millennium Development 
Goals (MDGs) can be seen as cause of neglect for tropical diseases.  Neglect also does not 
occur naturally, but is caused by actors, or structures, or both.  Pharma companies and global 
public health policy are pinpointed to identify how neglect has been produced.  Crucially, what 
needs attention is not straightforwardly what is missing recognition, but understanding the type 
of absence becomes a central point.  Neglect is a special type of absence in being defined by 
what it is not, as with NTDs.   
 
While methodology for the study of absences proves of use for researching neglect, Sudeepa 
Abeysinghe (2015) also sees neglect through NTDs as a counter case for the ignorance 
literature where the negative impacts of the social construction of non-knowledge is 
emphasized.  The connection with the ignorance literature and NTDs through Abeysinghe's 
working paper is welcome, however ignorance may have been a too hastily applied label, 
possibly because there is not an advanced sociology of neglect literature.  She considers a key 
methodological point about how to investigate issues of ignorance, in that it is not merely the 
absence of knowledge but used as a rhetorical and constitutive device.   
 
In relation to this thesis, ignorance may be one aspect of neglect but I argue that lack of 
knowledge or information is one of many other possibilities, which is why the absence literature 
forms a more inclusive theoretical basis to draw upon.  Looking for a methodological framework 
for exploring absence, I found that Frickel in 'Absences: Methodological Note about Nothing, In 
Particular' (2014) takes a step toward a conceptual understanding of holes or gaps.  In doing so 
he also notes that STS is characterized by a relative absence of absence-related research, in 
that:  
 
"The vast majority of published STS research is about knowledge production, not the non-
production of knowledge; our accounts typically privilege action over inaction; we study 
processes of becoming or emergence, far more than processes of winnowing or submergence; 
we are more interested in beginnings and successes than endings and failures" (2014, p. 87). 
 
It is this 'undone science' that Frickel (2014) describes as he studies 'social movement and 
other civil society actors' to find areas ignored by scientific and regulatory communities, for 
which he explores: "What explains the selection of certain areas of scientific research and 
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technological design choices and the neglect of others?" (Frickel et al., 2010, p. 88).  Frickel 
offers ten methodological considerations to study absences, which I use to varying degrees in 
this thesis (2014, pp. 89-90).  These considerations amount to treating neglect not only as an 
absence of something but a social object and process in its own right, through the making of 
neglect, that requires: (1) explaining structural conditions; (2) questioning otherness; (3) 
considering the of meaning of neglect and to whom; (4) a scope with concise and conceptually 
bounded definitions; (5) considering history, culture and organizational contexts; (6) measuring 
the shape of neglect in temporal and spatial terms; (7) measurement of relations; (8) and 
densities of neglect; (9) comparison of neglect through case studies; and finally (10) reflexivity 
of my treatment of neglect.  See Appendix 7 for more detail.  This methodological underpinning 
is not where I end with neglect.  I undertake a deeper exploration of the concept in Chapter 3 
and will return to thinking on neglect throughout the entire thesis. 
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2.7 Concluding thoughts  
 
This chapter has covered the foundations that I have laid out to research new conceptual 
ground in relation to NTDs, from the point of view of the advocacy and measurement to address 
neglect.  In the first part I outlined my methods for qualitative research and set out my three 
main research aims.  First was to connect NTDs conceptually with tropical diseases through a 
brief history of policy; second to explore the policy development of NTDs through advocacy 
(concentrating on activist scientists) and measurement (to provide evidence and persuade); and 
third to provide examples of neglect through endemic country stories, mainly encompassing 
Brazil and China. 
 
In the second part I discussed my main documentary sources and introduced the terms I use 
throughout.  These are: 'activist scientists', 'policy repackaging' and, 'elite policy movement'.  I 
explained what I mean by these, the reasons for limiting my scope, and why I have chosen 
these terms.  It is my contention that NTD research could benefit from new theoretical 
vocabulary.  My overarching objective is to conceptualize what neglect means in policy. 
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Chapter 3. Approaches to policy problems 
3.1 Introduction 
The introductory chapter explained how NTDs have been presented as a policy problem and 
why I am interested in how these diseases arrived at this position.  The theory I draw upon for 
my research is grounded in the way that policy problems can be approached, to make sense of 
the 'who, what, why and where' that leads to a topic being considered as a problem for policy.  
This chapter therefore aims to provide a theoretical basis on which to build and interpret my 
empirical research on NTDs by considering: Whom is it a problem for and what causes it? 
Where did it originate?  Why does it persist?  What constitutes a problem for policy?  These 
questions will be revisited throughout the thesis, with the intention of contributing to the debate 
about the nature of policy problems.  In particular I bring together a number of strands of 
literature about policy problems: (1) the constitution of policy problems; (2) innovation for 
solutions; (3) the landscape of global health; and (4) neglect as a concept in policy. 
 
Firstly, I ask what a policy problem is.  The idea of problematization is a starting point to explore 
how a policy problem is constituted.  I use policy in a broad sense as I have described in the 
previous chapters, where other actors – including those in the public, private and philanthropic 
sectors – can contribute.  I cover problem types, how measurement and advocacy is used to 
problematize, and how policy can be expressed as narrative. 
 
Secondly, this chapter will cover the role of innovation in solutions, influenced by the language 
and ideas of economics.  I introduce innovation into thinking about NTD policy because it is 
pervasively present in strategy, rhetoric, and activities.  Consequently for a global health 
problem, innovation will be a part of the problem and solution rationale.  The role of innovation 
in policy problems will be revisited in various forms in different chapters.  In Chapter 5 
innovation is observed through the drug-based strategies as solutions for neglect that 
characterize how neglect is understood.  Then in Chapter 6 innovation is understood as the 
difference between the old 'field-hand' science of tropical medicine, transitioning to a modern 
science of biotechnology and genomics, as well as challenges to the innovation system. 
 
Thirdly, the various disciplinary approaches taken to policy problems, including how my own 
approach has been informed, builds upon methodological questions put forward in Chapter 2.  
However, this is a topic that cannot be covered in one step and remains a thread that I return to 
throughout the thesis.  
 
Fourthly, I will discuss the meaning of context or setting for global health, through the particular 
actors involved and an evolving landscape.  Health actors are described here as groups of 
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individuals, organizations, and institutions that play a major part in global health policy 
processes, providing the landscape of which NTDs are part of.  Chapter 4 expands on this 
premise in charting the background to NTDs as a policy problem through timelines of major 
events and milestones, the evolving disease lists and the various health actors involved, set 
amongst changing health institutions, initiatives, and advocacy. 
 
I then move to the particularity of the NTD policy problem characterization: neglect.  Neglect is 
one description of many that can be used to characterize a policy problem and the concept is 
my central concern in this thesis.  Neglect features in each chapter as I address the particular 
assumptions made about the nature of problems and solutions through the neglected label.  
Later in this chapter I compare 'neglect' with closely related characterizations of absence and 
care.  To summarize, I draw upon four areas of literature:  
 
1. Problematization in policy.  Problematization is an idea that has a well-established 
intellectual basis through the work of Michel Foucault.  I also bring in scholarship by public 
policy theorists who address policy problems, and present the value of understanding 
policy as narrative.  I consider problem types on the grounds of solvability by through the 
'wicked problems' and 'anticipatory problems' literature, and make the case for attention to 
'neglected problems'.  An ongoing theme in this thesis is the use of measurement and 
advocacy in constituting policy problems.  I primarily discuss 'evidence-based 
policymaking' and 'social movements' as how measurement and advocacy are commonly 
described in policy. 
2. Innovation conceptualization for solutions.  I consider the interaction between policy and 
ideas of innovation as solutions to policy problems.  Economics and political science have 
formed much of the mainstream thinking, supplemented and challenged through 
contributions by management science, organizational studies, sociology, innovation 
studies, and science and technology studies (STS). 
3. Disciplinary lens: economicization, historicism, and interdisciplinarity.  Economists, 
historians and a variety of disciplinary actors from epidemiologists to health economists 
and anthropologists are influential within global public health policy, often as part of 
interdisciplinary teams.  The disciplinary lens taken by analysts towards policy problems 
has been most evident through economics but other disciplines are also proving influential. 
4. Global health actors and landscape.  A body of literature has developed charting a new 
era of 'global health'.  Katherine Kenny calls global health the "...preferred label for 
attempts to govern the health of the global population" and so it is an idea closely tied to 
interaction and decision-making in the pursuit of health (Kenny, 2015, p. 9).  Sophie 
Harman describes how new institutions and older institutions, including non-governmental 
organizations (NGOs), and private philanthropy have led to a blurred landscape of global 
health governance lacking the "...leadership as to how such institutions could work 
together" (2014).  From here I will consider the understanding of neglect, from constructing 
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a policy problem to the approaches to tackle NTDs, as a feature of policy by drawing on the 
absence and care literature in sociology and STS. 
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3.2 Problematization in policy  
3.2.1 Problem types  
The nature of problem types32 in policy is an under-explored question, despite early research by 
political theorists David Rochefort and Roger Cobb (1993) on the broader topic of 'problem 
definition'.  It should also be noted that despite being used interchangeably, issues and 
problems are different in that, "(L)exically, an issue is a dispute between parties in which they 
join in the hope of arriving at a decision or solution" (Strydom, 1999, p. 71).  A divergence of 
opinion is already assumed in how to reach a solution, which is not an uncommon situation for 
policy problems, as it is unlikely that all parties will be in agreement about the best course of 
action to reach a resolution.  The difference then is that an issue is the emphasis of competing 
parties and their claims to reach a decision or solution, while a problem emphasizes that a 
situation is not wanted and needs dealing with, even if it is difficult to achieve.  Therefore issues 
are more about relationships and problems about identification. 
 
A problem is: "A matter or situation regarded as unwelcome or harmful and needing to be dealt 
with and overcome" (Oxford Dictionaries).  It is recognizing that an undesirable situation exists 
that must be resolved, while a second definition of problem is: "A thing that is difficult to 
achieve" (ibid.).  Therefore, a degree of difficulty is already implicit.  To identify problems, make 
lists, prioritize, is determined by how undesirable the situation is and the difficulty or ease it is to 
solve.  Therefore importance, urgency, and solvability are key tenets of what it means to 
address a problem.  However, directing efforts towards identifying and strategizing problems 
concerning the public, society, or humankind, has not always happened on a coordinated or 
high-level manner.  
 
The most famous early instance listing problems was by David Hilbert over a century ago, when 
he defined a set of 23 unsolved mathematical problems.  These problems were listed as a set of 
'Grand Challenges' and would be repeated by other disciplines.  A global outlook on policy 
problems has produced more concerted efforts towards generating lists and directing 
organizational efforts towards solutions.  The Bill and Melinda Gates Foundation 'revitalized' the 
concept in 2003 by identifying 14 Grand Challenges in global health, extending funding to 
$100m in 2008 through their 'Grand Challenges Explorations' five-year initiative (Grand 
Challenges Canada/Grand Défis Canada, 2011).  The initiative concentrates on basic research, 
as Bill Gates describes: "By harnessing the world’s capacity for scientific innovation, I believe 
we can transform health in the developing world and save millions of lives" (quoted by Kelly & 
Beisel, 2011, p. 79).  Other governments, universities and NGOs have since adopted the term, 
including the Canadian Government (Grand Challenges Canada/Grand Défis Canada, 2011), 
																																																								
32 In 'problem types' I mean ideal types in the Weberian sense as an abstract, hypothetical concept 
(Hekman, 1983), to produce a broad characterization of the nature of a problem. 
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which focuses on global health and UCL (University College London) with six challenges across 
different topic areas including global health.33  
 
The listing of problems in a goal-orientated way, has been viewed by some to represent a 
techno-scientific optimism.  As Kelly and Beisel caution it is a, "... problematic analogy between 
global health and algebraic puzzles" (2011, p. 79).  I question whether global problem lists are 
thus a continuation of the modernist epoch described by Isabelle Stengers?: 
 
"...fifty years ago, when the grand perspectives on techno-scientific innovation were 
synonymous with progress, it would have been quasi-inconceivable not to turn with confidence 
to the scientists and technologists, not to expect from them the solution to problems that 
concern the development they have been so proud to be the motor of. But here too – even if it is 
less evident – confidence has also been profoundly shaken. It is not in the least bit ensured that 
the sciences, such as we know them at least, are equipped to respond to the threats of the 
future" (2015, p. 29). 
 
Stengers sees the 'grand perspectives' of listing problems as part of an optimistic view of 
scientists and technologists.  However, their ability to address future threats remains uncertain.  
Indeed, it is the anticipatory problems looking to the future that appear the least solvable by 
science and technology.  Other considerations about types of policy problem tend to centre 
upon broad topics with an extrinsic as opposed to intrinsic view of problems.  They are based 
on the spheres that problems inhabit (health, development, environment, welfare – as we see 
with how 'Grand Challenges' are ordered).  These are based around public perceptions and 
government resources.  Fewer sources focus on characteristics describing the nature of 
problems, in terms of their solvability.   
 
The characterizations that I am interested in are problems and their relation to solvability, which 
plays on dichotomies.  Problems can be wicked (opposed to tame) by level of difficulty; 
anticipatory (opposed to established) by degree of determinability; or neglected (opposed to 
acknowledged) by amount of attention and care.  These problem types may be described as 
meta-characterizations, as there are many ways that problems can be characterized but I am 
looking for larger groupings that have been popular in discussions of policy problems.  I propose 
Table 2, as a description of the major types of policy problem based on common 
characterizations of solvability and opposite (or alternative) scenarios.  
 
Type of problem Opposite scenario Values Reference 
Wicked  
weaker and stronger levels of 
difficulty with super wicked to 
Tame, simple/ 
straightforward 
Past and future, 
technical, local 
and global, 
(Rittel & Webber, 
1973) 
(Cairney, 2012; 																																																								
33 UCL Grand Challenges, https://www.ucl.ac.uk/grand-challenges, Accessed 2/4/16. 
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insoluble or complex and complicated everyone Ramalingam, 2014) 
Anticipatory 
grades of determinacy from 
predictive, forecasted to speculative 
Established, 
current, immediate 
Future, 
technical, global 
(Anderson, 2010) 
Neglected  
with wider/public portrayal low-profile 
and unrecognized 
Prevalent, 
acknowledged, well-
known, high-profile 
Political, local, 
minority groups 
(Rappert & Balmer, 
2016) 
(Harman, 2014) 
Table 5 Major types of policy problem and opposite scenarios 
Looking at this collection of characterizations I can make some observations about different 
types of problem.  Here we can see where a 'neglected' characterization might fit in relation to 
other characterizations and what those different policy treatments might mean.  It is certainly the 
case that characterizations follow hype and trends, as certain characterizations are more 
popularly used at various times than others.  The values encompassed relate predominately to 
how the problem manifests in time and space (local/global or past-looking/future-looking), who 
is affected (a particular group or everyone) and who is responsible for solutions (depending on a 
whether it is a technical or political problem).  Characterizations may also say something about 
what types of problems are of concern.  I identify three problem types on the grounds of 
solvability, which are outcome-orientated ways of looking at problems.  What connects the 
problem types is that they confront knowability and knowledge, where uncertainty defines both 
problems and solutions.  Existing knowledge may limit the ability to solve problems, as does 
knowability in the capacity to know, which might be limited by uncertainty. 
 
Wicked problems 
Wicked problems are those that, "...are difficult or impossible to solve because of incomplete, 
contradictory, and changing requirements" (Ramalingam, 2014).  What is the remedy for difficult 
or even impossible solvability?  Complexity theory has been one proposal, for example the 
'Complex Systems Tools project' is a UK Department For International Development (DFID) 
project looking at what research tools can be developed to study complex systems (ibid.).  With 
an emphasis on systems, it aims to be a reaction and response to the non-linearity of problems 
(Goldstein, 1999).  As a broad field, which purports to span the natural and social sciences, 
some have called it more of a 'research approach' or even a 'new scientific paradigm'.  
Complexity theory has taken off in the last forty years in an effort to address large-scale, 
indeterminate and multi-level problems.  Cairney offers the following definition:  
 
"Complexity theory is generally sold as a new approach to science in which we identify (and 
then explain) systems or processes that lack the order and stability required to produce 
universal rules about behaviour and outcomes. When applied to the sciences as a whole, it is 
described as a revolutionary break from the ‘reductionist’ approach to science and the 
‘paradigm of order'..." (Cairney, 2012, p. 347).   
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The focus is on interconnectedness, adaptation and unpredictability rather than a mechanistic 
and reductionist means of science.  The method for addressing problems relies on quantitative 
experimentation through models and simulations, creating computer assisted or generated 
versions of real-world scenarios, outcomes and interventions.  
 
Anticipatory problems 
Human geographer Ben Anderson has described how: "Across different domains of life the 
future is now problematized as a disruption, a surprise. This problematization of the future as 
indeterminate or uncertain has been met with an extraordinary proliferation of anticipatory 
action" (2010, p. 777).  He argues that we need to think about the future to avoid assumptions 
about linear temporality but not as a "blank separate from the present or that the future is a telos 
towards which the present is heading" (ibid., p. 778).  Thus we begin to see more concern with 
anticipatory problems.  As Adams et al. describe: "One defining quality of our current moment is 
its characteristic state of anticipation, of thinking and living toward the future. Anticipation has 
epistemic value, a virtue emerging through actuarial saturation as sciences of the actual are 
displaced by speculative forecast.  It is a politics of temporality and affect" (2009, p. 246, 
emphasis original).  Anticipation has been commonplace in governing emerging technologies 
through geo-engineering, nanotechnology, and synthetic biology as soon-to-be problems 
(Guston, 2010).  Current unforeseeable problems caused by unknown social and ethical 
consequences – for example of 'de-extinction' (using DNA techniques to bring back extinct 
species (Zimmer, 2013), the existential threat of asteroids (Matheny, 2007) or uncontrollability of 
artificial intelligence (Bostrom, 2002). 
 
Neglected problems 
I will discuss the term ‘neglected’ as a characterization throughout this chapter.  Perhaps as a 
distinct policy problem category it has not been developed fully in the literature, especially 
compared with wicked problems (Gusfield, 1976) and anticipatory problems (Anderson, 2010).  
To some extent the idea of neglect has been considered in the public policy literature but 
without a name given to it.  Bachrach and Baratz in the 1960s already conceptualized the study 
of governmental decision-making where: "Policies reflect not only the preferences and power of 
those groups whose problems have been addressed" and the ability of groups to limit 
institutional attention to issues reinforcing or augment the status quo (in Zahariadis, 2016, p. 2). 
Subsequent research interest has been in the 'pre-political', 'pre-decision-making' and non-
decision-making in the 1970s, followed by explorations of the 'policy agenda' (Cobb & Elder, 
1971).  Today the absence and ignorance literature opens the door to how attention, through 
knowledge and non-knowledge is applied to policy. 
 
Solutions proposed for neglect is a recognition that attention is needed, as well as associated 
funding and resources.  As a specific policy topic, neglect often encompasses vulnerable groups 
who are unable to care adequately for themselves, from children to the elderly who are 
 53 
subjected to a 'passive form of abuse' (Pillemer & Finkelhor, 1988).  Still, neglect as a descriptor 
may have fallen in use over time as indicated by looking at a Google Books Ngram Viewer. 
 
Figure 1 References to neglect in books 1800 – 2016   
(Google Books Ngram Viewer) 
 
Through these characterizations there are some general observations to be made.  Two states 
of opposite problem scenarios are commonly described (as shown in the Table 2, p. 51).  A 
problem is presumed to be a negative state that is fixed, at least in one moment in time, with 
uncertainty about the state of a problem downplayed.  This downplaying is ironic as these 
problem types are characterized (and have in common their uncertainty) in regard to knowledge 
and knowability.  Problems are portrayed as existing in stable, knowable and certain states that 
move in a direct line to solution.  For Turnbull this direct line is a reliance on the scientific 
method, to move on an "...artificial, instrumental path from problem to solution" (2008, p. 85) 
 
If we have a negative scenario there must be an imagined possibility of a positive, improved 
scenario.  A name for such a negative-positive scenario is a 'balance routine', used in ignorance 
studies for the assumption that there are two sides to every problem (Proctor & Schiebinger, 
2008).  Alternatively, Stengers proposes ways to conceive of a positive ontology for a 
problematic through an effort to "...'slow down' reasoning and create an opportunity to arouse a 
slightly different awareness of the problems and solutions mobilizing us" (in Latour & Weibel, 
2005, p. 994).  Differentiation and dichotomy remains a constant source of enquiry for STS 
scholars and others in the social sciences.34   
 
Latour has famously objected to the naturalized dichotomy between nature and society, in 
subject-object and fact-value distinctions (McGonigle, 2012).  Along with other scholars, he has 
shown that in actuality types are rarely fixed with connections not easily separated.  Problem 																																																								
34 The most famous study of ‘others’ is perhaps Said’s classic Orientalism thesis (2003 [1973]).  This was 
not only a postcolonial study of difference explained by unequal power relations but a way of viewing the 
distinction made between the east and west structurally, as a discourse.  Similarly in reference to regimes, 
Bauer (1997, p. 55) identifies a structural difference in the opposite universes of, '"...universalist, scientific 
and technological world with particularistic national or religious regimes, having both 'positive 
consequences' but also 'massive de-socialization'.   
 54 
types exist on a scale that may regress, may be part solved, are medium-term (or hold short-
term and long-term components) have multiple characterizations or two-and-fro between states.  
The optimism and plausibility of solutions are apparent with a leaning to techno-scientific 
progress, more commonly described as innovation.   
 
What do problem types and the dichotomy produced between negative and positive scenarios 
tell us about how problems are constituted?  If neglect is a particular problem type, with a 
positive scenario of acknowledgement and a high profile, how does a problem come to be 
identified in the first place and secondly with what type of characterization (e.g. neglected, 
anticipatory or wicked)?  To answer these questions I turn to the rich literature on 
problematization and policy problems.   
 
Michel Foucault describes problematization as being about understanding how and why 
something becomes a problem and the forging of knowledge and relationships to make a 
certain thing an object of thought (1999).  The process of problematization is not solely a 
theoretical one, because problematization while being a constructed social action is in fact “an 
‘answer’ to a concrete solution which is real" (ibid, p. 75).  In relation to science or innovation 
policy, problematization thus has been employed to challenge assumptions of a problem in the 
first place.  As Joly notes problematization in policy is framed in terms of: “You have a problem 
and I have the solution” and “involves the definition of the problem that has to be fixed” (Joly, 
2010, p. 6).  He gives the example of genetically modified organisms (GMOs) in the 1980s 
being positioned as a solution for the problem of world hunger and disease, while today the 
focus has moved onto global warming and sustainable agriculture (ibid).   
 
Such a description of policy problematization is the basis to a large section of the literature on 
'framing'.  Framing is a persistent idea throughout the policy literature (See Daviter, 2007; Lau & 
Schlesinger, 2005; Steensland, 2008).  'Frame analysis', is a research method to analyze how 
people define and interpret situations or activities, by rendering meaning through the ability to, 
"...locate, perceive, identify, and label" (Goffman, 1974, p. 21).  More specifically the process of 
'framing' is the process of constructing a frame, through an, "...active, processual phenomenon 
that implies agency and contention at the level" (Benford & Snow, 2000, p. 614).  
 
Frames construct both problems and possible solutions.  As Nick Turnbull describes, policy 
solutions to be understood in policy science as "...hypothetical conclusions which are supposed 
to resolve social problems in practice" (2008, p. 83).  Problem-solving to define policy problems 
was also pursued by political scientist Harold Lasswell through a 'scientific' approach to apply 
scientific knowledge and the use of scientific rationality, methods, and principles (Turnbull, 
2008).  However, Lasswell was heavily criticized for his simplistic view of problems and lack 
recognition of framing (or problem/political agendas) in setting a problem definition on a 
particular path. 
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A number of scholars have further researched how ‘policy problems’ are challenged by asking 
what a problem is represented to be within policy (See Gusfield, 1976; Majone, 1989).  Carol 
Bacchi (1999), inspired by Foucault has further researched problematization in a policy context.  
Bacchi aims to delve into the way problems are conceptualized in policy making and analysis by 
interrogating the assumption that ‘problems’ are readily identifiable and objective (2010, p. 1).  
She also reminds us that we are mainly talking about social problems when we discuss 
problems for policy as unique to modern societies, in the public responsibility to act through 
moral reasoning (Bacchi, 1991, p. 6).   
 
Social problems tend to be defined as a harmful condition or situation.  The social problem 
literature is closely related to policy problem research but with less emphasis on the policy 
process and more on how society or the public view and construct problems.  For example, 
Hilgartner and Bosk (1988) make an argument about the role of public attention in determining 
the 'rise and fall' of social problems.  Their analysis concentrates on how linkages are made 
across public arenas, where social problems grow in attention but competition and a need for 
drama requires new problem definitions to be repeatedly introduced.  This emphasis is on the 
public and public arenas, without a full consideration of the role of policy involving other actors 
and arenas.   
 
Chaufen et al. note how the social problem characterization has fallen out of fashion (2012).  
This may be because of the connotation of social problems with moralizing, correct and 
incorrect moral behaviours.  As a result, in the health arena social problems are often reframed 
as medical problems.  These problems are argued to be part a 'medicalization' of life, an idea 
developed by Ivan Illich to describe medical interference (disguised as care) overstepping due 
reason (1975).  Illich argues how the wide definition of ill health expands the scope of medical 
care, the outcome of which is a denial of humanity in the process of, “...transforming pain, 
illness, and death from a personal problem into a technical [one]” (Illich, 2003 in Chaufan et al., 
2012).35   
 
The push toward treating social or personal problems as technical ones is reflected in 
government approaches to policy problems.  Governments receive a large share of attention in 
how policy is conceived, even though policy problems involve more than government and 
affected public, with a variety of institutions, actors and processes engaged in problem solving.  
The common discussions by policy analysts36 about what counts as a problem for policy and 																																																								
35 IIlich used the "Pyrrhic victories over some tropical diseases" as an example of the belief in an almost 
limitless progress of medicine, which would then face new challenges in the perpetuation of disease 
through economic and technological factors. (1975, p. 73).  
36 Policy analysis was a late addition as a research field in the 1960s.  At first being a 'tool' of government 
policy analysis has attempted to become more reflexive and self-appraising (Gale, 2001, p. 380) with 
concern for being informed, rigorous and based upon research rather than commentary and critique.   
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the best way to act have therefore been directed at the policy makers.  Many have been 
preoccupied with the use of evidence, in contributing to policy being arbitrary and uninformed.  
The claim is that: “Policy choices are based on fads, revered exemplars, or abstract theories, 
rather than solid evidence” (Simmons et al., 2007, p. 451).   
3.2.2 Evidence and narrative constructing policy problems 
The use of evidence in policy has been heavily influenced by the 'Evidence-based policymaking’ 
(EBPM) approach.  EBPM aims to counter the grounds for policymaking deemed to be arbitrary 
and uninformed, either following political motivations, or borne out of laziness and poor practice.  
According to Ian Sanderson, EBPM is derived from 'evidence-based medicine' (EBM) in seeking 
to use information and knowledge more effectively to justify intervention, particularly in the UK 
and US (2002, p. 1).  A general critique of the evidence emphasis by policy analysts has been 
provided by Majone (1989) who argues that an image projected is one of "technical, nonpartisan 
problem solvers", while in fact they are more akin to lawyers than engineer or scientist, making 
policy arguments.  Further, the pursuit of being objective and atheoretical can mean policy 
analysis becomes too abstract, which Gale has argued EBPM leads to a “to-ing and fro-ing 
between theory and data” (Gale, 2001, p. 380).  Finally EBPM has also been scrutinized by 
those who object to “...the continuing influence of the ‘modernist’ faith in progress informed by 
reason” (Sanderson, 2002, p. 1).  As Cairney describes, the roots of EBPM lies in:  
 
"...the early post-war idea that the policymaking process will be improved when we make it more 
scientific and, therefore, better able to incorporate scientific evidence...This idea has given way 
to a more recent sense that policymaking will always be messy, and that an appeal to the 
primacy of science or ‘the evidence’ can go too far" (Cairney, 2015, p. ix).   
 
Evidence can be used in different ways for political means with no guarantee of neutrality and 
objectivity.  This acknowledgement of the uses of evidence is why some prefer the term 
‘evidence-influenced’ or ‘evidence aware’ policy with the understanding of a hierarchy of 
knowledge being imposed (Nutley et al., in Marston & Watts, 2003).  Alternatively, Gale urges 
us not to think of policy development over time, in terms of progress but rather as ‘temporary 
policy settlements’ acknowledging power flows and intentions (2001, p. 389).   
 
Constructivists would go further than materialist acknowledgement of power flows and interests, 
questioning the existence of an objective scientific knowledge at all and limitations of cultural 
and historical contingencies in drawing policy implications (Sanderson 2002, p.6).  Indeed 
constructivist theory has much to add in a focus on ideas, in exploring policy norms from 
institutions and epistemic communities, as well as the social construction of problems.  
Simmons, Dobbin, and Garrett (2007, p. 451) describe the social construction of policy as 
constructing both legitimate ends and appropriate means that varies, “...from one period to the 
next”.  
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There is also a spectrum of constructivism to note, from ‘hard’ to ‘soft’, making different claims 
and holding varying degrees of skepticism about scientific knowledge and the relation with 
social practices (Robbins, 2012).  Hard constructivists will see social constructs as defining our 
world and science is one social method among many, meaning it cannot adjudicate for all 
claims about what is real in the world.  Soft constructivists tend to believe there is a real and 
independent objective world but our concepts of reality are also real, reflecting, "...incomplete, 
incorrect, biased, and false understandings of an empirical reality" (ibid., p. 128).  
 
It must also be kept in mind that “...interests, like everything else, can be constructed” (Latour, 
2005, p. 145).  Certainly interests can inform our understanding of actions and behaviour in a 
policy context but there is also a critique of the ‘interests approach’.  STS scholars including 
Woolgar, Gilbert, Mulkay and Knorr Cetina see utility in uncovering the social processes for the 
production of knowledge but remind us that to be aware of our own constructions in putting 
forward another representation of the world (Webster, 1991, p. 21-2).  Therefore, when 
considering underlying rationales for apparent interests, our own representation of interests 
must also be considered.   
 
One challenge is that interests of actors and their core identity are assumed to go hand in hand.  
Ikeda recognizes the fusion of actors and core identities in the, “...public interest view of public 
policy, which in effect treats persons who have moved from the private sector to government 
employment as having been thereby transformed from self-interested profit-seeking actors into 
public-spirited and selfless public servants” (2002, p. 6).  Even differing interests may be 
constrained by the possible options: “policy analysts can appear very similar to policy makers 
who seek to construct policy problems in ways that match the answers they already have 
available” (Gale, 2001, p. 384).  Presumed (stereotypical) interests ascribed to actors will be 
important to keep in mind, especially later in this chapter when discussing public health actors.  
Evidence is one aspect of policy that prompts debate.  Another is the need for policy to appear 
in the form of a narrative, which I will be sensitive to throughout the thesis.  I will discuss 
problem narratives in the next section through the example of 'market failure' in relation to 
innovation policy problems, which I also argue is a central narrative story for NTDs.  
 
I have discussed in the previous section how evidence has been an important part of producing 
policy problems and solutions, giving a technical appearance rather than relying on 
argumentation.  Evidence is a route to achieve an appearance of technicality but also important 
is what form of evidence is presented and what story is told.  Policy problems require an 
outwardly objective and justificational identification.  In this sense identifying a problem for 
intervention is often characterized in terms of market failure, where market forces or private 
actors do not provide immediate solutions.  
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Market failure arises from a status quo (or equilibrium) where the market generally provides for 
societal needs and wants, but when this is not met (e.g. when it is difficult to derive profits or no 
one is responsible for delivery) government or other non-market actors must amend market 
conditions or offer provision.  NTDs can be understood a result of a market failure for drug and 
other medical innovations.  A typical argument might be: "...the pharmaceutical industry has little 
incentive to invest in research and development (R&D) for infectious diseases that 
predominantly plague poor nations, as medicines cannot be sold there at a price that would 
allow pharmaceutical firms to cover their high R&D costs" (Mueller-Langer, 2013, p. 185).  WHO 
director Margaret Chan called for a public–private partnership (PPP) approach to tackling NTDs, 
in response to market failure of affordable medicines.37  
 
I question why a market failure explanation is required and what might be missing in this 
characterization of the policy problem.  Grounded in welfare economics, market failure is given 
as a starting point to summarize a policy and determine future action, providing economic 
legitimization.  In critiquing this economic theory, public choice theorists (interested in 
economics applied to politics), challenge the assumption of a perfect government rather than 
focusing on market failure itself (Tullock et al 2002; Ikeda, 2002).   
 
In essence my argument is that market failure provides a policy narrative: a starting point and 
signposting for policy problems but it also directs the potential solution, in providing a narrative 
for the problematization of a policy problem.  Narrative is essential in this analysis and how it is 
delivered through an economicized language.  The imagery is of a well-functioning machine that 
operates well but cannot cater for all social needs in their entirety, with an underlying 
assumption that the market provides more than it can and should.  Regulation and government 
intervention must then step in to remedy a sometimes-malfunctioning market.  Another way of 
challenging a malfunctioning market, or to that point a malfunctioning government is bottom up 
through publics and civil society.  One vehicle is through social movements, discussed next.   
3.2.3 Advocacy through social movements and scientist activism  
NTDs involve an element of social movement, as defined by Hess (in Hackett et al., 2008) in a 
goal of “fundamental social change”.  For example, this sentiment can be seen in the scientists 
at the WHO proclaiming: “it seems to us ethically unacceptable that infected human populations 
are not administered medication that is freely available while livestock and companion animals 
are regularly dewormed every year” (Montresor et al., 2013, p. 1).  Scientists have been 
challenging established organizations from pharma companies, donor countries to the WHO in 
their dealing with NTDs, making moral arguments for increased societal concern. 
 																																																								
37	WHO, http://www.who.int/neglected_diseases/WHA_66_seventh_day_resolution_adopted/en/ 
 2013, Accessed 2/4/16.   
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What have scholars said about advocacy for societal concern for policy problems?  The 
discussion has tended to centre on social movements.  I discuss these next, also pointing out 
the difference between advocacy and activism.  The interest in social change through social 
movements is something that STS has increasingly focused upon.  Moore argues (in Hackett et 
al., 2008, p. 475) that focus has been not only directed at state actors, such as “science, 
medicine, and industries” but at patients and other non-state groups.  These groups include 
‘health social movements’ where ‘the public’ is the driving force (ibid.).  Klawiter gives the 
example of the change in scale and scope of health activism: “the rapid growth in the number, 
size and funding of women’s cancer and breast cancer organisations; the development of new 
discourses, cognitive frameworks and other forms of cultural production; the proliferation of new 
projects, campaigns and coalitions” (2004, p. 847).  A reason given for such a change in focus 
is argued to be neoliberal policies undercutting the "social understanding by which citizens 
support the state in return for services and protections such as security and health” (ibid.).  
Hess similarly describes ‘alternative industrial movements’ which operate through 
institutionalized channels rather than disruptive tactics, including “advocates, entrepreneurs, 
scientists, and countervailing industries” in calling for a shift in corporate product standards or 
support for new technologies and products. (Hess, 2015, p. 73). 
 
David Hess also sees scientists as key figures in supporting social movements: “When 
scientists step out of their role as researchers to defend the need for policy reform that is 
contrary to the official articulations of public interest by elites, they form a scientific 
counterpublic, often in alliance with social movements and other civil society organizations”.38  
Scientists can be advocates for policy reform, acting beyond their academic work, in 
establishing projects and organizations, working for NGOs and public institutes.  Frickel, 
Torcasso, and Anderson have incorporated the role of (scientific and technical) expertise in 
social movements, as they say, "...social movements now regularly deploy as well as challenge 
expert knowledge claims" (2015, p. 5). 
 
When it comes to NTDs it is worth pointing out early on that scientists do not act predominantly 
in alliance with social movements and other civil society organizations as Hess often observes.  
Related developments have been the ‘political opportunity structure’ literature developed by 
sociologists to look at the conditions where social movements influence policy structures, as 
well as the ‘advocacy coalition framework’ in public policy to look at the influence of competing 
interest groups on policy outcomes (Sell & Prakash, 2004, p. 146).  Similarly, Frickel and Gross 
argue scientific and intellectual movements or ‘SIMs’ as “collective efforts to pursue research 
programs or projects for thought in the face of resistance from others in the scientific or 
intellectual community” (Frickel & Gross, 2005, p. 206).   
 
																																																								
38 Hess, http://www.davidjhess.org/movements-and-publics.html, Accessed 1/12/15.   
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Patient action is a gaping hole in any reference to NTD policy discussions.  NTD patients have 
been characterized as having a minimal political voice, as in this WHO description: “Neglected 
tropical diseases such as leprosy, lymphatic filariasis and leishmaniasis are feared and the 
source of strong social stigma and prejudice.  As a result, these diseases are often hidden – out 
of sight, poorly documented and silent” (WHO, 2006, p. 3).  Still, there may very well be other 
reasons for a lack of voice for patients such as priority for financial concerns or upholding 
traditional ways of life.   
 
Critical global health researchers have focused on health actors who have gained a more 
prominent role on the global stage, such as patients themselves.  In fact much of the global 
health literature I draw upon in this thesis is 'critical global health'.  It is a research area 
engaging with the emergence of health actors and their governance activities, largely using 
post-structural thinking (Biehl & Petryna, 2013; McInnes et al., 2012).  Study of global health 
from a critical perspective encompasses a number of methodological approaches, such as the 
post-colonial analysis employed by Warwick Anderson (2014) or sociological view of 
philanthropy for health by Lindsey McGoey (McGoey, n.d.).  A growing number of scholars, 
including Adams (2016a), Biehl (2016), and Reubi (2016) advocate an ethnographical approach 
and I draw upon these scholars, particularly Adams through her work on metrics in Chapter 7 in 
the thesis.  
 
Critical global health theorist João Biehl notes the, “...collision between local values and 
international public health agendas” revealed by ‘peopling’ global health by bringing out people’s 
stories of how they experience current practices (Biehl & Petryna, 2014, p. 381).  People may 
hold insights and knowledge about these diseases and the policies employed to tackle them, 
with a potential for use on a policy level, for which anthropologists and others have tried to un-
tap.  On a wider health level, Petryna and Biehl identify how:  
 
“In key developing democracies — such as Brazil, India, and South Africa — we see activists 
and patients engaged in struggles over access to high-quality care and, at a more fundamental 
level, debating the meaning, object and implications of health conceived as a right rather than a 
privilege or commodity” (Biehl & Petryna, 2014, p. 398). 
 
Other actors that may have been under-researched are scientists taking on an activist role.  
This role compares with publics becoming expert-activists or experts collaborating with certain 
publics.  For example, Epstein (1995) in his seminal work on HIV/AIDS activism, coined the 
terms ‘treatment activism’ and ‘lay experts’ to convey the concern of activists in pursuing 
medical advancement in the treatment of their disease and ability to be credible interlocutors 
with experts.  Also Novas (2009) highlighted the partnership between Sharon Dobkin a patient, 
and, Dr Melvin Van Woert an academic scientist who together lobbied Congress sponsor to 
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develop a therapy for the rare condition myoclonus.  Novas emphasized the symbiosis of patient 
groups and academic scientists for rare disease advocacy: 
 
“The claims of academic scientists played an important role in supporting the struggles of 
patients’ organizations. They helped to define the contours of the problem, illustrate the 
difficulties they encountered in attempting to develop promising treatments for rare conditions, 
and often gave moving accounts of the suffering they witnessed in their clinical practices.” 
(Novas, 2009, p. 16). 
 
it has been contemporary expectations that policy 'concerns' must be elaborated by patient 
groups.  Activist scientists, working without patient groups I argue, have been central for NTD 
policy change.  By describing scientists as activists, I am emphasizing an active campaigning 
for policy change, just as activists driving a social movement would be doing.  It is a stronger 
form of advocacy, denoting action in support of a cause.  There is some historical precedence 
for activist scientists, as Donohoe notes (2012) in 'many noteworthy examples' of physicians. In 
fact activist scientists are not wholy novel but closely reflect an earlier paternalistic era of expert-
led activism for policy change. Another critical global health scholar Vincanne Adams has 
identified an eminent physician in the 19th century, pathologist Rudolph Virchow, as one figure 
who made valuable contributions to social medicine, arguing that "...many diseases result from 
the unequal distribution of civilization's advantages" (Adams, 2012, p. 339).  He believed 
physicians to be "...natural advocates of the poor, 'if medicine is really to accomplish its great 
task it must intervene in political and social life'..." (Virchow quoted in Adams, 2012, p. 339). 
 
Virchow was an advocate through his socially minded philosophical views and voicing his 
opinion as a legislator against child labour, and for public medical care, universal education, and 
democracy (ibid.).  Where he goes beyond advocate to become an activist is in taking action 
and having impact, by founding the journal 'Medical Reform' and improving a number of areas 
related to public health from water and sewage systems, food inspection, to the education and 
training of health professions (ibid.).  This move is what made him an archetype of the politically 
engaged medical scientist.  For Adams it is ironic that this leading scientist was deemed a 
radical in his commitment to the idea that (medical) science was also political, and view that 
only under certain political circumstances could scientific truth be made apparent (1998, p. 160). 
 
Donohoe (2012) writes that to be a politically active physician may be more difficult today.  
While it is unclear what golden era he is referring to when physicians could be politically active, 
he is specifically talking about the American context.  He has argued that in the US there are 
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lower adjusted voting rates than the general population and limited issues when lobbying 
Congress39 with a low number of physician-legislators (ibid.).  
 
In the history of tropical medicine, it has also been a precarious position to be a policy-engaged 
scientist.  Worboys notes that Sir Patrick Manson, often called the 'father of tropical medicine' 
through his public reputation was appointed physician and medical advisor to the Colonial Office 
in 1897 (in Lemaine et al., 1976, p. 85).  He acted in the capacity of a 'firm's doctor' in an 
'influential policy-advisory role' with direct access to the Secretary of State (ibid.).  However, this 
position was officially mandated and compared starkly with his contemporary Ronald Ross.  As 
a working scientist, Ross tried to suggest to the Colonial Office a new scheme of sanitary 
commissioners, to which he was firmly rebuked.  Lemaine et al. saw the message as being: 
"...scientists should confine themselves to research and not become involved in practical policy" 
(ibid., p. 92).  It appeared that scientists could be instrumental in policy but there was a small 
scope in how to do so, only if formally designated, with limited room at the top.  Jasanoff 
describes how the separation is part of a ‘Jeffersonian ideal of democracy’ to keep political 
authority away from experts, in reflection of the “…popular conviction that decisions cannot be 
wholly legitimate if they are comprehensible only to the initiated” (Jasanoff, 1990, p. 11).      
 
In more extreme circumstances it is evident that science and politics cannot be easily 
separated.  The politicization of medicine has often arisen when politics is closely embroiled in 
both problem and solution explanations for ill health.  The book 'Doctors for Democracy' about 
the 1990 Nepali revolution instigated by a group of medical professionals illustrates this point 
well: "Observing that social inequality and poverty were the root causes of ill health among the 
masses, some doctors reasoned that the most direct medical interventions they could promote 
were those of political and social reform" (Adams, 1998, pp. 4–5).   
 
Rationalization of the role of politics in science reflects a conundrum about objective truth, if 
scientific fact is to be independent of social and political constitution.  A view is that politics may 
compromise objectivity, which should be apolitical but as the case of the Nepalese doctors 
showed: "Politics, in their view, could be used to reveal and attend to objective truths and 
therefore could enhance medical practice without compromising scientific objectivity.  This 
objectivity was born from the perceived efficacy of technical interventions provided by a 
scientific approach to social problems”  (Adams, 1998, pp. 4–5).  Adams argues that medicine is 
different as a socially engaged humanistic science opposed to pure science.  For her, the 
politicization of medicine through politically active medical professionals merges two insights: 
"(1) that medicine must become political to eradicate the cause of ill health and (2) that 
medically scientific truths are usually formulated in contested political contexts" (ibid., p. 172).  																																																								
39 The issues US doctors pursued when lobbying government were reimbursement and funding for 
research rather than social justice issues such as, "...access to care for the uninsured, tobacco control, 
women's rights, violence prevention..." (ibid.). 
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Chapter 6 will detail how scientists have become activists in a policy movement for NTDs and 
their rationalizations in the face of concerns for scientific objectivity. 
 
This chapter has explored problematization in policy, beginning with problem types and where 
neglected problems fit.  I then looked at the use of evidence in policy through the rationales for 
EBPM and how these are often described through narratives, such as market failure to justify 
policy action.  Finally I addressed the role of advocacy in policy through social movements 
behind problem generation and activist scientists challenging the politics-science distinction.  
The literature and themes I have considered have been centred on how policy problems are 
constituted.  Next I turn to innovation as presented as a solution to policy problems to explore 
the underlining theoretical frameworks employed to understand how NTDs are addressed. 
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3.3 Innovation conceptualization for solutions 
3.3.1 Explaining innovation solutions through models and tools 
 
Science has long been presented as a solution to societal problems.  The twentieth century saw 
'big science' have a transformative effect on society through a 'leap in scale and organization', 
with physics and chemistry becoming directly useful and science becoming a goal-directed 
economic endeavour (Riecken, 1969).  Some, such as Riecken, have argued that science has 
more implications for 'action' than social sciences, which can be a "...curious kind of 
'understanding'..." (ibid.).  Turnbull (2008, pp. 82-4) has argued this basis comes from an 
enlightenment view of social science identifying problems rather than solving them and where 
science is the most 'sophisticated expression' of problem-solving rationality.  Others, for 
example Fujimura (1987), talk about how science can produce 'doable problems' in the 
alignment of 'experiment, laboratory, and social world'.  
 
Innovation poses a new relationship with policy problems.  In a conventional and widespread 
definition of "...bringing a new product into the market or into practical use" (Schroeder, 2007, p. 
37) there is an emphasis on economic significance and promotion of economic growth.  
Therefore, innovation connects science and technology to the wellbeing of the economy, to 
create a concept that is viewed as intrinsically positive and desirable.  Today the link between 
science, technology and the economy is argued to be the 'raison d’etre' for science policy and 
later innovation policy (Webster, 1991, p. 35).   
 
However, innovation as a buzzword is still a contested term in that it is often used ambiguously, 
with different parties bringing their own meanings to the table.   What I would like to draw 
attention to are the economic meanings as opposed to socio-political meanings.  Economists 
tend to refer to 'technological' innovation in the commercialization of ideas, as described above, 
particularly technological advancement rather than innovation in ideas, things, and behaviours 
(Godin, 2010).  This is the concept of new products, processes, and services entering the 
market mechanism.   
 
Innovation applied as a solution to policy problems carries an air of neutrality most often 
referring to technological innovation but the social and political cannot be demarcated explicitly, 
so it must be asked who innovation is for in society and why?  This question is relevant for 
global health now more than ever.  Innovation is presented as a solution to many of the 
challenges we face on big global topics such as health, the environment, poverty, and 
wellbeing.  Joly et al. (2010, p. 5) describe how innovation is presented as a solution in itself, a 
way to “solve human problems” in areas spanning health to sustainability.  When looking at 
policy problems it is common for innovation to be involved (such as OECD, (2011) ‘Fostering 
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Innovation to Address Social Challenges’).  In contrast, a lack of innovation is characterized as 
a problem, which presents innovation as one-dimensional in character – more innovation being 
good and less innovation being bad.  Accordingly a lack of innovation is presented as part of 
that problem and it is easy conceptual slippage for the amount of innovation itself to be 
characterized as a problem.  
 
The main measure of whether there is more or less innovation is through the level of R&D, as a 
discrete element of innovation whose relationship to economic growth is complex, involving 
continuous feedback (Webster, 1991, p. 100).  Governments set targets and offer incentives for 
R&D as an activity encouraged for innovation, with the view that the market typically under-
invests.  However measuring the impact of policies related to science, technology and 
innovation has faced difficulties.  The statistical relationship between economic growth and R&D 
investment has not proved very forthcoming (ibid.).    
 
R&D investment forms part of a linear model of innovation.  As Mata and Louçã (2009) explore, 
there has been a need to formalize innovation studies through theory development, where a 
model-building approach was championed.  Godin points out: “One of the first (theoretical) 
frameworks developed for historically understanding the relation of science and technology to 
the economy has been the ‘linear model of innovation’...” (2006, p. 639).  The model generally 
describes the process of technological change sequentially from an idea (drawing from the 
science base through basic research then applied research), that moves to development, 
production and finally diffusion within markets and wider society.40  As a model it outlines a 
linear progression of discrete stages, shown in the Figure 2 below.   
BASIC RESEARCH
(E.G. SOFTWARE 
ALGORITHMS)
APPLIED RESEARCH
(E.G. APPLICATION 
OF ALGORITHMS IN 
PRODUCTS)
DEVELOPMENT
(E.G. PRODUCT 
DEVELOPMENT)
MARKET LAUNCH
(E.G. MARKET 
STUDY AND 
PRODUCT 
LAUNCH)
PRODUCTION
(E.G. MASS 
PRODUCTION OF 
PRODUCTS)
 
Figure 2 'The linear model of innovation'  
(Bhirud, Rodrigues, & Desai, 2005) 
The model is linear because it is based on an input-output framework that progresses from one 
stage to another through a series of steps.  For NTDs the assumption is that an input change 
will result in outputs that mean these diseases are better dealt with.  Godin argues that the 
linear model never existed in the form and usage depicted by later theorists arguing for an 
abandonment of the model in favour of a new version.  Others including David Edgerton 
																																																								
40 Godin notes two further generations of the linear model – a statistical correlation between research and 
economic growth, productivity, industrial competitiveness, and 'National Innovation Systems' (NIS).  
Adoption of the linear model fed into a larger policy project justifying government support of science and 
innovation, as well as the role of “industrialists, consultants and business schools, seconded by 
economists” in a theoretical construction of innovation (Godin, 2006, p. 640-1).   
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(Edgerton, 2004) had made this claim before but Godin and Lane (2013) make a more nuanced 
argument, pointing out that Edgerton concentrates on the originators of the demand-pull model.   
 
The demand-pull model was an early alternative to the linear model, providing a supply-side 
view of innovation.41   The supply-side view posits that investment in R&D and scientific 
discovery leads to innovation, while the demand side comes from the opposite direction in that 
consumers drive innovation through market demand.  With the linear model of innovation, R&D 
is a means to an end for innovation and economic growth is the dominant and established view. 
The linear model of innovation is widely adopted, in making this relationship between R&D, 
innovation and economic growth (despite critique of the model as not reflecting complexity and 
collaborative or open ways of doing innovation).  We will see what the effect of an emphasis on 
R&D has for NTDs in later chapters.    
3.3.2 Health for development  
A similar reversal in the demand-pull to supply-push example of linearity can be found in the 
relationship between health, innovation, and development.  The idea of 'development for health' 
has been long established.  A first point is that poverty and low socio-economic status causes ill 
health, shown by the political economy of health (Doyal & Pennell, 1979) and social 
determinants of health (SDH) literatures (Marmot, 2007).  A second point, applied to a country 
level is that the economy needs to develop first for health outcomes to improve.  This argument 
comes from a technocratic interpretation of ‘stages of development’ where economic 
development is sought first with societal improvement expected to follow.  Countries want to 
move up the escalator of progress through 'Rostow's stages theory' of economic growth "...from 
a pre-industrial state to full economic maturity" (see Rostow, 1971).  This 'stages theory' was 
prevalent in the early postwar period, where to miss a stage could be a disaster:  
 
"Essentially, the theory says that development proceeds through a linear succession of stages 
copied from the historical experience of existing industrial countries.  This was a historicism in 
drawing theory from past experiences or examples but also wanted to do away with connections 
to the past that do not match a pursuit of modernity… the goal was predetermined – it was to be 
just like contemporary America" (Biel, 2000, p. 74). 
 
The idea would later be reversed, such that health could precede and contribute to 
development.  As Morel describes: “Health, science and technology are increasingly being 
recognized as prerequisites for economic and social development, and not merely as their 
consequences” (2003, p. S35).  Linearity is reversed from 'development to health' to 'health for 
development' (see Figure 3 below).  I argue that this change had important implications for 
global health policy.  Instead of identifying poor health being caused by underdevelopment, 																																																								
41 Keynesian economics, widely accepted post-war up until the 1970s and encouraged the consideration 
of demand-side factors.    
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improved health could be a reason leading to economic development.  Here I am using the term 
economic development as a marker of a country's progress, as is understood through common 
metrics to measure improvements in a country (e.g. GDP, literacy, life expectancy, poverty 
rates).  Policies addressing health could move away from a systemic emphasis to economic 
development (on policies and investment in health systems and infrastructure) to vertical 
programs addressing individual health issues.  
 
Development for Health: 
ECONOMIC
DEVELOPMENT
RISE IN LIVING 
STANDARDS
IMPROVED 
HEALTH 
OUTCOMES
 
Health for Development:  
ECONOMIC 
DEVELOPMENT
MORE PRODUCTIVE 
WORKFORCE
IMPROVED 
HEALTH 
OUTCOMES
 
Figure 3 Reverse linearity of development for health 
 
The switch in emphasis to 'health for development' can be seen the policy arguments for NTDs 
as diseases said to be both a cause and a result of poverty and underdevelopment, in a self-
reinforcing cycle, with health accepted as a precursor.  As a result, demonstrating impact upon 
economic development reinforces the rationale for intervention in NTDs, as an expected 
consequence of health improvement.   
 
China was 'proof' as seen through the so-called 'barefoot doctors' that it was economically 
advantageous to invest in health (Zhang et al., 2008).  China's community health workers or 
'barefoot doctors' had elementary training in diagnostics, immunization, education, simple 
treatment, and liaison with the qualified medical sector.  They were a cheap resource to improve 
health and more generally a health intervention being used to promote economic development.  
However, they are also an example of a politically driven health intervention.   
 
Adams (1998), explores the linking of politics and medicine.  She gives the example of the 
barefoot-doctor program to reflect "...the call for political solutions to basic health problems" (pp. 
166–7).  The program was seen by many as a successful intervention, driven by supportive 
political ideals of the Cultural Revolution, which began in 1966.  The Cultural Revolution had 
meant that, “…high-technology orientations became an object of scorn, and so the basic 
essentials of scientific medical intervention were recast in a framework that made national 
medical traditions appropriate for health care in the Chinese countryside" (ibid., p. 167).  'Expert' 
knowledge was seen to be opposed to 'Red' knowledge and downgraded, with also the 
discrediting to an extent of stages of development from which 'development for health' was 
grounded in.  A move towards the 'health for development' model allows for NTDs to be more 
appealing as a concern and has shaped the means of dealing with these diseases.  Similarly to 
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the example of 'barefoot doctors' the shift to 'health for development' is grounded in a view of 
what expertise can provide legitimate evidence.  Therefore, the type of expert knowledge being 
relied upon becomes central to determining how policy problems and solutions are viewed.  I 
take this consideration of expertise further in the next section, which deals with the various 
disciplinary lens that have been applied to NTDs.  
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3.4 Disciplinary lens: Economicization, historicism, and 
interdisciplinarity  
3.4.1 Economicization (or reverse politicization) 
This thesis has at its core policy problems and their solutions.  In the first section I have 
discussed the literature relating to problematization of policy problems through the use of 
narrative, paying attention to how problems are addressed through the use of measurement and 
advocacy (with reference to EBPM and social movements).  In the previous section I engaged 
with solutions proposed to policy problems through innovation conceptualization as a dominant 
theme and also the role of models. 
 
In this section I develop further the idea of how disciplines guide policy problem-solving.  I 
explore the expertise of economics, history and an interdisciplinary lens, which will include 
anthropology and epidemiology.  What one discipline offers to policy over others depends on a 
number of factors.  I have already made the point that economic thinking is prevalent throughout 
approaches to policy problems and in policymaking, but why is economics especially useful to 
policymakers?  As discussed previously, economic impact is desirable and a marker of 
progress, with economics being the discipline that is able to foresee and influence such 
outcomes.  According to McCloskey in subscribing to a modernist methodology the chief goal of 
economics is prediction and control: "The common claim that prediction is the defining feature of 
a real science, and that economics possesses the feature..." (1998, p. 487).  Other disciplinary 
approaches may be downplayed and economics is sometimes accused of ignoring other 
political and social considerations.   
 
Majone (1989) also posits that the very methodology of policymaking – 'decisionism' – favours 
economics as a generalized logic of choice, where political actors make rational choices from 
available alternatives, which are the best means to achieve objectives.  Here, microeconomics 
and decision theory as sub-disciplines of economics have been influential, with policy analysts 
seeking to extend the principles of rational choice from private economic transactions to public 
policymaking.  This policy approach based on rational decision-makers may now be outmoded 
but its legacy can be found in 'Nudge theory' (Thaler & Sunstein, 2008).  Nudge theory is a 
product of the introduction of psychology to economics42 and brings behavioural economics into 
policymaking, assuming irrational rather than rational actors. 43   Economic ideas and the 
language of economics have also gained further ground through a defining role in innovation 
																																																								
42 Psychologists Amos Tversky and Daniel Kahneman are largely responsible for introducing psychology 
into economics. 43 While embracing irrationality, Nudge attempts to intervene pushing toward more group rationally 
beneficial decisions resolving for example public goods problems. 
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policy.  As already discussed, the 'linear model of innovation' and 'market failure' are prevalent 
ideas within innovation policy narratives.  
 
Economic rationale and justification in policy and intervention can be questioned.  Economic 
approaches and ideas prevailing within policy may be best described as 'economicization' (or 
economization).  Muniesa and Linhardt define economicization as, "...an aspect of practices, 
procedures and activities in which the calculability of things is put forward and in which, 
accordingly, action is subjected to optimality and hence made prone to economic assessment" 
(2009, p. 12).  The objection to economicization is in the depoliticization of action, which 
contradicts the nature of what the state does and is, in being essentially political (Muniesa, 
2014, p. 114).   
 
Muniesa and Linhardt explain the two movements of 'politicization' and 'economization', with 
politicization of the state being "...an emphasis on political will in the conduct of government and 
in the orientation of civil services and public administrations, but also to procedures or practices 
aiming at democratizing decisions or at taking into account states of dissent..." (2009, p. 12).  
Callon, similarly notes the difference of an economic rather than political outlook to state 
behaviours (2010).  Economicization is an approach I will be aware of throughout this thesis as 
a treatment of NTDs as a policy problem, later explored as a 'policy packaging' where 
depoliticization is highlighted.   
3.4.2 Historicism and historiography 
Another disciplinary approach that I address is history, drawing on the history of tropical 
medicine and also providing a recent policy history of NTDs in this thesis.  I next consider the 
use of historicism and historiography to understand and present policy problems.  A 
definitionally vague and broad term, Karl Popper defined historicism as predicting the future 
course of history and thought it to be a poor method.  He refuted historicism not only in the 
ability to bear fruits ('The poverty of historicism', 1957) but eventually to be logically impossible 
('The logic of scientific discovery', 1959).  Popper relied on an innovation or scientific progress 
thesis, which he described as the growth of knowledge, including scientific ideas.  The growth of 
knowledge produces uncertainty in the future such that it is impossible to be predictive based on 
the past.  Historicism has still been a popular current in policy theories and prescriptions, 
present for example in the stages of economic growth theory.   
 
However, as Reynolds discusses (2008) the alternative meaning of historicism is more than 
being a predicting tool of Popper.  A common usage of the term is a 'mundane historicism', 
which has its root in opposition to the enlightenment ideal of an ahistorical and universal 
rationality (ibid.).  Therefore: (1) ‘mundane historicism’ is to understand things in their historical 
context; (2) ‘methodological historicism’ the method for understanding history distinct from those 
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of the natural sciences that is closer to histiography; (3) ‘Popperian historicism’ – which I have 
discussed – is having predictive power in finding laws, rhythms and patterns in history (ibid.). 
 
The use of history, both the mundane and methodological sense, in order to inform policy-
making and to better understand public policy has had some resurgence in recent years (see 
Berridge, 2008; Guldi & Armitage, 2014; Rennie, 1998).  This may be a lighter version of 
historicism in using historical fact to 'confirm' theory, interpretation and even prediction.  Haddon 
et al., who ran a focus group with policy makers about the value of history, found that: "History 
was talked about as a source of invaluable knowledge about a policy area; in providing 
instructive parallels; or as a means to challenge existing paradigms and identify major paradigm 
shifts" (2015, p. 2).  What surprised me was the unacknowledged historical basis to innovation 
theory and adapted for innovation policy, particularly from management science.  Historicism in 
the non-Popperian, mundane sense provides the content to these theories of knowledge.  Thus, 
for NTDs, historicism has been a defining feature through the theories of science, innovation, 
and economic development applied to disease.  
 
Historiography is perhaps more straightforward to define.  It is the methodology that historians 
employ for their discipline, which can be taken as a study of the history of historical writing, in 
how individual historians have interpreted events and also by extension the historical work on a 
specific topic (such as tropical diseases).  The historiography of tropical diseases and tropical 
medicine has been an ongoing project, ordered through national perspectives and also 
transnational networks of colony or empire, by national institutions and scientists.   
 
One aspect of this historiography then has been the focus on the "...conventional portrayal of 
tropical medicine" as being "...imbedded in the imperial enterprise of their respective countries", 
while the colonized context adds "neocolonial, developmentalist, nationalist, and patriotic 
features to tropical medicine" (Coutinho in Armus, 2003, p. 90).  Coutinho argues that an 
endemic disease was only a problem to the colonizer when the colony was theirs.  Once 
independence is gained, the disease will become part of the newly independent country's 
search for national identity.   
 
Elements of more established tropical disease and the beginning of an NTD historiography can 
be found across chapters.  Chapter 4 will concentrate on the historical events that led to the 
creation of NTDs.  Chapter 5 goes further back in time to how the tropical disease category was 
formed.  In Chapter 6 I explore historical initiatives, particularly 'The Great Neglected Diseases 
of Mankind' program (1977–2000) and how their legacy would be instrumental in the creation of 
NTDs.   Therefore, a consideration of historicism informing policy runs throughout this thesis, 
although it is the historiography of tropical medicine and tropical diseases that forms a basis for 
charting the policy development of NTDs. 
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3.4.3 Interdisciplinarity in policy problems 
Historians and economists, to whom I will add epidemiologists and anthropologists, all have 
growing positions within global health policy.  Researchers from these disciplines, particularly 
epidemiology and anthropology, often enter public health research projects as part of 
interdisciplinary teams.  They have provided at times critical voices to the rationales and 
methods of NTDs activity.  As this thesis is looking at asking the question of how policy 
problems are constituted in relation to NTDs, involving different disciplinary approaches, it is 
also important to unpack the concept of interdisciplinarity.   This background to disciplinary 
approaches will be particularly pertinent for Chapter 7 when I discuss NTD discourses.  The 
different technical choices sometimes constitute a cultural divide but also offer varied insights.   
 
Interdisciplinary work between social and natural science is happening through the integration of 
societal issues and concerns into scientific practice. Doubleday and Viseu (2010) have 
questioned how, to date, there had not been a significant discussion on the inclusion of social 
science by bringing in societal considerations (and how this has worked in practice).   They are 
wary that, "...policy documents suggest this integration is a relatively straightforward process" 
(ibid., p. 55).  One solution offered has been to standardize and manage interdisciplinary work 
through the practice of 'embedded research'.  This practice typically refers to a close working 
relationship with research subjects, including a sometimes contributory or collaboratory role to 
their research (or an attempt to somehow change, inform or add to existing practices that are 
related).  Embedded research is not a neutral position, with the implications discussed in the 
remainder of this section.   
 
Parker, Polman, and Allen (2016, p. S6) discuss how in the context of NTDs scholars of 
different disciplines have worked collaboratively.  Most commonly if they were more senior they 
would work on 'parallel tramlines' separately on their own research or as ‘handmaidens of 
biomedicine’ if more junior in schools of public health:  
 
"In the world of NTDs, and global health more generally, it would be fair to say that it is rare 
indeed for an epidemiologist, parasitologist or public health specialist to work on an equal 
footing with an anthropologist, historian or political scientist" (Parker, Polman, & Allen, 2016, p. 
S6). 
 
They describe the ‘qualitative’ social research that is undertaken as elaborating on a, 
"...‘factorial model of disease’ with complex social and cultural processes being conceptualized 
as discrete, measurable ‘factors’, acting as ‘barriers’ to the effective implementation of global 
health interventions" (ibid.). 
 
This is a relatively critical perspective taken by Melissa Parker and Tim Allen who are 
anthropologists (Polman is an epidemiologist).  Anthropologists have been sought after in public 
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health and biomedical research to unlock cultural secrets in being able to understand and 
gather insight from local communities (Krumeich, et al., 2001).  In turn they have also found in 
health a rich topic of research, hence the emergence of the 'medical anthropologist' in the 1960s 
(Basehart, 1964).  Writer Robert Desowitz noticed this changing positioning of anthropologists:  
 
"The generic anthropologist began to disappear in the 1950s and 1960s. The biomedical 
researchers–geneticists, epidemiologists, and microbiologists–discovered the anthropologist's 
utility in gaining entry into tribal groups as well as their providing a ready-made source of 
important demographic data. In turn, the anthropologists discovered biology and their calling 
evolved into specialities" (2004, p. 178).   
 
For anthropological research on NTDs the focus is on aetiology, signs or symptoms and 
treatments of individual diseases.44  Anthropologists Parker and Allen are among the few who 
have looked at NTDs as a group.  Although they do so narrowly by country and are interested in 
the control method for five of the NTDs called 'mass drug administration' (MDA), which Allen 
describes as, "...the largest global health programme that the world has ever seen" (Allen, 
2016).   
 
They are interested in advocacy for NTDs and have been critical of some aspects, including 
what they see as an over-promise in the global drive for NTDs, through 'grand claims' and 
aspirations to achieve the 'Millennium Development Goals' (MDGs) and 'making poverty history'.  
In their view NTD aspirations have generated 'unprecedented attention' to NTDs (Parker & 
Allen, 2011, p. 2).  Through a community study in Uganda they ask the question: 'Does mass 
drug administration for the integrated treatment of neglected tropical diseases really work?' 
(2011).  Again the question of politicization returns as a concern:  
 
"Large amounts of funding are being allocated to the control of neglected tropical diseases. 
Strategies primarily rely on the mass distribution of drugs to adults and children living in 
endemic areas. The approach is presented as morally appropriate, technically effective, and 
context-free." (2013, p. 224).   
 
As Adams describes, postmodern critical theory politicizes social problems, “...by situating them 
in historical and cultural contexts, to implicate themselves in the process of collecting and 
analyzing data, and to relativize their findings” (Lindlof & Taylor, 2011, p. 52).  The charge of 
Parker and Allen is that, "...normative ideas about global health programs are used to set aside 
social and biological evidence" (ibid.).  As anthropologists it is the 'local details' that are set 
aside but also the country context: 																																																								
44 Anthropologists have uncovered reasons for low take up of drugs because of the experience of 
schistosomiasis differing for children and adults (Hewlett & Cline, 1997).  Many may be asymptomatic but 
blood in the urine making 'red urine' only tends to be a sign of infection in children so there is a perception 
that adults do not suffer from the same infection.  Adults then are more reluctant to take drugs. 
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"... resistance to the take-up of free drugs was linked by many of those with whom we lived to a 
sense of marginalization, and sometimes outright oppression by the Ugandan government... 
while some people benefitted from the treatment program, it was unrealistic to assume that it 
would lift such impoverished and politically excluded populations out of poverty. It is mostly 
neglected people who are infected with neglected diseases—and this fact could not just be 
wished away" (ibid., p. 224).   
 
In '(D)e-politicizing parasites: reflections on attempts to control the control of neglected tropical 
diseases', Parker and Allen use as a starting point Ferguson's 'anti-politics' thesis (1994), which 
draws on Foucault in considering hegemonic discourses (ibid.).  The original critique by 
Ferguson related to the aid and development industry, arguing that social realties were 
depoliticized as a way of control.  He argued that technical solutions are implemented context-
free using international expertise.  Parker and Allen view his account as ignoring the 
complexities of the development industry and find it more interesting how rhetoric was believed, 
such that discourse was used as an instrumental tool for vested interests. 
 
Parker and Allen similarly employ a depoliticization argument for their own research.  In this 
case it is directed at the scientists, policymakers and development workers implementing NTD 
policies.  They challenge how the optimism for MDA in controlling NTDs, driven by these actors, 
ignored a more politicized view of how populations would accept this intervention and whether it 
was dealing with the root problem.  What does not come across so clearly was that Parker and 
Allen were invited by one of the actors they are indirectly critical of – Alan Fenwick – who runs 
the Schistosomiasis Control Initiative (SCI), who enabled them to be embedded in the project to 
implement MDA in Uganda (Reisz, 2013).  As described in a Times newspaper article in 2013: 
"Their work had been 'carried out in close collaboration with [those responsible for the control of 
the worms, insects or snails that transmit diseases], and with relevant district authorities" (ibid.).   
 
My contention is that opposition between disciplines was played upon in this instance, through 
the contradiction between an anthropological outlook, as opposed to the advocacy work of 
scientists and other global health actors, to strengthen the claims of Parker and Allen.  They 
have demonstrated how another disciplinary approach provides a new angle to the NTD policy 
problem and solution.  Less contentious interdisciplinary working can be said to be the 
emergence of interdisciplinary fields, where the convergence of academic fields is a process of 
compromise.  A 1963 article by economist Kenneth Arrow is often cited as the beginning of 
health economics as a sub-discipline, by considering a market for health care (Cardoso, 2008).   
 
The Arrow article was followed by an influential publication in 1972 of Michael Grossman's 
model of health production where he considered how to account for demand in health (ibid.).  
Since then economists have gained a greater role in public health through the emergence of the 
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‘health economist’45 which has led to the wide adoption of concepts and tools, one example 
being the ‘Global Burden of Disease’ work and development of the 'disability-adjusted life year' 
(DALY) measure pioneered by the physician and health economist Chris Murray along with 
epidemiologist Alan Lopez.  This work by economists is described as a “…systematic effort to 
quantify the comparative magnitude of health loss due to diseases, injuries, and risk factors by 
age, sex, and geography over time” (IHME, http://healthdata.org,, Accessed 2/4/14).  I will 
discuss this work in detail in Chapter 7 as well as what could be termed a disciplinary clash with 
the so-called ‘worm wars’, centred on methodological terms between economists and 
epidemiologists.  Indeed, while health economists and epidemiologists often research the same 
topics, using different disciplinary approaches, this instance may be viewed as social scientists 
(economists) entering the natural science world (epidemiologists).  However, the convergence 
to the interdisciplinary means also natural scientists entering social science, albeit limited 
through involvement in policy.   
 
For epidemiologists the encouragement today is to have policy impact through ‘translational 
epidemiology’ (Feldscher, 2013; Khoury, Gwinn, & Ioannidis, 2010).  Translational epidemiology 
harks back to the beginnings of public health interventions, which also coincided with the 
emergence of epidemiology as a "...respected subject in medicine rather than simply a fringe 
discipline" (Holland, Olsen, & Florey, 2007, p. 3).46  I aim to draw upon mixture of disciplinary 
approaches throughout this thesis, with a view to what disciplinary approaches applied to NTDs 
as a policy problem and potential solutions.  Next I focus on the particular policy landscape for 
NTDs of global health.  
																																																								
45 For a sociological review of the health economist see (Ashmore, Mulkay, & Pinch, 1989). 
46 An early translational epidemiology example was English doctor John Snow locating the source of 
cholera during an epidemic to a water pump.  Following this were “…a number of other public health 
policies influenced by epidemiologic findings, including cigarette advertising bans, food labelling 
requirements, and air pollution standards” (Feldscher, 2013). 
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3.5 Global health actors and landscape 
In order to understand NTDs as a policy problem invokes a discussion of how 'global health' 
contributes to the constitution of policy problems.  As a starting point it is important to recognize 
that global health is a new phenomenon.  The idea of global health policies did not come into 
being until the 1950s after institutions with a global remit such as the WHO were established 
(Brown, et al., 2006; Ng & Ruger, 2011; Ruger, 2005).   
 
Tropical diseases and now 'neglected' tropical diseases straddle these two eras of public health.  
This period spans from the health exploits of empire and colonialization.  The first directions of 
efforts were for the benefit of the colonizers, with the colonized as second priority (Trouiller et 
al., 2002) and the problems of disease were sometimes worsened by colonizers (Farley, 2003, 
p. 2).47  Post-empire priorities were similarly skewed.  In the dying days of empire, the 'triumph' 
of tropical medicine was the "...last justification for imperialism" (ibid.).  Then after the colonies 
gained independence the ‘health of the natives’ was used as justification for ongoing colonial 
presence, with the continuation of the US military in the Philippines and Puerto Rico (Biss, 
2014). 
 
The change to 'global health' means that theoretically the health of the poorest populations is 
prioritized, with health initiatives targeted at the poorest and most vulnerable.  The idea of 
'public health' whether on a national level or globally, is meant to be for everyone but what is 
really meant is that it is for the poor (Biss, 2014).  The rich can already guarantee health to a 
large extent, so to make health 'public' is to enable access and quality of care for those who 
cannot easily pay.  On a country level, making health public extends to structural inadequacy, 
from health systems and basic infrastructure to trained medical practitioners and researchers.  
In addition to – who is the 'public'? – is the question of where global health knowledge is coming 
from.  It is not as simple as to assume research is done globally (i.e. in all countries), or is it only 
developed country research that flows to developing countries (which may have been more 
characteristic of the idea of international health).  
 
How did global health emerge and what is the difference to international health?  Brown et al 
(2006) describe the transition from ‘international’ to ‘global’ public health.  While international 
health has generally referred to epidemics spanning across geographical borders, global health 
is concerned with the public health needs of all people regardless of national boundaries (ibid., 
p. 62).  If this is the ideal that is strived for, international health becomes outmoded.  As Harman 
(2014) notes during the Ebola epidemic from 2013 to 2015, the response was: "...indicative of 
international rather than global health governance" in the failure of co-operation and 
collaboration, which did not happen across institutions and states.  																																																								
47 Example of the problems of diseases caused by colonialists, were the 'scorched earth' policies of 
clearing land and insecticide use to control rinderpest, exacerbated sleeping sickness (Scoones, 2014). 
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There is still some debate about whether global health and public health 48  are usefully 
distinguishable today.  Both encompass a population-based study to view health as a problem 
of populations and not only on an individual or group basis.  This population perspective has 
grown in popularity alongside epidemiology and health economics to look at causes and 
understandings of health beyond a strict bio-medical determination.  I have opted to follow Fried 
et al. who argued that:  
 
“Global health and public health are indistinguishable. Both view health in terms of physical, 
mental, and social wellbeing, rather than merely the absence of disease. Both emphasise 
population-level policies, as well as individual approaches to health promotion. And both 
address the root causes of ill-health through a broad array of scientific, social, cultural, and 
economic strategies” (Fried et al., 2010, p. 535). 
 
Global health has tended to be the all-encompassing term; therefore I use global health to also 
encompass public health as a combined idea in this thesis.  The global and public aspects of 
health are important in order to view NTDs, so I am interested in the academic and policy 
discussions that consider both.  What much of the joint discussion has centred upon is the 
postwar institutionalization and internationalization of public health, which resulted in a 
demarcation of tropical diseases from development.  Kelly and Beisel (2011) summarize the 
changes:  
 
“On one hand, the creation of the WHO as distinct from agencies such as the International 
Monetary Fund narrowed the scope of public health initiatives. On the other, the 
internationalization of public health and the subsequent dismantling of colonial governments 
centralized medical expertise; health decisions were no longer the province of local 
governments but of committees in Geneva and New York" (Kelly & Beisel, 2011, p. 76). 
 
The institutional set-up changed from a local to global system of economic governance following 
World War II, including medical research towards 'large-scale science' that is, "...driven by 
public-private partnerships, international research collaborations and large-scale development 
donors” (Schumaker, 2000, in Cooter & Pickstone, 2003, p. 78).  By looking at trends of data on 
global funding towards public health we can have an indication of where economic governance 
is being driven.  In 1990 global health funding was dominated by the WHO alongside USA and 
other donor countries including France, Sweden and Japan – but by 2011 the NGO share had 
increased dramatically, particularly from new funds (IHME, 2010).  These included ‘The Global 
Fund to Fight AIDS, Tuberculosis and Malaria’ (GFATM), and the Global Alliance for Vaccines 
and Immunization (GAVI) and the Bill & Melinda Gates Foundation (ibid).  Funding for NTDs has 																																																								
48 Public health may have the furthest historical roots in the “sanitary movement and contagion eras” 
(Awofeso, 2004, p. 705). 
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followed a similar pattern except industry funding plays a bigger role, which is most likely to be 
due to the drug solution focus.   
 
The ‘Global Funding of Innovation for Neglected Diseases (G-FINDER) Survey’ has been 
tracking funding patterns for investment in NTDs (Moran et al., 2012, p. 11).  While the tracking 
only covers R&D, it is capturing some wider trends.  Public investment is still the biggest funding 
source, but this is followed by the private sector and philanthropic organizations, with industry 
investment increasing 'dramatically' (ibid).  The increase reflects how over the past decade the 
multinational pharmaceutical companies, so-called 'big pharma', made concerted efforts to 
engage with certain global health issues, and have been drawn to NTDs in recent years.   
 
Therefore, global health has emerged from an institutionalization and globalizing of health, 
which has seen the entrance of new, predominately private sector and philanthropic health 
actors. Still the WHO, with some variability, has remained a central player with strategic 
influence, including for NTDs.  The WHO has been involved with framing the policy problem 
throughout, not straying far from the first 2006 report on NTDs description:  
 
“With little political voice, neglected tropical diseases have a low profile and status in public 
health priorities. Lack of reliable statistics and unpronounceable names of diseases have all 
hampered efforts to bring them out of the shadows” (WHO, 2006, p. II).   
 
The role of the WHO and its institutional development in providing strategic influence is further 
discussed in the next chapter.  In this section I have discussed how the concept of 'global 
health' emerged and the establishment new health actors, drawing on research in critical global 
health.  I ended on a note about the continued significance of the WHO, whose institutional 
changes has reflected a changing global health landscape.  Next I will turn to understandings of 
neglect that go beyond those of the established institutions such as WHO.  
3.6 Neglect as a policy characterization 
 
Returning to types of problem characterizations, I want to revisit the first section of this chapter.  
I argue that neglect has a special link with health, being the opposite of care by describing 
neglect in the negative as the absence of concern or care – a point that I will revisit in the 
preceding chapters.  Care is central to public health, from a micro level of caring for the sick to 
the macro of caring for populations and caring about what makes them sick.49  Conversely 
Sophie Harman (2012) in looking at care in global health governance finds that different 
practices of policy can promote care and in some cases the opposite – harm, which is why she 																																																								
49 Chaufan et al (2012), see a tension between 'cure' and 'care', reflected in the historic preference of the 
US government to invest in NIH biomedical research budgets over basic access or universal healthcare.  
This may be taken to be illustrative also of the innovation approaches discussed as a response against 
neglect that relies on feeling and thought rather than action and information.   
 79 
describes 'neglected health' as a result of the dominance of one issue over another.  Neglect of 
health, happens in issues "...sidelined or ignored because of global prioritising such as health 
systems and maternal health" (ibid., p. 122).  It means that the success advocacy of some, for 
example pandemic and emerging disease fears (HIV/AIDS, pandemic flu, Ebola), has a 
negative effect on others.  Therefore, care applied disproportionately, or too much care directed 
to certain issues can produce neglect.  Still, this argument does not address how care is 
decided or normatively why we care about some issues over overs. 
 
Caring for NTDs happens in a different way for other health issues.  Situating NTDs as the 
'other' has an effect in how we imagine them as diseases, especially in relation to other global 
health issues.  Looking at imaginaries helps to explain what is claimed about neglect, by whom 
and why.  Imaginaries are an approach popular in STS to describe a future-looking scenario, 
where 'sociotechnical imaginaries' of how science and technologies produce "social and 
collective visions of good and attainable futures". 50   However, in applying the idea of 
imaginaries I am mainly referring to Taylor's use of the term in making sense of social life and 
normatively enabling it: "The social imaginary is not a set of ideas; rather it is what enables, 
through making sense of, the practices of a society" (Taylor, 2004, p. 91).  
 
How neglect is imagined, is a topic that is beginning be explored in the absence literature, albeit 
not always explicitly.  As Balmer and Rappert (2015) put it, topics generate concern or 'non-
concern' and take the limelight, setting priorities and policy agendas.   Rappert (in Chapter 1. 
Sensing Absence: How to See What Isn't There in the Study of Science and Security) highlights 
how it is the 'social problems' and 'social movements' literatures where there is an implicit 
commentary that those matters do not generate interest and debate.  An imaginary of neglect is 
thus present in thinking about why topics are in the limelight, and also how priority and agenda 
setting decisions are made.  Absence theorists are interested in why there is lack of concern, 
interest and debate for topics and why we think some topics matter and others not – it is not 
spelt out, but this is neglect. 
 
Similarly the call to action by the ignorance studies literature resonates with understanding the 
nature of neglect.  As Proctor and Schiebinger describe, in their seminal book in the field 
'Agnotology: The Making and Unmaking of Ignorance', 51  neglect is a mechanism behind 
ignorance: 
 
																																																								
50 Sociotechnical imaginaries are not as "explicit, less issue-specific, less goal-directed, and less politically 
accountable" as problem frames and policy agendas, and are "more futuristic and less grounded in 
historical memory" then master narratives" as well as not being confined by discourse as media packages 
but "often associated with active exercises of state power and the management of political dissent" 
(Harvard STS Program, http://sts.hks.harvard.edu/research/platforms/imaginaries/#references, Accessed 
2/4/14). 
51 Agnotology refers to "...the study of culturally induced uncertainty" (Stilgoe, 2016). 
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"Our goal here is to explore how ignorance is produced or maintained in diverse settings, 
through mechanisms such as deliberate or inadvertent neglect, secrecy and suppression, 
document destruction, unquestioned tradition, and myriad forms of inherent (or avoidable) 
culturopolitical selectivity..." (2008, p. vii - viii). 
 
Therefore deliberate or inadvertent neglect produces or maintains ignorance.  The distinction 
between deliberate or not, implies it can be conscious or not, done purposefully out of lack of 
concern or care, or done inadvertently, supposedly through a lack of systemic concern or care.  
It may be inadvertent neglect through misunderstanding or because inquiry is selective and to 
an extent has to be out of necessity. Taking one step further, deliberate ignorance may be 
caused by neglect as an active construct, actively engineered and used as a strategic ploy to 
control social processes.  This tactical component means that ignorance can be politicized and 
directs focus towards who is creating ignorance and why.  Proctor and Schiebinger go on to 
state the connection with forms of knowledge as a reason for neglect: 
 
Our primary purpose here is to promote the study of ignorance, by developing tools for 
understanding how and why various forms of knowledge have 'not come to be' or disappeared, 
or have been delayed or long neglected, for better or for worse, at various points in history 
(ibid.). 
 
The postcolonial and feminist critiques of ignorance, in offering alternative views of knowledge, 
are a persuasive current in this work as it helps to explain the structural and directed causes of 
ignorance.  Neglect can also produce and reproduce ignorance.  As these, "...claims to 
ignorance can sometimes serve to promote policy production" (Abeysinghe, 2015).  Proctor and 
Schiebinger (2008) argue ignorance can have more neutral or even positive societal benefit, 
such as a coping mechanism for information and knowledge overload.   
 
The next step is looking at how issues are identified or not and how they are formulated as 
problems for redress, with institutions, systemic issues, mitigation procedures, and temporality 
being themes.  Shiffman has most prominently brought forward the question of: 'A social 
explanation for the rise and fall of global health issues' (Shiffman, 2009) on the grounds of 
attention and neglect.  He argues that material factors (e.g. mortality, morbidity, and cost 
effectiveness) do not offer sufficient explanation for the attention of leaders in global health and 
social explanation is needed (ibid., p. 608).  He acknowledges the importance of rhetorical 
'problem claims' on the grounds of severity and neglect, as well as frames in a social 
constructivist understanding of why issues decline or ascend in global health (ibid. p. 609).  I will 
explore frames later in this thesis and make the argument for why 'repackaging' is the way that I 
want to portray an issue of problem for policy.  While Shiffman (ibid., p. 611) looks for reasons 
to explain a lack of political attention (grouped around policy communities, ideas, and 
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institutions), I concentrate on the nature of neglect and types of forms that neglect manifests.  
This focus lends itself more to a literature on the nature of knowledge and non-knowledge. 
 
Thus returning to Proctor and Schiebinger (2008) again, their argument is that things (or 
knowledge) is not simply present and absent – they are made so, in what is concealed and 
revealed or whether it is an issue of concern or non-concern (ibid., p. 6).  For neglect taken as 
separate object of analysis, I argue much can be drawn from the idea that neglect and non-
neglect (or even concern or attention) are interwoven.  Interestingly, neglect appears to be an 
important characterization of ignorance as a research problem: "...this strategy can also lead to 
an acknowledgement of non-knowledge that so far has been neglected, but is suddenly taken 
seriously and may even be seen as fundamental" (Gross, 2007, p. 748). 
 
Neglect of non-knowledge then is a feature of why ignorance has not been researched 
extensively in the past, although this point has not been fully appreciated in the literature that, 
"...closed ignorance means that ‘we either neglect problems themselves, or do not take notice of 
intuitive insights, experience, information, models and methods of solution which are available 
inside of society’...." (ibid.).  The presentation of ignorance is as a field of study that has not 
been given due attention, it has been neglected and deserves a concerted effort to rectify. 
 
However, my main contention is that neglect itself is a different characterization to absence or 
ignorance in the implicit assignment of blame and responsibility, and an unequal relationship 
between the neglector and the neglected.  Crucially, what needs attention is not simply this or 
that missing recognition.  The type of absence becomes a central point to understand, and 
neglect is a special type of absence.  The object of neglect in this thesis – NTDs – is defined by 
what it is not and the many reasons and ways something is neglected through lacking and 
absence.  I will conclude this chapter in the next section by reflecting on the policy environment 
to create neglect as one of competition, which both promotes division and connections to be 
made. 
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3.7 Conclusion: Competition and connection 
 
I have aimed to highlight through this chapter how the literature on policy problems and 
solutions is closely tied to questions about the use of measurement and advocacy in policy, as 
well as various disciplinary lens in which to view problem-solving.  These strands of policy 
dialogue will be connected again in the proceeding chapters.  I will explore a policy history of 
NTDs in Chapter 4, how the policy problem of NTDs has been represented in global health in 
Chapter 5, the form of advocacy taken to promote NTDs in Chapter 6, and dominant public 
discourses on NTDs, including how measurement evidence has been used in Chapter 7.   
 
I have treated in this chapter: policy problems, solutions, and the global health context 
somewhat separately.  I want to emphasize the on-going tension of how policy problems can be 
in or out of fashion, prioritized or not, imagined to be neglected, and subject to lobbying and 
profiling.  While global health policy has blossomed into an active field with numerous new 
actors and disciplinary contributors both competition and congruity remains an intrinsic part.  As 
Naomi Klein describes, for those actors who seek to promote particular issues and movements, 
connecting disparate threads is a means of achieving justice against the status quo: 
 
"We face so many overlapping and intersecting crises ...Overcoming these disconnections – 
strengthening the threads tying together our various issues and movements – is, I would argue, 
the most pressing task of anyone concerned with social and economic justice. It is the only way 
to build a counterpower sufficiently robust to win against the forces protecting the highly 
profitable but increasingly untenable status quo" (2016, p. 15).   
 
Or as Stengers has described along similar lines, to understand a policy problem (in her 
example climate change and growing social inequalities) cannot be done in isolation, and this 
will be a guiding point for chapters that will follow: 
 
"...There has been an epochal shift: the possibility of a global climate crisis is now upon us. 
Pollution, the poison of pesticides, the exhaustion of natural resources, falling water tables, 
growing social inequalities – these are all problems that can no longer be treated separately..." 
(Stengers, 2015, back cover). 
 
Where to connect and where to divide becomes an ongoing question for NTDs and determines 
how an individual policy problem is constructed.  The theme of what connection and division is 
taking place in an evolving global health landscape and in understanding neglect will be further 
examined.  The next steps for the empirical research are to uncover the various events and 
milestones that have made up the recent policy history of NTDs.  In the next chapter I will delve 
into the case of NTDs as a policy problem, analyzing the conceptual origins and what the 
dominant strategies for tackling these diseases have been and why. 
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Chapter 4. Scene-setting: Timelines, disease lists, and 
health actors  
4.1 A history of NTDs as a policy issue 
 
The previous chapter set out the theoretical basis for considering policy problems and their 
solutions.  The current chapter aims to set the scene and tell the story of NTDs as a specific 
policy problem, through a policy history.  Historical accounts of policy are argued by Haddon et 
al. (2015) to be used by social researchers for three main purposes: one, for comparative case 
studies; two, to provide a broader temporal context for understanding framing, narratives and 
discourses; and three, to track how policy paradigms change over time.  NTDs have a short 
policy history, since the term was created in the early 2000s, but preceding this creation was the 
longer history of tropical diseases (discussed further in Chapter 5).  I will cover NTDs as a term, 
then discuss how policy developed, including the categorization of the NTD disease list and end 
with an analysis of what arose as dominant strategies for policy influence and effect.  Since this 
overview of the policy development of NTDs will become pertinent over the next three chapters, 
an exploration of the institutional setting for early NTD related initiatives is required. 
 
Beginning in the 1970s, this chapter will explore the history of NTDs as a policy issue, with 
sensitivity given to how historical accounts can be misinformed, used instrumentally, mythicized, 
or contested.  I primarily use a comparison of two initiatives that were precursors for the concept 
of NTDs and provide the context for why key milestones or events happened and a commentary 
on how the policy thinking has changed over time.  Firstly, the chapter will confront the ‘short 
policy history’ of NTDs, in the coining of the term and the individuals and institutions that were 
involved.  I begin with two early initiatives from the WHO and Rockefeller Foundation that 
spurred advocacy for NTDs in the 1970s.  The reason for the focus on these initiatives, with an 
interest in absences that have created neglect, is that I want to know why the current 
conceptualization of NTDs did not arise directly from an early WHO initiative.   
 
Secondly, I will elaborate on the policy development of NTDs and provide a background of the 
key events, actors, and initiatives.  Changing at the same time as the policies directed toward 
NTDS were the classificatory lists of diseases that constituted NTDs – in viewing this change I 
am concerned with which diseases have counted as NTDs and why.  There is an ambivalence 
of categorizations of NTDs that has to do with finding coherent criteria for inclusions or 
exclusion that also has policy appeal.  I discuss how different lists occurred, through the London 
Declaration list of 10, WHO list of 17 and PLOS (Public Library of Science) Neglected Tropical 
Diseases Journal list of 38.  I also show how country or regional NTD characteristics challenge 
an all-encompassing view.   
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Thirdly I will conclude by discussing the strategies of policy influence and effect that came to 
dominate.  I argue how the targeting of intervention on five NTDs resulting from historical 
contingency and scientific challenge has lead to some of the diseases being 'tool-ready', which 
will be explained later.  I found that the dominant strategies to treat NTDs came from global 
campaigns including the Sustainable Development Goals (SDGs), the significance of political 
connections, and the emergence of new institutions, including the work of the Gates 
Foundation, focusing on drug donation and R&D to tackle NTDs. 
 
Before tackling these issues, it is crucial to look at the term of NTDs.  I draw on the theoretical 
basis set out in Chapter 2 (Methods and Methodology) and 3 (Approaches to Policy Problems) 
for how “neglect” can be understood drawing on sociological studies of absence and ignorance.  
In Science and Technology Studies (STS), there has been some emphasis on risks and 
uncertainty but as scholars have more recently pointed out, we are more comfortable with 
considering calculable risks "(B)ut there are areas of uncertainty or ignorance in which we 
cannot calculate probabilities and we cannot predict consequences" (Stilgoe, 2016).  Neglect 
weighs in as needing calculability, which is why defining NTDs is important and a rationale for 
why they are neglected.    
 
The question this chapter and following chapters will be preoccupied with is by whom and why 
neglect is originated and perpetuated, along with the attempts to redress neglect.  The broad 
categories of neglect have concentrated on 'who are the neglectors?' and have been an early 
point addressed in the academic literature (see Holt, Gillam, & Ngondi, 2012; Liese & Schubert, 
2009; Morel et al., 2005).  As I already touched upon in the previous chapter, these categories 
have been centred on science (universities, research institutes), the market (pharmaceutical 
companies) and public health (donors, international organizations, philanthropy).  In this chapter 
I explore those categories further in order to determine what meaning-making and rationales are 
at play in order to present different sites of neglect.   
 
The group that has been consistently active in their commitment to and also in encouraging a 
renewed interest in NTDs is the donor community.  Big pharma on the other hand has faced 
pressure to address issues of global health and this influenced their increased involvement, 
through donation programs.  The result has been that more pharma companies donated drugs 
as part of their corporate social responsibility obligations.  However, the pharmaceutical industry 
did not form a concerted campaign for advocacy or an expansion of attention towards NTDs.  I 
argue that the legacy in the conceptualization of NTDs can be found in two early initiatives that 
spurred advocacy for NTDs. 
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4.2 Two early initiatives: 'Bringing science into tropical disease 
research' 
 
The donor community in the 1970s marked out the territory for NTD policy, through two early 
initiatives that were run by the major global health actors – the Rockefeller Foundation and the 
WHO.  I will discuss the role of these initiatives in originating NTDs in this section.  The 
Rockefeller Foundation was established as the Rockefeller Sanitary Commission in 1909 as a 
philanthropic organization funded with an endowment of $3.4bn from the JD Rockefeller Sr.’s 
incredibly profitable Standard Oil Company, founded in the 1870s (Farley, 2004).  Rockefeller 
had as his principal aid in philanthropy a former businessman and Baptist minister called 
Frederick Gates, who decided upon a medical focus.  Gates had felt medicine to be a neglected 
area that deserved more attention: “…'I had begun to realize how woefully neglected had been 
the scientific study of medicine in the United States.’ What was needed, he concluded was a 
research institute given to ‘uninterrupted study and investigation, on ample salary, entirely 
independent of practice’…” (ibid., p. 3).  It was an example of scientization52 of medicine with a 
desire to scale up funding, bring it into an independent and exploratory laboratory setting, away 
from patients, hospitals and the ‘practice’ of health.  Also indicated was a need to concentrate 
on a neglected topic. 
 
Scientific research as being a philanthropic ‘cause’ may sound unusual but many of the most 
well-established and well-funded philanthropic organizations have this as their mission.53  In an 
era before big science projects of national importance during and after World War II, and when 
major government funding organizations were in their infancy, philanthropy played a crucial role 
for research.54  Global health efforts were more of a rarity before the post-war era, and as a 
result would come to the health realm relatively late.  The WHO was established as a 
specialized agency of UN concerned with international public health in 1948.55  Arguably, the 
WHO’s largest and most successful role has been in the global campaign for the eradication of 
smallpox, yet the initial priorities were wide-ranging: "malaria, tuberculosis, venereal diseases, 
maternal and child health, sanitary engineering, and nutrition" (McCarthy, 2002, p. 1111). 
 
It would be much later in the histories of the Rockefeller Foundation and the WHO – in the 
1970s to 1990s – that the preparatory groundwork was set for the creation of NTDs.  The first 
initiative, established by the WHO, was the Special Programme for Research and Training in 																																																								
52 Scientization is defined as: "to treat with a scientific approach" (Merriam-Webster Dictionary). 
53 Philanthropic organizations with a research mission include the Wellcome Trust and Cancer Research 
UK. 
54 The National Institutes of Health (NIH) established in 1887 in the US and government funding of the 
Royal Society initiated in 1850 and1913 when the Medical Research Committee (later the Medical 
Research Council) was be established (Kaiserfeld, 2013; Rosen, 1993). 
55 The WHO was preceded by the Health Agency of the League of Nations established in 1920 but during 
WWII "international health work came almost to a standstill" (WHO, 2011c). 
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Tropical Diseases (TDR) (1974 – present). The Rockefeller Foundation established the second 
major NTD initiative, the 'Great Neglected Diseases of Mankind' - GND (1978 – 1988).  It may 
not have been appreciated within the public health literature, conducting separate analyses 
(Farley, 2004; Keating, 2014; Remme et al., 2002; Zhou, Wayling, & Bergquist, 2010) but the 
purposes of the two initiatives were similar.   
 
Both were premised on bringing science into research for tropical diseases through 'capacity 
building'.  Capacity building in this context meant building the scientific expertise and research 
capabilities of those working on NTDs, particularly focusing on developing countries, by 
providing the support and network of developed countries.  To begin with, the driving goal of the 
TDR was to develop new drugs (and other innovations) for neglected infectious diseases in 
developing countries and have developing country scientists advance their research skills.56  In 
line with a capacity building approach, the endemic country took centre stage – although this did 
still assume a transfer of knowledge and resources from developed to developing countries.  
For the GND it was, also to develop drugs for neglected diseases but with a greater emphasis 
on basic research and to introduce new scientific techniques.   
 
The diseases that the initiatives included both held similarities with the current NTD grouping.  
The TDR included seven diseases that would be later included in the WHO 13, (with the 
exception of malaria).  At the time, the first director of the TDR, Adetokunbo Lucas noted: 
"These diseases were selected by the criteria of their public health importance, the lack of 
effective tools for their control, and the likelihood that research can yield the new tools which 
could bring significant advances in their control" (in Fudenberg, 1983, p. 160).  As of 2016, TDR 
also includes malaria, Ebola and TB.  The TDR as the 'Special Programme for Research and 
Training in Tropical Diseases' does not make the distinction of malaria and TB as being 
relatively less neglected as part of the 'big three' and nor is Ebola out of scope as an emerging 
disease.  As the focus is on capacity building and scientific progress there is still much to be 
achieved for these diseases.  Rockefeller’s 'Great Neglected Diseases of Mankind' - GND - also 
included diseases not typically described as NTDs, such as diarrheal diseases and other typical 
diseases of poverty not tropical by nature (see Table 3 below for a comparison of the diseases 
covered by the TDR, in both 1978 and 2016, and the GND in 1978).   
 
 
 
 
 
 																																																								
56 The Division of Control of Tropical Diseases (CTD) established in 1990, jointly steered the TDR's 
applied field research in providing technical advice and assistance for endemic countries.  In 2007 CTD 
was incorporated into the HIV/AIDS, TB and Malaria cluster (Lee & Fang, 2013).
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 TDR 1978 TDR 2016 GND 1978 
Chagas disease x x  
dengue  x  
diarrheal diseases   x 
Ebola  x  
filariasis (inc. lymphatic filariasis and onchocerciasis) x x  
HAT x x  
helminthiasis (inc. hookworm)  x x 
leishmaniasis x x  
leprosy x x  
malaria x x x 
schistosomiasis x x x 
TB  x  
Table 6 Comparing TDR diseases to GND diseases  
(Compiled from: U.S. Congress Office of Technology Assessment, 1985; Lucas, 2013) 
 
It would be much later that the WHO also latched onto 'neglected' as a descriptor for tropical 
diseases.  The WHO made references to 'neglect' and also the GND, but this tended to be as a 
rhetorical device, as described by the WHO in 1990: "Human commitment and resources are 
required of the world, if tropical diseases are not to become the great neglected diseases of 
mankind" (WHO TDR-CTD; emphasis added).  While the TDR may initially appear to be the 
natural home for the creation of NTDs this proved not to be the case.  According to one of the 
activist scientists:  
 
"TDR I think dropped the ball... They lost the disease focus... the point is that TDR never 
invented or had anything to do with the concept of NTDs... they were involved in some excellent 
work on oncho [onchocerciasis]... they did fundamental early work... TDR are basically an 
organization that take donor money and redistribute it, the work is done by scientists who apply 
for grants" (Interview with author, activist scientist, 2016).   
 
In losing the 'disease focus' what is being implied is that the TDR became more concerned with 
the distribution of donor money and encouraging capacity building of scientists.  This account is 
one explicit statement about the lack of WHO involvement in originating the concept of NTDs 
but is reflected from my other informants.  The point was made that the WHO is not well placed 
for advocacy and conceptual input into disease issues.  As Nick Kourgialis from Helen Keller 
International (an organization concerned with causes and consequences of blindness and 
malnutrition) explained in our interview:  "So they’re a critical partner but I'm not sure that 
they've been as directly involved with or important in the advocacy that occurs on the country 
level, in the US, in the UK and others" (Interview with author, Kourgialis, 2016).  Their role was 
more centred on setting global standards and criteria (e.g. elimination) for reporting and 
guidance on clinical protocols to highlight the importance of issues and providing a forum for 
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discussions and assessing progress.  Therefore, it is clear while providing early leadership on 
policy and scientific research, the TDR were not involved in the conceptual construct of NTDs.  
Some institutional groundwork was laid as tropical diseases were embedded early on in the 
WHO machinery.   
 
As Keusch writes (in Parker & Sommer, 2010), the TDR was a somewhat unique entity within 
the WHO, as a partnership with the United Nations Development Programme (UNDP) and the 
World Bank.  The TDR had more independence than usual in being supported by external 
funds, so that it could determine how to put resources to use without interference from WHO 
leadership and was determined to keep a degree of independence (ibid.).57  This reliance on 
external funds and partners, and encouragement of drug donation, also may have opened the 
door for private sector and philanthropic actors to become involved later.    
 
Other scholars have explored the institutional settings of the WHO and the Rockefeller 
Foundation (Haynes, 1999), yet their research has not gone beyond tropical diseases and 
extended to NTDs.  I make the point that institutionally, the Rockefeller Foundation did not need 
to reach the type of consensus that the WHO needed as a multi-constituency representative 
body.  
 
Scientific research as the main type of capacity-building was a main pursuit of both programs.  
The GND at the time of its operation was heavily interested in attracting the ‘crème de la crème’ 
of scientific talent, whether that was in developed or developing countries.  The TDR was 
scaling research effort across organizations.  In a profile on the WHO website, Lucas (2013 
[1978], p. 220) stated how he was hopeful at inception that the TDR "...will produce results 
which would otherwise not have been attained through the traditional isolated and disjointed 
approach to such problems" (Fleck, 2015, pp. 292-3).  The TDR wanted to bring produce 
scientific results via developing countries by building their talent base (see Fleck, 2015; Lucas, 
2013).  Also expectations for new biotechnology advances to solve old problems was high, as 
Lucas described:  
 
"...the vigorous application of recent advances in modern biology would yield a better 
understanding of parasites and parasitism... an interdisciplinary approach using the modern 
tools of research in immunology, histochemistry, biochemistry, molecular biology, genetics... by 
focusing attention of scientists on the needs and opportunities for research in this area, more 
rapid progress can be made" (2013 [1978], p. 220).  
 
																																																								
57 When some governments disapproved of grant recipients (e.g. Burma), the TDR made their case that 
they had, "...the right to work with all Member States. Still, we had problems with some individuals. Some 
countries insisted that the government should nominate grant recipients. We refused, saying that it had to 
be about science not political favours" (Fleck, 2015, p. 293). 
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The scientific focus, especially the application of new scientific specialties would become less 
pronounced and was certainly a perceived need in the 1970s in both GND and TDR.  
 
At the WHO, the TDR focus in later years has moved onto how research can support and 
improve health outcomes as opposed to an exploratory introduction of biotechnology. The 
current director (as of 2017) John Reeder explained in an interview with the UN-associated 
news website Genève Internationale58 that, "...really, it's about putting research into the service 
of improving people's health" (Genève Internationale, 2014, Accessed 23/4/15).  This outlook is 
a concern for implementation, and operational research, to consider country capacity, delivery, 
and uptake, as Reeder argues: "What is needed today is different than when we started. Today 
there are many new medicines and diagnostic tools, but they aren't always getting to the people 
who need them... Our strategic shift has been downstream towards the diseases in country" 
(ibid.).   
 
When I interviewed Bernadette Ramirez a scientist working in Reeder's unit, she described how 
as part of financial prioritization at the WHO, TDR underwent a “refocus of strategy in light of 
limited resources and reprioritization exercise” (Interview with author, 2013).  The focus would 
remain on capacity building, "...looking at current gaps to add value for the needs of the 
community" (ibid.).  In terms of involvement in cutting-edge research, she explained the view 
that there already was enough "...capacity on the ground as far as [drug] discovery" (ibid.).  TDR 
could facilitate 'R&D mapping' and research networks had been set up and were embedded in 
disease endemic countries but, "...TDR is no longer pursuing drug discovery as a major activity" 
(ibid.) 
 
My overall argument is that this approach, in attracting the best scientific talent would have the 
biggest legacy to bring about NTDs (a point that I will discuss at length in Chapter 6).  The TDR 
and GND, and their institutional setting show how the ground was set for the concept of NTDs to 
emerge.  I make the argument that the WHO was unable to be the originators of NTDs and this 
was because their advocacy ability was limited.  I point towards the GND as being the 
conceptual origin for NTDs and further explain why this is the case in Chapter 6, drawing on 
historical sources and interviews.   
 
In the remaining section, I consider the ongoing role of the WHO and the Rockefeller 
Foundation, and what the GND and TDR say about the transition from tropical disease to NTDs.  
This is a key point because there is very little in the literature making this point, apart from 
largely historical accounts (Hotez et al., 2012; Lammie et al., 2007) that look toward the new 
configuration of tropical diseases as NTDs.  
 
																																																								
58 Genève Internationale is run by the state of Geneva. 
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The WHO has been criticized for not paying enough attention to diseases of the poor.  While the 
TDR could also be seen as a return to the original goal of 'health for all' (Gillam, 2008) in not 
forgetting the poorest communities for some this ambition did not go far enough.59  This was 
certainly the view of Kenneth Warren, the director of the GND, that the WHO had not 
concentrated on "...those few diseases that caused the highest mortality among the world’s 
poor" (Keating, 2014, S.25).  Their limited advocacy role is still acknowledged.  Similarly Kari 
Stoever at the 'Global Network for Neglected Tropical Diseases', one of the main advocacy 
NGOs established in 2006, spoke of the difficult position the WHO held:  
 
"Because of the way they're set up, they're set up to be a bureaucracy and to gain consensus 
and when you're an advocate you've got to drive to a goal and it's usually very short term... 
you're trying to push the needle faster than the WHO would be able to convene or develop 
consensus among their members" (Interview with author, Stoever, 2016). 
 
It has been the case that from inception in 1948 until the late 1990s the WHO fared variably, 
described as moving:  
 
"...from a commanding position as the unquestioned leader of international health to a much-
diminished role in the crowded and contested world of global health... WHO was marked from 
its early days by political and diplomatic entanglements and budgetary constraints that, over five 
decades, compromised the organization and restricted its operating capacity. Indeed, those 
entanglements and constraints eventually pushed WHO in the 1990s to try to reinvent itself as a 
coordinator of global health in a world with many new and powerful players" (Brown & Cueto in 
Parker & Sommer, 2010, p. 18).   
 
For the Rockefeller Foundation I make the point that the change of topics of focus is why it has 
not continued influence with NTDs.  Chen remarks in how, "(F)oundations are strange creatures 
since they are not driven by the accountability of the ballot box, scrutiny of the media, or even 
restrictive regulations" (2014, p. 719).  Therefore the topics of focus are often directed by the 
individual preferences of the foundation rather than an international organization such as the 
WHO, which needs to reach consensus between its members.   
 
Before the launch of the GND, the Rockefeller Foundation had been concerned with population 
growth and agricultural science (or rather the prospect of the green revolution to solve world 
hunger).60  The programs in health sciences, which had been the flagship programs at the 																																																								59 The place of NTDs as a priority by the WHO in the goals of universal health coverage and essential 
health interventions can be seen in this statement by director Margaret Chan: “We are moving ahead 
towards achieving universal health coverage with essential health interventions for neglected tropical 
diseases, the ultimate expression of fairness” (WHO, 2013, p. vi). 
60 NTDs have often been a footnote in history affected by a focus on other scientific areas such as 
population growth and the green revolution, where also the later backlash against overuse of pesticides 
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foundation's creation by the 1970s had been waning.  In 2016, population growth is not viewed 
as such a threatening concern.  China has relaxed its one child policy, which since 2015 is 
being formally phased out (BBC News, 2015), also global fertility rates are dropping and even 
reverse population growth is seen in some countries such as Japan (Walsh, 2012).61  For 
example, a major debate was about whether to pursue the control and elimination of malaria 
because of a knock-on effect would be improved child mortality, worsening the problem of 
population growth.  There was discussion among academics, policy makers and in the media 
about the desirability of halting the malarial ‘cull’ which was a 30-40 per cent infant mortality rate 
to prevent population explosion in Asia and Africa (Fuller, 2015; Smith, 2015). 
 
However, in the 1960s and 1970s population growth was a major concern and a threat to the 
developed countries, as shown by such dystopian sci-fi films as “Soylent Green” released in 
1973, imagining some of the horrors of too many people scrambling for limited resources 
(Haberman, 2015).  This anxiety about the population growing faster than available resources, 
also predated the green revolution of high-yielding, disease-resistant crops, and the rapid 
economic growth of developing countries such as Brazil and India now seeing declines in birth 
rate growth (ibid.).   
 
The Division of Health Sciences at the Rockefeller Foundation reflected these popular 
sentiments, prevalent in academic circles and the public imagination, however it would 
experience changes that would bring health concerns back into the picture.  Four key members 
of the division had retired, opening the door for a change of direction (Kreier, 2014).  As Warren 
remarked, because of, "...the relative lack of constraints upon voluntary organizations, this could 
have been in many different directions" but the leadership of the Director John H. Knowles had 
set this focus on health (ibid., p. 336).  The topic of focus was to be: "... the major diseases of 
the forgotten three-quarters of the world's people in developing countries" and in a sense a 
return to the foundation's roots, as it had began with a major global hookworm campaign (ibid.).  
 
Both the TDR and GND, had returned, through these initiatives to the founding ideals of their 
institutions, and this I argue was in order to leave behind 'colonial baggage'.  The outlook of the 
initiatives marked a discontinuity with colonial health and was the beginning of a new 'global 
health'.  As the next chapter will discuss further, a previous colonial shaping of tropical diseases 
meant that in the post-colonial era a new approach would be sought.  The emphasis on 
'capacity-building' and 'cutting-edge scientific advances' of the TDR and GND signaled a new 
approach to tropical diseases.  These two initiatives formed a view on how best to go about 
addressing tropical diseases, in ways that differed from the colonial campaigns that existed until 
most countries achieved decolonization by the 1970s.   																																																																																																																																																																		
and insecticide (sometimes also called a green revolution in the concern for the environment) had a 
detrimental effect on their use for vector control (Kinkela, 2011). 
61  
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On a final note, the colonial history is a lingering point even in the names of the initiatives.  The 
TDR kept tropical diseases in its name and mission statement (although the acronym 'TDR' is 
used mostly). The director of the TDR in 2007, Robert Ridley, defended the decision years later 
in a profile on the WHO website: 
 
"Q: The concept of “tropical diseases” originates from the medicine practiced by 19th century 
colonial powers to protect themselves in the tropics. Have you considered changing your name? 
 
A: There has been some discussion about the name. Our new strategy refers more to 
“infectious diseases of poverty”, but if you look at the terms “tropical disease and tropical 
medicine” they still cover a field that is generally recognized today. You still have associations 
and institutes with the name and – at WHO – a department of neglected tropical diseases. The 
name has other connotations which we should be aware of, but given the recognition of the 
name and loyalty to TDR, particularly in developing countries, we decided to keep it" (Bulletin of 
the World Health Organization, 2007). 
 
The GND on the other hand chose to rename what was largely a group of tropical diseases, to 
emphasize the common humanity implicated in 'diseases of mankind'62 and the scale and 
problem of 'the great neglected'.63  Maybe it had been the historian in Warren (who had studied 
history and literature before switching to medicine), as director of the GND, who proposed the 
grandiose title.  However, the word 'great' had been used in tropical medicine to elevate the 
importance, scientifically and to society of tackling theses diseases, just as neglected would 
similarly be used in a instrumental way, this time to highlight moral obligation and need.  The 
wording 'mankind' was a part of what the foundation was about, “to promote the well-being of 
mankind throughout the world” (Birn et al., 2013, p. 1618).  In any case, the GND was the 
beginning of the NTD brand and would have a conceptual legacy for NTDs that I will go on to 
discuss the significance through Chapter 6.  
 
In the next section I look towards the reasons why new activities and organizational structures 
have been required to further the NTD cause, a symptom also of the change in global health.  
The WHO has been both an influential entity but also an overly bureaucratic institution, that my 
informants did not view as an advocacy organization.  After the launch of the TDR the WHO 
endured a 'declining role', confounded by the relative ascendance of the World Bank, which was 																																																								
62 "Mankind' was the common word used at that time before being replaced by the gender-neutral 
'humankind'.  The GND had parallels then to the 'mankind' reference in the Rockefeller charter: “to promote 
the well-being of mankind throughout the world”, described variously as 'noble' (Keating, 2014) and less 
sympathetically as 'lofty' (Schanke, 2007). 63  Other uses of 'great' as a characterization of tropical diseases included Ronald Ross in his 
autobiography, 'Memoirs of 1923', providing the subtitle "with a full Account of the Great Malaria Problem 
and its Solution” (Bynum & Porter, 2013, p. 562).  
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able to intervene more actively in world health affairs through 'structural adjustment policies' that 
tying health to the economy and financial support (Kenny, 2015).  The organization has had to 
contend with new entrants into global health, particularly from the early 2000s onward.   
 
Similarly the Rockefeller Foundation after some initial success with the GND program would find 
it difficult to maintain relevance following the proliferation of global governance institutions.  
From the WHO and other UN agencies to the World Bank, widening the health focus in their 
activities both institutions would face increased competition.  Moreover, after the turn of this 
century the Rockefeller Foundation would be overtaken by the Gates Foundation as the 
foremost philanthropic donor in public health.  Therefore, while both institutions would have a 
contribution towards the NTD policy cause, it would take a very different set of actors to take 
tropical diseases forward in a new global health landscape. 
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4.3 Timeline of key events 
 
The stage was then set for a number of milestones in the creation of NTDs as a policy and 
disease category from the first NTD paper in 2004, to the Berlin meeting in 2005 quickly 
followed by the creation of the WHO department for NTDs and the first WHO report on NTDs.  
This collection of milestones then reached a pinnacle with a landmark event in 2012 'The 
London Declaration' and the formal instillation of NTDs on policy agendas through the 2015 
Sustainable Development Goals (SDGs).  Below I show a timeline of these key events. 
2000 MDGs
Gavi, the Vaccine Alliance (2000) The Global Fund to fight AIDS, 
Tuberculosis and Malaria (2002) 
2003 NTD branding and funding 
First Berlin Meeting (2003), First NTD Paper (2004), WHO Department for NTDs 
(2005), The Global Network for NTDs (2006), PLOS Neglected Tropical Diseases 
(2007), G8 Meeting in Japan (2008), Presidential Initiative on NTDs and DFID 
Committment (2008), Bill & Melinda Gates Foundation funds Global Network 
(2009), First WHO report (2010)
2012 The London Declaration and WHO Roadmap
2015 SDGs
1970s - 1990s Pre-MDGs
GNDs (1978 – 1988), TDR (1974– present)
 
Figure 4 Timeline of main events in creation of NTDs from 1970 – 2015  
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4.4 From the Berlin meeting to The London Declaration 
4.4.1 The Berlin meeting 
 
The "historical meeting in Berlin" took place between the 18–20th April, 2005 (Savioli, 
Montresor, & Gabrielli, 2011, p. 486).  It is described by WHO representatives Savioli et al from 
the Department of Control of Neglected Tropical Diseases as when the WHO "formally 
rebranded this area of work, previously vaguely defined as 'other communicable diseases' or 
'other tropical diseases,' meaning other than malaria, tuberculosis, and HIV/AIDS, as neglected 
tropical diseases" (ibid.).  This view was supported by activist scientist Alan Fenwick, who 
argued that is was at the meeting that much of the groundwork and discussions for coining 
NTDs happened:  
 
"...it was a mixture of people who were interested in the various diseases and a selection of 
African Ministers of Health and whatnot, and we sat down and we talked, and we said what are 
we going to do? ...And so the big question came up, can we integrate what we’re doing and who 
the hell can pronounce all these names? I’m the only one who can pronounce all these names 
and spell them. And so we needed a collective phrase and we discussed a number of different 
phrases and neglected topical diseases was the one that was selected, NTDs" (Interview with 
author conducted with Erman Sozudogru, Fenwick, 2015). 
 
This international workshop was intended to be a 'Strategic and technical meeting on intensified 
control of neglected tropical diseases' (WHO, 2005).  It was co-hosted by WHO, the German 
Ministry for Economic Cooperation and Development, the German Ministry of Health, Deutsche 
Gesellshaft für Technische Zusammenarbeit (GTZ), Kredinstalt für Wiederaufbau (KFW), and 
the TDR.  Present were a variety of, "(E)xperts from public health, economics, human rights, 
research" which explains the focus on these areas in the proceeding report (ibid.).   
 
There had been an earlier meeting in Berlin in 2003 convened by the WHO and GTZ on the 
'Intensified control of neglected tropical diseases', which was an important initial meeting in 
defining a collective response against these diseases (WHO, 2004a).  Although the 'Berlin 
Meeting'64 that most commentators refer to as the defining one was in 2005, which lead to the 
creation of WHO Department for NTDs.  Molyneux describes how: "...Dr Anarfi Asamoa-Baah 
aba now the Deputy Director General [at the WHO] was at that meeting and decided he would 
create the department... He said I'm going to do it tomorrow... so that's when it happened that 
the Department at the WHO was created" (Interview with author, activist scientist, 2016). 																																																								64 Other meetings followed the Berlin Meeting, on April 17-18, 2007, the WHO convened the first 'Global 
Partners' Meeting' on NTDs with 200 participants from public, private and philanthropic sectors, including 
Blaise Compaoré, President of Burkina Faso, and Samuel Eto'o, a Cameroonian footballer (Savioli et al., 
2011, p. 487).  
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Why was this meeting important?  It coordinated efforts towards a new strategic approach.  
Savioli et al. called this a paradigm change within the WHO: 
 
"In 2003, under the leadership of Dr. J. W. Lee, just appointed Director General, the World 
Health Organization (WHO) started a process of paradigm shift in the control and elimination of 
neglected tropical diseases (NTDs). The shift consisted of the adoption of a new vision that 
abandoned a purely academic approach to adopt one more responsive to the needs of affected 
individuals and communities. As a consequence, it entailed a strategic rethinking and a move 
away from a “theoretical,” structural classification based on disease biology toward a “practical” 
one based on the available tools employed to control such diseases" (in Relman & Choffnes, 
2011, p. 481). 
 
The shift was based on the new drug strategy of preventative chemotherapy through Mass 
Drug Administration (or MDA, discussed in the next chapter).  As described by Savioli attention 
was directed towards policy design and outcomes rather than a technical approach considering 
the diseases separately.  The door was also opened to consider a societal understanding and 
apply a social science lens with economics and human rights, and also public health – as both 
a "science and art of preventing disease, prolonging life and promoting health" (Acheson, 
1988).65 
4.4.2 The first paper 
 
The Berlin meeting was an occasion for the term NTDs to come into being as the best 
descriptor of a group of tropical diseases that multiple partners were working on, with 
agreement among many of the central stakeholders.  However, the term still needed to be 
further conceptualized and promoted.  I have identified the paper most explicitly referring to 
NTDs and would prove influential in considering the policy intervention of NTDs as “'Rapid-
impact interventions': how a policy of integrated control for Africa's neglected tropical diseases 
could benefit the poor” (Molyneux, Hotez, & Fenwick, 2005b).66  The three main activist 
scientists who wrote this paper were David Molyneux, Peter Hotez, and Alan Fenwick, for PLOS 
Medicine in 2005.  In the paper they questioned the lack of attention for the successes of NTD 
interventions from policy makers, donors and public health officials.  The vertical programs were 
working well but could be combined for 'integrated control' and rapid impact'.  Synergies could 
																																																								
65 Public health as a science and art was a popular definition from the late 1980s, coming from an 
influential public health inquiry by Acheson – the first since 1871 for the UK Government on 'Future 
Development to the Public Health Function', which used WHO categories as a basis for categorization 
(Robotham & Frost, 2005). 66 The first paper on NTDs was followed by an expanded 2006 paper, 'Incorporating a Rapid-Impact 
Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and Malaria' (Hotez 
et al., 2006).   
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be produced by combining delivery of four drugs in a 'rapid impact package' aimed at five NTDs 
(schistosomiasis, trachoma, lymphatic filariasis, onchocerciasis and soil-transmitted helminths).   
 
These diseases could be treated through the same drugs or delivered through a similar 
treatment (MDA), especially as at-risk populations often suffered from more than one parasite 
(called polyparasitism of infestation with two or more parasite species in the same host (Zhou et 
al., 2010, p. 22), with cost-effectiveness results. The NGO 'Global Network for Neglected 
Tropical Diseases' calls this 'The Solution' on their webpage: "We have the tools available to 
defeat the most common neglected tropical diseases (NTDs), and we can do it in our lifetime. 
Unlike many other global health problems we face today, the solution is relatively simple. For 
just 50 cents, we can provide a person with treatment against the most common NTDs for an 
entire year".67  
 
When I interviewed Molyneux, he stated the most important paper where he put down his 
thoughts about neglect but also the successes achieved was already published in 2004 in the 
Lancet.  This first NTD paper was titled: 'Neglected' diseases but unrecognized successes – 
challenges and opportunities for infectious disease control' including six NTDs (Chagas' 
disease, guinea worm, lymphatic filariasis, onchocerciasis, schistosomiases and geohelminths) 
and also polio as his 'neglected' diseases.  His primary motivational argument was that there 
already existed successful interventions that were not being sufficiently implemented.  
Therefore, it was the interventions and the success of interventions that were being neglected 
not the diseases per se.  The contrast that Molyneux wanted to make was the 'inherent 
difficulty' in controlling the 'big three' as opposed to the relative ease of controlling 'chronic 
biologically stable disabling infections' (Molyneux, 2004, p. 382).  For him, NTDs did not arise 
from the MDGs.  Instead the MDGs served as a rhetorical device to demonstrate NTDs had 
been sidelined in funding streams and priority setting.  Therefore, according to Molyneux, the 
MDG argument was applied post hoc and was not itself a spur for activity.  He was surprised by 
the reaction to his 2004 paper and the paper with Hotez and Fenwick the next year in how the 
term NTD caught on: 
 
 "None of this was done deliberately... when I wrote that paper in 2004 and then it just then took 
off, it resonated because we were struggling... we couldn't persuade a donor, be a bilateral 
donor... to actually buy-in to the concept of a single disease, we had to find another thing and I 
was frustrated... from 2004 to significant contributions from a whole range of parties... effective 
partnerships across the patch, I certainly would have dreamt of almost 12 years afterwards 
from first paper, completely unthinkable" (Second interview with author, Molyneux, 2016). 
 
The single diseases stood up poorly to the big three and so the MDGs would later form a useful 
marker in which to provide evidence that NTDs were neglected.  Perhaps more concerning to 																																																								
67 Global Network, http://www.globalnetwork.org/, Accessed 9/12/12. 
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Molyneux was the excessive interest in emerging and re-emerging infectious diseases 
perceived as a threat (Ebola, West Nile virus, nipah virus, and SARS) but a low significance in 
global public health terms (burden of disease) demonstrated by DALYs attributed (ibid., p. 180). 
 
These academic contributions were policy engaged and orientated.  Many papers were later 
published about NTDs, with authors describing what they viewed as the state of affairs and 
what should be done about them.  Further thought and action came in numerous forms from the 
establishment of PLOS Neglected Tropical Diseases journal in 2007, the G8 Meeting in Japan 
in 2008 which set NTDs as a priority, to the Presidential Initiative on NTDs and DFID 
Commitment also in 2008, and the first WHO report on NTDs in 2010.  
4.4.3 The London Declaration and disease lists 
 
A culmination of events occurred on the 30th of January 2012 at 'The London Declaration'.  On 
this day, a collection of international politicians, pharmaceutical CEOs and heads of global 
health organizations, including Bill Gates and the Director of the World Health Organization 
Margaret Chan, descended on London.  What was striking about this gathering of leaders was 
the presence of big pharma, led by Bill Gates as a domineering force in public health through 
the philanthropic Bill & Melinda Gates Foundation.  Gates was already completely changing the 
landscape of public health through his $39.6 billion endowment to the foundation as of 31 
December 2015 from 2006 with priorities set in the areas of health, development and 
education.68  By the account of Molyneux, Gates was central, but there were others who were 
instrumental in making the London Declaration happen: "It was DIFID [UK Government 
Department for International Development] and Gates... supported by pharma partners 
particularly by Andrew Whitty from GSK [GlaxoSmithKline]69 with Lorenzo Savioli driving the 
agenda from the WHO side” (First interview with author, Molyneux, 2016).   
 
This was a meeting for setting goals and forming a collective vision to tackle NTDs, echoing the 
Millennium Development Goals (MDGs) 12 years before.   The MDGs were eight targets set to 
be reached by 2015, addressing the needs of the world’s poorest people and agreed by all 
countries at UN.  The collective prioritization of NTDs and goal-setting at the London 
Declaration was reminiscent of the MDGs but this time directed specifically at NTDs.  Many 
involved in NTDs highlighted the omission by the MDGs and how donor attention and funding 
was directed towards the 'big three'.  As Molyneux describes, policy-makers and politicians, 
"...overfocus on unachievable objectives and targets around the ‘big three’ diseases, which if 
the planet was viewed by aliens would be seen as the only diseases that existed on the planet" 
(2008, p. 509).  																																																								
68 Gates Foundation, http://www.gatesfoundation.org/What-We-Do/Global-Health/Neglected-Tropical-
Diseases, Accessed 2/4/14.  
69 A British pharma company. 
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At the London Declaration, only 10 of the 17 WHO diseases were addressed, as the signatories 
decided that these were the ones that could be controlled or eliminated by the end of the 
decade: the diseases ripe for 'immediate targeted assistance'.  This scope was in line with the 
early papers about integrating successful vertical programmes and explains the pharma 
company involvement.  What the London Declaration was really about was the continuation of 
existing drug donation and research programs with some encouragement of further R&D.  The 
commitments summarized, were as follows: 
 
  
• Sustain, expand and extend programs, drug supply and access 
• Advance R&D, collaboration/coordination 
• Funding for implementation and technical support to evaluate and monitor the interventions 
 
 
Table 7 Summary of London Declaration commitments 	
Through a public announcement of commitments to NTDs the intention was to address this 
shortfall and to coordinate action by 2020.  NTDs were described as such:  
 
"These diseases, many of which have afflicted humanity for millennia, affect more than 1.4 
billion people. They sicken, disable, and disfigure, keeping people in cycles of poverty and 
costing developing economies billions of dollars every year.  Until recently, NTDs saw little 
attention from all but a small handful of dedicated supporters. But as their impact grew clearer, 
more were urged into action" (Uniting to Combat NTDs, 2014, p. 4). 
 
This is a typical description of NTDs.  These are diseases of and causing poverty that have 
been around a long time (some for millennia), disabling and disfiguring more than killing, still 
affecting many with an impact on their economies.  The final point is the one that must be 
emphasized the most.  It is an acknowledgement that NTDs have been a neglected problem 
but the situation is improving.  There are a number of diseases that can be included in this 
group, although it is striking there is no global consensus of what these diseases are or any 
standardized definition, with different organizations defining these diseases differently.  
 
Other organizations' disease lists also tend to have lower more manageable numbers than the 
17 making up the WHO list, with one exception.  The open-access journal PLOS Neglected 
Tropical Diseases’ promotes a list of 38, and the journal is open to suggestions for other 
diseases to be included with appropriate rationale.  The PLOS journal was established in 2007 
through a $1.1 million grant from the Gates Foundation and with Peter Hotez as the founding 
Editor-and-Chief (The Official PLOS Blog, http://blogs.plos.org/plos/2006/09/announcing-plos-
neglected-tropical-diseases/, Accessed 1/5/16).  It has science, policy and advocacy mission 
according to Hotez to: "...be both catalytic and transformative in promoting science, policy, and 
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advocacy for these diseases of the poor" (ibid.).  The main focus is on poverty and the chronic 
aspect of these diseases described as: "poverty-promoting chronic infectious diseases" with an 
impact on "child health and development, pregnancy, and worker productivity, as well as their 
stigmatizing features" (PLOS Neglected Tropical Diseases, 
http://journals.plos.org/plosntds/s/journal-information, Accessed 4/16/5).  The diseases in 
addition to the WHO 17 are many viral and bacterial diseases, and five (loiasis, Japanese 
encephalitis, Jungle yellow fever, cholera and pinta) are those originally listed by Patrick 
Manson.  A British physician he was founding director of the London School of Hygiene and 
Tropical Medicine (LSHTM) and largely behind creating the specialism of tropical medicine.  His 
book 'Manson's Tropical Diseases: A Manual of the Diseases of Warm Climates' (1898),70 was 
definitive in the construction of the tropical disease grouping and lists a catalogue of 65 
infections or diseases from the minor 'prickly heat' to the more serious malaria and yellow 
fever.71  This list will be discussed in greater detail in the next chapter.  
 
The reason for those diseases not to be included in the WHO list appears to be because of the 
lower incidence rate, or lower level of severity, or both.  Japanese encephalitis and jungle yellow 
fever cause periodic outbreaks, which is why the WHO groups them under information for 
emergencies.  Other diseases listed are what the WHO call 'Water-based diseases' and 
diseases that come under 'International travel and health'.  I have ordered these different groups 
into the figure below.   
																																																								
70 Manson developed the 'mosquito theory' of infectious disease transmission, founded the LSHTM in 
1899, and was the first president of the Royal Society.  In fact these diseases reflect partly the older 
tradition of 'diseases of warm climates' included in the title.  He places more of an emphasis on the 
European coping with a tropical environment than what came to be the colonial project of tropical 
medicine, a more all-encompassing programme of health and sanitation. However, while reflecting on the 
older tradition, Manson wanted to break with the medico-geographical distinction and bring in modern 
scientific grounds for differences in disease in temperate and tropical climates (see Edmond, 2006) 
71 The sub-categories Manson outlined are: fevers, general diseases of undetermined nature, abdominal 
diseases, infective granulomatous diseases, animal parasites and associated diseases, intestinal 
parasites, skin diseases, and local diseases of uncertain nature.  One undetermined disease was the yet 
to be discovered cause of sleeping sickness (human African trypanosomiasis) transmitted by the tsetse fly. 
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Enteric pathogens
Diarrheal Foodborne
Disease
Scabies
Myiasis
Leptospirosis
Cholera
Japanese encephalitis
Water-related
Diseases
Giardiais
Loiasis (Loa loa)
Toxocariais and other Larva Migrans
Rift Valley Fever
Viral hemorrhagic fevers
Bartonella
Bovine Tuberculosis in Humans
Paracoccidiomycosis
Mycetoma
Treponematoses
No Category
International Travel and 
Heath Diseases
Amebiasis
Balantidiasis
Cholera
Japanese encephalitis
Jungle yellow fever
Loiasis (Loa loa)
Treponematoses (Pinta)
Manson’s Tropical
Diseases
 
Figure 5 PLOS NTDs in addition to the WHO 17 
(Figure by author. Source material from PLOS Neglected Tropical Diseases, 
http://journals.plos.org/plosntds/s/journal-information, Accessed 5/4/14, WHO, 2013b) 
 
PLOS has more reason to have a wide scope as an academic endeavour, where there will be 
public health and biological similarities across a wide range of diseases.  The main restriction is 
the 'big three' being excluded, as there exists many other outlets for them. 
 
To conclude this section, the variation in the number of diseases is representative of how NTDs 
are diversely described.  Therefore the NTD label is not a purely biomedical description, as it is 
related to several social characteristics, such as poverty, stigma and voicelessness.  I will go 
into more detail on categorization in the next section.  Teasing out ideas about why certain 
categories or characterizations are used will provide insight about the 'claims-making' of policy 
problems (Conrad and Barker, 2010, p. S68).  NTDs can thus be understood through other 
groupings than individual diseases.  The different ways to divide up these diseases put forward 
rationale for disease inclusion.  What these sub-groupings of NTDs say about the criteria 
determining which diseases are included and why will be discussed next. 
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4.4.4 Different ways to cut a pie 
 
The descriptor the WHO commonly uses for NTDs is by pathogen – ranging from viral (dengue 
fever and rabies) and bacterial (leprosy and blinding trachoma) to the less well-known protozoa 
diseases, including Chagas (closely linked with Latin America) and African sleeping sickness 
(only affecting sub-Saharan Africa).  Then there is a large group of helminths (worms, such as 
guinea worm, lymphatic filariasis and schistosomiasis) see Fig. 6 below.  
 
 
Figure 6 NTDs by pathogen  
(Cotton, 2015) 
Another pathogen distinction the WHO uses has been macro and micro pathogens.  They call 
this an 'arbitrary classification', but also point out that the division, "...enabled Anderson and 
May in 1991 to elucidate principles governing the population dynamics, epidemiology and 
courses of infection of pathogens that severely impair human health" (WHO, 2010, p. 39).  
Therefore, they were informed by the basic distinction in order to derive epidemiological 
principles.  Microparasites have simple life cycles and can replicate within the host causing a 
range of infections from acute, recurrent, inapparent to subclinical.72  On the other hand, 
macroparasites have complex life-cycles involving intermediate and reservoir hosts, so 
infections tend to be chronic rather than acute, resulting in lower mortality rates (ibid.).  The 
pathogen distinctions are helpful to understand that the worm macroparasite group is the largest 
and mostly disability inducing, compared with the microparasites of which particularly the 
viruses and protozoa result in higher mortality.   
 																																																								
72 The WHO defines infection as: "acute (death or recovery), recurrent (repeated growth and decay of 
organisms in the host) or unapparent (dormant and difficult to detect) to subclinical (symptomless but 
detectable)" (WHO, 2010). 
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Box 1 NTDs as micro and macro parasitic pathogens  
(WHO, 2013a) 
Another distinction is coverage by geographic region, for which diseases are most prevalent 
and where.  The table 8 divides NTDs by regions.73   
   
 
 
 
 
 
 
																																																								
73 For a breakdown of country classification by region See  United Nations Statistics Division: 
http://unstats.un.org/unsd/methods/m49/m49regin.htm#developed, Accessed 2/4/14. 
Causes of neglected tropical diseases:  
Microparasitic pathogens Macroparasitic pathogens 
• Buruli ulcer 
• Chagas disease 
• Dengue 
• Human African trypanosomiasis 
• Leshmaniases 
• Leprosy 
• Rabies 
• Trachoma 
• Treponematoses 
 
• Cysticercosis 
• Dracunculiasis 
• Echinococcosis 
• Foodborn trematodiases 
• Lymphatic filarias 
• Onchercerciasis 
• Schistosomiasis  
• Soil-transmitted helminthiases 
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Table 8 NTDs by region  
(WHO, 2007, p. 3) 
Africa has the highest number of 14 NTDs, followed by the Americas at 10 and where Chagas is 
unique.  In the Americas there are also two tiers of specificities and priorities.  For the Western 
Pacific region, which includes China, there are four diseases including dengue, although 
incidence is now rising in Brazil.  Both the Americas and Western Pacific regions share 
lymphatic filariasis, schistosomiasis and soil-transmitted helminths as problems.  South East 
Asia, which has many developed countries in the region, has NTDs that are targeted for 
elimination.  The European and Eastern Mediterranean regions as to be expected have lower 
Specificities and priorities by WHO region 
 
Africa Blinding trachoma 
Buruli ulcer 
Cysticercosis 
Dracunculiasis 
Echinococcosis 
Human African trypanosomiasis 
Leishmaniases 
Leprosy 
Lymphatic filariasis 
Onchocerciasis 
Rabies 
Schistosomiases 
Soil-transmitted helminthiasis 
Yaws 
The Americas  
 
First tier 
Blinding trachoma 
Chagas disease 
Leprosy 
Lymphatic filariasis 
Onchocerciasis 
Schistosomiasis 
Soil-transmitted helminthiasis 
 
Second tier 
Fungal and ectoparasitic skin diseases 
Leishmaniasis 
Parasitic zoonoses 
The Eastern Mediterranean  
 
Leishmaniases 
Schistosomiases 
Soil-transmitted helminthiasis 
Rabies 
Other zoonotic diseases 
European Anthrax 
Brucellosis 
Rabies 
Soil-transmitted helminthiasis 
Tularaemia 
South-East Asia  
 
Diseases targeted for elimination 
Anthroponotic leishmaniasis (Kala azar) 
Leprosy 
Lymphatic filariasis 
Yaws 
The Western Pacific  
 
Dengue 
Lymphatic filariasis 
Schistosomiasis 
Soil-transmitted 	
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levels of NTDs and the severity is lower, including 'other zoonic diseases' in the table as well as 
anthrax and brucellosis, which are not typically classed as NTDs.   
 
These country and regional NTD characteristics challenge an all-encompassing view of the 
diseases.  NTDs as a category applied to the African region is appropriate as this region has 14 
of the 17 NTDs.  However, for other regions such as the Americas and the Western Pacific, the 
number of NTDs is more limited and so diseases have a specific regional character.  Therefore, 
it is the individual diseases themselves that make the NTD grouping the most unclear, 
contentious and debatable, a point that I will turn to in the next section. 
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4.5 Listing diseases and the politics of categorization 
 
As Rosenberg describes, "...disease classifications serve to rationalize, mediate, and legitimate 
relationships between individuals and institutions in a bureaucratic society" (in Rosenberg & 
Golden, 1992, pp. xxi).  What is at stake in listing diseases and what are the consequences of 
the creation of categories to include or exclude?  The table below compares the WHO list of 17 
diseases to the London Declaration list of 10 diseases, also pointing out the five diseases 
targeted by United States Agency for International Development (USAID with the project 
ENVISION) through MDA.  These five are controlled and treated through what is generally 
regarded as cheap and effective drugs.  However, some drug improvements are needed, such 
as medicines effective at killing or sterilizing adult worms for lymphatic filariasis and making 
praziquantel more child-friendly (effective at lower doses and less bitter taste).  For these five 
diseases therefore, addressing neglect is to provide funding and support for existing MDA 
programs and ensure implementation.74  This is an important point as for a core group of 
diseases the main strategy is to continue MDA and ensure implementation, rather than more 
R&D or funding. 
Table 9 WHO lists of diseases compared with the London Declaration list 
(Compiled from: Uniting to Combat NTDs, 2015; WHO, http://www.who.int/topics/emerging_diseases/en/, 
2015, Accessed 7/4/14)  
																																																								
74 Prevention strategies exist related to diagnosis, education, improved water and sanitation or other 
strategies (table salt/ cooking salt fortified with DEC for lymphatic filariasis).   
WHO 17 NTDs MDA (also 
constitutes USAID 
targeted list) 
Targeted for 
elimination or 
eradication 
London 
Declaration 
1. Buruli ulcer    
2. Chagas disease  x x 
3. Dengue and Chikungunya    
4. Dracunculiasis (guinea-worm 
disease) 
 x x 
5. Echinococcosis    
6. Endemic treponematoses (Yaws)  x  
7. Foodborne trematodiases    
8. Human African trypanosomiasis 
(sleeping sickness) 
 x x 
9. Leishmaniasis  x x 
10. Leprosy (Hansen disease)  x x 
11. Lymphatic filariasis x x x 
12. Onchocerciasis (river blindness) x x x 
13. Rabies  x  
14. Schistosomiasis x  x 
15. Soil-transmitted helminthiases 
(hookworm, roundworm, 
whipworm) 
x  x 
16. Taeniasis/Cysticercosis    
17. Trachoma x x x 	
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These inclusions and exclusions point to what the nature of NTDs might be.  The other five 
diseases targeted by The London Declaration are being controlled and treated through 
intensified disease management, and so targeted by the WHO for elimination or eradication.75  
Excluded from the London Declaration is dengue, which has been somewhat an oddity in the 
NTD group (affecting richer communities and not being a chronic disease).  I discuss dengue 
and its contradictory status as not being a disease of poverty or characteristically chronic in 
more depth in the next chapter.   
 
Also excluded are six other diseases: buruli ulcer, cysticercosis/taeniasis, echinococcosis, 
foodborne trematodiases, rabies, endemic treponematoses (yaws).  These other diseases sit in 
a sub-category in that they are either treatable by antibiotics or animal/food management 
requiring public health measures in behaviour modifications and regulations.  The point is that a 
variety of common tools exist to treat them but they still remain persistent because what is 
required is more of a systematic change.  Therefore, the London Declaration focuses on a more 
targeted 'tool-ready' list (and USAID even more so) where there is one easily deployable and 
effective measure of MDA.  
 
The earliest NTD report by the WHO, the 'Report of an International Workshop Berlin' (2004) 
'tools for control' were a focus.  The discussion focused on the, "...development of new tools and 
refinement of existing ones" (ibid., p. 41).  Effective control tools are available for many NTDs 
but research is still needed according to the WHO in understanding the pathogens (through 
genomics or molecular biology) and to identify problems in implementation and determine their 
economic viability.  In particular geographical coverage can be limited by diagnostic and 
treatment protocols (ibid., p. 42).  Of the tools available, MDA is emphasized as "...safe, rapidly 
effective, and easy to administer in resource-poor settings, delivered by non-specialists, only 
once-yearly contact... major open-ended drug donations are making these tools available to all 
in need, as long as needed" (ibid., p. 56).  For other diseases the development is required of 
tools, "...simple and practical for use under difficult conditions, as well as safe and effective" 
(ibid., p. 55). 
 
In deciding whether an effective control tool exists or not, NTDs are evaluated on whether they 
are 'tool-ready' for public health interventions.  Tool readiness depends on several questions: 
What options are available for decision-making and implementation?  What is the public health 
strategy and plan for action?  Molyneux and Ward (2015) call the successful development 
avermectin and artemisinin as 'public health tools' as recognized by a Nobel Prize.  Hotez and 
Pecoul (2010, p. 1) had previously outlined how 'tool deficient' NTDs are as a group, in the 
options and effectiveness tools available.   																																																								
75 Dracunculiasis and leprosy are respectively close to eradication and elimination.  Human African 
trypanosomiasis stands out in prevention and treatment, although elimination is viewed as possible.  
Similarly Chagas disease and visceral leishmaniasis are viewed as controllable.   
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They questioned if NTDs had the correct tools available to them, referring to the whole plethora 
of interventions for NTDs including: drugs, operational research on implementation, field-based 
diagnostics, health education for prevention, case detection and treatment, vector-control 
strategies as well as improvements in water and sanitation.  Although they make the point that 
all NTDs are tool deficient in that tools exist to control, or even eliminate NTDs, but the tools and 
implementation strategies are "suboptimal, incomplete, or inadequate to sustain elimination 
efforts... Consequently, substantial investments in R&D are urgently needed to develop new-
generation control tools and strategies for their improved use and implementation" (ibid, p. 2–3).  
What comes across is a 'mixed bag' of policy tools available for NTDs.   
 
The term 'policy tool' has lineage within the public policy literature – from the 1980s and 1990s 
policy design literature to a more current work on instrumentation through policy strategy and 
implementation (Howlett, 1991).  A ‘tools approach' by government is a popular means of 
intervention used to overcome impediments to policy-relevant actions (Schneider & Ingram, 
1990, p. 510), and moving the focus away from policy impact to policy choice (Salamon & Lund, 
1989).  Gales and Lascoumes (2007) describe a policy tool as a 'micro device', which can be 
paralleled in health policy with individual interventions for a disease.  I have found that for NTDs 
the language of 'tools' becomes an essential part of talking about solutions and tools are linked 
to innovation.  As pointed out already, varied 'tool-kit' is imagined for dealing with NTDs.  Some 
diseases are described as 'tool-ready', meaning that they have the appropriate innovations at 
hand, or 'tool-deficient' when innovation is lacking.  These descriptions add to a technical 
characterization to the NTD policy problem where more innovation is equivalent to more tools to 
have at one's disposal. 
 
The Table 6 below from the 2007 WHO report ''Global Plan To Combat Neglected Tropical 
Diseases 2008–2015' shows which NTDs are determined as tool-deficient or 'tool-ready'.  Here, 
tool-ready refers to interventions that can be used effectively to control or eliminate NTDs.  The 
report refers to both NTDs and zoonoses, which may be why anthrax, brucellosis and Japanese 
encephalitis are included in this list.  The table displays a relatively even split between NTDs 
that are tool-ready or deficient.  
 
Tool-ready diseases targeted for elimination 
or eradication by resolutions of the World 
Health Assembly and regional committees 
Dracunculiasis 
Leprosy 
Lymphatic filariasis 
Other tool-ready diseases Anthroponotic leishmaniasis 
Blinding trachoma 
Cysticercosis 
Echinococcosis 
Rabies 
Schistosomiases 
Soil-transmitted helminthiasis 
Yaws 
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Tool-deficient diseases Anthrax 
Brucellosis 
Buruli ulcer 
Chagas disease 
Dengue 
Human African trypanosomiasis 
Japanese encephalitis 
Leishmaniases 
 
Table 10 'Selected neglected tropical diseases and zoonoses to be addressed within the Global 
Plan' 
(Adapted from WHO, 2007, p. 2) 
In other words, what is included and what is not, is important to determine the character of the 
NTD distinction.  For example excluded from the NTD group are diarrheal diseases.76  One 
reason for the exclusion could be that these diseases have existed as one of the "major tropical 
scourges but did not fit the 'insect-vector model' of the turn of the 20th century" (Worboys in 
Bynum & Porter, 2013, p. 522).  Diarrheal diseases are 'WASH-related diseases', with WASH 
standing for inadequate water, sanitation, and hygiene, with some NTDs included in this list.77  
Infections that cause diarrheal disease for example are cholera, dysentery and typhoid.  The 
lines drawn are fuzzy and stretched, have been based on historical contingencies.  Diarrheal 
diseases form part of an even broader list of 'infectious diseases of poverty', listed in Box 2: 
 
 
Box 2 List of infectious diseases of poverty  
(Adapted from WHO, 2012)  	
Malnutrition (or more specifically under-nutrition or nutrient deficiency) does not make an entry 
into this list of infectious diseases of poverty.  First it is a serious public health problem in poor 
communities but as a 'condition' rather than a 'disease' so it stands alone from the diseases of 
poverty but is intricately linked with disease as both a risk factor and outcome.  Second it is also 
a MDG so more often included under the banner of infant mortality and maternal mortality, with 
treatable childhood diseases (measles, pertussis and polio). 
 
																																																								
76 Diarrheal diseases are infections of the intestinal tract, with the two most common etiological agents are 
Rotavirus and the bacteria E. coli. 77 The WASH NTDs are soil-transmitted helminthiases, guinea worm and schistosomiasis, all causes by 
parasitic worms except trachoma, which is caused by bacteria.  
Infectious diseases of poverty (NTDs in bold) 
 
• the big 3, also called the three primary poverty-related diseases (PRDs):  
HIV, TB and malaria diarrheal diseases 
• salmonella infections  
• helminth  
• bacterial pneumonia & meningitis 
• kinetoplastids (human African trypanosomiasis, Chagas disease, and leishmaniasis) 
• dengue 
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As should be clear by now, what makes the NTD list and what does not (and indeed many other 
lists in public health categorization) appears arbitrary in some ways.  Therefore, Bhopal et al. 
question the usefulness of the NTD grouping, specifically with different organizations referring to 
various sub-categories (and even some additions) to the larger WHO grouping:  
 
"Different stakeholders using the same term at any given time to encompass different diseases 
makes it difficult to set specific targets for control or to lobby for funding for NTDs as a group. 
Consequently, attention and funding are more aligned with the success of advocacy groups for 
individual diseases, with heavy reliance on pharmaceutical company donations, than to any 
objective criteria such as disease burden, attributed deaths or the need for new drugs, 
diagnostics and vaccines" (2013, p. 1).   
 
Their conclusion is that the NTDs that get the most attention are those part of advocacy groups 
for individual diseases and it appears in referring to pharma donations that they means the five 
NTDs controlled through MDA.  It is true that individual diseases are still being lobbied for by 
deploying shorter lists from the WHO 17, through USAID or the London Declaration (with five 
other diseases).78  Nick Kourgialis from the NGO Helen Keller International notes that it is an 
'interesting discussion' whether to expand the range of diseases from these core five  (Interview 
with author, Kourgialis, 2016).  He cites pressure from organizations that represent the other 
diseases.  However, he also recognizes the difficulty in trying to cover a large range of diseases 
rather than focusing on the smaller group where public health tools are already available to 
address them, especially where eradication or elimination appears close:  
 
"...I mean, you know, there's been a lot of debate about that because there the question is 
whether we, detract from the current efforts to really finish the job to eliminate the diseases that 
we're focusing on now and there's a lot of investments that still need to be made and we don't 
want to lose that momentum or progress that's been achieved, because if we stop that, we kind 
of revert back to situation you had several years ago" (Interview with author, Kourgialis, 2016). 
 
What Bhopal et al. (2013) ignore is the historical contingency and scientific challenge that has 
lead to this position of some diseases being 'tool-ready' and others not, which is why five NTD 
diseases are targeted.  Furthermore, the solution they propose is a committee within the WHO 
Department of Control of Neglected Tropical Diseases, to regularly review, "...which new 
diseases should fall under the NTD umbrella" and how the, "...successful branding technique of 
the NTDs can be magnified to deal with current and future neglected diseases" (ibid.).  The 
claim of a lack of coordination and long-term vision is not well grounded, as it has been a 
defining aim of the NTD advocacy campaign.   
 																																																								
78 These are: onchocerciasis, schistosomiasis, trachoma, lymphatic filariasis, soil-transmitted helminthiasis 
(whipworm, hookwom, roundworm). 
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The clearest example was the London Declaration where coordination was evident across 
stakeholder groups in projecting a long-term vision.  This vision has been further re-enforced by 
the Sustainable Development Goals and WHO country NTD plans.  To be coordinated, new 
multi-partner NGOs have been established ('The Global Network for Neglected Tropical 
Diseases' and 'Uniting against NTDs) and existing NGOs have adapted their remits (e.g. Helen 
Keller International).  The contention of Bhopal et al. is to look towards the WHO to provide 
better leadership on NTDs.  However, this argument does not take into account the leadership 
that has been provided by other groups such as NGOs, and activist scientists (which I will 
profile in Chapter 6). 
 
To highlight the role of NGOs but also their connection to activist scientists and the Bill and 
Melinda Gates Foundation (BMGF) as funders, see the table below.  The major 12 NGOs 
addressing NTDs span in their focus from treatment, funding, information, network/advocacy 
and as I have mentioned already sight charities and worm charities.  Two activist scientists that 
I will later profile in Chapter 6 have had a central involvement in almost half of the NGOs, and all 
of the NGOs apart from one (Deworm the World, shaded in table) are directly funded by the 
Gates Foundation.  Peter Hotez is the president of one NGO (The Sabin Vaccine Institute), 
which spun out a key initiative (The Global Network).  Alan Fenwick established an NGO (SCI) 
and helped to found another (The End Fund) and is a partner of one more (Deworm the Worm).  
Incidentally one of the founders of 'Deworm the World' was development economist Michael 
Kremer who had written an influential paper on deworming three years before, and I will expand 
on the discourse surrounding this paper in Chapter 7.  Advocacy for NTDs is an elite movement 
with many of founders of the NGOs being scientists, doctors and academics or from existing 
organizations. 
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SIGHT CHARITIES
(WITH WIDENED 
REMIT)
WORM
CHARITIES/ 
INITIATIVES
Project Zero Campaign 
Huffington 
Post 
2016
London 
Declaration
2012
Helen Keller 
and George 
Kessler, wine 
merchant
1915
BMGF -
BMGF -
BMGF, The 
END Fund, 
Merck, Pfizer
-
http://www.huffingtonp
ost.com/topic/project-z
ero
- Raising funds for 
DNDi
Uniting to Combat NTDs
http://unitingtocombat
ntds.org
- Annual target report
Helen Keller
International
www.hki.org/
John Wilson a 
blind activist
1950
2002
Imperial 
University, 
London
2007
Evidence for 
Action
1986
Run by the 
Carter Center
BMGF, The END 
Fund, USAID, 
Conrad Hilton 
Foundation, 
DFID, EU
BMGF, USAID
The END Fund, 
Good Ventures, 
GiveWell, 
Children's 
Investment Fund 
Foundation
BMGF, CDC, DFID
-
Alan Fenwick 
founded
Alan Fenwick 
a partner 
through SCI
Sightsavers
International
http://www.sightsavers.
org
Deworm the World
Initiative
https://www.evidenceact
ion.org 
Guinea Worm
Eradication Campaign
https://www.cartercente
r.org
Schistosomiasis Control 
Initiative (SCI)
https://www.imperial.ac.
uk/schistosomiasis-cont
rol-initiative
The END Fund
FUNDING
INFORMATION
www.end.org/
- Funds NGOs
Policy Cures
Legatum 
Foundation 
and others
2012
Mary Moran, 
George 
Institute
http://www.policycure
s.org/
- G-FINDER reports
2004
BMGF, 
Legatum 
Foundation, 
Campbell 
Family 
Foundation
BMGF, Wellcome 
Trust, AusAID, 
DNDi, Deutsche 
Stiftung 
Weltbevölkerung
Alan Fenwick 
helped found
-
Global Network for
Neglected Tropical
Diseases
Sabin Vaccine 
Institute
2006 BMGF Peter Hotez, 
establishedNETWORK/
ADVOCACY
www.globalnetwork.
org/
- End 7 Campaign
 
Table 11 Major NTD NGOs by type 
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The diseases that these NGOs cover all vary.  Only 'Project Zero' by the Huffington Post 
working with DNDi covers the full WHO 17.   A yearlong media and fundraising campaign 
funded by the Gates Foundation, it was launched in 2016 to raise awareness around NTDs and 
efforts to eliminate them.  The question of which diseases fall under the umbrella of NTDs is an 
ongoing debate but one that reflects the competitive and dynamic nature of global public health 
itself, for which reviews take place continually, including by the WHO.  Now that NTDs have 
some policy currency, there is an obvious temptation to expand the grouping (as the WHO has 
done, moving from 13 to 17 diseases).   
 
However, there is a concern about diluting the branding that is recognized by the WHO and a 
need for coherence (an aspect of the WHO's strategic remit) in why diseases are included or 
not.  This criteria on inclusion was formalized on January 2016, at the 138th session of the 
WHO Executive Board, with the request for the Strategic and Technical Advisory Group (STAG) 
for Neglected Tropical Diseases to develop a "systematic, technically driven process for the 
adoption of additional diseases as NTDs" (WHO, 2016b).  This includes proposed criteria for 
classifying a condition as an NTD and process for review of the list of NTDs.  The first point has 
been that WHO Regional Offices (ROs) have their own lists, "...which reflect diversity in 
geographical distribution of these diseases, and in some regions, they are considered the 
responsibility of other Departments" (ibid., p 1-2).  The second point is on the ground of what 
advocacy connected to being labeled an NTD could do:  
 
"There are other conditions that could be classified as NTDs for the purpose of advocacy to 
motivate action or research for the development of new solutions in low resource settings. 
These are diseases or conditions that constitute important health issues in populations affected 
by poverty, but they do not fit the programmatic context as currently defined in WHO’s HQ NTD 
Department’s portfolio. Such diseases or conditions may however be included in the NTD list if, 
based on STAG recommendation, they can benefit from increased international attention in 
terms of advocacy, mobilization of resources for R&D and development of highly needed novel 
products and tools, or approaches for control or elimination" (ibid., p. 2). 
 
Criteria for inclusion is given as: 
Box 3 NTD disease conditions criteria for inclusion (Adapted from WHO, 2016) 
Disease conditions that: 
1. disproportionately affect populations living in poverty; and cause important morbidity 
and mortality – including stigma and discrimination – in such populations, justifying 
a global response. 
2. primarily affect populations living in tropical and sub-tropical areas 
3. are immediately amenable to broad control, elimination or eradication by applying one 
or more of the five public health strategies adopted by the Department for Control of 
NTDs and/or 
4. are relatively neglected by research – i.e., resource allocation is not commensurate 
with the magnitude of the problem – when it comes to developing new diagnostics, 
medicines and other control tools 
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This demonstrates flexibility on the part of the WHO.  The regional office for the Americas has 
two diseases not included in the WHO 17: fascioliasis and hydatidosis.  However an 
overzealous reviewing process presents a danger, as I have noted already, in diluting the NTD 
brand if the diseases listed are widened or changed too frequently.  For example the case has 
been made for surgical conditions (Ozgediz & Riviello, 2008) and the WHO also lists 'other 
neglected conditions', which are described "in addition to the listed 17 NTDs".79  While sense 
needs to be made out of the label, caution should be applied in the use of the brand, especially 
if the end is in sight for some NTDs but not others and even though that illusive end point is still 
yet to be reached. 
4.6 Categories of inclusion or exclusion 
 
What is included or not can tell us what importance we place on one thing over another.  An 
often cited definition of categories in STS, used as a starting point by Bowker and Star in their 
monograph on classification (1999), is by Goodwin: 
 
“In so far as the coding scheme establishes an orientation toward the world, it constitutes a 
structure of intentionality whose proper locus is not the isolated, Cartesian mind, but a much 
larger organizational system, one that is characteristically mediated through mundane 
bureaucratic documents such as forms” (Goodwin 1996, p. 65). 
 
This description already points towards categorization being more than a means of ordering but 
as reflecting a way of looking at the world that is part of larger hierarchies and power structures. 
In 'Sorting things out: Classification and Its Consequences', Bowker and Star cover an extensive 
array of case studies showing categories as historically situated artifacts with membership of 
certain groupings (Bowker & Star, 1999, p. 285). The contribution of Bowker and Star is in not 
theorizing categories originating from the abstract sphere but also as a product of communities 
of practice or the social world, where we conduct certain activities together.  They identify two 
sets of relationship that exist along the same trajectory: between people being given 
membership and objects being naturalized.   
 
Bowker had noted earlier that standardized representations are needed so that uncertainties or 
conflicts over meaning are overlooked, seen particularly through how "...medical classifications 
split up the world into useful categories" (1998, p. 187).  Medicine may require more of an 
ordering that other areas of human endeavor and the effect of such can be deep and 
widespread.  Chaufan et al. note in relatedly that: "medical categories have the ability to create 
a social and moral order with a life of its own" (2012, p. 793). 
																																																								
79 the other neglected conditions are chronic suppurative otitis media (CSOM), mycetoma, nodding 
syndrome (NS), podoconiosis, scabies, snakebite and strongyloidiasis (van de Sande et al., 2014). 
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4.7 Global campaigns and the 'Sustainable development goals' 
 
Other diseases of poverty do have their own existing successful groupings.  Cholera, dysentery 
and typhoid all have vaccinations available to prevent illness and are closely associated with the 
WASH campaign, including a number of initiatives such as the World Water Day, World Toilet 
Day, International Decade for Action 'Water for Life' 2005-2015.80  These campaigns are public 
facing.  For NTDS there have also been global campaigns against individual diseases.   
 
One of the first internationally coordinated initiatives addressing a NTD was the Onchocerciasis 
Control Programme (OCP), launched in 1974, with UN co-sponsorship (Liese, Rosenberg, & 
Schratz, 2010).  OCP marked a highpoint for the WHO in the considerable success achieved.  
Accounts estimate a total of 27,000 individuals saved from going blind and 3 million children 
were kept safe from onchocerciasis (Brown and Cueto in Parker & Sommer, 2010, p. 24).  The 
programme was further boosted by the efforts of the Carter Center since 1996 with the goal of 
eradication, followed by regional programs in Africa and the Americas.  Guinea worm (also 
pursued by the Carter Center since 1986), leprosy and lymphatic filariasis were other notable 
global programs,81 all of which were essentially elimination and eradication programs.  The 
OCP had come after the failure of the 'Global Malaria Eradication Programme', which began in 
1958 with the monumental task to eradicate malaria, but was formally abandoned in 1969  
(Feachem et al., 2010).  The failure82 may have had ongoing effects for the chosen methods of 
intervention for NTDs being drug rather than environmental based, as the main method used in 
the Programme was chemical insecticide spraying of DDT to kill mosquitos.    
 
The London Declaration was the most high-profile public-facing event for NTDs and it was 
preceded by the creation of the 'Global Network for Neglected Tropical Diseases' in 2006.  The 
Global Network is an advocacy group established by the Sabin Vaccine Institute, with Peter 
Hotez as the president, and has funding from the Bill & Melinda Gates Foundation.83  The 
Global Network runs the 'END7 campaign', launched in 2012, with the focus is on the seven 
most common NTDs that represent 90% of the total NTD disease burden.   
 
The Global Network is different from the other campaigns discussed in that it is specifically an 
advocacy program to raise the profile of NTDs with the public, philanthropists, policy makers 
and politicians.  Kari Stoever who was the managing director noted how single disease 
programs had been operating independently but the idea behind NTDs and the work of the 																																																								
80 UN, Water http://www.unwater.org/campaigns/world-water-day/en/, Accessed 1/4/14.   
81 Notable global programs include the: Guinea Worm Eradication Program launched in 1980 at CDC; The 
Global Alliance for the Elimination of Leprosy launched in 1999; and The WHO Global Programme to 
Eliminate Lymphatic Filariasis (GPELF) launched in 2000. 
82 Malaria was eliminated in "Taiwan, much of the Caribbean, the Balkans, parts of northern Africa, the 
northern region of Australia, and a large swath of the South Pacific" (Gladwell, 2001).  
83 Global Network, http://www.globalnetwork.org/, Accessed 6/4/14 
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network was to group the diseases together (Interview with author, Stoever, 2016).  Similarly 
one of the founding partners of the network was Helen Keller International, an NGO concerned 
specifically with blindness and malnutrition rather than NTDs generally.  They found that 
organizationally they would need to change their strategy to adapt to the new NTD banner, with 
the approval of funding agencies such as USAID:  
 
"...there was not a lot of collaboration across program areas, until, these were, particularly by 
USAID were put under the umbrella of NTDs and, and there were five targeted diseases. So in 
order to pursue this integrated approach that was being you know, advocated by the USAID we 
had to add capacity to address these other diseases too, schistosomiasis and LF... the 
integrated approach was really what was required and, and everybody was interested in the 
logic of that and the fact that these particular drugs that were focused on were tool-ready and 
there was really a strong case to be made for why the focus should be on these drugs, the 
commitment of the drug companies and other factors. And, you know, many of the people at the 
time had developed a very compelling case to Congress... with the drug companies, convincing 
people that the real progress could be made in addressing these problems. So for us in order 
to, to really be part of this effort we had to expand the scope of our activities " (Interview with 
author, Kourgialis, 2016). 
 
An 'integrated approach' would allow Helen Keller to benefit from cost efficiencies in order to 
scale up efforts and also market the diseases better.  The adoption of the approach was 
spurred by, in 2006, the launched an integrated NTD Control Program by USAID.  The program 
was the first 'global effort' to, "...support country programs to integrate and scale up delivery of 
preventive chemotherapy for five targeted NTDs".84  It was based on donations of treatments, to 
fund the scale up of treatment, working with disease-specific national control programs to 
integrate MDA.  Stoever describes the intentions of the network and how momentum was built: 
 
"These programmes were operating quite robustly as single disease programs around the world 
but no one had put them all together in any single country and scaled it.  So the Global Network 
was really there to help facilitate that, bring resources, technical experts together to talk about 
how you would then take vertical programs and create a horizontal approach and cost efficiency 
for that.  We were awarded a grant from the Bill & Melinda Gates Foundation and that enabled 
us to set up a governance mechanism that would facilitate global scale up.  We were quite 
successful on the advocacy front, mostly in the US to begin with, which enabled countries to 
access new money to begin the harmonization process while the Global Network and partners 
advocated for more funding.  This became a tipping point issue because we started to get 
access to private donors as well as other governments and foundations.  We were  featured at 
the Clinton Global Initiative three years in a row, and then went to Davos in 2009, so we were 
getting lot of exposure around the idea" (Interview with author, Stoever, 2016). 																																																								
84 USAID’s Neglected Tropical Disease Program, http://www.neglecteddiseases.gov, Accessed 5/4/14.  
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The success of the Global Network was premised on the political connections forged, on 
platforms such as the Clinton Global Initiative Annual Meeting and annual World Economic 
forum in Davos.  In the US the connection with Congress – going right up to the president – was 
also crucial. 
4.8 Political influence 
 
Previously Jimmy Carter (president 1977–1981) had promoted onchocerciasis eradication after 
his presidency, through the work of his private foundation the Carter Center. However, NTDs 
were soon to attract attention of a current president.  Molyneux puts the connection with the 
Bush Whitehouse as being down to Stoever, who was the Managing Director of the Global 
Network (First Interview with author, Molyneux, 2016).  This involved liaising with the chief of 
staff on the idea of NTDs when President George W. Bush (2001–2009) went to Africa in 2008 
and he felt he had to announce something.  Bush later announced $350m in funding for NTD 
treatment over a 5-year period.  He incorporated integrated NTD control through MDA and the 
scale up of national programs into the US government's broader global health agenda, 
especially in sub-Saharan Africa (Hotez & Goraleski, 2011).  Barack Obama then expanded 
programs through his Global Health Initiative.   
 
One NGO worker also spoke of the work of Hotez advocating in Washington, tailoring his 
message to the audience, including the staff members of Senators in Congress:  
 
"you have to understand your audience and so you really have to tailor the message to 
particular individuals and try to find whatever levers you have, that you have to switch to get 
them on board. And you need certain champions within different settings... I remember, Peter 
Hotez visited the Hill and talked to some people from book parties where you know, very 
religious and talk about the Biblical plagues and try to make an association of these diseases 
with those, the old biblical plagues and try to you know, create a connection in mind with the 
impact that these diseases were having. And, and so you use whatever you can to convey the 
importance of this and to link it to people’s own concerns and attitudes. So yes, it doesn’t take 
just one approach but you really have to lay out the information and, and provide an economic 
argument, certainly, but also talk about people's personal stories whenever you can" (Interview 
with author, NGO worker, 2016). 
 
In the UK advocacy activity in political circles was matched, taking place there directly through 
activist scientists.  Stephen O'Brien was an MP of Eddisbury in the Liverpool area as well as the 
International Development Minister85 and was connected with Molyneux at the Liverpool School 
of Tropical Medicine (LSTM).  Born in Tanzania, O'Brien founded and chaired an All Party 																																																								
85 In 2015 O'Brien would become the Undersecretary Humanitarian Affairs at the UN. 
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Parliamentary Group on Malaria and Neglected Tropical Diseases in 2004 and pushed the 
agenda in the British Parliament.  Molyneux viewed his "...sympathy for the cause having been 
born in Tanzania" (First interview with author, Molyneux, 2016).  O'Brien argued on the value for 
money point that, "(T)hose initiatives potentially have the most phenomenal value for money for 
the British people, as UK taxpayers, to be part of supporting" (House of Commons International 
Development Committee, 2012).   
 
Another high-profile politician, Baroness Helene Hayman became interested in NTDs through 
her son who was working with the Sabin Vaccine Institute.  In 2011 when she completed her 
appointment as Lord Speaker, she took over as Vice-Chair of the all-parliamentary group.  The 
group was set up to deal with malaria, and had added NTDs to its remit in 2009.  Through her 
political career Baroness Hayman has seen the competition between diseases, in terms of, 
“what is at the top of current political priorities, or public awareness” and is why she, "...favours 
an evidence-led approach taking into account value for money where NTDs score strongly” 
(Interview with author, Hayman, 2013).  NTDs have become a bi-partisan, cross party issue and 
this wide political support has often relied on individual links to political decision-makers. 
 
The political backdrop has also been important in determining the type of advocacy campaign 
pursued.  As Chaufan et al. (2012) point out the importance of political opportunity structure of 
the US system for disease specific research approach to funding.  I argue also the UK system is 
receptive to a 'disease specific approach to funding' along with the emphasizing of disease 
categories that has created a particular opportunity structure.  In reference to Alzheimer’s 
disease (AD) emerging as a major health and social concern they contend: 
 
"The emergence of AD as a social problem that would require significant resources occurred 
within political and historical contexts that provided a reasonable probability that such a disease 
specific research approach to funding would succeed. These contexts were given by existing 
opportunity structures in America that support what one observer has called the 'health politics 
of anguish'... Disease-specific or 'categorical' approaches were the strategy used by the NIH to 
'open wide the public’s purse was to call attention to one disease at a time' and allow 'medical 
researchers [to go] directly to Congress.to take advantage of the distinctive good will medicine 
enjoyed'..." (Chaufan et al., 2012, p. 790) 
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4.9 The Gates Foundation and technological solutionism 
 
For philanthropic support the major route for funding would be through the Bill & Melinda Gates 
Foundation.  Gates set up his foundation following the model set out by Rockefeller and also 
Carnegie, in large scale philanthropy and applying business approaches (Solomon, 2011).  
Following this rationale, the foundation has achieved a tremendous amount since inception in 
1994 as a new global health actor.  Spending around US$3 billion annually it has "inaugurated 
an important new era of scientific commitment to global health predicaments" (Lancet, 2009).  In 
deciding what areas of interest to concentrate on to have the greatest impact the Gateses have 
said:  
 
"(W)e concentrate on a few areas of giving so we can learn about the best approaches and 
have the greatest possible impact... We choose these issues by asking: which problems affect 
the most people, and which have been neglected in the past" (ibid, p. 21).   
 
Here the concept of neglect played a central part in their strategy of choosing issues "to solve 
problems where no one else had stepped in", also informed by the scale of the problem and 
impact that was possible (ibid, p. 22).  However, this line of thinking was not initially obvious.  
Kari Stoever recounts how the Bill & Melinda Gates Foundation was not interested in NTDs.  Bill 
Gates was at firs skeptical but a few years later he said to her that investing in NTDs was one of 
his proudest moments (Interview with author, Stoever, 2016).   
 
Gates has been described as "relentlessly rational" (Smith, 2015, p. 148).  He had been a 
believer in Thomas Malthus, the 18/19th century economist who warned about the growth of 
populations faster than the means of subsistence.  The Gateses had begun with a Malthus 
inspired approach when they began looking at public health in 1997 to focus on birth control, 
"The logic was crisp and Bill Gates-friendly. Health = resources ÷ people. And since resources, 
as Gates noted, are relatively fixed, the answer lay in population control. Thus, vaccines made 
no sense to him: Why save kids only to consign them to life in overcrowded countries where 
they risked starving to death or being killed in civil war?" (ibid.). 
 
However, his thinking would change as he gathered more information about global health, 
seeing for example that if infant mortality rates dropped, people in developing countries had 
fewer children, as they would expect more children to survive into adulthood.  Gates had been 
given an 82 book reading list in order to learn about international public health by William 
Foege, the former director of the CDC (Smith, 2015).  He had stepped down from overseeing 
daily operations at Microsoft in 2008 to focus on the Foundation full time and begun to be 
acquainted with NTDs.  His favourite read from all the books in the reading list was the 1993 
World Bank Report and he described what caught his attention exactly:  
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"...'It was just a graph that had, you know, these twelve diseases that kill,' said Gates.  These 
included leishmaniasis, schistosomiasis, trachoma–the list of leading scourges, preventable at 
low cost, whose names he'd also never seen before. 'I thought, 'This is 'bizarre',' Gates said. ' 
'Why isn't this being covered?'..." (Gates quoted by Smith, 2015, p. 145).   
 
There was an appeal in the neglected aspect, as it gave the feeling of making a difference for 
the largest number, and measurement information about which diseases were a problem 
contributed to revealing this neglect:  
 
"We couldn't believe it. You think in philanthropy that your dollars will just be marginal, because 
the really juicy obvious things will all have been taken. So you look at this stuff and we are like, 
wow! When somebody is saying to you we can save many lives for hundreds of dollars each, 
the answer has to be no, no, no. That would have already been done" (ibid.). 
 
Large amounts of funding has been made available to NTDs as stated in 2016: "To date, our 
team has committed more than US$1.02 billion in grants to organizations developing new tools 
and methods of delivery that make these tools widely available. We also advocate for increased 
international funding to support these efforts".86  It is 'new tools and methods' that are sought, as 
the Gates approach to global health problems also reflects a belief in the funding of science and 
technology to both see inequities and help address them (Solomon, 2011, p. 23).   
 
How solutions are thought of is reflective of a technological 'solutionism' espoused by the writer 
Evgeny Morozov as the a dominant ideology of everything needing to be fixed but that we 
should rather be asking questions about the problem at hand.  Solutionism according to 
Morozov is, “(R)ecasting all complex social situations either as neatly defined problems with 
definite, computable solutions or as transparent and self-evident processes” for which he 
questions “both the means and the ends of Silicon Valley’s latest quest to ‘solve problems’.” 
(Morozov, 2014, pp. 15-27).  The technological aspect to solutionism puts forward a quick fix 
rather than concentrating on more intellectually demanding reform (ibid., p. 34). 
 
Little external scrutiny is directed towards this large-scale problem-solving.  As Devi Sridhar and 
Rajaie Batniji (Lancet, 2009) have argued, there is not enough transparency or accountability of 
the Foundation's operation.  Most grants go to organizations in high-income countries and multi-
national company collaborators and other important health programmes are distorted by the 
large grants (McCoy, 2009).  Perhaps the most extensive recent critique has been Linsey 
McGoey (2015) in 'No Such Thing as a Free Gift' where she catalogues some of the failings in 
the Gates approach to global health problems from the tech solutionism focus on vaccines and 																																																								
86 Gates Foundation, http://www.gatesfoundation.org/What-We-Do/Global-Health/Neglected-Tropical-
Diseases, Accessed 3/4/16.   
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disease eradication that discount simpler, short-run solutions.  As shown by the 'London 
Declaration' that Gates helped to orchestrate, NTDs are supported mainly through drug 
donation for those NTDs closest to elimination or eradication.  
 
4.9.1 From drug donation to R&D 
Aside from the sizeable donations by Gates primarily toward information collection (G-FINDER) 
as well as advocacy (The Global Network and The London Declaration) the biggest donations 
have been drugs and this has been generally well received and leveraged.  Compared to other 
areas of public health, donations may be viewed more skeptically.  For example in 2016 the 
NGO 'Doctors without Borders' refused a one-million-dose donation by Pfizer of the vaccine 
Prevnar 13 (PCV13) against Pneumonia.  In justifying the decision this was a quote from MSF 
to The Atlantic: 
 
“...'I'm not absolutely against donations,' MSF’s vaccine pharmacist Alain Alsahani told me by 
phone from Paris. In cases of neglected disease where there is little or no market for a product, 
he explained, “donation becomes a more interesting option for some countries to get access. 
But in the case of PCV, that's not a solution at all, in any way'..." (Hamblin, 2016)  
 
The rationale in this case was that the donation did not justify the costs of delivering the vaccine 
and it was not sustainable nor for a large enough number that included all who would need it.  
However, drug donations have formed the basis of advocacy for NTDs and have been built 
upon as an intervention strategy.  Drug donations have constituted large-scale interventions for 
NTDs, notably beginning with the first NTD donation by Merck for onchocerciasis in 1987.  This 
initial donation would lead to pharma companies becoming involved in NTDs through drug 
donation programs.  Merck was the first company to do a large-scale donation of the drug 
ivermectin (marketed as mectizan) through the 'Merck Mectizan Donation Program' (MDP) 
operating in sub-Saharan Africa, Latin America, and Yemen in the Middle East, constituting 33 
of the 35 endemic countries (Sturchio, 2001).   
 
Ivermectin had followed a successful and very profitable drug for deworming animals, which 
scientists in Merck realized could have applications to humans.  The subsequent donation had 
not been a foregone conclusion, as Merck sought avenues for donors to pay for the drug.  After 
exhausting all options the decision was made by the CEO to donate the drug, in an 
unprecedented move for the size and reach of such a donation by a pharma company.  Many 
other drug donation programs followed (see table below), although it was not until the 2000s 
these rose sharply in number, to be also extended and expanded with the London Declaration in 
2012. 
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Year Disease and drug Company 
1987 Onchocerciasis: ivermectin Merck & Co. Inc 
1998 Blinding trachoma: azithromycin Pfizer 
1998 
(expansion 
2010) 
Lymphatic filariasis, STH: albendazole GSK 
2000 Leprosy: multi-drug therapy (rifampicin, clofazimine and 
dapsone in blister packs and loose clofazimine) 
Novartis 
2001 HAT: eflornithine, melarsoprol and pentamidine Sanofi87  
2002 HAT: suramin Bayer 
2007 Schistosomiasis: praziquantel Merck KGaA 
2009 HAT: nifurtimox-eflornithine treatment combination (NEC) Bayer (PPP with Sanofi to 
donate) 
2009 Fascioliasis (a foodborne trematodiase): Triclabendazole Novartis 
2011 Visceral leshmaniasis: AmBisome Gilead (Provided at 
discount since 1992) 
2012 Lymphatic filariasis: diethylcarbamazine: DEC Eisai 
 
Table 12 Drug donation for NTDs by date  
(Compiled from WHO, 2012a) 
However, for every success story of drug donation there is another of failure, highlighting the 
precarious nature of depending on free drugs (often at the whim of a pharma companies).  One 
example is the drug eflornithine used to treat HAT with fewer (of the quite terrible) side effects 
compared with previous drugs.  Eflornithine had been registered in 1990 by the German pharma 
company Aventis for treating cancer and subsequently adapted as a female facial hair reduction 
cream but uptake and sales were low so the company stopped production. This episode led, in 
the late 1990s, "to an outcry among public health specialists, who persuaded the company to 
reinstate production and, from 2001, to supply the drug for free in Africa" a commitment that has 
continued after Aventis was acquired by Sanofi in 2004 (Jack, 2016).   
 
Despite commitments being made, the supply of drugs is not guaranteed – this is surprisingly so 
even if responsibility is transferred to government.  For example 2012 saw a global shortage of 
the Chagas drug benznidazole.  Nine years previously, the technology and production of 																																																								
87 French company Aventis which later became part of Sanofi discontinued production of elflornithine as it 
was not profitable but Médecins Sans Frontières and the WHO persuaded the continued manufacture 
forces with which led to a comprehensive donation agreement (Potet, 2014). 
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benznidazole had been transferred from the pharma company Roche, to Lafepe which is a 
Brazilian government pharmaceutical company (Manne et al., 2012, pp. 173-4).  For a 
government-run operation it could be expected that the drug would be produced without the 
limitations of profit seeking but production proved to be insufficient and inconsistent, a problem 
that mounted over the subsequent years. 
 
This issue on the whole is an isolated one.  Still an over-reliance on drug donation programs, 
when quantities being produced need to be sustained may be especially problematic when 
production plants are not invested in or fail, or the companies go out of business or are acquired 
by other companies.  Whether the production plants are run by pharma or governments may 
become a bigger problem in the future, as drug donations have been the basis for which the 
NTD advocacy case and policies have been built.  As Stoever describes: 
 
"...you've got to first start with the basics, the basics are find the people who are infected and 
get them treated once a year, then strengthen health systems and work with other groups to 
improve the morbidities, for those who had morbidities, then it was develop new tools, new 
diagnostics, and not necessarily new drugs at that time although there was some new drugs 
under development... and then it was improve the R&D agenda for neglected tropical diseases 
and then when we went to that, working with Lorenzo Savioli and Dirk Engleson at the WHO, 
that agenda got quite broad, then we're including diseases like loa loa and guinea worm and... I 
think they even put snakebite at some point, in the NTD category at WHO... people started 
piling on, once we had political will the agenda broadened quite a bit" (Interview with author, 
Stoever, 2016). 
 
All donations typically form a type of public private partnership (PPP) for organization and 
delivery.  Drug donation PPPs would later move onto an R&D agenda where pharma 
consciously sought to develop drugs for NTDs, as companies still have to keep drugs affordable 
and innovate for new drugs sometimes through product development partnerships (PDPs) 
where collaboration centres on producing a new product.  R&D projects are expanding to bring 
in new and improved drugs diagnostics and treatments.  It was a criticism of both the TDR and 
GND that they did not directly produce new drugs, diagnostics or vaccines.  The TDR director 
John Reeder has argued that organizing doing this spun out from TDR in supporting clinical 
trials: "TDR identified the need for a new type of structure – a product development partnership 
(PDP). The Medicines for Malaria Venture, the Foundation for Innovative New Diagnostics and 
the Drugs for Neglected Diseases initiative were incubated within TDR and then spun out as 
independent entities" (International Innovation, 2014, p. 8).  Although others have placed more 
emphasis on alternative actors originating these organizations. 
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By 2004 there were over 60 R&D projects88 according to the G-FINDER survey (Moran, 
Guzman, Burke, & Francisco, 2006).  Of these, four new PPPs conducted nearly 75% of 
neglected disease drug development projects (ibid.).  There are: The Institute for OneWorld 
Health 'iOWH' founded in 2000, to develop drugs, vaccines and technologies for a range of 
diseases from malaria to diarrhea.  The Drugs for Neglected Diseases initiative 'DNDi', founded 
in 2003, had a focus on the kinetoplastid diseases and that same year the Foundation for 
Innovative Diagnostics (FIND) was also established.  Other PPPs concentrate on specific 
diseases.  Pharma company Novartis has an active dengue R&D programme at their 'Institute 
for Tropical Diseases' in Singapore (along with TB and Malaria), a leprosy donation program 
and fund for R&D in Neglected Diseases (FRIND).  Also the small independent pharma 
company Immtech has an R&D programme for Human African trypanosomiasis (HAT).  
 
Stoever has expressed how PPPs have become standard models: "... to take a methodology 
and apply it for issue x.... what we learnt in the international space on global health is now being 
applied more and more to domestic issues at least in the US" (Interview with author, Stoever, 
2016).  She also notes the change in role of pharma from principally providing drug donations: 
"today I think there's more leadership from the private sector, I like that pharma is embracing 
this more and is very proud of it" (ibid.).  There is a lot of activity within the pharma sector 
directed towards NTDs today. 
 
Despite the drug dominance through NGOs and public discourse, the WHO has advocated an 
'integrated approach' through national plans and a 'three-pronged' strategy of, "...ensuring 
broader coverage with rapid impact interventions; strengthening vector control to reduce the 
transmission of several diseases; and improving surveillance and quality of care for diseases 
with limited control tools" (WHO, 2007, pp. 5-6)  This 'three-pronged' strategy later became a 
'five-pronged' strategy of: 
 
1. mass drug administration 
2. innovative and intensified disease management 
3. vector control and pesticide management 
4. safe-drinking water, basic sanitation and hygiene services, and education; and 
5. veterinary public-health services 
(Salaam-Blyther, 2014, p. 3). 
 
Still drug interventions come first and tend to underpin much of the other activity, with R&D also 
supporting every stage. 
 																																																								
88 Two Malaria and TB projects are counted in the 60 R&D projects: Medicines for Malaria Venture 'MMV' 
and the Global Alliance for TB Drug Development 'TB Alliance' (Moran, Guzman, Burke, & Francisco, 
2006).  They also include TDR, which they say "has operated as a de-facto PPP since the mid-1970s" 
(ibid). 
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4.9.2 Other sites of neglect 
 
Big pharma is positioned as a main protagonist in why NTDs are neglected.  However, often 
other sites of neglect such as the media are ignored.  Conall Watson an epidemiologist at the 
London School of Hygiene and Tropical Medicine (LSHTM) spoke of the difference media 
attention makes to a health issue such as typhoid: 
 
"Unless you can paint stuff as scientific breakthrough I don't know how much of this stuff gets 
picked up in the mainstream press... there are many ways to block typhoid transmission... [other 
than the breakthroughs that are reported on]" (Interview with author, Watson, 2013). 
 
In policy setting typhoid can be a difficult topic to broach, especially in terms of communication, 
and then the messages do not transfer well into the media: 
 
"People don't really like to talk about poo on hands and using soap and that sort of stuff it's 
much nicer to talk about clean water and new vaccinations, which I completely understand.  And 
I suppose the other aspect that we don't often talk about is treatment and use of appropriate 
antibiotics"  (Interview with author, Watson, 2013). 
 
The incremental work of the international research community and day-to-day typhoid treatment 
and control is not followed in the mainstream media, as it does not really fit with news agendas.  
News reporting is selective to scientific breakthrough and more attention-grabbing interventions, 
such as the use of innovation and technology in sanitation or vaccination.  Therefore, media 
attention is difficult to sustain outside of more obvious news-grabbing headlines. 
 
Balasegaram et al. (2008) surveyed NTDs in the news from 1 January 2003 to 1 June 2007.  
This light-touch study only looked at English language media and was constrained in a number 
of other aspects but it was the first study using a content analysis of NTD media coverage.  
Qualitative interviews of the study revealed that American journalists struggled to cover global 
health issues as foreign news budgets had been slashed.  They had further difficulty in reporting 
on relatively unknown diseases with limited information – finding it hard to get hold of 
spokespeople from the Gates Foundation or the WHO or stories from the field. The main 
findings of the study, which focused on leishmaniasis and trypanosomiasis, found the frames 
that were important depicted the reality of the diseases but beyond descriptive frames the 
popular focuses were: 
   
• 'Big pharma' where the industry was on the defensive or under pressure 
• scientific developments from genetic research 
• blood safety amidst the threat from Chagas (almost all US media articles) 
 
Table 13 Popular media frames for NTDs (Balasegaram et al., 2008, p. 4). 
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As might be expected, placing responsibility and blame for the problem of NTDs, with a focus on 
big pharma, is a major topic within the media.  Science is positioned as a main solution for 
NTDs and also making the news are threats to developed countries as seen with the blood 
safety controversy.  Seemingly absent are the global public health actors, a situation that may 
have changed more recently as we observe greater scrutiny of actors such as Gates (Lancet, 
2009; McGoey, 2015b; Sridhar & Batniji, 2008).  The question of who is viewed as responsible 
for NTDs and why responsibility is allocated will be an ongoing theme explored through the 
subsequent chapters.  
 
Despite media reporting only covering limited topics, the advocacy for NTDs has proved 
successful, a marker of which is in how NTDs have since been included in the Sustainable 
Development Goals (SDGs) for 2030.  Dominic Haslam (2016) the director of policy and 
programme strategy at NGO Sightsavers called the SDGs a, "...once-in-a-generation chance to 
reframe NTDs within a more mainstream approach to health and development".  Similarly, 
Molyneux, one of the activist scientists also reflected on what the SDGs meant as a sign of 
achievement and ongoing accountability of the global health community to NTDs: 
 
"To have got NTDs included in the sustainable development goals for me was the most 
important achievement.  Had they not been there I would have thought that our efforts and 
advocacy would have failed.  So I really believe that was a big plus because they’re embedded 
there semi-legally and so we can always point to them as being the targets" (Second interview 
with author, Molyneux, 2016).   
 
Exclusion from the MDGs in 2000 had set the ball rolling for NTDs in the first place, now the 
SDG, set out in 2015 specifically states: “By 2030 end the epidemics of AIDS, tuberculosis, 
malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other 
communicable diseases” (Target 3.3, Sustainable Development Knowledge Platform, 
https://sustainabledevelopment.un.org/?menu=1300, Accessed 9/4/14).  As there are 17 SDGs 
compared with the 8 MDGs, the expanded agenda has been questioned.  Haslam views the 
SDGs to be potentially unwieldy and undeliverable but he remains optimistic: "...the SDGs are a 
bold attempt to 'leave no one behind', a call I believe will see NTDs and other so-called ‘lost 
causes’ – and the millions of people they represent – finally brought out of the fringes of the 
development agenda" (2015).  Next I will conclude this chapter by putting into perspective this 
'end point' of the SDGs with what has passed before, through a summary of the events and 
milestones that led to the point, and why they mattered.  
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4.10 Conclusion: Beyond the SDGs  
 
I began this chapter with a discussion of two formative initiatives on tropical diseases starting in 
the 1970s.  On one hand the WHO's TDR initiative showed an early commitment to diseases of 
the poor but ultimately was not the conceptual origin for NTDs.  As I have outlined the reasons 
why were based in the institutional limitations of the WHO and the changing landscape of global 
health.  On the other hand the Rockefeller Foundation's GND initiative, while clearly having an 
influence in the naming of NTDs, would have more relevance for NTDs in encouraging scientists 
to be interested in tropical diseases.  Therefore the GND was crucial in creating activist 
scientists and future branding of NTDs, something I explore in depth in Chapter 6.  Next in this 
chapter I moved on to the key events in the policy development of NTDs, highlighting the two 
seemingly straightforward bookends with the MDGs in 2000 and the SDGs in 2015.  The SDGs 
in comparison to the earlier MDGs include NTDs as a global policy priority and commitment.  
NTDs have now been confirmed as a mainstream concern through the same institutional setting 
that had previously left these diseases unacknowledged.  The event milestones tracked this 
move from outlier to status quo through the MDGs to SDGs.   
 
During the policy development of NTDs, organizations have used different lists of NTDs.  The 
WHO has also provided distinctions based on pathogen and geography.  The geographical 
distinction is something I will return to in Chapter 8 as a way of understanding NTDs that 
challenges the donor and recipient country distinction on nationalist grounds.  As I have shown, 
how the grouping of NTDs has changed over the policy development speaks to the state of 
public health globally.  The WHO expanded their own grouping from 13 to 17, PLOS expanded 
this group and the London Declaration and others shrank this group further.  The expansion is a 
reflection of the competitive nature of public health and the need to align disease to groups 
appropriately for policy reasons. 
 
Still, the global health policy climate is changing.  There exists an optimism in the changing face 
of global public health with a greater awareness of and interest in issues, and more people want 
to take a part: "I think with the emergence of Ebola...  there are just more kids that want to study 
in this space, they don't necessarily all want to be scientists but they want to work in global 
health" (Interview with author, Stoever, 2016).  The next chapter will further explore what the 
changing face of public health means through the politics of disease categories, going back to 
the time of topical diseases to review just how much has changed. 
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Chapter 5. The politics of disease categories  
5.1 Introduction: The transition of tropical diseases 
 
Why did the addition of the word 'neglected' and a new grouping of diseases have such a 
tremendous effect in global health?  Why was the word 'tropical' retained as a descriptor for 17 
diseases largely impacting on poor communities?  While the last chapter provided a recent 
policy history of NTDs this chapter aims to address these questions about the politics of the 
NTD disease category.  I will explore the origins of 'tropical' and 'neglected' as categories and 
ask how this has shaped the definition of the policy problem and solution for NTDs.  The 
problem of NTDs has been presented as a problem through a number of straightforward 
narratives that I unravel in this chapter, where proposed solutions for NTDs are surrounded by 
optimism.   
 
The place to begin in considering the transition from 'tropical diseases' to 'neglected tropical 
diseases' is to interrogate what is meant by tropical and neglected as categories.  While NTDs 
could be taken as a single unit and a categorization in itself, my argument is that 'tropical' and 
'neglected' form distinct categories on their own, separate from a prescribed categorization set 
out by the creators and advocates of NTDs.  There is value in looking at all three categories: the 
'tropical', the 'neglected' and 'NTDs' as discrete units.  Defining disease, the 'tropical' not related 
to disease, and a detailed history of tropical diseases are out of the scope of this analysis.89   
 
I ask what is tropical both in terms of historical and geographic location.  This line of enquiry on 
a historical and geographic basis has precedence in exploring the social embeddedness of 
disease and has been central to questioning colonial accounts of disease (Anderson, 1996; 
Bewell, 2003; Blaut, 2012).  In exploring the tropical there is a vast literature on the role of 
tropical medicine in support of the colonial project (Amaral, 2008; Arnold, 1996; Chakrabarti, 
2013; McNeil Jr., 2012; Neill, 2012) and a relatively more recent literature on the policy 
developments for NTDs (Hotez et al., 2014; Molyneux et al., 2005b; Parker, Allen, & Hastings, 
2008).  These two literatures rarely meet in the middle.  Therefore, tropical diseases become 
diseases of the past, a matter of historical record and only to be understood through the context 
of colonialism and empire.  NTDs are not mature as a disease grouping to have historical 
account and as discussed in Chapter 1 have not received much of a social science gaze, with 
sociological and anthropological research being limited.  NTDs are a fledging field for social 																																																								
89 Defining disease may be, as philosopher Alex Broadbent puts it in the context of NTDs "...a 
philosophically more onerous task" (2011, p. 51) but for this chapter, the 'tropical' and the 'neglected' 
understanding are more relevant.  I am less interested in making philosophical observations about disease 
as others have already dedicated efforts to extensively (as noted, see Broadbent, 2011).  Also for a 
comprehensive study of the of the 'tropical' both in popular imagination and through representations that 
go beyond disease, see Nancy Leys Stepan's book 'Picturing Tropical Nature' (2001) where she finds 
'tropical' to both encompass nature (animals, plants) and people (in culture and aesthetics).  A history of 
tropical disease has been covered more thoroughly through other accounts (see Packard, 2007).    
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science research but to understand these diseases in any depth requires a connection with the 
past.  Therefore, in this chapter the tropical category is explored through: (1) a brief colonial as 
well as post-colonial history and (2) current geography, where the chronic characterization of 
disease and a concept of 'blue marble health' in viewing distribution of disease becomes 
relevant.   
 
The neglected category is more difficult to pin down.  To understand, on one hand, what is 
neglect from the definitions of the problem, I have surveyed the policy literature and grouped 
these definitions under themes.  On the other hand, understanding what is neglect through 
solutions proposed by international bodies, I have taken a micro-view of WHO strategies in 
particular for individual NTD diseases.   Here the divisions between environment-based and 
drug-based strategies offer insight into where neglect lies.  To explore the neglected category I 
have made greater use of primary sources.  I draw primarily from media reports, practitioner 
accounts, and from policy documents of government bodies and international organizations 
including the World Health Organization (WHO), Uniting to Combat NTDs, Centres for Disease 
Control (CDC), National Institutes of Health (NIH), The Drugs for Neglected Diseases Initiative 
(DNDi), and The Food and Drug Administration (FDA).   
 
It becomes apparent that measurement is an important component in bringing forth a workable 
definition and solution for neglect.   The adoption of measurement is both as a metric to 
determine status, track progress (to collect evidence), but also as a device in the argumentation 
and rationale for why NTDs are important and require attention (to present evidence).  I argue 
that the metrics that have mattered for NTDs spans from:  
1. '10/90 gap' illustrating how low R&D is for NTDs compared to other diseases 
2. 'DALYs' showing burden of disease through a chronic or high-morbidity character of 
NTDs  
3. '50 cents per person' pointing to cost-effective interventions for a core of NTDs   
 
Metrics prove to be crucial in creating a story that translates into an easily digestible problem 
and solution definition.  First however, I begin with an illustration of how the tropical disease 
category has transitioned to NTDs. 
5.1.1 A Nobel Prize view of disease  
 
The specialism of tropical medicine has been of research interest across what is now an 
extensive historical, sociological, geographical, political science and anthropological literature 
(LSHTM, 2014).  Joined together are the two literatures of tropical medicine in the context of 
empire (Amaral, 2008; Arnold, 1996; Chakrabarti, 2013; McNeil Jr., 2012; Neill, 2012) and the 
new policy developments of NTDs (Hotez et al., 2014; Molyneux et al., 2005b; Parker et al., 
2008).  While drawing from these disciplines, this thesis follows the STS tradition, a concern 
 130 
with scientists as key actors and the policy ideas that intersect science, technology and society.  
Therefore, I want to provide a backdrop to the politics of the NTD category by comparing how 
scientists within the tropical medicine tradition and the recent NTD tradition have been received 
in their wider academic community and also publically.  This comparison looks to how scientific 
research on tropical diseases and NTDs have been scientifically acknowledged. 
One avenue acknowledging importance of NTDs includes the height of scientific recognition 
through Nobel Prizes.  I want to make a point about the history of scientific prestige and 
recognition and how this has transitioned from tropical medicine through to NTDs.  This is one 
way of showing how diseases were viewed as worthy of scientific enquiry with the associated 
moral motivations and resources directed.  See Table 9 for a timeline of Nobel prizes awarded 
for tropical diseases and NTDs.      
The Nobel Prize in Physiology or Medicine for tropical diseases and NTDs* 
Year Award Disease Intervention 
1902 Ronald Ross "for his work on malaria, by which he 
has shown how it enters the organism and thereby 
has laid the foundation for successful research on 
this disease and methods of combating it" 
Malaria Informed interventions for 
malaria  
Discovered mosquitos transmitted 
malaria 
1907 Charles Louis Alphonse Laveran "in recognition of 
his work on the role played by protozoa in causing 
diseases" 
Protozoa Informed interventions for 
malaria and HAT 
Discovered protozoan parasites 
responsible for malaria and HAT 
1948 Paul Hermann Müller "for his discovery of the high 
efficiency of DDT as a contact poison against 
several arthropods" 
Arthropods  Vector control 
Discovered DDT poison spray to kill 
malaria carrying mosquitos (also used to 
control typhus) 
1951 Max Theiler "for his discoveries concerning yellow 
fever and how to combat it" 
Yellow fever  Vaccine 
Discovered (through experimentation) an 
attenuated 17D mutant strain of the virus 
2015 William C. Campbell and Satoshi Ōmura "for their 
discoveries concerning a novel therapy against 
infections caused by roundworm parasites" and 
Youyou Tu "for her discoveries concerning a novel 
therapy against Malaria" 
Roundworm 
parasites and 
malaria 
Drugs 
 
Discoveries of ivermectin for 
onchocerciasis and lymphatic filariasis, 
and artemisinin for malaria (later 
developed into ACTs) 
*Not included in this list but interesting to note was the 1927 Nobel Prize awarded to Julius Wagner-
Jauregg "for his discovery of the therapeutic value of malaria inoculation in the treatment of dementia 
paralytica", which was malaria treatment by inducing a high fever to treat tertiary syphilis 
 
Table 14 Timeline of Nobel Prizes for tropical diseases and NTDs (Adapted from Nobel Prize, 
http://www.nobelprize.org/alfred_nobel/will/, Accessed 9/7/16) 
 131 
Ross was one of the 'greats' of tropical medicine who won the 1902 Nobel Prize in Physiology 
or Medicine for his work on the transmission of the malaria parasite through mosquitos.  Malaria 
is often seen as the most dangerous tropical disease, being both deadly and scientifically 
complex, having up to 40 species of mosquito that can transmit the parasite, all with different 
breeding preferences (Dobson, 2015).  Following Ross, who received the Nobel Prize a year 
after it was established, Laveran was also recognized for his work on malaria and HAT protozoa 
parasites soon after in 1907.   
By 1948 Müller had discovered DDT, which would become the main weapon against malaria, 
beginning with the regional malaria elimination campaigns in the late 1940s and culminating 
with the Global Malaria Eradication Program, which began in 1955 (WHO, 2011b).  The 
addition, also in the 1950s of the yellow fever discoveries by Theiler, would push both malaria 
and yellow fever into the 'not neglected' tropical disease camp.90  
This timeline demonstrates how tropical medicine has had a long connection with scientific 
prestige and recognition.  Colonial medicine, which effectively was tropical medicine, 
encouraged these advancements.  Nearly all of the scientists awarded the prizes were 
European: Ross (British), Laveran (French), and Müller (Swiss), with the exception being Theiler 
(South African-American).  Ross and Laveran directly served colonial interests, with Ross a 
surgeon in the Indian Medical Services and Laveran an army doctor in Algeria (Kelly & Beisel, 
2011, p. 74).  
After World War II the interest in tropical medicine waned.  It would not be until 2015 that work 
on NTDs would be recognized by the Nobel Committee, and would include two scientists not 
from Europe but from an endemic country for NTDs (China) and previously endemic Japan.  
The Japanese academic Satoshi Ōmura was awarded the Nobel Prize for their discoveries 
surrounding roundworm parasites with American scientist William C. Campbell who led a lab at 
Merck (The Nobel Assembly at Karolinska Institute, 2015).  Ōmura cultured a strain of bacteria, 
which was then purified by Campbell as avermectin and chemically modified to produce the 
drug ivermectin, effective against two NTDs onchocerciasis and lymphatic filariasis.   
Also sharing the 2015 prize was Chinese scientist Tu Youyou from the China Academy of 
Traditional Chinese Medicine, for ‘her discoveries concerning a novel therapy against Malaria’.  
It was about forty years after she and her team had discovered the method to isolate Artemisinin 
from the herb Artemisia annua (qinghao, 青蒿素).91  The reception was one of overwhelming 
enthusiasm towards China’s long-awaited Nobel.  The last was in 2012 in Literature and before 
that Peace in 2010 and Physics in 1957.  What is largely absent from much of the press 																																																								
90 Yellow fever was one of the most feared diseases because outbreaks were little understood, quarantine 
did not seem to work and it frequently also caused economic disaster (Bryant, Holmes, & Barrett, 2007).   
91 Chinese herbalists had used Artemisinin for thousands of years to treat many illnesses, including 
malaria.   
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coverage for these discoveries was the difficulty of moving the treatments from scientific 
discovery to drugs to help the world's poor.  A strikingly downplayed was the involvement of 
Merck, where Campbell was working during the discovery and development of the drug 
ivermectin (the bioactive agent was called avermectin) as well as the involvement of the WHO in 
the research project.   
The Nobel Prize is premised on individual scientific discovery, thus Merck is only mentioned 
very briefly in the press materials, in the biography of Campbell (The Nobel Assembly at 
Karolinska Institute, 2015).  Similarly the long and complicated struggle of Tu's discovery to 
reach the market does not find a place in the Nobel Prize announcement and only sparked 
moderate interest in the news stories that followed.  Missing is an account of the agency 
involved in pushing for a discovery to be adopted as a public health intervention.  Even though 
these discoveries happened in the 1960s and 70s there was a significantly longer lag than for 
the tropical disease discoveries, which may have reflected the sidelining of these diseases, that 
would need social and political recognition before scientific recognition was granted. 
In Alfred Nobel’s will, he wrote that ‘prizes [shall be annually distributed] to those who, during 
the preceding year, shall have conferred the greatest benefit to mankind’.92  It is a prerequisite 
then not only to reward discoveries for their intrinsic scientific worth but for their impact in the 
social world.  The 2015 Nobel Committee awarded Campbell, Ōmura and Tu because their 
discoveries helped "to combat these debilitating diseases that affect hundreds of millions of 
people annually" (ibid.).  The consequences of ‘global health’ in improving human wellbeing was 
emphasized in another Nobel Prize, the Peace Prize, awarded to Médecins Sans Frontières 
(MSF) in 1999.  This event was described by Jackson and Stephenson as having 'powerful 
symbolic meaning':  
"Peace, so far mostly celebrated by the Nobel Committee in its political dimension and 
embodied by individual heroes, was now linked to health (reworking the connection between 
health and security... With this award, actions imbued with humanitarian values and principles of 
social justice were recognised in the same capacity that economics and politics had previously 
been, as vital tools to forge a better world. The Nobel Peace Prize followed MSF’s linking of the 
moral imperative to consider neglected populations and diseases with the failure of market 
solutions to support institutional efforts to address the needs of the poorest... It also raised the 
profile and gave a new political status to non-governmental actors (such as NGOs) as key 
actors in global politics, a point of recognition following long years of NGOs’ playing important 
political roles." (Jackson & Stephenson, 2014, p. 999). 
 
NTDs came into prominence not only in a new period of science but a new period of global 
health involving actors and priorities that had not previously existed.  Global health was shown 																																																								
92 Nobel Prize http://www.nobelprize.org/alfred_nobel/will/, Accessed 2/4/16.  'Mankind' was the common 
word used at that time before being replaced by the gender-neutral 'humankind'.  
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to cross boundaries of social concern to be awarded the prize for peace.  Moreover, also 
recognized was the value of moral consideration through neglect.  These sorts of statements 
would form part of a general tide towards concern about neglect, in the populations and 
diseases of neglect.  The concept of neglect is saying that there is an absence and lacking that 
we should be paying attention to or caring about.  Therefore, beneath neglect is a moral and 
normative underpinning.    
 
My aim has been to show how tropical disease has been positioned in relation to scientific 
interest, research commitment and recognition, and what changed for the new categorization of 
NTDs.  In the next section I want to delve further into what changed within the categories of the 
individual diseases that were included or not.  I will start with which diseases originally counted 
as tropical and why.       
 
5.1.2 Transitioning categories  
 
Tropical medicine has been varyingly attributed to diseases thought to be common or more 
specific to the tropics and sub-tropical regions.  Today definitions of NTDs do still differ 
depending on the source, as mentioned in Chapter 1, with the most definitive list of 17 NTDs is 
given by the WHO (with the sub-categories of virus, bacteria, protozoa, helminth).  Patrick 
Manson at the turn of the 20th century listed 10 of the 13 (later to become 17) NTDs listed by 
the WHO (see below Table 10) drawn from his much larger list of 65 (see Appendix 8).93 
 
'17 WHO' 'WHO 13' 'Manson 10' 
1. Buruli ulcer x  
2. Chagas disease x  
3. Dengue and chikungunya  x 
4. Dracunculiasis (guinea-worm disease) x x 
5. Echinococcosis   
6. Endemic treponematoses (Yaws)  x 
7. Foodborne trematodiases   
8. Human African trypanosomiasis (sleeping sickness) x x 
9. Leishmaniasis x x 
10. Leprosy (Hansen disease) x x 
11. Lymphatic filariasis x x 																																																								
93 In the latest edition of Manson's book in 2013 (Farrar et al., 2013) subcategories largely remain: viral 
infections (HIV added), bacterial infections (tropical rickettsial infections responsible for many undiagnosed 
febrile illnesses included), fungal infections, mycobacterial infections (TB would not have been especially 
tropical in Manson's time), protozoan infections (malaria), helminthic infections (schistosomiasis) and 
ectoparasites (scabies).  These include tropical diseases not judged to be neglected: the 'big three' 
(HIV/AIDS/ TB and malaria) and those in the Millennium Development Goals: nutrition and maternal/child 
health.  Other health concerns in the tropics that now arguably compete with NTDs are non-communicable 
diseases (NCDs) and environmental disorders. 
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12. Onchocerciasis (river blindness) x x 
13. Rabies   
14. Schistosomiasis x x 
15. Soil-transmitted helminthiases x (hookworm, 
roundworm, whipworm) 
x 
16. Taeniasis/Cysticercosis   
17. Trachoma x  
 
Table 15 Comparing WHO list of NTDs to Manson's list of tropical diseases  
(Compiled from Manson, 1898; WHO, 2015, Accessed 2/4/16) 
Two of the missing diseases appear to have predated discovery (Chagas disease and buruli 
ulcer)94 and many diseases are not often seen (plague) or ever seen today (goundou).  Others 
have fallen in importance where vaccines have been developed (yellow fever, Japanese 
encephalitis, typhoid), are mild conditions easily treatable with medicine like antibiotics (heat-
stroke, prickly heat, boils) and what are now called genetic diseases (Mediterranean fever, 
ainhum, pemphigus contagiosus).  Another large section of diseases includes archaic medical 
terms, being more symptoms than diseases (craw-craw) or hold commonalities with NTDs but 
are not the specific type now viewed as a problem.  For example, dog tapeworm (distomum 
heterophytes), not echinococcosis or tapeworms taenia nana and madagascariensis, or pig 
tapeworm (taenia solium) the leading cause of preventable epilepsy.  
 
Finally there are still the time-persistent diseases associated with poverty of once pandemic 
diseases that now cluster in the tropics: malaria, cholera and dysentery.  Malaria has since 
joined the 'big three' grouping and cholera and dysentery are typically called 'diseases of 
poverty' and 'diarrheal related' but tend to be of most concern during humanitarian emergencies 
when they can become epidemic.  Conversely, rabies would now join this group of clustering in 
the tropics but at the time was persistent in central Europe for much of the 19th century and is 
likely to be why Manson did not list it as tropical.   
 
The relationship between disease and scientific discovery and economic development certainly 
has not been static, despite the persistence of some diseases.  Exploring how tropical diseases 
have become 'neglected' exposes an evolving conception of disease in relation to science and 
development.  This extends to the very premise about the category of tropical disease 
challenging preconceived notions.  Robert Desowitz, a tropical disease specialist and popular 
science writer, noted on the notion of 'typically tropical': "Well, these diseases that we call 
"typically tropical" have been as American as the heart attack" (quoted by Killheffer, 1997).  For 
the scientists connected with these diseases it has been an ever-moving conception of which 
diseases require attention and the suitable role for science.  When Desowitz began his career in 
the 1950s he was told: “(M)alaria is about to be totally eradicated, and you will never make a 																																																								
94 Chagas was not described until 1909 and buruli ulcer was only described a year before the publication.   
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career, let alone a living, from it” (Desowitz, 1987, p. 12).  This was why he switched to 
trypanosomiasis research but “(B)y the 1970s, malaria was more of a threat than ever, at the 
expense of interest in the trypanosomiases” (Wilkinson, 2004).   
 
Such an anecdote is emblematic of a group of diseases that have existed for a long time and 
are closely connected to the promise of eradication, to varying degrees, where at least the 
possibility appears in sight.  If some diseases are close to eradication or elimination we may ask 
why are they neglected?  Even though some treatments are highly effective, Musgrove and 
Hotez find that control, basic research, drug (including vaccine and diagnostic) development is 
still inadequate in relation to the burden (Musgrove & Hotez, 2009).   
 
However, the eradication goal as a policy strategy is stretched further through current calls, 
based on a neglected criterion.  Eradication is closely tied with the 'neglected' advocacy of today 
as Reidpath et al point out: "The NTDs advocacy has relied on (a) appeals to alleviate the 
suffering of societies’ most neglected, and (b) the scientific promise of the ultimate cure... Most 
recently we have even had the idea of a 'vaccine against poverty' peddled in the international 
literature" (2011, p. 8).  The very idea of eradication however, goes further back and is closely 
tied historically to an imperial view of tropical medicine.  Stepan finds the Rockefeller campaigns 
with imperial overtones against the tropical diseases of hookworm, yellow fever and malaria as 
pioneering the eradication concept (Stepan, 2013, p. 7).  Even though, as Cueto and Palmer 
point out, diseases such as hookworm had already been discovered by Central American 
physicians, predating the American discoveries of the disease in 1900 and national campaigns 
were already underway before the Rockefeller 'crusade' of eradication (2014, p. 314).  
Eradication now carries weight with the technology solutionism of big pharma drug 
development, global public health machinery and the technocratic Bill and Melinda Gates 
Foundation.    
 
Two NTDs are currently set out as targets for eradication by the WHO: guinea worm and yaws, 
with eight for regional and global elimination: trachoma, Chagas disease, African sleeping 
sickness, leishmaniases, lymphatic filariasis, river blindness, rabies and schistosomiasis (see: 
WHO, 2015). Eradication by definition is a global endeavour and requires cooperation across 
countries.  This compares to elimination, where disease transmission is interrupted only within a 
defined geographic area (Hopkins, 2011, p. 19).  Some of the diseases once also prevalent in 
developed countries have now been eliminated.   
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5.2 What is 'tropical'? 
 
To start with tropical, there are two parts to the tropical categorization, the place of tropical in 
history and the place in geography.  Of course these overlap but can be thought of in terms of 
colonial history and current geography.   
5.2.1 Colonial history 
 
To provide a general definition of colonialism, the term tends to be described as a practice, 
while imperialism is the idea driving the practice.  As described by Ake, imperialism constitutes 
the, "... subordination of one country to another or at any rate the attempt to subordinate one 
country to another in order to maintain a relationship of unequal exchange.  The subordination 
may be military, economic, political, cultural, or some combination of these" (1982, p. 136).  
Loomba describes colonialism as the practice of "the conquest and control of other people's 
land and goods" (2005, p. 20).95 
 
By the time of the Treaty of Paris in 1783,96 Spain's dominance as a European power had been 
broken, giving way to a new era of English colonialism.  A few years following, 1787 is identified 
by Nancy Stepan as when the phrase 'tropical disease' was first used in English medical work 
for illnesses associated with hot climates (2001, p. 17).  Stepan goes on to say: "Almost by 
definition, tropical medicine was a colonial medicine" (ibid., p. 28).  It existed, as Natalie Ring 
describes, to play "...a pivotal role in negotiating the relationship between the colonized and the 
colonizers since it constituted a powerful discourse of authority and modernity" (Ring, 2003, p. 
5).  Post-empire the field is remains in what has been called "...a residual category, 
synonymous with the additional requirements of imperial medical practice" (Worboys in Bynum 
& Porter, 2013, p. 512).   
 
Tropical medicine has been a problem-based specialism – based on the problem of undertaking 
medical practice in the tropical colonies, rather than a biomedical basis to the disease grouping 
(e.g. based on pathogen or geography) (Lemaine et al., 1976).  This is point is striking, to think 
of today when organizations from universities, governments and NGOs pose global problems as 
'grand challenges',97 and perceive it novel to use science and knowledge to address society 
problems.  
 																																																								
95	Earlier definitions of colonialism only referred to the colonizers establishing 'new' land but in every 
instance of colonization there were already original inhabitants. 
96 The Treaty of Paris was signed at the end of the '7 years war' with Great Britain victorious over France 
and Spain, marking a new dominance of Britain, expanding to have a global empire (see Blackburn, 1988) 
97 Grand Challenges are run by the Canadian government (Canada/Grand Défis Canada, 2011); and 
University College London (UCL Grand Challenges, https://www.ucl.ac.uk/grand-challenges; Bill and 
Melinda Gates Foundation http://gcgh.grandchallenges.org/, Accessed 13/8/16).  
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Even at the time of creation the category posed difficulties.  Manson, "...acknowledged that the 
term tropical diseases was 'more convenient than accurate'..." (ibid.).  However, this grouping of 
convenience has had consequences in inheriting the 'geographical assumptions' of colonial 
medicine (Bewell, 2003, p. 36).  The associated meanings of tropical have included 'climatic 
handicaps', 'inertia', 'degeneration', 'primordial' and 'treacherous', demarking a "...sharp moral 
and topographical distinctions between tropical and temperate climates" (Ring, 2003, pp. 1-2).  
These derogatory meanings have led to scientists and policy-makers – especially from the 
tropics – disputing and challenging the tropical disease characterization.   
 
Afrânio Peixoto, the Chair of Hygiene at Rio de Janeiro’s Faculty of Medicine was a vocal 
objector to the designation because of the denotation of biogeographic curse or fate of climate 
being responsible for disease.  He argued that tropical medicine: "...reinforced the prejudices 
associated with climatic determinism and old stereotypes created by Europeans who 'defamed' 
the 'torrid' countries as insalubrious lands unsuited to civilization.  Peixoto declared that there 
were no tropical diseases since there were no climatic diseases" (Kropf, 2011).  Some 
objections were more confrontational.  This is an account from Desowitz working on tropical 
medicine in the 1960s:  
 
"In 1962, when Indonesia's dictator, Sukarno, was in flower, I attended a meeting of the 
Southeast Asian Ministers of Education (Secretariat Tropical Medicine Project).  The 
representative from Indonesia opened the session by hotly proclaiming that there was no such 
thing as 'tropical' medicine; it was a colonial term of denigration (the implication being that the 
whites were hygienic and the natives unsanitary)..." (Desowitz, 1997, p. 11).   
 
This reaction was not without reason as a sanitary survey was often 'an integral part' of British 
colonial medicine and if the question of a nation's authority and modernity are at stake, it is not 
surprising that there is a need to create distance from what had been seen as diseases of 
domination and backwardness or an uncivilized past (Ring, 2003, p. 3).  As Hotta wrote in 1989, 
"bacteriology, parasitology, dietetics, sanitary hygiene, etc. derived from, or evolved in parallel 
with tropical medicine" (Hen, 1989, p. 2).  Still, an intellectual movement of the postcolonial 
world has been criticizing science and medicine in general, as an instrument of Western 
hegemony through a cultural specificity of scientific truths (see Adams, 1998, p. 9).   
 
One reaction has been to oppose universalist objectivity but in the case of tropical disease we 
have seen almost the reverse happening.  Sandra Harding (1993) describes a 'strategy of 
universalization' in rejecting the concept of tropical diseases.  Here in reaction to the relativist 
version of disease through tropical places and people was the attachment of disease to a 
universal idea.  This was reflected at a later date through an example taken from the late 1990s, 
in the suggestion that a new term be used:   
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"...when the organisation of European Schools of Tropical Medicine (TropMed Europe) met in 
Addis Ababa in 1997, they were persuaded by African Colleagues that the term ‘tropical 
medicine’ still had patronizing colonial overtones and should be replaced by ‘international 
medicine’ although that decision was never implemented" (Eddleston et al, 2008).     
 
The history of tropical medicine has therefore involved the interplay between universality and 
particularity.  The tropical regions were viewed as particular with their climate of heat and 
moisture being deemed inhospitable to white people.  The formulation of 'germ theory' hailed an 
era of 'new tropical medicine' (Lemaineet al., 1976, pp. 84-5).  A generalized 'European 
approach' could be applied because the causes of disease were germs, so that scientific 
knowledge could defeat disease and allow for tropical colonialization (ibid.).  Post World War II, 
tropical medicine would be influenced by other scientific disciplines: "fundamental biology, 
chemistry, physics, etc." leading to experimental and clinical medicine (Hen, 1989, p. 2). 
 
This colonial past left open a number of possible re-directions to take tropical medicine.  What 
approach would be taken universalist or particularlist?  Would it be understood as region-based 
or pathogen-based?  Would expertise rely on on-the-ground public health experience or the 
introduction of new scientific disciplines?  Post-empire it looked as if that the name tropical 
medicine might be dropped altogether. 
5.2.2 Tropical re-relevance 
 
Evidently the change to 'international medicine' did not happen (at least not on a wholesale 
basis)98 and so a persisting concern amongst tropical disease advocates was whether the term 
'tropical disease' lacked relevance.  The association with colonialism would be a driver for a 
renaming, to escape the framing that arises from the aims and visions of a colonial past.  The 
new term 'NTDs' has appeared to displace some of these previous colonial connotations.  
However, it seems this might go full circle.  Bill Gates for example has spoken of his hopes for 
the neglected to be gone with, still referencing the tropical: “Maybe as the decade goes on, 
people will wonder if these should be called neglected diseases. Maybe as the milestones go 
on, we will call them just tropical diseases” (Gates quoted by Boseley, 2012).  Hotez and 
Musgrove have similarly said: "Lymphatic filariasis, onchocerciasis, schistosomiasis, soil-
transmitted helminth infections, and trachoma are starting to lose the 'N' from NTD" (2009, p. 
1700).  The message being sent out is that tropical has been a point of tension and after the 
renaming it turns into something ostensibly more neutral.  However, the intention behind the 
renaming is that it will serve a purpose and be no longer used at some point. 																																																								
98 Reference to international medicine tends to be made under the banner of international health, referring 
to health for developing countries.  The LSHTM have an MSc programme entitled 'Tropical Medicine & 
International Health', there is a journal called Tropical Medicine & International Health, and also a 
European Congress on Tropical Medicine and International Health.  NTDs could be now said to sit within 
global public health, as the current conceptualization of international health. 
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What we are left with is an interesting conflict that arises when calling something neglected.  To 
label something as neglected by measurement is a labeling act, an evocation for it to be no 
longer.  The diseases are called neglected so that at a point in the future it will no longer be 
neglected.  Thus it is only a temporary term if the hopes of the advocates are realized.  
However, neglect will exist on a scale and the diseases within will be relatively more or less 
neglected.  This is an impreciseness and definitional quality that is not based on biology and 
something that some in the scientific community were initially opposed to in the early days of the 
term.  For example, Simon Croft a Professor of Parasitology at the London School of Hygiene 
and Tropical Medicine (LSHTM), highlighted that 'neglect' was a labeling concept but could 
cause difficulty in the division made across biological categories:  
 
“If you start labeling things as neglected, I understand it from an advocacy point of view but… 
some people don’t start looking across the board at the discipline, strategy.  Whatever you’re 
doing on infectious diseases it’s the same principles... you don’t want to fragment things too 
much... it’s great for advocacy to raise the profile and get lots of publicity” (Interview with author, 
Simon Croft, 2014). 
5.2.3 Current geography 
 
The second positioning of tropical is in geography.  The geographical assignment, as pointed 
out by Manson in establishing the tropical medicine speciality (Manson, 1898), is more 
convenient than accurate, to assign diseases a locality within tropical or semi-tropical regions.  
The boundaries were stretched and blurred as to which countries counted as tropical.  As 
Stepan points out Algeria was considered medically tropical in the late 19th century, even 
though it was not in a literal geographic sense.  'Tropical' was more than a geographic concept 
and, "...signified a place of racial otherness to the temperate world" (Stepan, 2001).  Also the 
diseases that counted as tropical did not easily fit classification and it is inaccurate to think of 
these diseases as a foreign 'other', located in the tropics.  Manson noted at the turn of the 20th 
century that "...a volume on diseases peculiar to the tropics would occupy six pages or so" 
(Worboys in Bynum & Porter, 2013, p. 512).  Tropical diseases are certainly more fluid than 
would be expected and their geography is constantly shifting.  What we have called tropical 
diseases in the past, malaria for example has existed in the US southern states and went as far 
north as Boston and even Montreal (Conn, 2011).   
 
This is not ancient history either.  Up until the beginning of the 20th century the mosquito-borne 
diseases malaria and yellow fever were a serious problem in the farming regions of the US 
(Desowitz, 1991).  At the turn of the 20th century, one out of every eight citizens of Memphis, 
Tennessee was dying of yellow fever before it was eradicated in 1949 (Conn, 2011).  A 'pin up' 
calendar for US troops was made by The Center for Disease Control (CDC), which was founded 
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during World War II as the Office of Malaria Control (see Figure 7).  The agency was charged 
with eradicating malaria in the South of the US, especially around military bases, running 
mosquito abatement programs and publicity campaigns until the malaria was finally eradicated 
in the US in 1951.  
 
Figure 7 'Pin-up' calendar poster by Office of Malaria Control 
(NPR.com ‘How The U.S. Stopped Malaria, One Cartoon At A Time’, 2012)  
In Italy malaria99 was also called the 'Italian National Disease'.  By 1904 the country had begun 
a 'crusade against malaria', involving the state, local government and medical profession 
through mass quinine purchase,100 a 'quinine tax' of employers and landowners, support of the 
Italian Red Cross and rural health stations to administer the treatment (Snowden, 2006).  The 
idea of nationhood was prevalent throughout, as Prime Minister Sonnino stated in 1910: "...the 
fight against the terrible scourge of malaria constitutes an important economic, social, and 
public health interest for our nation... No effort must be neglected. Only the contribution of 
everyone, no one excepted, and the unremitting employment of every available means... will 
make it possible to achieve significant and lasting results" (ibid., p. 61).  Thus, now forgotten, 
tropical diseases have been significant in the histories and defining the character of now 
developed countries, reflecting their culture and society.101  Forgetting has been a part of 
neglect, it is an inadvertent neglect of a past once known but can also be deliberate by ignoring 
the past. 																																																								
99 I have to note the US did not have the more deadly malaria parasite (plasmodium falciparum) that was 
found in Italy and is what health officials tend to be more concerned about.  Although there is an argument 
that plasmodium vivax should not be regarded as relatively benign because of how debilitating and 
sometimes life-threating it can be.   
100 Quinine was the main malaria treatment at the time. 
101 The Italian malaria campaign proponents described it as being based on "rational scientific methods" 
but the religiosity off the campaign was marked (ibid., p. 56).  The health clinic doctors were told to be 
"...apostles of health and hygiene" and open air clinics held at the end of public mass were set up so that 
people could be "...treated, medicated and evangelized (ibid., pp. 58–59).   
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5.2.4 Challenging geographic classification: chronically tropical 
 
Today yellow fever and malaria no longer tend to be classed as NTDs.  This brings me next to 
diseases that could be thought of as tropical diseases but are not.  HIV/AIDS and tuberculosis 
(TB), although having high incidence rates in the tropics, are now not viewed as especially 
tropical.   Kamat (2013) explains the shift in perceptions for malaria between 2001 – 2013: 
"...malaria is no longer indexed as a 'tropical disease'; it is placed on par with HIV/AIDS and 
tuberculosis as a global killer, at least discursively, demanding renewed attention and enormous 
resources." (p. 221).  This change was partly a result of the Millennium Development Goals 
(MDGs), agreed by all member countries at the UN and leading development institutions.   
 
It propelled malaria, HIV/AIDS and TB as targets for global attention in 2000, rather than being 
consigned to the tropics.  These are global killers, because of the scale of deaths, and so the 
sixth goal out of the eight poverty reduction goals was, “...to combat AIDS, malaria, and other 
diseases” (see: United Nations Statistics Division, 
http://unstats.un.org/unsd/methods/m49/m49regin.htm#developed, Accessed 2/4/14).  TB was 
later to be included in this grouping, through the 'Global Fund to Fight AIDS, TB and Malaria'.  
This example shows how other disease constructs form an identity (the big three) giving rise to 
disease identities in relation, so that the 'other diseases' in the MDGs became NTDs.  We can 
indeed learn from the outliers to NTDs, in yellow fever – argued by some that it should be 
included but it is not and dengue fever – argued by some that it should not to be included but is.  
 
Yellow fever 
 
Yellow fever is not viewed as a particularly neglected disease, although it is certainly tropical 
with the virus endemic across a huge tropical area of Africa and Latin America covering 44 
countries, with an estimated 29,000 – 60,000 deaths in 2013.102  An effective vaccine exists and 
control programs have been successful in the past.  Therefore, the existence of a vaccine and 
effective control programs appear to work against yellow fever being included.  However, rabies 
is included when an effective vaccine exists and it is certainly not a chronic disease.  Why is it 
included?  It may be because rabies is a zoonic disease, which better fits the NTD profile and 
vaccination programs are expensive, especially when better animal management can also work, 
and it affects the rural poor living in remote areas (Bourhy et al., 2010).  Therefore half of the 
characteristics of rabies are a very good fit while the other half are not, which may have tipped 
the balance, where half of the yellow fever characteristics are a moderately good fit and the 
other half not. 
 
																																																								
102 WHO, www.who.int/neglected_diseases/NTD_STAG_report_2015.pdf, 2016b, Accessed 2/4/14. 
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Stepan also suggests yellow fever has been more prominent in the imagination as being more 
deadly than other diseases, despite killing fewer people other diseases common in the 
nineteenth century: "...yellow fever, like cholera, was notorious because of the swiftness with 
which it invaded a community, its high mortality rate (usually twenty percent), and above all 
because it did not easily fit any known patterns of transmission" (1978, p. 397).  With the 
capacity to bring cities and major industrial projects to a standstill, partly due to the confusion of 
the etiology of disease, yellow fever once struck fear in many.  However, some do identify it as 
neglected today on the basis of lack of research:  
 
"...'Yellow fever is truly a neglected tropical disease... Even though it continues to cause fatality, 
it remains understudied. While it is true there is a highly effective vaccine, it remains extremely 
challenging to get comprehensive vaccine coverage in sub-Saharan Africa and Latin America.  
Moreover, the vaccine works well if you are between one and 55 years old.  It is not safe for 
babies or the elderly, who could develop yellow fever from the vaccine'...” (Pittalwala, 2014).   
 
It is also likely not to have been included in the NTD grouping because it is an arbovirus 
(arthropod-borne virus found in mosquitoes, ticks, flies transmitting pathogens to humans), while 
NTDs are more dominated by parasitic, protozoal and bacterial diseases.  This exclusion on the 
grounds of pathogen, has led to some scholars, such as LaBeaud making the case for the 
inclusion of arboviruses as a group of diseases dominated by "...helminths, protozoa, and many 
tropical bacterial species"  ('Why Arboviruses Can Be Neglected Tropical Diseases', 2008, p. 1).  
The list goes on for diseases that scientists argue should be included:  
 
"...snakebite is a disease that kills 100,000 a year so should be on list, I think there's a 
momentum there, now Sanofi has stopped making the anti-venom Africa and Africa are in 
serious trouble... so I'm really a great advocate for snakebite" (First interview with author, 
Molyneux, 2016). 
 
Conversely, arguments attest for other diseases to be taken off the list, as I shall explore next 
with dengue. 
 
Dengue 
 
Dengue is an example of the changing perception of NTDs as it is an arbovirus and the last 
disease to be included in the NTD list in 2010 (Hotez, 2011).  As yellow fever incidence rates 
are rising where regular vaccine programs have not been implemented, we may see future 
inclusion.  What appeared to justify inclusion of dengue is the lack of an effective treatment (no 
drug or vaccine) and its presence in the tropics but the presence is rising "...both in space and 
time, becoming less and less seasonal, and occurring in more parts of the world" (Conn, 2011).  
Therefore previous lack of research and intervention tools are crucial, as well as a rising burden 
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that has not been acknowledged, as Cameron Simmons argues, “(D)engue is neglected in the 
sense that the true scale of the disease burden is poorly understood and certainly 
underestimated" (in Regnier, 2012).   
 
However it does raise questions apart from being an arbovirus and not chronic, by not being a 
disease strongly related with poverty and being a semi-commercial disease for drug companies.  
Participants at a workshop held by the Institute of Medicine, based in Washington, questioned 
the inclusion of dengue as an NTD, on the grounds of it not being a chronic disease.  The 
following is the account from the workshop in 2011, where "(T)here was considerable 
controversy as to whether or not Dengue is an NTD" with some arguing dengue is an emerging 
(acute febrile) illness, rather than a chronic debilitating one and "therefore does not fit the NTD 
model" (Relman & Choffnes, 2011).  The 'chronic disease nature' is a feature of neglect (which I 
will cover more on in the next section about the neglected category) as compared with other 
infectious diseases.  Chronic infectious diseases more rarely cause 'explosive outbreaks' 
making them less visible and they are not well exported to developed countries even though 
they are communicable, so not seen as a threat (Relman and Choffnes, 2011, p. 17).  
Therefore, the idea of diseases being 'tropical' is in part due to containment in developing 
countries.  An example of an explosive outbreak that might be thought of as a tropical disease in 
2014 was Ebola.  However, Ebola, another arbovirus, is classed as an emerging disease103 
even though it is to be found in tropical regions and some do argue it has been neglected.  
 
Dengue has been described as semi-commercial 104  in that some aspects of treatment 
development in the past have not been commercially viable, but other avenues such as the 
creation of a vaccine have potentially high rewards if targeted toward richer consumers and 
countries.  Sanofi has invested €1.3bn in their dengue vaccine and expect to recoup their costs: 
"...analysts at Deutsche Bank say it could become the world’s best-selling vaccine with 
revenues of €1bn a year" (Ward, 2014).  If pharma can successfully target consumers and 
governments in high-income countries such as Singapore and middle-income countries (Brazil 
and China), they will see profits – especially as dengue does not affect the poor 
disproportionately.  For example, the middle class was the proportionally predominant group 
affected during the epidemic in Dhaka Bangladesh and upper social classes had higher sero 
prevalence rates105 in Fortaleza and San Luis epidemics in Brazil (Guha-Sapir & Schimmer, 
2005, p. 5).   
 																																																								
103 Emerging infectious diseases are identified by the WHO to have arisen in the last 20 years and were 
previously unknown (as well as being incurable).  They include HIV/AIDS, hepatitis C, lyme disease, 
hantavirus (pulmonary syndrome) and SARS (severe acute respiratory syndrome) (WHO 'Emerging 
diseases' http://www.who.int/topics/emerging_diseases/en/, Accessed 2/4/14).   
104 Certainly dengue is a more commercial disease relative to other NTDs, which is why NGOs such a 
Policy Cures use the semi-commercial label (Moran et al., 2012).   
105 Prevalence rates mean "the frequency of individuals in a population that have a particular element (as 
antibodies to HIV) in their blood serum" (Merriam Webster Dictionary) 
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Mulligan et al (2015) through a systematic review of the research literature found that the 
relationship between dengue and poverty is not well established.  In an earlier paper they 
questioned what the consequences were in "public health policies that construe dengue as a 
disease of poverty" and whether there are more appropriate policies for dengue in middle or 
upper-middle class communities than the current construction as an NTD (Mulligan et al, 2012, 
p. 409).  While it is evident that global strategies for dengue in poor communities become 
adapted to local conditions, Mulligan et al also make the political observation that:  
 
"For the WHO, reconsidering dengue-poverty connections may also mean revisiting the 
question of why dengue is a neglected tropical disease, shifting responsibility for dengue from 
the characteristics of poor populations and communities themselves to the political decisions 
that have resulted in under-investment in this rapidly spreading infectious disease" (ibid. 415-6).   
 
They point toward the decisions of rapidly developing countries where better urban planning is 
needed, alongside a consideration of public health policies related to new living situations (ibid.).  
As Gavin Screaton describes, “(D)engue is predominantly a disease of urbanisation... It poses 
major challenges to healthcare systems in developing countries because of its epidemic 
potential causing explosive outbreaks in some major cities” (Regnier, 2012b).   
 
The inconsistencies for dengue with other NTDs form part of a larger debate about disease 
categorization.  The inclusion in the NTD list appears to have been driven by concern about 
incidence rates and epidemics after the disease was made an international public health priority 
by the WHO in 2002.  There is no other obvious group for dengue to have gone under (apart 
from perhaps 're-emerging diseases') and so NTDs provide a helpful banner.  However, the 
arguments made by both Mulligan et al and the participants at the Institute of Medicine 
Workshop expose the consequences of categorization.  On a national level the dengue strategy 
that is characterized by poverty may avoid political questions of urbanization and development, 
as well as not being well suited to local needs.  On a global level there may be raised concerns 
for dengue, not as a chronic disease but rather for the potential of crossing borders and posing 
an epidemic threat. 
5.2.5 Blue marble health 
 
What then are the consequences of over-focusing on the tropical – in the nature of NTDs being 
chronic infections and in the poorest countries – and not addressing other considerations?  The 
contradiction between the geographically tropical imagination of these diseases and what some 
argue as more accurate characterization by poverty (whether that be in a tropical country or 
otherwise) is the concept espoused by Peter Hotez called 'blue marble health'.  The idea of blue 
marble health is that there is a blurring of health between developed and developing countries 
so that within G20 countries we also see NTDs.  Hotez makes the argument that NTDs still exist 
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in developed countries within poor communities.  Diseases do not affect countries 
homogenously; instead there are severe local inequalities and disparities.  There exist many 
layers of inequality in global health and this point is made in reference to the photograph of 
Earth taken by the Apollo 17 astronauts to portray how the extreme poor living among the 
wealthy disproportionately suffering from the world's NTDs.  Hotez described the 'Blue Marble 
Health' idea when I interviewed him: 
"...we’re finding paradoxically that more that half the 
neglected diseases are occurring among the G20 
countries but they are occurring in areas of poverty in 
those countries. Places like Southern Mexico or 
Northern Argentina or Northeastern Brazil or in 
Indonesia... countries have the ability to afford 
treatments for neglected tropical diseases so it calls on 
the G20 countries to take responsibility for their own 
diseases, and, I’ll just say that we are often now 
finding this hidden burden of neglected tropical 
diseases" (Interview with author, Hotez, 2014) 
 
Figure 8 'Blue Marble Earth'  
(NASA http://www.nasa.gov/, Accessed 10/12/16) 
 
To summarize, it is already evident that the tropical category causes some tension, as there 
may be some diseases that are tropical but not neglected and vice versa.  The disputes about 
where inclusion lines are drawn signifies how tropical disease is related to a particular idea of 
disease that goes beyond even the geographical location and historical categories.  From here 
we next question the neglected categorization and this too is far from straightforward. 
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5.3 What is 'neglected'?  
 
The neglected category is arguably even more contentious.  It is significant that we attribute a 
social-political categorization to a group of diseases.  Similar terms that refer to the place of 
diseases in society and politics, are 'diseases of poverty' such as diarrhea and pneumonia or on 
the other end of the scale 'lifestyle diseases' caused by obesity and smoking.  The influence of 
epidemiology can be seen to have had a profound effect through concern for the distribution 
and determinants of disease and also social determinants of health (SDH) (Raphael, 2006).  
However, these disease categories can be problematic in terms of the values and choices made 
whether for individuals and/or societies.   
 
What is the difference between a disease of poverty and a lifestyle disease?  Ironically today, a 
disease such as scurvy could be placed in the category of lifestyle diseases (Dobson, 2015), 
caused by a particular way of living.  In the past the disease was seen to be due to a lack of 
scientific knowledge but now the knowledge is available and it is preventable, responsibility and 
blame is passed to the patient.  Today, both groups of diseases whether poverty or lifestyle, 
may focus blame on the individual or society.  Although lifestyle diseases connote more of an 
element of choice compared with poverty where people might be blamed for their initial 
predicament but are constrained in their choices.  Thus the argument might follow that the state 
should not fund treatment for such a disease.  Similarly, a disease of poverty connotes stigma, 
so again there might be social consequences for being within this category.106 At the Institute 
for Tropical Medicine in São Paulo the doctors praised recent media campaigns addressing the 
taboo of TB (Interview with author, Scientist at Institute for Tropical Medicine, 2014).  Over time 
a reaction to NTDs has been stigma and social marginalization, documented by sociological 
research on the cultural meaning of stigmatized illness:  
 
"Drawing on the work of Goffman, Gussow and Tracy (1968) were the first to distinguish 
'stigmatized illness' as a category using the case of leprosy. Subsequent researchers examined 
the construction and impact of a number of stigmatized illnesses, including mental illness, 
epilepsy, cancer, HIV/AIDS, and sexually transmitted diseases (STDs).  These researchers 
have identified how some illnesses become stigmatized, the impacts of stigma, the ways 
individuals and collectivities manage stigma, and how illness stigma can change over time" 
(Conrad and Barker, 2010, p. S69).   
 
Leprosy is a NTD but many of the other NTDs also have similar features in terms of 
disfigurement and disability (e.g. visceral leishmaniasis and trachoma).  The stigma perpetuates 
the hidden nature of these diseases.  It is a, "...lack of political voice among those afflicted by 																																																								106 The Argentinian soccer player Lionel Messi spoke out about Chagas disease after watching an Al 
Jazeera documentary on the issue (DNDi, 2013, Accessed 2/4/14).  
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neglected tropical diseases... neglect diseases of neglected people" (Relman & Choffnes, 2011, 
p. 17).  Therefore, the neglected description can be argued to be an acknowledgement of the 
already socio-political nature of disease, as we see through stigma and how this has left 
patients hidden and voiceless. 
5.3.1 Definitions of neglect 
 
The NTD group as outlined by the WHO relies on a 'new conceptual framework' based in the 
number of commonalities decided by the organization and set out in the first report on NTDs in 
2010.  As the WHO points out in the report these are a medically diverse set of diseases (2010) 
and thus need justification for grouping.  These commonalities do offer insight into the policy 
rationale for grouping NTDs and form a backdrop to the exploration of categories in this chapter: 
 
  
• A proxy for poverty and disadvantage  
• Affect populations with low visibility and little political voice 
• Do not travel widely 
• Cause stigma and discrimination, especially of girls and women 
• Have an important impact on morbidity and mortality 
• Are relatively neglected by research 
• Can be controlled, prevented and possibly eliminated using effective and feasible solutions 
 
Table 16 WHO listed commonalities of NTDs 
(Source: WHO, 2010) 
 
Others have followed suit in considering the WHO list of commonalities and providing further 
detail.  Relman and Choffnes have drawn on the NTD experts (Pecoul and Hotez) to give some 
explanation behind the WHO commonalities (See Box 4 below).  The authors place further 
emphasis on how ‘underdevelopment’ is exacerbated; contrast between those affected and 
decision-makers in capital cities; the effect of stigma and discrimination for women’s marriage 
prospects and vulnerability to abuse or abandonment; and NTDs not travelling easily and so a 
threat to inhabitants of high-income countries.  This list appears to draw out the unequal aspects 
of NTDs between a number on dualities between: the developed and underdeveloped; decision-
makers and voiceless; women and men; and high-income inhabitants and low-income 
inhabitants. 
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Box 4 NTDs and their common features  
(Adapted from Relman & Choffnes, 2011) 
These commonality lists have since evolved into a more affirmative 'criteria for inclusion' 
displayed in the last chapter, with the 'STAG' group for Neglected Tropical Diseases developing 
the process for the adoption of additional diseases as NTDs on January 2016 (WHO, 2016b).  
The criteria largely repeats the commonalities set out in the first WHO report (2010), adding 
further detail as Relman and Choffnes have done in identifying common features of NTDs.  
However, the wording emphasizes the poverty element in how NTDs "disproportionately affect 
populations living in poverty" and that this is "justifying a global response" (ibid., p. 2).  A return 
is also made to the tropical and sub-tropical character, in describing NTDs to "primarily affect 
populations" living in the areas.  Neglect by research is still there and the point is made stronger 
in saying that the research allocation is unfair, particularly in "new diagnostics, medicines and 
other control tools" (ibid.).  Therefore, it is the lack of options for intervention and advancements 
in existing technologies (e.g. diagnostics) that is the problem, rather than there not having been 
ground-breaking research and viable control tools for many NTDs.   
 
Some commonalities have notably been dropped, including the political voice of those affected, 
including the emphasis on stigma for girls and women, and the lack of travel of NTDs.  This may 
signal the downplaying of a human rights element, while the major introduction has been the 
third criteria that the diseases: "are immediately amenable to broad control, elimination or 
eradication by applying one or more of the five public health strategies adopted by the 
Department for Control of NTDs" (ibid.).  However, this is under the proviso 'and/or' that are 
	 NTDs and Their Common Features 
 
The list of NTDs is vast and virtually open ended. For the time being, WHO's work is confined to a list 
of 17 selected helminth, protozoal, and bacterial diseases. There are 149 countries and territories 
where TDs are transmitted, and at least 100 of them are endemic for 2 or more diseases and 30 are 
endemic for 6 or more (WHO, 2010d). 
 
The NTDs are quite a diverse and heterogeneous group of diseases. However, they share a number 
of common features: 
 
1.  The Hallmark of Poverty and Underdevelopment 
The most striking common feature of the NTDs is that they affect almost exclusively poor and 
marginalized populations (Hotez et al., 2009)  
2.  Diseases of Non-Decision Makers 
Affected populations often live in remote rural area, in conflict zones, or in urban slums and have little 
political voice. They cannot readily influence administrative and governmental decisions that affect 
their health and often seem to have not constituency that speaks on their behalf. Diseases associated 
with rural poverty may have little impact on decision makers in capital cities (Pecoul, 2005) 
3.  Association with Stigma and Discrimination, Especially of Women 
Many NTDs produce disfigurement and disability, leading to stigma and social discrimination. Their 
impact disproportionally affects women, whose marriage prospects may diminish or who may be left 
vulnerable to abuse and abandonment 
4.  Not Travelling 
Unlike influenza, HIV/AIDS, malaria, and, to a lesser extent, tuberculosis, NTDs generally do not travel 
and seem to present little threat to inhabitants of high-income countries. Rather, the distribution of 
NTDs is restricted by climate and its effect on the distribution of vectors and reservoir hosts there 
appears to be little risk of transmission beyond the tropics (Pecoul, 2005).  	
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relatively neglected by research.  The mixed strategy for surveillance, control, elimination, and 
eradication of NTDs is acknowledged.  What we are left with is neither solely a problem of 
research for new innovative solutions nor a problem of the attention, resource, funding, and 
implementation of existing tools.   
 
If neglect is both an outward signal and symptom of neglect in research and implementation, 
what are the underlying causes?  Looking at the common definitions of neglect we can see that 
these can be grouped under themes, which are often presented in terms of the contradiction 
(e.g. between the poor and wealthy): 
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a. Poverty and 
inequality: NTDs 
affect large 
numbers the 
poorest/ 
marginalized, 
especially women 
and children but are 
not a problem for 
wealthy so do not 
receive the same 
attention as other 
diseases. 
 
"NTDs are called “neglected” because they generally are not considered public 
health problems in wealthier nations and historically have not received as 
much attention as other diseases" (NIH, 
http://www.niaid.nih.gov/topics/tropicaldiseases/, Accessed 2/4/14). 
 
"1 billion people are affected by one or more neglected tropical diseases 
(NTDs). They are named neglected because these diseases persist exclusively 
in the poorest and the most marginalized communities, and have been 
largely eliminated elsewhere and thus are often forgotten" (WHO, 2016a). 
 
"(NTDs) are a group of parasitic and bacterial diseases that cause substantial 
illness for more than one billion people globally. Affecting the world's poorest 
people, NTDs impair physical and cognitive development, contribute to mother 
and child illness and death, make it difficult to farm or earn a living, and 
limit productivity in the workplace. As a result, NTDs trap the poor in a cycle 
of poverty and disease" (CDC,  http://www.cdc.gov/globalhealth/ntd/, Accessed 
2/4/14). 
 
"The people who are most affected by these diseases are often the poorest 
populations, living in remote, rural areas, urban slums or conflict zones. 
Neglected tropical diseases persist under conditions of poverty and are 
concentrated almost exclusively in impoverished populations in the developing 
world.  Lacking a strong political voice, people affected by these tropical 
diseases have a low profile and status in public health priorities" (WHO 
Features, http://www.who.int/features/qa/58/en/ 012, Accessed 2/4/14) 
 
 
b. Under-
development: NTDs 
have existed for a 
long time and 
reinforce poverty/ 
underdevelopment 
through their 
impact/cost. 
"These diseases, many of which have afflicted humanity for millennia, affect 
more than 1.4 billion people. They sicken, disable, and disfigure, keeping 
people in cycles of poverty and costing developing economies billions of 
dollars every year.  Until recently, NTDs saw little attention from all but a 
small handful of dedicated supporters” (Uniting to Combat NTDs, 2014). 
 
"(NTDs) are a diverse group of diseases with distinct characteristics that thrive 
mainly among the poorest populations. The 17 NTDs prioritized by WHO are 
endemic in 149 countries and affect more than 1.4 billion people, costing 
developing economies billions of dollars" (WHO, 2013,  Accessed 2/4/14). 
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Table 17 Definitions of neglect in the policy literature  
(Multiple sources, emphasis added) 
 
5.3.2 Measuring for attention: from the 10/90 gap to DALYs 
 
Many of the definitions of NTDs are on the related problems of poverty or under-development 
and their lack of attention from governments, NGOs and pharma companies.  The solution is 
often also presented alongside the need for prioritization, using existing safe and cost-effective 
'tools' or developing new treatments.  The lack of attention has been presented in terms of R&D 
for NTDs through the so-called '10/90 gap', which refers to resource allocation of global R&D 
compared with the disease burden.   
 
The 10/90 gap is the finding of a report by 'The Global Forum for Health Research' i(2004) that 
says only 10% expenditure on global R&D is dedicated to problems that primarily affect the 
poorest 90% of the world's population.107  The 10/90 gap only reflects R&D, with the argument 																																																								
107 Critiques of the 10/90 gap have argued that there has been a change in the epidemiology of developing 
countries, change in global health actors and also dispute of the size of the burden (Stevens, 2004). 
 
c. Prioritize to 
solve: High-
mortality diseases 
are given more 
attention, while  
NTDs disable/ 
debilitate rather 
than kill. Treatment 
cost is low through 
existing drugs but 
new ones are also 
needed. 
 
CDC also present a 'Fast Facts' section on their website (CDC  
http://www.cdc.gov/globalhealth/ntd/, Accessed 2/4/14): 
• 1bn people across 149 countries/territories are affected (by at least one NTD) 
• 100% of low-income countries are affected by at least five simultaneously 
• 534,000 people are killed worldwide every year  
• major disease burden, approx. 57 million years life lost to disability or death  
• treatment cost for most NTD MDA est. at less fifty cents per person, per yr  
 
"Many neglected tropical diseases can be prevented, eliminated or even 
eradicated with improved access to existing safe and cost-effective tools. 
Control relies on simple interventions that can be carried out by non-
specialists" (WHO Features,  
http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/, 2012,  
Accessed 2/4/14) 
 
"NTDs are infectious diseases that generally are rare or absent in developed 
countries, but are often widespread in the developing world... The availability of 
new safe and effective drugs for NTDs could provide public health benefit for 
overall global health, but because these diseases are found primarily in 
developing countries, existing incentives have been insufficient to encourage 
development of new drug therapies" (FDA, 2014). 	
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that the market share of pharmaceutical businesses is too small for the 90% of the world who 
are poor, as pharma lacks profit incentive (Liese et al., 2010).  Smith calls the 10/90 gap "(A) 
staggering example of neglect... International aid couldn't just be the distribution of existing 
cures. It needed broad innovation" (Smith, 2015).   Here it is a mismatch between needs and 
investment that mark NTDs out.  So the 10/90 gap became a part of the argumentation that the 
problem of NTDs lies in R&D, which would require a change in the innovation system from 
NGOs and the WHO to academics (Bosman & Mwinga, 2000; Hotez & Pecoul, 2010; Kilama, 
2009).108  Even if the 10/90 gap is not explicitly mentioned the unequal research spending by 
pharma is frequently referred to in media articles on NTDs (see Balasegaram et al., 2008). 
 
R&D disparity is an important inclusion because it is in this context that neglect becomes 
striking.  The WHO in 2007 stated:  "Lack of reliable statistics on the burden of NTDs has 
hampered raising awareness of decision-makers on NTDs and zoonoses. 109   Accurate 
assessment of the disease burden is crucial to prioritize use of limited resources, provide timely 
treatments and prevent diseases" (WHO, 2007, p. 14).  However, it is more than simply 
representing reality.  The neglect of NTDs is highlighted through the numbers of people 
affected.  NTDs compare with the small numbers of people affected by rare diseases 
(sometimes referred to as orphan diseases), which can lack attention and investment as their 
rarity means they only affect a small proportion of people.  Additionally, orphan diseases 
sometimes include common diseases without a drug company 'adopting them'.  The US Orphan 
Drug Act for example includes non-rare diseases and the European Organisation for Rare 
Diseases includes neglected diseases.  
 
The 10/90 gap as a measure, marked the beginning of metrics being used in relation to NTDs, 
to make a policy case for attention.  Christopher Murray, the health economist, has been an 
influential figure behind the drive for better tools for measurement in health.  The Gates 
Foundation invested in the Seattle-based 'Institute for Health Metrics and Evaluation' where 
Murray is Director.  In some part NTDs have also been influential for Murray.  In fact Murray met 
Kenneth Warren the director of the GND in the mid-1980s.  These were his thoughts on the 
program:  
 
“I think the GND program had a great effect. He coined the term and it has stuck, and now 
people compete to call their disease ‘neglected’; there is a bit of a war about what the borders 
are, what is in and what is not. Is leprosy neglected? Is rabies? There are a lot of different 
definitions of what is neglected, and I think that the concept can reasonably be traced back to 
Ken” (Keating, 2014, p. S28).  
 																																																								
108 Unite for sight, http://www.uniteforsight.org/global-impact-lab/global-health-research, Accessed 5/6/13. 
109 "A zoonosis is any disease or infection that is naturally transmissible from vertebrate animals to 
humans" (WHO, 2015). 
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Furthermore, the NTD schistosomiasis was somewhat of a catalyst for Murray in his journey to 
create the 'DALY' metric, which stands for disability-adjusted life year'.  The DALY is described 
as a "...measurement of the gap between current health status and an ideal health situation 
where the entire population lives to an advanced age, free of disease and disability".110  In the 
part biographical account Epic Measures (Smith, 2015), which charts Murray's career in global 
health, a defining moment was when Murray travelled with his family to South Africa where they 
ran a hospital.  One day Murray found a sick man and had been horrified after he had brought 
the man in and his stomach had exploded, a severe complication of schistosomiasis.  It stuck 
with him that the disease was one he had not even heard about before and that it could be so 
devastating.  
 
DALYs were developed by the World Bank and WHO in 1993, through the Global Disease 
Burden Study led by Murray with Alan Lopez (Smith, 2014).  Murray describes that: “The 
original idea was you want a metric that can also be used in economic studies: If you spend X 
amount of money, this is how much health you’ll get” (ibid.).  The intention has been also said to 
be in assisting health priority setting otherwise influenced by politics and other pressures.  It is 
also through the DALY measure that NTDs can be exposed, by estimating the burden of 
disease.  These estimates renewed interest in the underlying epidemiological parameters.  For 
example as NTDs mainly cause morbidity rather than mortality, the assessment of the average 
disability incurred by a diseased individual is crucial for correctly compiling data to global burden 
estimates.  The disability weights (DW) are based on a non-expert or patient opinion but were 
developed through "highly educated" focus groups (Zhou et al. 2010, Part B, p. 59).   
 
DALYs form a way to support a particular description of the world and how to act upon it.  
Through the description supplied by the DALY, morbidity is put on par or to a raised position as 
mortality, working in favour of NTDs to emphasize the size of this problem (ibid., p. 3).  Now we 
have DALYs NTDs can be described as: "...the fourth most devastating group of communicable 
diseases behind lower respiratory infections, HIV, and diarrheal diseases – ranking higher than 
either malaria or tuberculosis" (The Henry J. Kaiser Family Foundation, 2015).  How NTDs are 
more debilitating and disabling than life-threatening can be captured, and further constructed as 
a grouping.  This measure provides standardized estimates for years of life lost due to disease, 
injury and risk factors over time.  One DALY is equal to the loss of one healthy life year, as the 
sum of: Years of Life Lost (YLL) due to premature mortality in the population and Years Lost 
due to Disability (YLD) for people living with the health condition or its consequences.111  As 
shown in Figure 9 below, NTDs tend to cause more of the 'Years Lost due to Disability' than 
'Years of Life Lost'. 
 																																																								
110 WHO Programmes, http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/, 2015b, 
Accessed 2/4/14. 
111 WHO Programmes, http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/, 2015b, 
Accessed 2/4/15. 
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Figure 9 YLDs and YLL of NTDs in 'The Global Burden of Disease Study 2010' 
(Hotez et al., 2014) 
Of course as the NTD grouping is not completely coherent there are four outliers in rabies, 
dengue, leishmaniasis and African trypanosomiasis.  These are more fatal than disabling but it 
can be argued that these diseases should not be fatal if control measures are followed:   
(1) Rabies is preventable, with the existence of a vaccination also available post-exposure;  
(2) Dengue has less than a 1% fatality rate if detected early with access to proper medical 
care.  While there is currently no known cure or treatment, several vaccine candidates 
are in clinical or pre-clinical development with the most advanced candidate in Phase III 
clinical trials (WHO Programmes, 2015a);  
(3) There are three types of leishmaniasis.  Only one of these, visceral leishmaniasis (also 
known as kala-azar) is fatal if untreated but all are treatable and curable;  
(4) Lastly African trypanosomiasis (also know as HAT or sleeping sickness) is both difficult 
to diagnose and treat but has been controlled on the African continent in the past 
through surveillance methods.  It should be noted that there are two forms of HAT 
depending on the parasite involved, one (Trypanosoma brucei gambiense) accounts for 
over 98% of reported cases causing a chronic infection for months or even years 
without major signs or symptoms and when more evident symptoms emerge the patient 
can be in an advanced disease stage (WHO Factsheet N°259, 2015).  The other 
(Trypanosoma brucei rhodesiense) only represents 2% of cases but causes an acute 
infection that develops rapidly and invades the central nervous system (ibid.).  The YLL 
may be due to the low survival rates if surveillance to prevent the disease transmission 
fails.  
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Therefore, these four diseases are not strictly disabling, unless we count the repeated illness 
and recovery times of several months.  Rabies is the one that clearly does not fit this profile 
because it will almost always lead to death, if a person is not vaccinated before infection or 
vaccinated immediately post-infection before symptoms appear (this has only been challenged 
more recently by survival by inducing coma, called the 'Milwaukee Protocol' Aramburo et al., 
2011).  However, the point is that all are preventable and do not need to be fatal. 
 
DALYs were an evolution of the earlier QALY (quality-adjusted life years) measure proposed by 
Zeckhauser and Shepard in 1976 and widely used in cost-effectiveness analyses for health 
interventions.  The two health economists invented the QALY in 1956 to "...determine the value 
for money of a medical intervention by quantifying the quality of life gained in relation to the cost 
of that intervention" (Adams, 2016, p. 26).  Where DALYs are a measure of the, "health loss in 
populations against a normative standard" QALYs tend to be used to,  "quantify health gains for 
interventions" (Mathers, Ezzati, & Lopez, 2007, p. 2).   
 
Some regard QALYs as a better measure of "subtle morbidities and long-term chronicity" (Zhou 
et al., 2010, Part A, p. 16) but Adams makes the interesting observation that it was "...a crisis of 
funding produced the QALY in the Global North, but I would argue that it was the crisis of data 
that produced its counterpart, the DALY, in the Global South" (Adams, 2016, p. 27).  In 
determining which diseases to bring attention to, the DALY has been crucial, while the QALY 
has told us more about which interventions to take. 
 
I have outlined that the DALY has the capacity to measure the disabling and debilitating nature 
of NTDs as a developing country concern.  However, does the DALY have an impact in 
highlighting NTDs within the Global Burden of Disease (GBD)?  In the early years NTDs did not 
show up very highly on overall disease burden (despite some surprise appearances) and "...the 
NTD community was dismayed by the previous WHO estimates between 1999 and 2004, which 
assigned DALYs that were equivalent to conditions of comparatively minor global health 
importance for major diseases such as schistosomiasis" (Hotez et al., 2014, p. 2).  The year 
2002 was deemed particularly bad as no NTD appeared in the 20 leading DALYs and led to a 
full revision of burden estimates for 2005.  Hotez and Musgrove in 2009 made the argument that 
because NTDs contribute or are underlying rather than identified as the direct cause of deaths 
they were overlooked.  For example schistosomiasis may lead to death by bladder cancer or 
deaths attributable to anemia from an NTD.  They also argued that uncertainty about prevalence 
and incidence led to under-reporting of YLDs. 
 
Later estimates calculated that the DALYs attributable to NTDs was US$56 million, however 
estimates dropped again in the 2012 GBD study it to be only US$26.05 million (See Molyneux, 
2014, p. 176).  This is quite a fall and constitutes only 1% of the total global disease burden.  
There are several reasons for such a discrepancy.  The first is in the geographic spread and 
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how this is measured as NTD rates vary (by nearly 1000-fold) across regions because of a 
concentration in the poorest countries.   A second point is that burden for diseases associated 
with long-term morbidity, is determined by DWs and "(T)here is considerable dispute of the DWs 
attributed to NTDs, and some case studies have seriously challenged both the DWs for different 
diseases, but also the numbers of people afflicted" (ibid., p. 5).  Also direct pathologies 
associated with NTDs that are not included in the NTD burden such as for cancer and 
neurological conditions and factors have been ignored in calculating the burden of NTDs, such 
as mental illness. 
 
At the other extreme, "...the higher DALY estimates for NTDs elevate the status of these 
diseases to a level at which they could be thought of as the fourth leg to a table built on 
HIV/AIDS, tuberculosis, and malaria" (Hotez et al., 2014, p. 2).  Collectively constructed, NTDs 
can be counted together adding up the number of DALYs that are attributable.  As Hotez et al. 
document the 2010 measure attempted to resolve earlier difference in estimate and also include 
more diseases, to provide a resulting figure of 48 million DALYs for NTDs, compared with 
tuberculosis (49 million), malaria (83 million) and HIV/AIDS (82 million), the later two accounting 
for two of the world’s major diseases (ibid.).   
 
It is important to remember the DALY measurement is a 'calculus of credibility',112 in that as I 
described previously, evidence is placed by policy actors on a hierarchy, with RCTs tending to 
be at the top.  DALYs are similarly statistically quantifiable metric and furthermore, they do not 
sit in isolation and go toward creating the 'Global Burden of Disease index', which ranks 
diseases according to their DALY score.  Therein comes the importance of measuring and 
creating metrics at all, to be able to list hierarchal and relationally problems for policy that allows 
on a managerial level comparison and prioritization of funding and resources, on a possibly 
more ideological level to determine need apart from so-called political pressures.  This is where 
much contention lies, as political process of democracy demands advocacy and different groups 
to petition elected representatives on the interests, values and causes they support.  To 'follow 
the numbers' may suppress these activities or these activities will adopt the measurement 
language through the DALY metric.   
 
The Gates Foundation now uses the concept of DALYs on a wide basis to help determine 
priorities and evaluate potential projects.  By quantifying years lost to poor health, disability,, an 
economic valuing of human life is made by measuring morbidity in addition to mortality.  The 
measure tends not to be used in economic analysis of cost-benefit but rather for cost-
effectiveness (Smith, 2015, p. 145).  Gates recounted the influence of the 1993 World 
Development Report with preliminary Global Burden of Disease findings: "...'It was just a graph 
that had, you know, these twelve diseases that kill,' said Gates. These included leishmaniasis, 																																																								
112 'Calculus of credibility' is a phrase used by Epstein to refer to how different news sources chose what 
they determine to be credible claims to make for their audiences.   
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schistosomiasis, trachoma–the leasing scourges, preventable at low cost, whose names he'd 
also never seen before" (ibid.).  
 
Following the Gales and Lascoumes definition (2007), DALYs are a tool for statistical 
categorization within the wider instrument of estimating the global burden of health.  However, 
there is a difference between the type of tool described within the NTD community referring to 
interventions and a metric such as a DALY.  This also resonates with public policy 
instrumentation in the problems posed and chosen path to make policy 'material and 
operational', orientating relations between political society and civil society.  Devices mix 
technical components (measuring, calculating, the rule of law, procedure) and social 
components (representation, symbol) (ibid). Instrumentation is expressed in a standardized 
form, combining obligations, financial relations, and methods of learning about populations 
through statistical observations (ibid.).   
 
Even if NTDs do not reach the top of the Global Burden of Disease (GBD), DALYs have 
increased awareness.  Activist scientists and NGOs have faired well in playing the 
measurement game.  Measurement advocacy started with the '10/90 gap', a narrative argument 
of neglect of R&D, especially from big pharma.  However this narrative was largely about the 
injustice of funding for health research and not matching needs.  More persuasively, DALYs 
have taken into account the particular needs associated with NTDs through their disabling 
nature, which had previously been overlooked on priority lists.  The quantification of disability is 
novel in public health, and so the interweaving of DALYs and NTDs has been more successful.  
The argument says why we should care about these diseases and why they are important. 
 
Already the second WHO (2013) report on NTDs referenced the 10/90 gap and the DALY 
measurement.  DALYs transformed NTDs into commensurable diseases to be measured 
alongside the big killers: HIV/AIDS, TB and malaria, where "(T)he calculated economic rates of 
return suggest that investment in control/elimination of neglected diseases produces an 
economic rate of return of 15–30%, and is capable of delivery on a large scale" (WHO, 2005, p. 
19).  However, as Moran et al. have identified, the "DALY approach has clear limitations and 
should be used with caution as a tool to allocate R&D spending" and they see deviation113 
caused by the mechanism (2006, p. 23).   
5.3.3 Neglect in measurement 
 
The selection and operation of metrics are not "...a matter of simple technical choices", but a 
mode of reasoning (Lascoumes & Le Gales, 2007, p. 8).  It is not only the interests behind 
metric or measurement instrument choice that matters but the relationship between metric, 																																																								
113 A limitation of DALYS that has been identified is malaria being favoured because it often kills the young 
and so the earlier the age of death, more DALYs are lost 
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publics, and politics.  Lascoumes and Le Gales argue that it is a particular representation and 
problematization of the issue that is at stake in metric choices, which tend to produce inertia to 
challenge the status quo (ibid., p. 10).  Their observations point toward what is not being 
represented or problematized through the metric, which I consider with the two NTD metrics.  
 
On one hand the representation of attention for NTDs the DALY measure was negative at first.  
As Canning, in the Berlin report contended, the measurement of NTD impact was in fact a 
reason for their neglect, because they "...do not score high from a disease burden perspective, 
and this lies at the crux for their neglect" (WHO, 2005).  He argued that NTDs have been 
subject to the moral imperative of the ‘rule of rescue’, that we should prioritize diseases that 
pose an imminent threat to life, where chronic and non life-threatening conditions are 
overlooked.  At the time of writing, NTDs were faring poorly in DALYs (for the period 1999–
2005) attributed on the Global Burden of Disease Index (Hotez et al., 2014).   
 
However, as the metric has grown in complexity, more NTDs have been included and as well as 
more detailed reporting on their disabling effects (ibid.).  Similarly the growing pervasiveness of 
the metric (Adams, 2016) that has both mortality and morbidity as a combined common 
measure has popularized the idea that morbidity is a major concern and it is measurable so 
action can be taken. 
 
On the other hand, the representation of the 10/90 gap concentrates on big pharma R&D 
investment but does not explain the lack of attention for NTDs from other sources.  Why have 
donor governments and NGOs not invested in R&D for NTDs?  As Canning has already alluded 
to, governments and NGOs have been more concerned with high-mortality diseases, while 
NTDs are less attractive in policy terms because of the number of deaths worldwide only being 
in the thousands.  Therefore neglect of NTDs by those actors has been due to other diseases 
being of higher priority on policy agendas, with attention directed at the 'big three' high-mortality 
diseases.  To be an attractive proposition for policy, the advocacy for NTDs needed to shift 
attention from mortality towards morbidity, which had a,, "high return on investment" in a low 
cost intervention that had productivity and economic development impacts to, "attract the ear of 
finance ministers" (WHO, 2005, p. 11).  DALYs have since been utilized by activist scientists 
and NGOs in a switch in opinion for NTDs, below are the types of headlines employed. 
 
The End Fund an NGO: "When measured in disability-adjusted life years, the NTD burden is 
greater than that of malaria or tuberculosis, and ranks among the top four most devastating 
groups of communicable diseases, along with lower respiratory infections, HIV/AIDS, and 
diarrheal diseases".114  
 
																																																								
114 The END Fund, http://www.end.org/whatwedo/ntdoverview, Accessed 4/6/16. 
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Activists scientists Hotez, Fenwick, Molyneux and others: "By some estimates, the neglected 
tropical diseases are second only to HIV/AIDS as a cause of disease burden, resulting in 
approximately 57 million DALYs annually" (Hotez et al., 2006). 
 
Instead of being problematized by DALYs as low in importance by being comparatively low 
mortality diseases they are characterized as high in importance by being high morbidity 
diseases.  In the section that follows I turn to understanding neglect in solutions that are posed 
in order to tackle NTDs. 
 
5.3.4 Finding neglect in solutions: '50 cents per person' 
If neglect is understood in how the policy problem of NTDs is defined, this is assisted through 
measurement of R&D investment (10/90 gap), and of disease burden (DALYs).  Moving onto an 
understanding of neglect in the solutions, in terms of what interventions will make the most 
difference, it has been a historical legacy of neglect that vaccines and drugs have not been 
developed for some of the NTDs.  Some of the existing drugs are old, in need of improvement, 
or need continuing research in case there is drug resistance.115   
 
For example, successful drugs such as praziquantel, used to effectively treat the 
schistosomiasis parasite may now be developing resistance.  Certainly penicillin, used to treat 
yaws, is at risk of resistance, with concerns also in the difficulty of refrigeration as well as 
training to administer in developing country settings (Broadbent, 2011, p. 55).  Other strategies 
for addressing these diseases are available, either suggested as an alternative or alongside a 
drug-based strategy.  Table 12 shows what strategies are recommended by the WHO for each 
disease.  Also see Appendix 9 for an earlier and briefer list of NTDs control strategies by the All-
Party Parliamentary Group on Malaria and Neglected Tropical Diseases (APPMG, 2009) and 
see the Appendix 10 for a comprehensive table of current strategies per disease. 
 
 
																																																								
115 It was not until 2009 that NECT (Nifurtimox and Eflornithine Combination Therapy) was introduced to 
treat the early stages of human African trypanosomiasis, as first new improved treatment option in 25yrs 
for stage 2 of disease.  The drugs that had been commonly used are pentamidine, which was discovered 
in 1940 and suramin to treat the rarer form of the disease, which was discovered in 1920 and can cause 
urinary tract and allergic reactions (WHO Factsheet N°259, 2015). 
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Table 18 Strategies by disease  
(Compiled from information on CDC http://CDC.gov.org; DNDi http://www.dndi.org; WHO, 2015) 
There are five NTDs (trachoma, lymphatic filariasis, onchocerciasis, schistosomiasis, and soil-
transmitted helminths) that are being addressed primarily through Mass Drug Administration 
(MDA) of anthelminthics and antiparasitics, along with antibiotics.  According to the NGO 
ENVISION: "(MDA) is the administration of drugs to entire populations, in order to control, 
prevent or eliminate common or widespread disease".116  MDA used to control NTDs has been 
hailed as an effective policy intervention, which the WHO describes as a ‘preventive 
chemotherapy’ to regularly and systematically administer medicines to populations who may 
either have an NTD or be at risk (WHO, 2012c).   
 
It is a cheap form of treatment at 50 cents per person, according to the CDC, as "...one of the 
best buys in public health – with a low cost of about $0.10 to $0.50 per person/year and the 
benefit of helping prevent or treat several different diseases" (CDC, 2010, p.2).  As Warren 
Lancaster, a senior vice president at NGO 'The End Fund' has put it: "for the donor community 
that's a very attractive proposition" (Interview with author, Lancaster, 2014).  Similarly, Professor 
Alan Fenwick describes MDA at 50 cents per person as "...the best buy for public health" 
(APPMG, 2009. p. 14),  acting as a marketing tool to 'sell' an attractive solution.  It proved to be 
a successful pitch for Fenwick, when the '50 cents per person' caught the eye of Alan 
McCormick, a Partner at global investment firm Legatum, following an interview Fenwick gave to 
the Financial Times in 2006: 
 
																																																								
116 ENVISION http://www.ntdenvision.org/, Accessed 2/4/14. 
Drug-based 
strategies 
 
trachoma, lymphatic filariasis, 
onchocerciasis, 
schistosomiasis, soil-
transmitted helminths (5) 
MDA of anthelminthics and antiparasitics, 
along with antibiotics 
buruli ulcer, leprosy, yaws, 
leishmaniasis (4) 
antibiotics or antifungals 
Environment
al-based 
strategies 
 
 
dracunculiasis  (1) 
 
safe drinking water, surveillance, awareness 
among affected and at-risk populations 
Chagas, dengue/chikungunya 
(2) 
vector control 
cysticercosis/taeniasis, rabies, 
echinococcosis, foodborne 
trematodiases (4) 
food hygiene and veterinary public health 
measures or animal management 
human African 
trypanosomiasis (1)  
surveillance through mobile screening teams 
of at-risk populations  
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"...a phrase from an interesting article on philanthropy implanted itself in his mind: that such 
treatable ailments ‘do not need innovation but simply modest funding and a little imagination in 
order to distribute drugs to those in need'... He was inspired by the idea that it might be possible 
to change the lives of millions, to free them from the burden of devastating illness, for as little as 
50 cents per person".117 
 
The result was the Legatum Foundation establishing 'The END Fund' as an NGO to finance 
control initiatives, and supplementing and creating new programs in a bid to control or eliminate 
the five most common NTDs.  However despite the impact, the '50 cents per person' proposition 
is not problem-free.  There is some worry about drug resistance from continued usage at this 
scale (Barry, Simon, Mistry, & Hotez, 2013) and acceptance by local communities dependent on 
perceptions and experiences.118 
 
Another four NTDs are treatable either through antibiotics or antifungals (buruli ulcer, leprosy, 
yaws, and leishmaniasis).  Still, environmental strategies are crucial for these diseases and are 
part of well-functioning health systems, including: information/education, clean water, sanitation, 
early detection/diagnosis/case management, surveillance, control of reservoir hosts, social 
mobilization and the strengthening of partnerships.  For lymphatic filariasis (also known as 
elephantiasis) in addition to MDA, the WHO recommends an alternative and equally effective 
environmental strategy.  This is the use of common table salt or cooking salt fortified with DEC 
(diethylcarbamazine) for one year in endemic regions, with vector control as a supplemental 
strategy.  Some diseases are in fact better addressed with environmental-based strategies, 
replacing drug-based strategies or supplementing them.  For example, safe drinking water 
through surveillance and awareness among affected and at-risk populations is the preferred 
strategy for dracunculiasis.   
 
Still, the preferred strategy is changeable, dependent on resources, disease spread, and 
research developments.  In the case of onchocerciasis, vector control had been successful in 
the past but was no longer considered feasible or cost-effective in the remaining APOC (African 
Programme for Onchocerciasis Control)119 countries, which is why MDA is now favoured.  Also 
for the mosquito-spread diseases Chagas, dengue, and chikungunya, vector control is the main 
strategy.  This is partly because no vaccine is available, so the strategy may change if one is 
developed, but also (in the case of Chagas and to some extent lymphatic filariasis) because 
clinical symptoms are often not present until the disease has advanced in adulthood, such that 
drugs are less effective and have side effects.  Food hygiene and veterinary public health 
measures or animal management (e.g. deworming of dogs, vaccination of pigs) are the best 																																																								
117 The Legatum Group, http://www.legatum.com/philanthropy/investing-in-development/united-voices/, 
Accessed 4/30/16. 
118 Malaria Consortium, http://www.malariaconsortium.org, Accessed 2/4/14.  
119 The APOC programme has closed as of December 2015 and the establishment of a new regional entity 
is expected to support country programmes. 
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strategies for cysticercosis/taeniasis, rabies, echinococcosis, and foodborne trematodiases.  
Although large-scale preventive chemotherapy in humans through MDA may also be required in 
endemic areas with high infection rates. 
 
Through comparing environment-based and drug-based strategies a number of points are 
striking in highlighting the diversity of these diseases (See Appendix 11 for a full list of diseases 
and the strategies recommended): 
 
1. The diseases that require a mainly drug-based strategy are limited to 10.  
2. There is difficulty in developing vaccines/drugs for diseases with a mosquito vector. 
Vector control strategies work best today but this may change and the development of 
vaccines needs to be considered against the amount of resources needed. 
3. Food and animal related illnesses are overlooked when considering NTDs in policy, as 
they require social/cultural change. 
4. A number of diseases are near elimination or eradication, requiring a large amount of 
resources (rather than disease control). 
5. Some outlier diseases appear to allow for limited strategies of control. 
  
I have shown that problem and solution definitions that are drug-based have 'policy appeal'.  
Metrics identify the policy problem of NTDs through the 10/90 gap, which says R&D for new 
drugs is not being directed at the diseases of the poor, and DALYs, which says we should pay 
attention to chronic diseases of the poor, following cost-effectiveness drugs distribution with 
MDA.  The metric of the '50 cents per person', presented by the NGOs such as 'The Global 
Network Against Neglected Tropical Diseases' and global commitments including the landmark 
'London Declaration' meeting in 2012, emphasize MDA of drugs as a central strategy and 
encourage involvement of big pharma.  These metrics present the degree of neglectedness to 
be on lack of R&D investment (10/90 gap), the disease burden not being recognized because of 
morbidity character of the disease (DALYs), and the success of low-cost-high-return 
interventions not known ('50 cents per person').  
 
However, by returning to the 17 diseases and analyzing what are the preferred individual 
strategies to control and eliminate or eradicated the disease, the drug-dominant strategy 
unravels.  As I have highlighted, drug-dominant strategies only apply to just over half of the 
diseases and some outlier diseases have very limited strategies for control.  Furthermore, the 
technical challenge of developing vaccines or drugs for diseases with a mosquito vector is high, 
while vector control strategies may be effective.  A number of diseases have had mixed 
strategies (both drug and environmental), which have been yielding results.  Included here are 
diseases that are near eradication as a result of vector control, community-level programs and 
health education alongside drugs (guinea worm and yaws).  These diseases now require 
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continued funding and resources, rather than new drugs or simply the implementation of 
existing drugs.   
 
5.3.5 Drug dominance 
 
Examining the preferred strategies to tackle individual NTDs shows that the existence of drugs 
does not guarantee successful implementation and neither does the development of new drugs. 
Clearly, a drug-based solution, emphasized by the measurement and quantification of neglect, 
forms a large part of the rhetoric of the problem – as a lack of R&D for new drugs or the 
distributions of existing drugs – but it has limits.  This preference is evident when we return to 
the very definition of what is a neglected disease.  When we return to first principles, to the 
definition of neglect for NTDs, it becomes more evident that the research funding argument 
assumes already that neglect is primarily pharmaceutical neglect.  Neglect from pharma 
companies is in not providing drugs, treatments and prevention or diagnostic tools.  Still, as 
Broadbent suggests pharmaceutical neglect may not be the best identification of the problem or 
solution: 
 
"...the thing that’s striking for me about the neglected disease stuff is that… is that people have 
said, look, not enough research money is being spent on these diseases and that’s what 
neglect is, and, you know, we should fix it by spending more research money on these 
diseases… it assumes that the way you’re going to get rid of these diseases is by developing 
more drugs… saying okay, we’ve got to spend more research money on diseases; that’s not a 
way of working out how to cure or treat neglected diseases; it’s a way of working out how to do 
so and make a profit from doing so" (Interview with author, Broadbent, 2014). 
 
In defining neglect, the concentration is on funding and resources and the potential for solutions 
to come about through R&D and innovation.  Broadbent identified a commercial angle to this, in 
how research money and a profitable product are needed, rather than say, social and political 
change, or more intangible changes.  He argues on similar grounds that other approaches can 
be taken, including a consideration of public health systems and initiatives.  This is especially 
true if there are strategies and public health tools available so it is not about starting from 
scratch or thinking that only solutions produced through research are viable:  
 
"… there are many other things you can do about diseases. There are public health initiatives. 
You can just arrange your society in a way that, you know, people receive better medical care... 
it just struck me that many of the neglected diseases actually are preventable as they stand... 
none of the actual neglected diseases that are normally listed as neglected diseases, count as 
being neglected in that sense which is quite strange... they’re all things that we could do 
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something about if we just, you know, built some better roads or, you know, delivered 
refrigerated penicillin in the right places" (Interview with author, Broadbent, 2014). 
 
What Broadbent appears to mean by saying that none of the neglected diseases count as being 
neglected – is from a pharmaceutical R&D perspective – because effective interventions are 
available for many NTDs.  If pharmaceutical companies through the policy literature have been 
placed in the driving seat for a solution for NTDs, this further pushes for drug-based solutions:  
 
"I mean I think if you look at the sort of interest of pharmaceuticals in this topic, I mean, you 
know, it's easy to sort of bash pharmaceuticals but, you know, ultimately they are not going to 
look for ways to help with neglected disease as simpliciter.120 They’re going to look for ways 
that will also make them money... in some cases that’s going to help, but for many things it’s 
just not clear to me that that’s… automatically the case" (Interview with author, Broadbent 
2014). 
 
Donations of existing drugs are a common way that a pharma company can help with NTDs but 
committing to R&D may be a more onerous step and also may also not be the best use of 
resources, as has been argued for vaccine development.  Yaqub and Nightingale consider this 
issue in depth: "...vaccines are difficult to develop and can cost $600m–$1bn to bring to market" 
(2012, p. 1).  The point they make persuasively is that investment does not guarantee success; 
some poorly funded programmes succeed and some well funded programmes fail, therefore 
vaccine development cannot only be thought of in terms of supply and demand where 
incentives are required (ibid.).  More research funding towards NTDs may not yield the results 
that are wanted and there is an opportunity cost in not directing resources towards other 
strategies that have proven to be effective.  The pursuit of such public health 'absolutes' as 
vaccines or eradication have to be viewed in the same context we apply to public health 
problems more generally: cost effectiveness, short term and long term goals, priority lists and 
wider health agendas.  As Molyneux describes: "This is where I differ from Peter Hotez, we 
haven't got the timelines on vaccines to actually make an impact" (First interview with author, 
2016).  
 
This point is acknowledged by the WHO and other public health actors, despite the policy push 
for certain types of solutions.  As Margaret Chan, director of the WHO, said when opening the 
London Declaration in 2012, that previously we may have relied too much on drug donation: "It 
is one solution... but it is not the only solution” (in Michael Regnier, 2012b).  Other participants 
repeatedly brought up the urgent need for clean water and sanitation in the communities at risk 
from NTDs but for big pharma they now see their responsibility as met, as Haruo Naito, the 
president and CEO of Eisai, said: “Supply of drugs will not be the bottleneck” (ibid.). 																																																								
120 ‘Simpliciter’ means simply or plainly but in philosophical terms tends to mean 'plainly, without 
qualification' (Philosophy Index). 
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It is in the characterizations of NTDs that the problematizations and potential solutions are 
made.  To summarize, 'tropical' and 'neglected' as categories to some extent constrain what the 
solution to NTDs looks like.  They invite a technology-based solution, which may overemphasize 
drug-orientated approaches after surveying the preferred strategies to deal with NTDs.  Drug 
donation and MDA on the scale of interventions are relatively simple and targeted, and more 
easily produce cost-effectiveness evidence.  Thus use of measurement tools further confirms a 
drug dominance, meaning that the understanding of neglect does not fully acknowledge 
structural and political causes. 
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5.4 Conclusion: Otherness as an imaginary of neglect  
 
How then do we make sense of neglect through these accounts?  The quandary of exploring the 
tropical category is of why NTDs persist when they have been more or less defeated in some 
parts of the world.  There known ways of controlling, eliminating and or even eradicating these 
diseases.  As countries have developed, they have been incredibly successful at tackling NTDs 
particularly through environmental interventions (sanitation, safe water, health systems and 
infrastructure).  There has also been an expansion of scientific knowledge directed at certain 
diseases, as seen with the development of a vaccine for yellow fever.  Certainly a lack of drugs 
does not provide a full reason for why NTDs are a problem.   
 
Uneven technological progress, is a concern held by Nelson (2011) who mainly looking at 
developed countries, asks why social problems persist despite high levels of technological 
advancement in other areas.  This proposition could be taken to a global scale: why do NTDs 
persist in some places and not in others?  This is not to say that countries were on an even 
basis in terms of burdens from tropical diseases but some countries have been able to control 
or eliminate these diseases – developed countries in both non-tropical and tropical regions.  A 
key insight from Nelson is to not only rely on political reasons for disparity but also science-
based explanations for why scientific solutionism applied to social problems is not always the 
correct remedy.   
 
The first point I want to make is the resource requirements and technical complexity of some of 
NTDs.  Dealing with NTDs may be possible through an enormous amount of resources for 
example with sanitation, water and hygiene systems, viewed to be part of a development 
solution.  Some countries such as Saudi Arabia are able to invest heavily in expensive seawater 
desalination to prevent the NTD schistosomiasis (Hotez, Savioli, et al., 2012) but these sort of 
interventions are not feasible in poorer countries.    
 
The technical solutions, which tend to be drug-based, have seen some successes but some of 
the diseases have still eluded scientists in part because of scientific complexity.  Mosquito 
vectors (causing malaria and dengue) and tsetse fly (causing Chagas disease and HAT) proved 
to be difficult challenges.  As Scoones points out, drawing on early work by ecologist John Ford, 
the difficulty may lie in how, "...disease, ecology, human practices and wider processes of 
development are deeply intertwined, and that narrowly focused efforts to eliminate the vector or 
parasite are doomed to failure" (Scoones, 2014, p. 2).  NTDs are both seen as a problem of 
poverty that is for development to solve and a problem of knowledge for science to solve.  Still 
neither science nor development can be end solutions in themselves.  Demographic change 
and urbanization has brought back dengue as a problem in some more developed countries and 
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a vaccine for rabies, often viewed as an ultimate technological fix (Sarewitz & Nelson, 2008), 
has not stopped deaths increasing in recent years (Bourhy et al., 2010). 
 
There are many different shades to neglect of NTDs but also other characterizations are apt, 
where we have the considerations of:  
  
• Difficulty   
• Complexity  
 
• Importance/urgency  
  
• Ranking/priority  
 
 
In technical solution 
In the types of diseases, their different pathogens, vectors, changing 
environments 
How high is mortality and morbidity, how many are affected, a time 
element, what could be an outbreak? 
One intervention over another, one disease over another, other 
problem topics, which can be most political 
 
Table 19 Consideration of policy problem characterizations 
 
Neglect is pertinent to attention, acknowledgement and care, and cannot be wholly 
characteristic of the disease group.  The sense then in which neglect is attributed to the 
diseases is crucial in showing how the problems and solutions have been imagined in various 
ways.  'Neglect' has been chosen by activist scientists and others involved in the advocacy for 
these diseases, as the most compelling way to characterize these diseases.  From an 
exploration of the categories of disease, my argument is that the neglect depiction fits well in 
repackaging tropical diseases because of the categories 'tropical' and 'neglect' come from the 
position of otherness.  The political aspect of otherness is contained in who gets to define 
neglect.  These diseases are located where the viewer is not, in the other tropical world of 
neglect.  If we consider who 'neglects' whom, there is the impression of a stronger force over a 
weaker one, therefore who does the caring and why becomes crucial.  The 'other' needs to be 
cared for as neglected people are, "those less able to demand services" (Detels & Gulliford, 
2015, p. 282).   
 
The emphasis is on the lack of agency or power of the neglected.  They are helpless and 
voiceless, as neglect in a holistic sense for a group of diseases does not lend itself to patient 
involvement.   One party lacks care, where the pharma company fits this mold, as do the 
developed governments and NGOs that are more interested in other problems.  The perceived 
lack of care sometimes extends to the media and specific actors or structures whether it be 
government officials or public health programmes.   
 
For NTDs, I have found through this research that there exists a diverse set of understandings 
of neglect and these perceptions and ideas shape decisions.  Fotaki (2010) similarly explores 
how imaginaries in the context of health policy making as more located in fantasy than reality, 
as inspired by psychoanalytic thinking imaginaries are the, "...societal fantasies originating in 
 168 
the imaginary strivings of the subject" (ibid. p. 704).  This produces a common understanding or 
visions about social reality and possibility so is both factual and normative.  The understanding 
of neglect is through relation to a community and the meaning given through current 
assumptions and expectations of the future.  Joao Nunes describes in the context of health that, 
"...one can understand the reality of health as shaped by an imaginary – an ensemble of deep-
seated meanings, expectations and assumptions that delimit actors' self-understandings and 
their range of desirable and possible action" (Nunes, 2013, p. 88). 
 
For Glasgow and Schrecker (2015) imaginaries of global health are deeply political and by this 
they mean shaped by neoliberal ideology, which purposefully diverts attention from both the 
social and political economic determinants.  While the globalized imaginaries understandings of 
neglect become evident through the global prescriptions of problem and solution for NTDs, with 
the WHO at the lead.  Too much of NTD policy ignores endemic countries themselves.  This is 
the next step in uncovering where neglect really lies.  This questioning about the role and 
understandings of disease remind us that NTDs will affect poor communities to varying degrees 
and they will be experienced as a problem alongside a host of other problems, some more of a 
concern and priority than others.  There are numerous dimensions.  Certain values are 
engrained in the construction of NTDs in an assignment of blame and responsibility, invisibility 
and visibility, voiceless and empowerment, attention and inattention, and stigma and 
acceptance.  Disease frames the debate about policy and society (Rosenberg & Golden, 1992, 
p. xxii) and so NTDs say more about inequality – the poorest communities and their participation 
and benefit from the advances of science, technology, and development.   
 
Therefore, the concept of neglect is problematic to use in universalist terms, as it is a subjective 
state, affected by localized or national understandings.  Should it then be left to individual 
countries to define neglect?  As Detels & Gulliford suggest: "...donors and the international 
community have a duty to help developing countries enhance their capacity so they can 
determine their own national and local health research and development priorities, such as 
neglected diseases" (2015, p. 283).  The next chapter treats the agency taken to address 
neglect through activist scientists and also scientists within endemic countries.  
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Chapter 6. Advocacy for neglect: The repackaging of 
NTDs 
6.1 Introduction 
 
This chapter explores how advocacy was used in the transformation of tropical diseases to 
NTDs, through a repackaging to foster action and mobilize resources.  The advocacy for NTDs 
has been a branding exercise to repackage tropical diseases into 'neglected tropical diseases' 
and part of an 'elite policy movement', explained in detail later.  I explore the roots of this 
movement and come to the conclusion that it is 'activist scientists' based in the UK and US who 
played a leading role.  However, this does not discount the contributions on the part of scientists 
in emerging countries, Brazil and China, their interactions with a policy movement, and 
furthermore what this says about their relation to NTD policy. 
 
I argue that it is a repackaging to use what already exists in a new form – not merely a 
reframing of the contextual discourse.  This arena for global civil society is described by Clifford 
Bob as, "...not an open forum marked by altruism, but a harsh, Darwinian marketplace where 
legions of desperate groups vie for scarce attention, sympathy, and money. In a context where 
marketing trumps justice..." (2009).  The outcome of competition has been to produce a new 
category of disease, as discussed in the previous chapter.  Some diseases are kept in and 
some are left out, with new criteria (albeit broad and changing) established to provide rationale 
for commonality between diseases. 
As separate categories, tropical diseases and NTDs have received different treatment in policy 
in terms of acknowledgement, attention, and care.  I began in the last chapter to describe how 
for tropical diseases the policy was part of a colonial endeavour, while NTDs have needed a 
new basis and rationale for interest.  I looked specifically at Nobel Prizes as a way of gaging 
scientific recognition.  In this chapter I am interested in NTDs as a new brand, which stems from 
a new name and ideas associated with it.  As a starting point, I want to point out usage of the 
term NTDs through references on the Medline PubMed database, listing scientific publications 
that are medically relevant, shows how the term has risen in popularity (see Figure 10).  There 
has been a sharp increase from 2006 onwards from eight references in 2005, to 28 in 2006 and 
then increasing every year until 2015 (the last year data was available) at 577 references.121  
Such a keyword search as a blunt measure is only an indication of how the term has entered 
the scientific literature and how 'tropical disease' may remain the more scientific term but not the 
issue more broadly.    																																																								
121 Surprisingly also it is only in the post-colonial era that the large increase in references to tropical 
diseases began. 
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Figure 10 PubMed references to 'neglected tropical diseases' and 'tropical diseases' 1950 – 2013  
(Medline PubMed trend, http://dan.corlan.net/medline-trend.html, Accessed 2/4/16) 	
Citations in the medical and health care literature are one indication of the biomedical 
community’s acknowledgement of the importance of NTDs.  NTDs today have a fit-for-purpose 
venue for publication through the PLOS (Public Library of Science) Neglected Tropical Diseases 
journal, launched in 2007 as a dedicated open-access peer-viewed journal.  However, there has 
also been coverage in high-profile scientific journals including, the Lancet and the BMJ (formerly 
the British Medical Journal).  The degree to which something is neglected is a difficult 
phenomenon to observe, one route to get an indication of neglect as I have begun to show, is 
through representation in the media and public forums.  I will show in the next section how 
branding is used to create a new disease category and raise its profile. 
6.1.1 A new disease brand 
The use of methods from commercial branding and marketing has become increasingly popular 
in public health (Crawshaw, 2013).  Diseases and health causes will naturally be connected with 
brands as seen with branding places and personalities, while individual patients or publics will 
tend to be treated as consumers.  Considering the branding of diseases, Richard Smith, editor 
of the BMJ until 2004122 reflected on the changing thinking about the importance of a brand in 
the medical context.  He said: "Like most doctors, until recently I thought of branding as 
poppycock, an extravagant and narcissistic way of wasting money. But it’s slowly dawned on 
me that I was wrong" (Smith, 2014b).  He had changed his opinion to health branding being 
necessary and even helpful, because, "(A) good brand will inspire and prompt action" (ibid.) by 
providing meaning and purpose through an exciting visual or verbal form, with a compelling 
narrative.  Smith had been convinced that awareness was not enough and only appeals to 																																																								
122 Smith has made headlines for his frank remarks, such as in one article after retirement where he was 
criticized saying that cancer was a good way to die (Smith, 2014a) 
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emotion would evoke action.123  The idea of simplifying disease, including presenting a solution 
in an easily digestible form can be seen with NTDs.  A phrase on the website of the advocacy 
NGO the 'Global Network for Neglected Tropical Diseases' says: "While the problem is huge, 
the solution to NTDs is simple".124  This solution relates to the NTDs where there are cheap 
effective drugs available to treat a population through mass drug administration (MDA).      
 
A brand begins with a name.  Take diseases named geographically such as Zika, after a forest 
in Uganda it was first identified and similarly for Ebola named after a river in Zaire in 1976 
(Hotez, 2016a).  These places will continue to be known through diseases.  People can also be 
implicated in connection to diseases, for example, on the patient side.  A clear example of this 
type of connection was seen with the early names for AIDS creating serious socio-political 
implications: gay-related immune deficiency or 4-H disease, referring to 'Haitians, homosexuals, 
hemophiliacs and heroin' (Donovan, 1995).  Or it can be on the doctor side.  The rare 
neurological defect was initially named Hallervorden-Spatz disease after the Nazi doctors Julius 
Hallervorden and Hugo Spatz, who first described it after researching on the brains of 
exterminated children (NDTV, 2013).  This led to families affected by the disease to urge a 
change in name to Neurodegeneration with Brain Iron Accumulation (NBIA) (ibid.).  According to 
Ab Osterhaus, a virologist, acronyms are another solution because they keep names short 
(Kupferschmidt, 2015).  However, people often forget what the letters stand for but even then 
they can cause problems as WHO official found in 2003 when they coined SARS, Hong Kong is 
officially known as Hong Kong SAR (for special administrative region). 
 
These might appear to be unintended consequences of naming but the WHO takes disease 
branding seriously.  In 2015 they urged naming to prevent inaccuracies and stigmas through 
'best practices' for naming new human infectious diseases.  Keiji Fukuda, the WHO’s assistant 
director general for health security argued these recommendations were necessary because of 
the emergence of diseases that can create “unintended negative impacts by stigmatizing certain 
communities or economic sectors” (Gladstone, 2015).  Following the guidelines could minimize 
negative impact of disease names on, "...trade, travel, tourism or animal welfare, and avoid 
causing offence to any cultural, social, national, regional, professional or ethnic groups” 
(Kupferschmidt, 2015).  However, others such as Christian Drosten, a virologist at the University 
of Bonn, Germany points to geographic names sometimes being justified.  It was clear that 
MERS, for example, was associated with the Middle East: “Would it have been better if we had 
named it novel betacoronavirus clade C, type 1?" adding, "You should not take political 
correctness so far that in the end no one is able to distinguish these diseases” (ibid.).  Diseases 
have social meaning too, which can be shaped or directed through their names. 																																																								
123	Smith was involved in an explicit version of a branding exercise, seen through a public event in 2014 at 
my university - UCL (University College London) called the 'NCD makeover show'.  I had first-hand 
experience of the aspiration and acceptability of disease branding to brand non-communicable diseases 
NCDs – an acronym confusingly close to NTDs.  Speakers included a representative from a branding 
company and also from broadcasting (the BBC), speaking about charity advertising (see: UCL, 2014).	
124 Global Network, http://www.globalnetwork.org/, Accessed 2/4/14. 
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Crucially, scientists working on tropical diseases saw one reason for the lack of attention from 
the global policy community as being the brand itself.  The weakness of the brand had been 
considered a number of times, specifically by a small circle of scientists influential in the field of 
tropical medicine and the WHO.  Their contention was that these diseases have "complex, hard-
to-pronounce names" and there was also the unresolved question of which diseases constituted 
the grouping, with the most common or treatable ones making it into most lists (Relman & 
Choffnes, 2010, p.17).  The scientists decided that these diseases needed to become a 
marketable commodity within a competitive market for public health resource.  Simon Croft 
reflects on this change from diseases with little in common to having a label on which to build 
advocacy and action: 
 
"Other than the label, the NTDs have little in common....The NTD label has had major success 
in raising the profile of this group of diseases over the past 15 years through a combination of 
advocacy and scientific and public health programs. This has ensured that NTDs are on the 
agenda of major international organizations, including the WHO, the UK's Department for 
International Development (DfID), and the Bill and Melinda Gates Foundation, all of which have 
dedicated NTD programs. In addition, organizations dedicated to NTDs, for example the Drugs 
for Neglected Diseases Initiative (DNDi, Geneva), have been established" (Croft, 2016, p. 1).  
 
Similarly, the WHO recognized the importance of "advocacy to change this situation" (WHO, 
2007, p. 24).125  By the time the WHO published their 'Roadmap' policy document for NTDs in 
2010, the writers remarked how: "(T)he NTD brand has proved to be a useful form of shorthand 
for communication" (WHO, 2012a).  According to branding expert Dorie Clark (Nordrum, 2014) 
NTDs act as a "brilliant umbrella term" because, "(I)t allows funders to feel like they are 
addressing something important that has been hidden for a long time”.  Therefore it 
straightforwardly conveys a message of moral urgency, justifying funding. 
 
A number of (similar) interpretations exist about how the NTD brand came about.  One account 
comes from an interview by the Wellcome Trust with Peter Hotez, President of the Sabin 
Vaccine Institute.  As Hotez describes:   
 
“The phrase was part of a drive to think about these diseases in a fresh light… After the launch 
of the Millennium Development Goals in 2000, a lot of attention fell on HIV, tuberculosis and 
malaria. Goal 6 called for action on those three ‘and other diseases… but those of us working 
on the ‘other diseases’ felt we were on the outside looking in. We were driven to think afresh, to 
‘rebrand’ these conditions” (Regnier, 2012a).   																																																								125 In a 2007 WHO report on NTDs, indicators for performance measurement included the fourth strategic 
area of 'Evidence for advocacy', which included, 'Increased media coverage of NTD issues' and 'Societal 
awareness about NTDs' (WHO, 2007, p. 24). 
 173 
 
The main instigators have been named as those scientists who established the ‘Global Network 
for Neglected Tropical Diseases’ in 2005 including “Professor Peter Hotez, President of the 
Sabin Vaccine Institute, Professor David Molyneux, a lymphatic filariasis researcher at the 
Liverpool School of Tropical Medicine” (ibid).126   These creation stories documenting the 
emergence of the new category and NTD brand point towards a small, concerted group of high-
profile scientists who had been working on NTDs, usually specializing in one or two specific 
diseases throughout their careers, at top-ranking universities as well as at the WHO.   
 
The story of the origins of something new serves a purpose, either to reaffirm the perspective of 
those involved in the creation or to make a point about the object of creation.  The activist 
scientists felt heavily involved in the creation of NTDs and because they had begun an agenda 
of high-profile advocacy and policy engagement.  Part of their role would be to be vocal about 
how instrumental they were in creating NTDs.  Further, it appears that in wanting to promote the 
cause of NTDs, there is the human-interest element of the scientist involvement that can be 
used to draw attention to the diseases.  An initial profile in USA Today first put a spotlight on 
Hotez in 2009 – as arguably the most famous of the activist scientists.  This news coverage was 
followed by a Wellcome Trust blog article in 2012 (also including Molyneux and Fenwick) and 
then a number of similar interpretations about how the NTD brand came about, many of them in 
the popular press through news stories and articles in science magazines: 
 
Date Title 
2009 
 
2012 
2014 
 This scientist's passion: Ending the scourge of parasitic diseases', US Today (Sternberg) 
 'Neglected tropical diseases: The campaign trail', The Wellcome Trust Blog (Regnier) 
'How Three Scientists ‘Marketed’ Neglected Tropical Diseases And Raised More Than $1 
Billion', International Business Times, (Nordrum) 
 
 
Table 20 Articles about the creation of NTDs 
 
The 2014 news story also emphasizes the three scientists as main protagonists (Hotez, 
Molyneux and Fenwick).  This is a business story in the 'International Business Times' rather 
than in more specialist science publications.  The focus is on the marketing and the amount of 
money raised (referring to the cost of treatments donated by pharma companies).  
 
Creation stories acknowledge the involvement of some actors and not of others, depending on 
where the emphasis is intended.  The role of the WHO in the creation of NTDs has not been 
emphasized.  It is through their own publications that they highlight their involvement (see WHO, 
2010).  The key scientist from the WHO was Lorenzo Savioli, who was the director of the 																																																								
126 Other instigators for the Global Network listed were "Dr Lorenzo Savioli of the World Health 
Organization, Dr Jeff Sachs at the Earth Institute, Dr Kathy Spahn of Helen Keller International and Dr 
Jacob Kumaresan, then at the International Trachoma Initiative” (ibid.) 
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Department of Control of Neglected Tropical Diseases.  Savioli, along with Antonio Montresor, 
and Albis Gabrielli wrote an article on 'Neglected tropical diseases: The development of a brand 
with no copyright. A shift from a disease-centered to a tool-centered strategic approach' (Savioli, 
Montresor, & Gabrielli, 2011, p. 281).  The authors from the WHO point to Dr Lee, the newly 
appointed Director General of the WHO in 2003, as responsible for starting a process of 
paradigm shift in the control and elimination of NTDs.  'Paradigm shift' is the specific choice of 
words chosen to connote strategic involvement to change thinking rather than adopting the 
rhetoric of branding or marketing and the direct words of creation or construction.  Savioli et al. 
therefore describe this as a strategic move away from a scientific classification of disease 
biology to a practical approach based on needs (ibid.. p. 281). 
 
Therefore, while it was central that the WHO was on board for such a change in the branding for 
NTDs, the activist scientists acted as a driving force.  One of the key roles of the organization 
was to provide leadership on diseases with part of this being categorizing diseases into groups 
on which to base action.  As Savioli et al. describe, it was a change in philosophical position 
about how diseases and their treatment were viewed.  
 
6.1.2 Borrowing from the past: 'Great Neglected Diseases' the proto 
brand  
 
As I began to uncover in Chapter 4, the NTD brand has a longer history.  However, it has now 
entered the mainstream, as Regnier points out the first research paper to 'use and define'127 the 
term ‘neglected tropical diseases’ (NTDs) was published in 2005, and since "...the phrase has 
become a standard part of global health vocabulary" (2012b).  Molyneux, Hotez, and Fenwick 
published the 2005 paper called 'Rapid-Impact Interventions: How a Policy of Integrated Control 
for Africa's Neglected Tropical Diseases Could Benefit the Poor'.  Before this paper Hotez and 
others referred to a number of different terms including 'tropical infectious diseases' or 'parasitic 
diseases' (Hotez, 2002; Hotez et al., 2004).  Why then was the concept of ‘neglected’ used for 
this repackaging?   
 
The wording, to some extent, was borrowed from the past.  Before NTDs, as described in 
Chapter 4, were 'The Great Neglected Diseases of Mankind' (GNDs), running from 1977 – 
2000.  Coming from the Rockefeller Foundation; the foremost philanthropic organization of that 
time, the GND name is compatible with the foundation's ambitious mission to promote the 
wellbeing of humanity.  This sort of description at the time appeared to be popular.  For 
example, the phrase 'great neglected opportunities' was used by Jonas Salk, the US virologist 
who developed the polio vaccine, at a 1981 meeting of donor agencies and scientists in the 																																																								
127 The WHO did make a reference to NTDs earlier (Remme et al., 2002) but did not consistently use the 
term or define it. 
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Rockefeller Foundation in New York (Warren & Bowers, 1982).  However, the GNDs were 
making reference to the type of diseases that could be NTDs, including many NTDs, especially 
the parasitic diseases, as Hotez noted: "(T)he emphasis was on parasitic infections that plagued 
people living in poverty" (Keating, 2014, p. S32).  Similarly the GND was reflecting the changes 
in 'neglected' and 'non-neglected' tropical diseases.  Malaria had already been downgraded 
during the lifespan of the program to a "great 'relatively' neglected disease" (Warren, 1978, 
p.176).  Therefore, there had already begun to be a distinction between the 'big three' and 
neglected other diseases.128  
 
In fact the GNDs followed a similar definition to those commonly used for NTDs, as Kenneth 
Warren, the director the GND, described: "These diseases are great in terms of the enormous 
numbers of people suffering from them and are neglected both financially and scientifically" 
(Warren, 1978, p 572).  The emphasis is on the large numbers of people affected and of course 
that these diseases are neglected is central to the current day NTD definition.  He also 
pondered on the type of neglect that was occurring – financial and scientific, how neglect was 
multi-causal, and that is not only rare diseases that are neglected: "There are many reasons, 
other than rarity, why diseases might be neglected, which go far beyond the profit motive" 
(Kenneth Warren in Scheinberg, 1989, p. 169).  This still holds today, as financial and scientific 
neglect identified by Warren but we could add social and political, which additional areas of 
neglect that I argue the rebranding has tried to address.  Pharmaceutical companies and donors 
might be the obvious sources of financial neglect, and the interest of the scientific community 
the cause of scientific neglect.  However, the media, public and governments are also sources 
of neglect socially and politically.  For Warren the financing was available to an extent with the 
Rockefeller endowment, so his emphasis was in garnering the attention of scientists and 
addressing the scientific neglect. 
 
6.1.2 Attracting scientific talent and the promise of biotechnology 
 
Where the program differed significantly from NTD activity today is in the core aspiration to bring 
in scientific talent, creating a network of high-quality investigators.  For Desowitz this sort of 
networking is something that science does well: "(G)lobalization was the business of science 
centuries before it became the business of business. Networking has been science's tradition 
and strength" (2004, p. 23).  The intention of the GND was to constitute a critical mass of 
talented scientists, attracting the brightest students, and conducting research of a quality that 
was rarely seen for tropical diseases in the 1970s (The Rockefeller Foundation, 1978, p. 25).  At 
the time, the view within in the community was that the most able and talented scientists were 
not directed towards diseases of the developing world.  The call of the Rockefeller Institute in 																																																								128 A dimension that remains a concern today: what is the level of neglect (neglected or more neglected) 
and at what scale (global or other) is a disease being addressed?     
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1978 would aim to change this situation in asking for "...outstanding basic and clinical scientists 
to shift their attention to these great neglected diseases" (ibid.). Such an encouragement of 
scientific interest on an individual level has appeared to have a lasting impact and may be why 
there is no longer the same need to actively attract scientific talent.   
 
Another aspect of bringing in the top scientists included applying the advances that had been 
made in biotechnology.  Parasitology had once been at the forefront of medical knowledge but 
"...by the 1970s, the discipline had fallen behind the revolutionary changes... taking place in 
molecular and cell biology, genetics and immunology" (Keating, 2014, S25).  So the work of 
Warren began as "...an early attempt to apply modern biomedical technology in the 
understanding of the mechanisms of disease prevalent in developing countries" (ibid. S24).  
According to Conrad Keating, a medical historian and biographer, Warren stands out in the 20th 
century in associating 'modern science' with tropical diseases.  It challenged a "romantic, post-
colonial attitude" to the new technologies (ibid. S28) and was not something that had been on 
the table before.  Therefore, molecular parasitology units were required to be established 
among partners.  Later on Hotez would describe how the network went beyond setting up new 
units, to training new tropical medicine scientists and creating opportunities for collaboration.  
Keating argued that tropical medicine collaboration happening on a 'global scale' had been 
unprecedented (Interview with author, Keating, 2014).  The GND formed a new geography of 
training in the next generation of tropical medicine scientists and in creating opportunities for 
collaboration: 
 
"... the activities of these molecular parasitology units would be integrated into a GND network 
that would meet regularly in Woods Hole or elsewhere. In addition to an extraordinary track 
record of scientific productivity and international scientific collaboration, the GND program and 
network trained an entire generation of scientists committed to tropical infections, many of 
whom remain close colleagues" (Hotez in Keating, 2014, p. S32).  
 
Warren was making a parasitology network attractive through the meetings.  A place like Woods 
Hole carried prestige but also acted as a retreat, being a harbour town in Cape Cod, 
Massachusetts on the east coast of the US.129  Hotez described the appeal of this network and 
the annual meeting:  
 
"They had these fantastic annual meetings where everyone funded by the Foundation would 
come to Woods Hole. We would go to these meetings every year and I would get the chance to 
meet all of these extraordinary people. This meant a lot because today I am still in touch with a 
lot of these same people who have gone on to have distinguished careers in tropical 
medicine..." (quoted in Esch, 2007, p. 46). 
 																																																								129	Woods Hole is a convening place for scientific meetings (Marton, Fensham, & Chaiklin, 1994). 
 177 
See photo below of the GND members meeting in Woods Hole (in the early 1980s). 
 
Figure 11 "A meeting of the Rockefeller Foundation GND program in Woods Hole during the early 
1980s"  
(Hotez, 2014, p. S32) 
Today scientists know they will be applying cutting edge science and also have the appeal of 
contributing to a social good.  Furthermore, it is not only biomedical scientists attracted to this 
field but statisticians, demographers, epidemiologists and health economists who embody the 
application of 'new science'.  They have become an important group, as the focus for NTD 
research has moved from scientific application to also questioning research and delivery 
structures.  The involvement of epidemiologists and health economists with NTDs will be 
discussed further in the next chapter.   
 
I interviewed Conrad Keating (with colleague Erman Sozudogru) a historian of science who 
spent time with Warren's 'supporters and detractors', including his wife who was present at most 
of his meetings and many of the GND members.  The descriptions of these diseases are 
dramatic to evoke emotion in 'great' and 'neglected'.  Even 'mankind' situates these diseases on 
a global and historical level of importance.  As Warren describes it would not only be the use of 
new techniques and application of cutting-edge science that would attract the new generation of 
scientists but a "new spirit of humanitarianism" (Kreier, 2014, p. 337).  Keating believes that the 
origin of the word neglected in the context of tropical diseases comes from the GND, which he 
admits is “...a rather grandiose title, but he invented really the lingua franca, so now, in your own 
case, this word ‘neglected’, this is where it comes from” (Interview with author, Keating, 2014).  
This view is supported by others including Simon Croft, who described how the concept of 
NTDs was first proposed by Warren in bringing attention to "...a large proportion of the human 
population who were poor, who suffered from chronic, disabling but rarely fatal diseases, and 
who were often stigmatized and unemployed" (Croft, 2016, p. 1). 
 
There was more contention about the term ‘great’ than over 'neglected', which was viewed by 
some as grandiose but “it was great because the diseases were killing many people, children 
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particularly, in the developing world” (ibid.).  Similarly Warren found that the GND term was not 
always well received as a renaming of a group of diseases in a marketing sense.  When Warren 
met with David Weatherall who was the founding Director of the Weatherall Institute of 
Molecular Medicine130  (WIMM) in Oxford in 1977: “…he didn’t think it would ever really take off, 
and people, I think they were already thinking about neglected diseases… from Weatherall’s 
point of view it seemed an odd title” (Interview with author, Keating, 2014).   
 
Keating also spoke of how ground-breaking the work of the GND was but the way it was as an 
exclusive club of carefully selected scientists.  The chances to open the network or scale up the 
activity were limited and may have affected the sustainability long-term of the program.  
However, the legacy of a small elite group of scientists has been impactful:  
 
"... one of the things that I think annoyed people about the GND was that it was a club. If you’re 
inside the club it was this great feeling. If you’re outside the club, you notice them. And I think 
there were accusations of these Johnny-come-latelys. People thought Warren was a kind of a 
Johnny-come-lately... he was trying to magnify the contribution of the GND and some people 
would say, you know, that was politically motivated but he certainly rubbed people up the wrong 
way.  I think there was an element, and it’s interesting, the quality of the cohort he chose have 
gone on to be people who have been enormously important in their separate fields... I think that 
it was very influential that Warren himself has been neglected… today, as we know ourselves, 
diseases are fighting to be put into this neglected square so he invented an interesting sort of 
language and he, himself, has been forgotten…" (Interview with author, Keating, 2014).   
 
Warren had discovered early on the 'neglected square' as Keating puts it.  He saw power in 
calling something neglected to spur action.  Warren's use of neglect is novel in that it brings to 
focus the advocacy of diseases to a much earlier stage.  Instead of only saying something 
needs to be cared about, it is actively characterized as requiring that care.  The GND diseases 
having the label 'neglected' was the equivalent of a red flag to mark them out.  It was not 
enough to present a problem and solution but to characterize the state of the issue in the first 
place, in order to be concerned about problem and solution.  
 
Indeed both descriptions of the GND diseases are dramatic to evoke emotion in 'great' and 
'neglected'.  Even 'mankind' situates these diseases on a global and historical level of 
importance.  For Keating the mankind encompassment that the GND made had a resounding 
effect on the discipline and it involved an inclusiveness of developing countries to attempt to 
leave behind a colonial past: 
 
"... the whole idea of tropical medicine, to medicine and to tropics, has changed because of that 
[the GND], and I think if you look at the amount of papers that are GND produced, if you look at 																																																								
130 David Weatherall was director from 1989 – 2000 with the centre named after him upon his retirement. 
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the amount of people who were funded in the developing world, it was about, of all the scientists 
in it, I think it was something like 56% were in the developed world and the rest in the 
developing world so it wasn’t, this wasn’t sort of colonialism, so in that way it was a much, much 
fairer system" (Interview with author, Keating, 2014). 
 
Even if Warren is now a forgotten figure, his influence is still being felt with the generation of 
scientists he sought to influence.  One of them was a young doctoral student called Peter Hotez, 
now one of the leading activist scientists behind the repackaging of NTDs.  Hotez was inspired 
by a 1962 Rockefeller publication at the age of 14 describing Hookworm: “....'The Great 
Infection of Mankind,' affecting 600 million people, he says. 'I thought, 'How can it be that this is 
one of the great scourges of humankind and nobody's working on it?'..." (Sternberg, 2009).  This 
view was further confirmed during Hotez's college years, with hookworm research being a 'great 
fit' with the GND program (Hotez, 2014, p. S32).  He was inspired by the work of the Rockefeller 
Foundation on GNDs just as Warren had set out to do with eminent young scientists of his day. 
 
The story of the branding of diseases has been about directing research collaboration and the 
arrangements that allow research to happen.  Such research direction was not deemed possible 
by chemist and philosopher Michael Polanyi (1962).  He saw attempts to guide the progress of 
scientific enquiry towards public welfare but did not believe science could be controlled in that 
way to meet social means.  However, Warren has shown a direction of science through the re-
organization of tropical medicine as a discipline and policy concern.  Through his leadership and 
coming from the Rockefeller Foundation, he had the remit and means to care about the GND 
diseases, he identified the problem and turned it into a scientific program and network.  The 
main gap he saw was the need to attract talented scientists who would apply advances in 
scientific understanding and technique.  Warren created interest and encouraged biotechnology 
to be used; by coopting the next generation of scientists, which would form the roots of the next 
era of tropical disease – except it would be the scientists themselves directing the action.  It is 
perhaps not surprising that this is a specialism that has given birth to 'activist scientist' as the 
high-profile scientist has been nurtured and revered.131   
																																																								
131 Cook (2007) calls the focus on individual tropical medicine scientists a domination of 'prima donnas'.  
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6.2 Activist scientists: Careers in an unmodern or modern science 
 
In comparison to what is now a slowly growing public interest in NTDs, during the heyday of 
tropical medicine public interest was at a high, including in the tropical medicine scientists 
themselves.  As Worboys writes, the "...mosquito-malaria work of Manson's disciple Ronald 
Ross had found the columns of the daily as well as the medical press" (Lemaine et al., 1976, p. 
85).  For the scientists during the colonial period, tropical medicine was often associated with a 
prestigious and exciting career.  For the tropical medicine 'father' Manson, after first working as 
a doctor in a lunatic asylum, his way of seeking advancement was "...in the fashion of the age, 
through a career overseas" (Lemaine et al., 1976).   
 
This public attention and career prestige would be followed by a wavering of interest post-
empire to reach a low point in the 1970s, when the diseases were associated with 'unmodern 
science'.  Tropical diseases only began to see a professional renaissance by the 1980s, a sea 
change engineered by several protagonists, one of whom was Warren at the GND, researched 
by his biographer Conrad Keating.  Keating reflected on the change in perceptions of a career in 
tropical medicine and the influence of Warren, when interviewing Nick White the Professor of 
Tropical Medicine Mahidol Oxford Research Unit:  
 
“…when he went into tropical medicine in the 1970s as a doctor, it had a very, very low status, 
and today, certainly in Oxford and I think in London, the brightest and the best want to go into 
tropical medicine.  Now, that is because of the application of science, the cutting edge of 
science …at the first meeting of the GND, so he [Kenneth Warren] got these people, young 
biologists, who’d never hear, didn’t know anything about a snail or a vector, you know, they 
were just people who were in at this new science for some reason, and the two people he got to 
speak to them in New York were George Nelson, and another great giant of British parasitology, 
and they were able to infuse these people with incredible stories about, you know, being out in 
the field in South America, and getting these people sort of interested in tropical diseases” 
(Interview with author, Keating, 2014). 
 
In 1993, Desowitz, similarly spoke of the promises of a new molecular science with a mixture of 
loss and trepidation: "(E)xpertise has been lost; the last generation of truly experienced 'field 
hands' are leaving the scene, lost to age and disuse" (Desowitz, 1993, p. 16).  The 'field hands' 
that he talks about spent their time in endemic countries and appeared to have a more direct 
link with the communities affected by the diseases.  For example, the connection with hygiene 
and sanitation was more pronounced.  As Worboys describes, in the early 20th century the 
European doctors had very different concerns: "(T)heir knowledge and practice was structured 
around clinical and hygiene concerns, not with advanced science and technology" (in Bynum & 
Porter, 2013, p. 522).  Desowitz was wary of the new phase of scientific enquiry into tropical 
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diseases, taking place both in the endemic and donor countries, speaking of a replacement: 
"...in the West and in the research centers of the tropics by the 'molecular types', more 
concerned with the exquisite intellectual changes of modish science than with seeking practical 
solutions" (Desowitz, 1993, p. 16).  It is noteworthy how Desowitz related the new science with 
impracticality.  The change that new science brought was the loss of something tacit borne 
through experience, compounded by the discontinuation of teaching of tropical medicine key 
competencies.  Desowitz goes on to question what biotechnology is promising and whether 
these promises are overly enthusiastic of the expected benefits.   
 
His view strikes a chord with the sociology of expectations literature, where researchers observe 
that socio-technical promises arise when a new scientific and technological field is emerging 
and there is a promise of "social desirability and warnings about its potential negation effects" 
(Lucivero, 2016, p. 37).  Desowitz envisions social desirability in the expectation of a 'quick fix', 
where:  
 
"(T)he razzledazzle and promise of biotechnology have led Third World health officials to expect 
the quick fix–the malaria vaccine 'just around the corner,' the genetically altered mosquito that 
yesterday's press release proclaims will be the last word in controlling vector-borne diseases; 
and confusing diagnosis with cure, the DNA probe techniques to detect parasites even at 
clinically insignificant levels" (Desowitz, 1991, p. 16).   
 
To Desowitz this promise was illusionary and produced negative effects in the distraction from 
more useful work: "(T)here is an imbalance, a discontinuity between research and reality.  This 
is an imbalance that has inhibited improvement in the health of tropical peoples; but in addition, 
I believe it has actually contributed to the deterioration of health" (1991, p. 16-17).  These words 
were written is the 1990s when the transition from the practical 'field hand' to the 'modish' 
molecular biologist was being made within tropical medicine.  The continued promise of 
biotechnology, in anticipation of a momentous payoff is still in operation today (see Nightingale 
& Martin, 2004).  Approximately 25 years later a malaria vaccine is inching closer still and 
genetically altered mosquitos have become a reality.  
 
Still, the momentous payoff is viewed with a skeptical eye as more time passes.  There is less 
of a harking back to the old practice of 'field hands' in the bush but a growing emphasis on 
'basic science' and the established techniques of testing on natural products.  Molyneux and 
Ward make this point when reflecting on the three 2015 Nobel Prize winners in Physiology or 
Medicine:  
 
"No rational drug design was employed and no magic bullets were sought. No synthetic 
chemistry or targeted design was involved in the initial discovery of the active products. The 
current mantra from the community is focused on the need for new products emerging from our 
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understanding of the science based on our ‘omic’ interrogation of these complex parasites and 
the identification of unique biochemical weak points for intervention. The fact that this approach 
has largely failed to date is not lost to most in the drug discovery area who can point to the 
success of ivermectin and artemisinin, drugs delivered through bio-prospection and ancient 
knowledge of herbal remedies" (Molyneux & Ward, 2015, p. 605) 
  
Today the recognition of tropical medicine once more through the Nobel Prize winners has been 
a boost to amplify the position of scientists.  Next I profile two activist scientists who have been 
instrumental in re-ordering the place of tropical diseases, the US scientist Peter Hotez and UK 
scientist Alan Fenwick.  I have already introduced these two actors earlier in the thesis.  As 
discussed in Chapter 4 they originally ‘coined’ the phrase ‘Neglected Tropical Diseases’ with the 
first use of the term in a paper in 2005 (Molyneux, Hotez, & Fenwick, 2005a).  They sought to 
make others aware of the policy focus on Millennium Development Goals (MDGs) in 2000 to 
malaria, TB and HIV/AIDS and how other endemic diseases were left out of the spotlight.  This 
contrast led to the construction of NTDs as a worthy cause by scientists appealing to policy and 
what has become a policy movement in the momentum created to promote these diseases.   
 
Therefore, I add activist scientists in addition to the more typical global health actors described 
already with: Pharma Companies, Research Institutes, NGOs, Universities and Governance 
Institutions.   
 
Table 21 Interviews by organization type 
 
This activist role for scientists is what I will discuss next with specific examples through Peter 
Hotez from the US and Alan Fenwick from the UK.  Even though they are charaterised through 
their geographic location I also want to emphasis their academic backgrounds, which are 
similar.  In the table below I show how all five of the activist scientists I followed were grounded 
in parasitology, as such their disease focus is limited to the five MDA treatable helminths, 
Pharma 
Companies 
Research 
Institutes 
NGOs Universities  Governance 
Institutions 
Activist 
Scientists 
4 21 7  14 4 5 
Denmark, 
Switzerland, 
Australia (e.g. 
Novo Nordisk, 
Novartis, 
Medicines 
Australia) 
Brazil, China, 
UK, Norway, 
Switzerland 
(e.g. Fiocruz, 
Shanghai 
Institute for 
Parasitic 
Diseases, 
NOKC)  
Switzerland, 
Australia  
(e.g. DNDi, 
FIND 
Diagnostics, 
The End 
Fund, Policy 
Cures, 
Link2China) 
UK, China, 
Brazil (e.g. 
Tsinghua 
University, 
LSHTM, 
University of 
São Paulo) 
 
Switzerland, 
and Sweden  
(WHO and 
European 
Centre for 
Disease 
Prevention 
and Control, 
UK All-Party 
Parliamentary 
Group) 
Australia, US, 
UK  
(The Synaptic 
Leap, 
Cambia, 
Sabin 
Vaccine 
Centre, SCI) 
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although difference in their specialisms within parasitology has led to differing courses of action 
to address NTDs.   
 
 Specialism NTD Interventions 
Peter Hotez - Molecular biology 
and Vaccinology 
- No field experience 
- Hookworm (also 
SARs, 
schistosomiasis, 
Chagas, 
leishmaniasis 
- The Global Network 
for NTDs 
- PLOS Neglected 
Tropical Diseases 
- US Science envoy 
Alan Fenwick - Parasitology 
- 35 years in the field 
(Tanzania, Sudan 
and Egypt) 
- Schistosomiasis - Schistosomiasis 
Control Initiative (SCI) 
at Imperial College 
London 
David Molyneux - Parasitology and 
medical 
entomology132  
- Field experience in 
Africa, Latin America 
and Middle East) 
- Lymphatic filariasis 
(previously HAT, 
leishmaniasis) 
- Lymphatic Filarias 
Support Centre, 
Liverpool School of 
Tropical Medicine 
(LSTM 
 
Table 22 Academic specialisms and interventions of three main activist scientists 
 
6.2.1 United States: Media-friendliness and scientific diplomacy 
 
Hotez is part of the new breed of activist scientist, although I acknowledge that there have been 
historical precedents and it is a continuation of a trend that has existed before.  It is true that 
there have been cases of individual scientists in the past, who figure-headed campaigns and 
went on to have deep policy impact.  They have desired for their discoveries to be meaningfully 
recognized and this has required an engagement with policy and politicians, from Albert Sabin 
for the oral polio vaccine to Richard Doll for the connection between smoking and lung cancer.  
In fact Hotez quotes Sabin at the beginning of his book on NTDs and is clearly inspired by his 
message: “(A) scientist who is also a human being cannot rest while knowledge which might 
reduce suffering rests on the shelf” (Hotez, 2013).  
 
Scientists have been deeply committed to causes such as climate change or anti-war advocacy 
in the 1960s and 1970s (see: Hart & Victor, 1993; Meyer, 1995).  However, in these cases they 
stand alongside many other interested voices.  Arguably in the case of NTDs, activist scientists 																																																								
132 Medical entomology is a branch of science that deals with the study of insects (Merriam-Webster online 
dictionary, n.d.). 
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do not have this type of multi-stakeholder backing and there has not been the same ownership 
over the policy debate.  The previous cases mentioned of Sabin and Doll, their policy 
intervention is very defined and specified.  They do not consider a whole group of diseases but 
an intervention concerning one disease.  Similarly the figures of tropical disease in the past 
have also been limited in the individual policy points they tended to make for narrow influence.   
 
Activist scientists like Hotez are deeply engaged in policy, coining and popularizing concepts 
about NTDs in order to put into policy or journalistic terms the issues they care deeply about.  
Hotez is a prolific writer and commentator in the media.133  To give an idea of scale, in 2015 he 
published 33 articles about NTDs.  A large number are in PLOS Neglected Tropical Diseases 
(where he is Editor-in-Chief), many in specialist health journals and three high-profile articles in 
journals Science and the Lancet.  The breadth of his media publications is wide including mass 
media venues from the Lancet (Hotez et al., 2009); Huffington Post (2014a); to New York Times 
(2012b).  Examples of more unusual connections between NTDs and other topics includes with 
the: South China Sea (2016b); 2014 World Cup (2014)' Global Christianity (2014a); and 'The 
four horsemen of the apocalypse: plague, death, famine and war' (2012). 
 
The varying definitions for NTDs mean Hotez can write about these diseases in terms of 
defense, foreign policy, diplomacy, security, equality, religion, conflict, economics and the list 
goes on.  Often they have similar messages but presented differently.  For example 'vaccine 
diplomacy', about scientific collaboration for and as a result of diplomatic relations, is a topic he 
did not invent but has written extensively about.134  As a US citizen he is particularly interested 
in the American context, playing on the intersection between global health and foreign policy, 
which has proved to be fruitful.  He has been US Science Envoy since 2014 where he focuses 
on vaccine science diplomacy and joint vaccine development with countries in the Middle East 
and North Africa (Pathak, 2014). 
 
Hotez has been a leading force in the US, particularly in galvanizing support in political circles 
and other realms of influence (including in academia through economist Jeffrey Sachs and 
celebrity endorsement such as Bollywood star Abhishek Bachchan).  He has played a role in 
building institutions such as the advocacy NGO the "Global Network for NTDs', establishing the 
first tropical medicine school in the USA 'The National School of Tropical Medicine' and is 
director of the Sabin Vaccine Institute, developing vaccines and expanding access to vaccines 
(and other medicines).   
 
The interest in tropical medicine began at a young age and transitioned into the new science era 
of molecular biology.  It was later in his career that his role has become that of an activist 
scientist.  Hotez does not describe himself in exactly those terms but often refers to being an 																																																								
133 The majority of articles are co-authored (4144 as of 2015). 
134 See Hotez (2008) for an article on Cold War diplomacy leading to the first successful polio vaccine.  
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advocate (see Regnier, 2012b).  I prefer the term activist as I think this conveys agency of 
wanting to bring about change rather than quietly supporting a cause.  When I interviewed him 
he spoke of this journey to activist in terms of signposts that have already been touched upon in 
this chapter, with the portrayal of tropical diseases in popular science (the bestselling book 
'Microbe Hunters' by Kruif, 1926) and the connection to Rockefeller: 
 
"Well, I’ve had a lifelong interest in Neglected Tropical Diseases although they were not 
originally called that. I’ve had interest in tropical diseases ever since I was in my adolescence, 
that’s when I knew I wanted to study tropical diseases. I had read Microbe Hunters as a child 
and that had a big influence and by the time I was 13/14 years old I had a copy of “Tropical 
Diseases” on my night table. So it’s kind of an odd beginning... and then went to the Rockefeller 
University and Cornell Medical College for their MBPhD program where I began to work on 
Hookworm infection" (Interview with author, Hotez, 2014).   
 
There has been a shaping of the tropical medicine discipline through these outlets, the book 
'Microbe Hunters' and Rockefeller University.  The history of science book Microbe Hunters is 
also referenced by other scientists, including several Nobel Prize winners, as an influence in 
their decision to study medicine (de Kruif, 2002).  The book described as "...one of the most 
successful pop science books of all time" (Henig, 2002) had a wide reach and appears to be 
accessible for younger readers.  Microbe Hunters venerated scientists as heroic adventurers 
and celebrated the momentous discoveries in tropical disease: sleeping sickness, malaria, and 
yellow fever.  The author Paul de Kruif had been at the Rockefeller Institute.  Similarly Hotez 
had gone onto Rockefeller University135  and he committed himself to being a laboratory 
investigator in order to develop vaccines for NTDs and it was only later that he became, as he 
calls himself a 'global health advocate'.  He described to me this change in the following 
statement:  
 
"I’ve had a lifelong interest also in trying to develop vaccines for helminth infections [a subgroup 
of NTDs] and that actually began when I was MBPhD student. So I very much started in 
Tropical Medicine as a Laboratory Investigator with no real intention of becoming a global health 
advocate; that actually happened much later in life" (Interview with author, Hotez, 2014).   
 
Hotez found that he wanted to build momentum after embarking in a career in infectious disease 
and tropical medicine.  For him the major part of advocating for tropical diseases was the 
renaming as NTDs: “The phrase was part of a drive to think about these diseases in a fresh 
light... I think as scientists we are taught not to be advocates... That’s something I’m trying to 
correct” (Regnier, 2012).  He similarly described how this policy interest materialized to a USA 
Today journalist: "One evening in 2004, in Geneva, Hotez found himself lamenting the lack of 																																																								
135 The Rockefeller Institute became a university in 1965 (The Rockefeller University, 
http://www.rockefeller.edu/about/history, Accessed 2/4/14). 
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interest in parasites with Alan Fenwick of the Imperial College in London and David Molyneux of 
the Liverpool School of Tropical Medicine. Over dinner, they founded the Global Network for 
Neglected Tropical Diseases to yank these afflictions out of the shadows" (Sternberg, 2009).  
They all had their areas of specialism within tropical disease but united under a common cause. 
Molyneux, Hotez, and Fenwick all focus on helminths, also known as parasitic worms and they 
form the biggest group of NTDs.  They may have received more airtime as a result compared 
with the viruses (e.g., dengue), bacteria (e.g. leprosy), or protozoa (e.g. Chagas). 
 
Again there is some precedence in the type of policy involvement that these scientists have 
engaged with and other tropical disease scientists did lay the groundwork.  One of the big 
names was Donald Hopkins, former director of all health programs at NGO the Carter Center.  
When I interviewed a Sandy Cairncross at the London School of Hygiene and Tropical Medicine 
(LSHTM) he gave this animated account of Hopkins:  
 
"...he got the idea and campaigned, and as an ex deputy director of the CDC he had enough 
contacts and influence to be successful.  He and his colleagues would attend all relevant 
meetings of the World Health Assembly and lobbied all the country delegates to vote for 
eradicating guinea worm... So they did a huge amount of advocacy and published a large 
number of papers with titles such as' 'guinea worm; an eradicable scourge'..." (Interview with 
author, Cairncross, 2014).   
 
Therefore, through the guinea worm (dracunculiasis) eradication campaign, the method of 
publishing in the popular press attention-grabbing headlines had already some precedence in 
the world of tropical disease.  Advocacy went right up to former President Jimmy Carter who 
had become a strong supporter to eradicate guinea worm.  He founded the Carter Center with 
wife Rosalynn to direct funds to 'advance human rights and alleviate human suffering', with 
guinea worm as their spearhead campaign (Hills, 2015).136  However, Philip Coyne a former 
World Bank medical expert, who partnered with the Guinea Worm programme, notes the 
difference in how such an NTD is treated today, even with the support brought by Carter: 
  
"...you know back in the late 90s it was fairly obscure. I mean you know the CDC and the Carter 
Center laboured in almost total obscurity for years on this disease.  And there were a lot of 
people that thought that it was a waste of time. It was a waste of resources to try and actually 
eradicate this disease... Jimmy Carter brought in... put the influence and fundraising ability of 
the Carter Center and now we’re this close [to eradication]" (Interview with author, Philip Coyne, 
2016).  
  
																																																								
136 Carter lobbied for guinea worm eradication after encountering an infected patient in Ghana while still 
president. 
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This campaign eventually reflected a culture of advocacy that requires high-level political 
influence.  It may be that the lobbying environment of American politics is why Hotez is a man 
on a crusade, who has made many high-profile connections from presidents to celebrities.  By 
2008 Hotez would have his own Presidential Initiative for Neglected Tropical Diseases 
established by Bush and continued by Obama (Hanson, 2008).   
 
In the UK, from the next example is of an activist scientist, Alan Fenwick who created 'The 
Schistosomiasis Control Initiative' (SCI) as a means to intervene on the ground in endemic 
countries.  The initiative comes out of an academic institution so is an example of a university 
taking practical means, grounded in academic expertise to address a societal challenge.  This 
engagement is part of the wider social remit of universities, while in the US with the 
predominance of private universities and trustees there is arguably a less receptive grounding 
for this type of project.    
6.2.2 United Kingdom: Change on the ground 
 
Alan Fenwick established the Schistosomiasis Control Initiative (SCI) at Imperial College, 
London.  SCI is unusual as a public health intervention program active in developing countries, 
because it was established by an academic and based at a university.  Another NGO providing 
NTD funding information that I have noted already – 'Policy Cures' – was established by Mary 
Moran at the London School of Economics & Political Science, and she later transferred it to the 
George Institute for International Health in Sydney.   
 
For Fenwick establishing SCI was putting his parasitology expertise into organizational practice.  
After working in Egypt for 15 years, reducing the prevalence of schistosomiasis until it was no 
longer a public health issue, he wanted to apply this knowledge in other countries (Regnier, 
2012a).  However, he faced a roadblock in that schistosomiasis did not require further research 
but implementation (ibid.).  Therefore, to best deal with this disease did not require new 
innovation arrangements but a convincing of funders that knowledge application was important 
in implementation and not only at the R&D stage. 
 
As he put it: “Many organisations are interested in supporting research… but this left 
schistosomiasis and others in limbo: most of the research had been done. We had the tools 
which, if implemented properly, could help some 200 million people in sub-Saharan Africa” 
(Regnier, 2012a).  The emphasis on R&D was having a harmful effect in this instance.  To relate 
this situation to another NTD, guinea worm, it has been noted previously that this disease is 
close to being eradicated without the need for drugs, vaccines, or other biomedical interventions 
(Michele Barry, 2007).  This is quite a remarkable feat: through health education137  and 																																																								
137 Health education was principally to learn to filter drinking water contaminated with water fleas infected 
with larvae of the guinea worm. 
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surveillance a disease can be defeated and goes against the biomedical model of disease 
treatment.  This solution clearly is not possible for many other diseases, including other NTDs 
but is starkly demonstrative that the biomedical solution is not the only one. 
 
Returning to schistosomiasis, new organizational arrangements were required through SCI.  In 
2002 Fenwick received funding from the Bill & Melinda Gates Foundation to buy and distribute 
praziquantel138  (an effective schistosomiasis drug treatment) to endemic African countries 
(Regnier, 2012a).  By introducing national control programmes Fenwick wanted to test a proof 
of principle: "Will these countries implement control if given access to drugs and funding?" 
(Regnier, 2012b).  SCI has proved to be a success, to treat both schistosomiasis and soil-
transmitted helminths.  At least from the point of view of charity evaluator 'GiveWell', which 
ranks it as one of the top charities to donate to, mainly because of the 'cost-effectiveness' of the 
interventions and need for funding. 139   Chapter 7 will address discourses about the 
effectiveness of de-worming and measuring policy problems through organizations such as 
GiveWell. 
 
Regnier from the Wellcome Trust asked Fenwick in 2012, how he felt that it has been, "...left 
largely to scientists to get programmes such as the SCI off the ground?", his answer: “I’ve never 
even thought about it... It’s invigorating. I passionately believe in treating schistosomiasis... it will 
be impossible to achieve any of the Millennium Development Goals without tackling NTDs” 
(2012b).  This feeling was similar for Hotez, with his focus has been on soil-transmitted 
helminths and vaccines.  Both Hotez and Fenwick have had a prominent role to play in raising 
the profile of NTDs and have framed the approach to tackle NTDs.   
 
When scientists enter the political arena there may be resistance to the adoption of a role 
viewed to be outside of their remit, going against an image of neutrality and objectivity.  There is 
also a perception that scientists do not want to take responsibility for social problems and 
embark on a political role but this is clearly not the case with NTDs.  Some have viewed this 
type of activism as quasi-religious in character, with one interviewee describing Hotez and 
Fenwick as 'evangelicals' with a 'missionary spirit' (Interview with author, scientist at LSHTM, 
2014).  This description not only conveys their commitment but an unfaltering single-
mindedness of following a mission.   
 
My argument is that that undertones of religiousity are why it can be claimed by some, including 
Parker and Allen, that NTD advocacy and interventions are undertaken with over-promise and 
optimism, without fully considering negative aspects of campaigns or non-technical causes of 
neglect.  There is a moral basis for why NTDs may be pursued single-mindedly, and this is 																																																								
138 The investment of the Gates Foundation into SCI goes against some accusations of the foundation that 
it is uninterested in implementation, although the framing as a 'proof of concept' project is likely to have 
helped (Lancet, 2009). 
139 GiveWell, www.givewell.org/about, Accessed 2/4/14.   
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more than the charge of a lack of social science critique for NTDs.  Keating also talked about 
“that religious thing” in considering the motivations of tropical disease scientists, based on a 
moral reasoning: “These people are altruistic-minded.  I mean, the idea of medicine is healing, 
you know, of healing people but there is, there are these things you see in the tropical group, 
that maybe are not apparent as in another.  You need that personal connection to care about 
somewhere far away from you that you don’t get reminded every day” (Interview with author, 
Keating, 2014). 
 
Religion and moral duty certainly has played an intermittent role in the motivations and vision for 
tropical diseases.  In the early days of Rockefeller, scientists motivated by 'religious-moral 
impulses' were pivotal in the establishment of the Rockefeller Foundation and driving the quest 
for a malaria cure (Desowitz, 1997, p.171).  Similarly feelings of a religious nature in making 
momentous discoveries for mankind have been noted by tropical medicine scientists, such as 
Ross speaking with Manson about his malaria experiments: "I have a sort of feeling it will 
succeed – I feel a kind of religious excitement over it!" (Kruif, 2002, p. 280).140  In my interviews 
with NTD scientists a religious rhetoric was not particularly present but belief, commitment and 
moral impulse were repeated themes: 
 
"…after my medical studies, I did not follow a regular MD career. After ten years as Professor at 
the University of Brasilia, I went to Rio de Janeiro invited as a researcher of the Oswaldo Cruz 
Foundation (Fiocruz) a 116-year-old institution affiliated to the Ministry of Health of Brazil. 
Fiocruz was created to fight endemic diseases that in the beginning of the 20th century were 
harming the economic development of the country. I wanted to do good science while at the 
same time addressing the needs of the poor" (Interview with author, Carlos Morel, 2014). 
 
“I was brought up into the 1960s when there was a tremendous amount of idealism to do 
something useful I suppose” (Interview with author, Simon Croft, 2014). 
 
"I just do what I think is right, I'm not on the bench doing basic science... I see myself as an 
ideas person... I think people publish things and nothing happens even though it's self-evident 
so I feel quite strongly about this.  I just do what I think is right and if people want to buy into it 
that's fine" (First interview with author, David Molyneux, 2016). 
 
Even for those scientists not on the high-profile NTD circuit, many are called to advocacy.  
Advocates rather than activists may be less visible in the pursuit of change but will take an issue 
and work towards addressing it.  David Warrell, Professor of Tropical Medicine and Infectious 																																																								
140 Religious connotations can also be found in stories of scientific discovery concerning tropical diseases 
involving a lot of fumbling around in the dark without any obvious leads.  It needed an almost religious 
dedication, belief and faith that a breakthrough would come and a commitment to the worthiness of the 
cause. 
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Diseases at the University of Oxford, has been a leading figure in tropical medicine, while not so 
much in the media spotlight and in policy circles.  Still in answering the question of "what is your 
ambition in life?" after a well established career his response was to ultimately have an impact 
on disease burden: "To improve the treatment and prevention of forgotten and unfashionable 
diseases like snake bite and rabies. They have too few champions and sponsors" (in Shakur, 
2005).  
 
The chapter so far has considered how activist scientists introduced a new disease brand, with 
an early basis for this brand being in the GND program.  I then argue how the GND program 
paved the way for the type of activist scientist, shown through a profile of Hotez and Fenwick, 
that I see as being eventually behind the creation and promotion of NTDs.  The GND therefore 
had a lasting impact in attracting young scientists to tropical medicine and to apply cutting edge 
science.  In the next section I will explore how pharma company scientists, in site not typically 
associated with advocacy, have been engaged in activism for NTDs.  
6.2.3 Pharma company scientists: Pushing for drug donation 
 
To a degree, one precursor to the activist role for NTDs can be seen in the pharma company 
scientists (including the CEO) who pushed for ivermectin to be developed for use in humans 
and then to be donated free and indefinitely in 1987.  As I have touched upon in Chapters 4 and 
5, ivermectin is a drug to treat river blindness (or onchocerciasis) and was the first NTD drug 
donation program, opening the door for many others.  Collins stresses the part that they played: 
“...pharmaceutical company employees were often vilified as the industry came under fire for its 
astronomical profit margins and the rising costs of pharmaceuticals, these employees, like many 
of us, saw themselves as moral agents working within an ethical framework” (Collins, 2004, pp. 
104-5).  The 'ethical' work of pharma companies is also a part of the 2015 Nobel Prize in 
Physiology or Medicine awarded to William C. Campbell and Satoshi Ōmura, that has not been 
well publicized – the involvement of Merck (and the WHO). 
 
Campbell was employed by the American pharmaceutical company Merck, from 1957 at their 
Institute for Therapeutic Research, and later from 1984-1990 as Senior Scientist and Director for 
Assay Research and Development.  It was Ōmura's isolated and cultured strains of soil sample 
streptomyces (that he had obtained near a Japanese golf course) that Campbell found a 
component effective against parasites in domestic and farm animals and purified that bioactive 
agent.  The collaboration between Campbell and Ōmura was part of, "a novel international 
Public Sector–Private Sector partnership" in the 1970s between Antibiotics Research Group at 
Tokyo’s Kitasato Institute, and Merck, Sharp and Dohme (MSD) based in the US (Crump & 
Ōmura, 2011).  
 
 191 
Ivermectin141 was developed by Merck in 1987 (marketed as Mectizan) (Gill, 2012)  and had 
become a 'blockbuster drug' 142  to treat animals for helminth infections, within two years 
generating annual sales of over $1 billion, "...a status maintained for two decades" (Crump, 
2014).  Once potential was found for humans and the company embarked on a joint research 
programme with the WHO (Collins, 2004).  Merck went on to engage in a number of 
partnerships for distribution, including enlisting the help of former president Jimmy Carter to act 
as marketer to high level officials in endemic countries (Saporta, 2012).  Such activities 
targeting an NTD had been isolated until then.  
 
When Merck decided the drug would be produced for free and made available for patients as 
long as it was required, this was an almost unprecedented undertaking. They had first pursued 
pricing the drug commercially before seeing this would not work for poor patients and had, 
“...turned to national and international organizations — such as the WHO, the U.S. Agency for 
International Development, the U.S. Department of State, European and African governments, 
and private foundations — but to no avail” (Collins, 2004). The senior management at Merck, 
particularly CEO Roy Vagelos, had been supportive throughout and the scientists involved were 
the ones who suggested the possibility of drug donation (ibid.).  Some make light of the fact that 
Vagelos was originally a university researcher, although it is not uncommon for pharma 
researchers to have previously worked in academia and may rather be attributed to the values 
held by Merck as an organization: 
 
“Abandoning the drug was unattractive both in terms of health benefits denied to suffering 
people in Africa, and in terms of characteristics of Merck and its situation: its corporate culture, 
its already-existing donation programs, and also its image now that many knew of the existence 
of this breakthrough...” (Coyne and Berk, 2001, p. 10-11).  
 
Therefore, the pushing of the scientists and how Merck envisioned itself through its corporate 
culture led to the “largest on-going medical donation program in history” treating more than 60 
million people annually (Merck Website).  Also lymphatic filariasis, another NTD, is now being 
treated by ivermectin.  Now the Merck donation success story is used as a case study in 
business schools of an 'ethical dilemma' for companies, in developing or distributing a drug for 
the poor, at cost to the company, while wanting to demonstrate social responsibility.  The 
donation did not begin as a dedicated research project but since then other pharma companies 
have followed suit with their own drug donation programs for NTDs.  Many of these programs 
similarly began as offshoots from commercial drugs for another disease or after no 
commercially viable market had been found (Coyne and Berk, 2001).  
																																																								
141 The bioactive agent of ivermectin was called avermectin and the subsequent chemically modified to 
produce the more effective compound. 
142 Blockbuster drugs are "...medicines that bring in more than $1 billion in sales every year" (Lorenzetti, 
2016) 
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6.2.4 Scientists adopting alternative approaches 
 
In comparison to the scientists who have been trying to raise the profile of NTDs, either through 
policy engagement or through their organizations, there are others who have been attempting to 
adopt alternative innovation frameworks.  For these scientists the problem of NTDs lies in the 
scientific and innovation system itself. 
 
Why these NTDs are neglected has commonly been pointed to the fault of the market and the 
private sector, while the public sector and third sector (charities, NGO, international 
organizations) are not placed to address such problems.  Two prominent examples that I 
identified of scientists to be pursuing new innovation arrangements to challenge a 
pharmaceutical model of dealing with NTDs can be found in Australia.  I interviewed Richard 
Jefferson who set up the NGO 'Cambia' and Matt Todd at the University of Sydney who is 
behind the initiative 'The Synaptic Leap'.  Their interest instead is in how innovation might be 
arranged differently through open approaches to innovation.  I found that their work inhabits a 
more experimental space, which has seen a less wide-reaching impact on NTDs. 
6.2.5 Australia: Alternative innovation frameworks  
 
Todd is a scientist working in the Chemistry department at the University of Sydney and is 
concerned with how open source innovation can assist in drug development.  As Christine Årdal 
and John-Arne Røttingen document (2012), there has been a great deal of theoretical 
discussion and a number of initial projects based on this idea.  Open source for drug discovery 
is a concept that “borrows two principal aspects from open source computing (i.e., collaboration 
and open access) and applies them to pharmaceutical innovation” (Årdal & Røttingen, 2012). 
 
Todd originally became interested in the NTD schistosomiasis as a post-doctoral researcher, 
drawn to molecules that are difficult to make and which hold practical applications.  The appeal 
of the open source philosophy came later: “it mimics the software development term… the aim 
is clear that the way to gain benefit is to share everything” (Interview with author, Todd, 2013).  
For Todd it is a way to share research in a complete state so that others can then take it and 
make changes that they see fit.  Based on this rationale, he began a project known as 'The 
Synaptic Leap' in 2006.   
 
The Synaptic Leap originally consisted of a group of online research communities for malaria, 
schistosomiasis, toxoplasma and TB.  A lab notebook was made visible in the public domain 
mimicking open source in software development.  The project on schistosomiasis was 
completed in 2011, resulting in improvements to the production of the most common drug used 
to treat the disease Praziquantel, and this work was published in peer-reviewed journals.  While 
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this project did yield some results, it is still unsual for entrepreneurial practices, particularly 
those adopting 'open source' approaches in academia. 
 
Other scientists have also taken on a larger entrepreneurial role to establish their own NGOs.  
Richard Jefferson founded Cambia in 1992.  It is now ranked as one of the world’s top NGOs 
(The Global Journal, 2013) and has been receptive to adopting open approaches to innovation.  
Cambia was the brainchild of Jefferson.  A molecular biologist by training, he was critical of 
multinationals such as Monsanto for controlling critical technologies through patents and access 
to capital.  For him the blockbuster mentality and rent-seeking model in biotechnology has not 
been working and inhibits innovation: “In that model, you invent a new process, find a drug 
target, or discover a new gene, then wrap it up in intellectual property protection and try to sell it 
to the highest bidder. That bidder then has to try to assemble the puzzle into something actually 
useful. It’s a slow, expensive, and cumbersome process” (Interview with author, Jefferson, 
2013).  As an alternative to this model he has sought to create accessible tools and 
technologies that enable equitable innovation.   
 
Openness for Jefferson is to create the infrastructure to make innovation equitable and 
transparent by allowing people to see and align self-interests between disparate groups.  In 
tackling NTDs his NGO Cambia provides 'The Lens' as a tool to search for patents.  He 
explained that there is not a direct initiative for NTDs because the focus is on “making it possible 
for people to be active in problems and their own solution-set” (Interview with author, Jefferson, 
2013).  Therefore, he wants to keep the possibilities of using the tool open.  Cambia has given a 
stage to science matters where ownership is of crucial importance, such as plant gene and 
genome intellectual properties (Jefferson, Köllhofer, Ehrich, & Jefferson, 2015).  However, it 
appears harder to see relevance in open innovation approaches applied to NTDs. 
 
On balance, my argument is that the need for openness to tackle NTDs, while being one 
strategy to direct research and funding efforts, is not a good match for how the policy problem is 
understood.  This thesis has intended to look beyond the obvious and intuitive idea that neglect 
of NTDs is mainly on a pharmaceutical basis, due to lack of R&D, and move towards a more 
encompassing view of neglect.  In addition, the emphasis on pharmaceutical responsibility does 
tend to get confused with treating NTDs as 'for-profit' diseases (e.g. HIV/AIDS which has 
patients in both the developed and developing world) where there is an issue with access from 
developing world because of intellectual property rights protecting for-profit research efforts.  
NTDs are generally not-for-profit diseases and so while open approaches have been novel, and 
may encourage collaborative working (mainly because it is in their remit), there are not any 
particular openness barriers that need dismantling.  Thus open approaches to innovation do not 
appear to be addressing a multi-faceted understanding of neglect in the case of NTDs.   
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Mary Moran outlines this line of argumentation in her critique of WHO pilot projects, which 
began in 2014 to fund research for NTDs.  Her claims are laid out in the provocatively titled 
Nature article: 'WHO plans for neglected diseases are wrong' (Moran, 2014).  When I 
interviewed her she summed up her paper: "Well, basically I'd say, look, I understand that 
there's problems with accessing commercial and intellectual property, but we don't have that 
problem in neglected diseases and the solutions you're proposing for neglected diseases don't 
fit here" (Interview with author, Moran, 2014).  Indeed pharma companies when launching open 
innovation projects give more of the impression of PR exercises, as opposed to the tried-and-
tested drug donation model that has been working for some time with NTDs. 
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6.3 Activists by another name? Scientists in China and Brazil  
 
In contrast to the activist scientists in the UK and US I want to gain insight from the scientists in 
emerging economies and how they are engaged in policy, through the institutions they are 
based at and through a public reception to scientific discovery.  The status of a scientific 
discovery serves to acknowledge the research prestige of a country, as does the reputation of 
national institutions.  Both Brazil and China had important discoveries in tropical diseases in the 
20th Century and have undergone institution building to an extent rivaling the traditional colonial 
tropical medicine schools.  It is in this context that I want to ask what the relationship of 
scientists in endemic countries has been with the NTD policy movement.  As discussed already 
there are similar descriptions of social movements or groupings and their interactions with policy 
and research (e.g. ‘political opportunity structures’, ‘advocacy coalition framework’ and 'scientific 
and intellectual movements or ‘SIMs’).  Haas provides the epistemic community definition, which 
comes close to the idea of a policy movement but does not completely capture the mode 
activism and goal of social change: "An epistemic community is a network of professionals with 
recognized expertise and competence in a particular domain and a policy-relevant knowledge 
within that domain or issue-area" (Haas, 1992, p. 3).  This description is certainly pertinent to 
the activist scientists, WHO, NGOs and pharma companies that have coalesced under the NTD 
domain.  However, a policy movement conveys what actors do with their expertise and 
competence. 
 
I argue that scientists in Brazil and China are working on NTDs create their own distinct 
epistemic community, facing a different environment with their own challenges and concerns.  I 
will explore the differing vision employed to tackle NTDs in Brazil and China, focusing on the 
differing histories and socio-cultural values at play.  For a policy movement to bring attention to 
NTDs activist scientists have been central but the rationale for intervention and means of 
justification in country context looks markedly different.   Initially it may appear that there lacks a 
prominent role of activist scientists in emerging economies, however this is not a full picture, 
especially when taking into account research histories of disease.  Activist scientists are part of 
the attempt to 'globalize' NTDs, alongside the WHO, Gates Foundation and other key 
stakeholders.   
 
Putting NTDs on the global agenda, the idea has been to 'scale up' efforts to a similar level of 
policy addressing the 'big three'.  At a national level there is another set of competing diseases, 
political interests, as well as research and innovation priorities.  Scientists within the nationalist 
discourse and their role within a nationalist project form a type of techno-nationalism (described 
by Edgerton, 2007), where a country's science and technology comes to represent a part of its 
national identity.  As with postcolonial critiques I will draw out some of the 'other' voices that 
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have been absent and marginalized, dominated by the stories of tropical medicine 'greats' and 
address the role of scientists in emerging countries in the next section.  
6.3.1 Endemic countries in a globalized NTD policy 
 
To fully address questions of technology, science, and national identity in Brazil and China 
would be a vast undertaking, so my aims are narrower, drawing upon fieldwork interviews in 
Brazil and China.  I reflect upon how NTD policy is positioned from the outside, the 
characterization of emerging economies with a growing innovation capacity, and the endemic 
country responses.  Adams, Gurney, and!Pendlebury have highlighted the growth and impact of 
research from Brazil and other emerging economies: "This establishes a new geography for 
NTD research with much benefit to affected populations" (Adams et al., 2012, p. 3).  Today 
NTDs form a significant research topic and base of knowledge for developing and emergent 
economies "because of obvious economic and social relevance... with a substantial volume of 
NTD papers in its portfolio" (ibid, p. 5).  
 
We see both in Brazil and China that diseases neglected on global level relate to some 
countries and not to others.  This universalist treatment is a danger in having one umbrella 
category for disease and of course the next question to ask is whose 'universal' is it?  For 
example, Chagas has been a major concern in Brazil and schistosomiasis in China.  As Yang et 
al note: "Although schistosomiasis is neglected at the global level, this problem is not the 
situation in China. Political will, coupled with financial, human, and technical resources, has 
successfully controlled schistosomiasis in most parts of the country" (2014, p. 884).  On the 
other hand, Chagas is only endemic in Latin America.  There is also the re-emergence of 
dengue in both countries.  It was repeatedly mentioned in my interviews in Brazil that São Paulo 
used to be free of dengue.  In recent years there have been many cases even in the richest 
areas, therefore the disease profile in the country is changing.  
 
Other diseases that affect the middle and upper classes, as well as growing populations, mean 
that NTDs face competition with non-communicable diseases (NCDs).  Yang et al argue, 
"(N)on-communicable diseases dominate the public health arena in China" (2014, p. 881).  Here 
neglect is sometimes characterized as a competition between the new diseases of the wealthy 
and the old diseases of the poor (Singh & Singh, 2008).  Others try to find connections between 
co-morbidities or in how greater numbers of poorer groups are affected by NCDs (Mehta et al., 
2016; Sridhar et al., 2013).  NTDs become less frequent in urban areas, meaning some medical 
schools no longer teach tropical disease pathology.  One scientist in Shanghai described how 
the doctors are concentrating on non-communicable diseases: “They concentrate on heart 
disease and diabetes” (Interview with author, Senior Researcher at Institute for Parasitic 
Disease, 2013).  Emerging economies such as Brazil and China face their own unique 
challenges in dealing with NTDs, not only from the perspective of the specific diseases that are 
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most prevalent but social and demographic changes.  Next I look closer at the individual 
countries. 
6.3.2 Collectivist science in China 
 
High-profile scientists have not dominated the field of tropical medicine in China.  Even for those 
who have been credited by the international community, the reception has been downplayed to 
some extent within China.  The aspiration for science to be a means to national salvation has 
been well documented (Cao, 2004; Wang, 2002) but the view of the scientist has been more 
conflictual, tied for instance to political allegiances.  This view is related to how the scientist is 
positioned within the national consciousness and a radically changing political climate for 
science.  The emphasis of science is on collective effort, and the perception of scientists is still 
connected with (a not particularly positive view of) elites.  Consequently, scientists have not 
played as active a role in policy and politics as seen in the UK, US and Australia.   
 
Collectively, the National Science Institute in China that conducts basic and applied research 
'Chinese Academy of Sciences' (CAS) is the main source of institutional prestige and clout.  
There are few occurrences of scientist involvement in policy and one of the strongest examples 
now dates back to 1986.  A letter from four leading scientists to former Chinese leader Deng 
Xiaoping set out a proposal to fund high-tech R&D (Gang & Tan, 2009).  The letter resulted in 
the establishment of the National High Technology Development Program.143  Afterwards a 
committee of 200 scientists set the initial strategy for basic science and applied technology.   
 
Surveys of public perception of scientist involvement in politics give some indication of why 
scientist may not take policy-orientated roles.  A Scientific American survey in 2010 showed that 
"almost one-third of scientifically literate Chinese people say that scientists should not get 
involved in politics, compared with around 10% of respondents in most of the rest of the world" 
(Cyranoski, 2010).  We cannot read too much into such a finding and the accompanying Nature 
article also noted that the small sample size in China compared to the US and Europe (ibid.).144  
It does point towards a more uneasy relationship between scientists and politics but one that is 
still very much open to interpretation.  Wu Yishan, a chief engineer at the Institute of Scientific 
and Technical Information of China in Beijing "...suggests that the negative connotation of 
'politics' in China, deriving from a 'politics first' movement during the communist Cultural 
Revolution that was used as an excuse for various abuses, might be to blame: it is not that 
scientists have nothing to contribute, but that politics itself is tainted" (ibid, p. 389).     
 
																																																								
143 '863 Program' related to the date of the letter, March 1963. 
144 "Far from being rigorous, the survey sampled countries unevenly, with thousands of respondents in the 
United States and several European countries, 1,195 in Japan and just 269 in China" (ibid.). 
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An example of the tumultuous past for the treatment of scientists during the Cultural Revolution 
can be seen through scientist T’ang Fei-fan.  In 1957 the isolation of elusive agent for the NTDs 
trachoma was discovered but as with artemisinin had not been known outside of China.  UK 
scientists had been simultaneously working to pinpoint this agent until an article by T’ang Fei-
fan et al (from Tong Ren Hospital in Beijing) in a Chinese Medical journal explaining the 
discovery, was stumbled upon by scientists (at the Lister Institute) (Cox, 1996; Taylor, 2008).  
What followed was an expansion in research on trachoma, however around the time of China's 
Cultural Revolution (1966 – 1976) scientists were unpopular.  In the lead up there had been 
infamous communist purges of 'disloyal' subjects in the 'Hundred Flowers' campaign of 1956 
when citizens were invited to express their views of the communist regime (Lu, 1969).  This 
period was followed by the 'Anti-rightist' campaign in 1957, a crackdown of those critical of the 
regime and ideology.  There are differing accounts of Tang's death in 1956, after 30 years of 
work in parasitology and only a year after isolating the trachoma virus, either it was by suicide 
after being labeled a 'rightist' or murder.145   
 
In celebrating Tang in an article, Cheng et al. (2011) recount how the renowned British scientist 
and Sinologist Joseph Needham said of Tang in a 1979 letter to the then director of the National 
Vaccine & Serum Institute of China:  “Dr. Feifan Tang (F. F. Tang) was indeed ‘a friend to man’ 
as our old English eighteenth-century phrase has it; he loved the Chinese people and was a 
doughty fighter in the fundamental field of preventive medicine. With all friends here, I salute his 
memory and I am sure he will never be forgotten in China.”  The authors also note how he may 
have been overlooked until more recently:  
 
"His research might have been continued for greater achievements if he had not been 
appointed to study vaccines of measles and poliomyelitis. Even so, he was still being 
questioned and judged. In 1958, he gave up his life to protect his integrity and dignity. Until 23 
years later when Dr. F. F. Tang was awarded the gold medal by the International Organization 
against Trachoma, his great contribution became [sic] to be treasured. In 1992, the Chinese 
government issued a postage stamp in his honor. A bronze statue of Dr. F. F. Tang stands in 
front of the National Vaccine & Serum Institute, Beijing. It is a great pity that the trachoma study 
was discontinued in China for a while. Today, when we are in the new era of innovation, the 
lessons from our predecessors should never be forgotten." (Cheng et al 2011, p. 350). 																																																								
145 More information about Tang can be found in the archives of the Carnegie Council, where a writer in 
1983 describes the contents of 'China Daily', which was the People's Republic of China (at the time) two-
year-old English-language newspaper: "Page five is the Culture page, which, in the rhetoric of the New 
China, includes Technology, Science, and Medicine. One issue tells a chilling story about Tang Feifan (the 
Western version of his name, 'F. F. Tang', is given in a picture caption), who attained international renown 
as the isolator of the virus that causes trachoma. The article ends: 'In 1958 Tang was unjustly accused of 
being 'reactionary.' On September 30, he committed suicide. His only son, Tang Shengwen, now works in 
the institute where his father devoted his life to research" (Hazard, 2009). 
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The science-politics tensions were obvious during this period but also the 1950s through to the 
1960s had been a peak time for NTD research in China.  Successes included public health 
control measures against hookworm through the Hookworm Commission, leprosy with a 
nationwide leprosy programme and then schistosomiasis, in an unusual campaign that saw 
peasants using sticks to remove parasite carrying worms from riverbanks (F. E. G. (ed.). Cox, 
1996).  
 
It remained difficult to separate science and politics and a prominent example of the blurring of 
science and politics goes back to the 1960s.  Artemisinin, which has become a key antimalarial, 
had been discovered and isolated in leaves of herb Artemisia annua.  Despite this momentous 
discovery, artemisinin was kept a secret from outside.  The drug was part of a large-scale secret 
government 'Project 523': "involving over 500 scientists in ∼60 different laboratories and 
institutes" (Miller & Su, 2011, p. 855).  The project combined western and indigenous knowledge 
enquiry to, "...research and develop new drugs the Western way, screen traditional medicine 
and folk remedies to search for a Chinese therapy, and find ways to prevent malaria infection in 
the first place" (Hao, 2011).  The program had been to treat soldiers in the Vietnam War at the 
request of the North Vietnamese leaders, so due to the military intentions it was shrouded in 
secrecy and also because "during the tumult of the Cultural Revolution, publication in scientific 
journals was forbidden" (Miller & Su, 2011, p. 855).  By 1977 the work of the group was 
published, albeit anonymously.  Secrecy continued until the Chinese economic reforms in the 
early 1980s, with the WHO only giving endorsement in 2000 and artemisinin was still not widely 
available until as late as 2006 (ibid.).  
 
These accounts paint communist China in not the most favourable light as a time of secrecy and 
isolation.  However, a 2005 BBC documentary 'Malaria Defeating the Curse' (Horizon) provides 
a more even handed portrayal where the political climate involving China, the US, and the WHO 
all contribute to why artemisinin was held back.  The point is made that it was not an ordinary 
scientific project.  The research was driven by politics – to directly assist the Vietnam war effort 
but also ideologically in the encouragement by Chairman Mao to explore traditional Chinese 
medicine, rather than relying exclusively on western science.  The protagonist in the story is 
Prof Ying Li from the Chinese Academy of Sciences (Shanghai Institute of Materia Medica) who 
commented:   
 
"The foreigners seemed to be snooping. They were so arrogant and contemptuous. They were 
astonished that we Chinese had managed to achieve this amazing breakthrough when they had 
spent so much time and effort on it and failed" ('Malaria Defeating the Curse' documentary, 
Horizon). 
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There may have been just reason for suspicion as the US military were on the WHO steering 
committee for anti-malarial drug development, as the military has had a long history in anti-
malarial drug development (ibid).  On the part of the western scientists the element of disbelief 
may have partly been grounded in the uncertainly of accurate information coming out of China, 
including previously exaggerated claims about eradicating schistosomiasis and curing malaria 
with acupuncture (ibid.).  Even though, NTDs were certainly a priority and 'The National Institute 
of Parasitic Diseases' was established in this heyday.  Established in 1951, it is one of the few 
institutes in China dedicated to NTDs as part of the China's Center for Disease Control and 
Prevention (CDC) network, the leading public health agency.   
 
Another aspect of secrecy has been that individual scientists were not well recognized.  In later 
years more attention has been given to individual actors on the international stage.  Attribution 
has recently gone to scientist Tu Youyou for the discovery of artemisinin.146  Tu was head of the 
research group at the Institute of Chinese Materia Medica for Project 523147 and part of a 
national project against malaria.  She received international recognition after being awarded the 
'Lasker prize' in 2011 a prestigious medical award and was the first Chinese person to win the 
Nobel Prize in Physiology or Medicine in 2015.  She had not been well known within China, with 
the Chinese newspaper Wen Wei Po remarking how she had been nearly completely forgotten 
until 2011.  Even Youyou herself has remarked modestly and with nationalist sentiment on 
receiving the Lasker prize: "(I)t is scientists' responsibility to continue fighting for the healthcare 
of all humans... What I have done is what I should have done in return for the education 
provided by my country" (McKenna, 2011).   
 
However, despite the publicity of recent years, it does appear that government interest in NTDs 
has waned.  The scientists see underfunding as a major inhibitor to their work, as described 
when I visited the institute: “we have good drugs but not money to introduce into the market… 
we should be supported by government or international governance” (Interview with author, 
Research director at Institute for Parasitic Diseases, 2013).  At the institute, despite having 
invested in more than 20 drug products in last 20 years, few are used in the field and the 
scientists are frustrated they are 'just sitting there' (Interview with author, Senior Researcher at 
Institute for Parasitic Diseases, 2013).  
 
This is not to say China has not had more recent successes against NTDs.  As Prof. Xiao-Nong 
Zhou, a senior scientist at the Institute notes in China “NTDs are one of the most prevalent 
infectious diseases, with more than 100 pathogens recorded to infect humans” but this situation 
is changing: “(D)ue to great efforts by government leadership, professional guidance and 																																																								
146  Forgotten also were contemporary artemisinin researchers - Yu Yagang and Zhong Yurong.  
Researchers at Beijing university call for the "roles of others need to be further studied and established" 
(Hao, 2011). 
147 Some numbers are believed to be auspicious in Chinese tradition (0,2,3,5,6,7,8,9) – the same reason 
why the National High Technology Development Program contained these numbers.   
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community involvement, NTDs have declined significantly with the increase in economic 
development in China” (2013).  For example, in 2007 lymphatic filariasis was eliminated in 
China.  However, now these diseases compete with the diseases of the middle and upper class, 
who are more heavily located in urban areas down the eastern coastal side of the country 
spanning from Beijing to Shanghai (see Hotez & Ehrenberg, 2010).  The rapid changes in the 
country pose new health risks and obligations.  
 
To summarize, the confrontation of NTDs in China has followed a specific path affected by a 
changing political environment, as well economic transformation in the country.  From secrecy 
during the time of Chairman Mao, to scientific recognition, and new health challenges, China 
has faced the NTD problem within a context of multiple concerns and influences.  The renaming 
and higher profile of NTDs has provided an opportunity to reflect on successes but as the China 
example has shown, individual country priorities will persist over global health prioritization.  In 
Brazil we can a similarly distinct interweaving of approaches to NTDs reflecting the country's 
historical circumstance, political events, and socio-cultural understandings of disease – 
particularly defined here through nation-building as a former Portuguese colony.  
6.3.3 Nationalist sentiments in Brazil  
 
Tropical medicine in Brazil has been deeply seated in nationalism, personified through the 
pioneering Brazilian doctors Oswaldo Cruz and Carlos Chagas.  They were two giants of public 
health in Brazil and in pursuit of NTD control and elimination.  Cruz had previously been director 
general of public health in Brazil, which saw him introduce three successful sanitation 
campaigns against yellow fever, followed by a smallpox vaccination campaign in 1904.  He was 
recognized by the international scientific community in 1907, at the 14th International Congress 
on Hygiene and Demography in Berlin, with the gold medal in recognition of the sanitation of Rio 
de Janeiro.  As Carlos Morel, Director of the Center for Technological Development in Health at 
Fiocruz, points out:  
 
"...by propagating the role that science should play in the development of Brazil, Oswaldo Cruz 
managed to conquer and receive support from the highest political level [President Rodrigues 
Alves]; being nominated Director of the Federal Department of Public Health, he could efficiently 
fight the diseases that were devastating Brazil’s economy, particularly yellow fever and plague" 
(Morel, 1999, p. 4). 
 
Cruz went on to be the founder and director of the Oswaldo Cruz Foundation or Fiocruz, a 
public health institution, established in 1900 (Fiocruz, http://portal.fiocruz.br/en, Accessed 
2/4/14).  He was able to attract collaboration from scientists of developed countries, particularly 
from Germany, who came to work in the institute (Morel, 1999, p. 4).  Moreover this 
collaboration has been a lasting connection, in the visiting fellow program and 'high level 
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scientist' program there are many from the USA followed by Germany and then a large selection 
of countries (Interview with author, Morel, 2014).   
 
Chagas took over the directorship of Fiocruz following Cruz's early death at 45.  It was Chagas, 
with guidance from Cruz, who discovered the parasite that caused American trypanosomiasis, 
later named Chagas disease.  Morel highlights the deep significance of the discovery for Brazil 
on the world stage: "How could one of the major medical discoveries happen in a poor country 
in the tropics, be published on the first volume of a local institutional journal and yet receive 
world-wide recognition and be one of the seeds of a whole school of thought and research 
which still today has such a profound influence in Latin American science?" (Morel, 1999, p. 3).   
 
The discovery is highlighted by Kro and Sà as a: "...symbolically significant event that 
represented the scientific project that Oswaldo Cruz sought to establish at Instituto de 
Manguinhos148... it was acclaimed as a symbol of Brazilian scientific capability" (2009, p. 14).  
Chagas disease was also a symbol of the poor and vulnerable in the country being left behind.  
Chagas spoke of the scourge of disease that would bear his name, in relation to large sections 
of the population being, "unable to participate in the progressive evolution of the country” and 
the news reporting picked up on this theme with headlines such as: "Brazil witnesses a step 
forward for mankind and a step backward in the brutal reality, which the authorities need to 
address without delay" (ibid.).149 
 
Chagas has enjoyed hero-status since, a ‘mythification’ connected to the, "...status and 
significance that the discovery and study of new disease played in the institutionalization of 
Brazilian medicine and science" (ibid, p. 24).   Although his status was not without contention, 
with doubts about the authorship of the discovery that some thought should have been 
attributed to Cruz, as the one who conducted the experiment (the findings of the Brazilian 
Academy later disproved this) (ibid., p. 26).  His critics further argued against him on ideological 
grounds, saying that his idea of a ‘diseased country’ was exaggerated and pessimistic and 
would discredit Brazil abroad (ibid).  Some scholars have argued that critique of Chagas 
prevented him from receiving a Nobel Prize (Kropf & Sá, 2009).   
 
The interplay between science and nationalist ideas has meant that political events have deeply 
impacted scientists at Fiocruz.  During the military dictatorial regime (1964 – 1985) the country 
was thrown into upheaval and in 1970 was the so-called “Massacre of Manguinhos”, when 
"renowned researchers from the Institute lost their political rights and were forced into 																																																								
148 The site of Fiocruz is on an old farm of 'Manguinhos'. 149 The announcement of Chagas’ discovery was held at the Academia Nacional de Medicina, electric 
lighting was used for the first time, "...a symbol of the Belle Époque prevailing in the recently refurbished 
capital" and disturbing footage of mostly children with neurological disorders, and the ‘barbeiro’ bug culprits 
to present an, "...antithesis of ‘civilization’ – in the center of medicine and capital of the country", with 
microscopes to see the new parasite (ibid, p. 25). 
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retirement" (ibid).  The instability intensified in the 1980s, as the Director of Brazil’s Center for 
Global Health at Fiocruz, Paulo Buss described how the 'intertwining' between medicine and 
politics became 'more pronounced' finding a role 'in the fight for democracy':  "Our slogan was 
that Health is Democracy and Democracy is Health... We organised a lot of meetings, putting 
together postgraduate courses in public health, civil society organisations, and so on. We felt it 
was very important to agree a construct of health as a right" (Pincock, 2011, p. 1738).  
 
Many within Fiocruz see the inclusion of health as a right to be important.  Today Buss has 
continued an outlook that health must be closely connected to policy and politics: "I think 
medicine and society, as well as doctors and politicians, do not have very precise boundaries. 
There is no precise boundary between my work as a doctor of public health and my work in the 
field of social policy. This is the field where we can transform the world” (ibid).  Along these lines 
Fiocruz has been at the forefront of efforts for dengue with the ‘Eliminar a Dengue: Desafio 
Brasil’, part of the international not-for-profit research effort 'Eliminate Dengue: Our 
Challenge'150 led from Monash University, Melbourne, Australia (Fiocruz Press Release, 2012) 
(Fiocruz Press Release).  The scientists I interviewed in Brazil often said reiterations of the 
phrase: "It's not just science, it's social" and the context for dealing with these diseases, which 
included a culture of inequality (Brazil was the last country to abolish slavery).   
 
Fiocruz remains the pre-eminent scientific and public health institution for research in Brazil and 
arguably Latin America (Fiocruz, http://portal.fiocruz.br/en, Accessed 2/4/14).  The Cruz-Chagas 
period represents what is viewed as a golden age in Brazilian research and public health, 
followed by attempts to emulate it since.  Cruz and Chagas wanted to rival developed countries 
in Brazilian scientific achievement but also to apply science to the deep social problems of 
poverty and inequality.  Later scientists at Fiocruz, became politically engaged as doctors who 
were pushing for democracy.  Better health was a demand that the government should provide 
for citizens, and as medical scientists and doctors they saw themselves as well placed to 
advocate for change.  As I showed with the China example, scientists in Brazil have been active 
in their involvement with tropical diseases, despite a sometimes turbulent political backdrop.  A 
political role in pursuit of other priorities overtook that of advocating for NTDs.  What both 
countries therefore represent is an autonomous course in dealing with NTDs that is quite 
separate from the brand created to repackage the diseases.  
 
This chapter has traced the emergence of an NTD brand, the pivotal role of activist scientists in 
the UK and US, and ended with how scientists are perceived in the endemic countries Brazil 
and China.  I began with the question of why activist scientists have not emerged in these 
countries or last least have not appeared to do so.  Through the course of this chapter I have 
argued that there have been some major contributions by scientists in Brazil and China.  In 																																																								
150 The Fiocruz project uses Wolbachia, a natural bacterium, introduced into the dengue carrying Aedes 
aegypti mosquito to stop the virus from growing (ibid).   
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China ground-breaking research by scientists was under-acknowledged because of a sensitive 
political environment and it has only been more recently that recognition has been bestowed.  In 
Brazil, the relationship between scientific recognition and praise is even more contradictory, 
being intertwined with nation-building and the need to project a modern disease-free state.  The 
possibility of scientists taking on a more advocacy or even activist role was constrained by 
these circumstances but also hampered by the way that a policy movement initiated in 
developed countries became 'global'.  This is a point that I will expand on in the concluding 
section. 
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6.4 Conclusion: An elite policy movement 
 
When the advocacy of a social movement is absent for a policy problem, as in the case of 
NTDs, an elite policy movement becomes viable.  A policy movement is not a grassroots but 
elite action, through the activist scientists that have created a new disease brand.  I have shown 
that alternatives for dominant public discourses and policy narratives can be offered by elites, 
and competition exists in elite groups for prominence of problems.  According to Sheila 
Jasanoff: "Not all societal adjustments rise to the level of protest movements nor arise from 
below, as in the formation of group resistance; to the contrary, many salient adjustments in 
actors' identities, with profound consequences for the day-to-day conduct of society, occur 
within elites" (2005, p.29).  Adams also wrestles with the idea that "...medical professionals 
have, by politicizing their medicine, managed to advocate service to the people while preserving 
their own positions of elites in a still highly stratified and unequal society...  with their status as 
bearers of modernity" (p. 224).  
 
However, the stories of Tu, T'ang, Cruz, and Chagas show scientists who were caught in 
political conflicts about the ways that NTD research was approached within their countries.  
Their stories also provide context as to the relationship with research and policy making taking 
place in developed countries.  Political upheavals and social-cultural changes have presented 
difficulties for NTD research and policy in Brazil and China.  However, these developments are 
not well captured in the policy movement for NTDs.  A globalizing policy towards NTDs relies on 
an idea of developed to developing country knowledge flows and donor-recipient relationship.  
For scientists in the developed countries, as has been explored, neglect is apparent in policy by 
donor governments, NGOs, international organizations, and through the pharmaceutical system.  
It is clear however, that the capabilities of Brazil and China are both different to those of low-
income countries and to each other.  While the 'neglected' aspect of NTDs is more apparent 
from the perspective of the donor through a policy movement, it is not so much of a clear-cut 
case from the other side.   
 
In the next chapter I cast an eye to the effect the policy movement for NTDs has had on two 
related discourses.  These discourses concern the measurement of economic impact through 
the 'worm wars' and a new conception of philanthropy 'effective altruism' drawing on a 
measurement ideology.  Here there is an overlap between the discursive activities to promote 
NTDs as a policy problem and the pervasive rationales for policy on measurement terms. 
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Chapter 7. Evidence for neglect: Discourses of 
measurement  
 
“The metric of success is lives saved, kids who aren’t crippled... Which is slightly different than 
units sold, profits achieved. But it’s all very measurable, and you can set ambitious goals and 
see how you do” (Bill Gates in Herper, 2011). 
 
"...only what can be measured, can be managed" (Nowotny, 2007, p. 479) 
 
7.1 Introduction: Measurement in global public health 
 
This thesis has been concerned with how evidence and advocacy have been used to transform 
tropical diseases into NTDs.  Chapter 5 began the discussion with how evidence through 
measurement is used and what is taken as evidence to characterize NTDs as a policy problem.  
I have highlighted two metrics that have been the most influential in measuring neglect.  The 
‘10/90 gap’ positioned NTDs as neglected in terms of pharma R&D, while the introduction of 
‘DALYs’ gave prominence to the disabling effects of NTDs as being neglected by governance 
institutions.  To present an attractive solution, the '50 cents per person' measure of the cost-
effectiveness of mass drug administration (MDA) for five NTDs was used.  Chapter 6 then 
explored the form of advocacy that has taken shape to direct NTDs into their current policy 
formation, to which I attribute significant agency to activist scientists.  This chapter takes a step 
back, to try to ascertain what these modes of policy constitution – evidence and advocacy – 
mean in a public arena.  I move from evidentiary practices to cases where evidence has been 
contested.  What have been the discursive effects and impact on ideas about NTDs, in where 
these diseases sit in public health policy, and how the policy problem is understood? 
 
Discourses present particular policy narratives, and in doing so conduct conceptual and 'social 
world' work, that stretches beyond the remit of the metrics in themselves.  I have provided an 
introductory commentary on discourse in the theory Chapter 3 but it is worth bringing in 
Annemarie Mol's description of a discourse in how: "...words, materialities and practices hang 
together in a specific, historically and culturally situated way" (2008, p. 9).  Discourse therefore, 
is a means through which various actors can affect a policy situation, providing persuasive 
evidence for why NTDs should be prioritized by policy agendas.   
 
I present two empirical cases of measurement discourses.  First is the so-called 'worm wars' 
and second 'effective altruism' (EA).  For this part of the research project I mainly relied on 
online material (websites, blogs, etc.) and drew on a small selection of my qualitative interviews, 
to shed light on aspects of the discourses.  I also attended public events that discussed the 
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discourse topics, including an 'International Society for NTDs' (ISNTD) Conference with a 
session on school-based deworming (April 2016, Institute for Child Health)151 and the second a 
talk by Peter Singer and others introducing about EA (April 2015, Harvard University, see: Min, 
2015)).  In addition, I had two informal meeting with EA community members. 
 
The worm wars and EA are public discourses of measurement where NTDs are implicated.  The 
measurement discourses encompass a range of ways of counting that I already began to 
discuss through the 10/90 gap and DALYs but now look to explore their underlying meanings 
and interactions in the world.  Measurement that provides economic development arguments for 
intervention constitute a dominant discourse but I aim to challenge this with an alternative 
discourse of human rights, as the moral pursuit of social justice as a global concern.  These are 
discourses that have occurred across various public arenas and form a dialogue about the role 
of measurement in policy.  
 
As we will see, the worm wars and EA are examples of NTDs entering the public arena through 
a discussion about measurement.  The public discourses that I explore encompass a host of 
theoretical and practical activities within a certain moment in time and geographical location.  
The 'worm wars' is a discourse conducted by predominantly academics (anthropologists and 
epidemiologists) and measurement commentators (the Cochrane report and media figures).  
Debate and discussion centres on an empirical relationship being made between a public health 
intervention on parasitic worms and the economic development impact.  What followed was a 
debate about what measurement evidence counts as proof.  
 
EA is a discourse driven by philosophers and philanthropists, and the EA 'community of 
members and supporters, about the effectiveness of philanthropic giving to causes such as 
NTDs and how to rank problems as well as their effective interventions.  Both the discourses 
have been quasi-academic, in that they have had academic roots that then spilt over into the 
public arena, with timing from the early 2000s onwards and being largely located in the US and 
UK, where the main protagonists are based.   
 
Global health since the turn of the 20th century has been reflecting long-term changes in what 
counts as robust and justifiable knowledge as well as the convergence of numerous spheres in 
policy.  Vincanne Adams as editor of 'Metrics: What Counts in Global Health' (2016) has 
explored the impact of metrics, as the vehicles of measurement, in shaping and governing 
global health.  She describes the situation: 
 
“The links among economy, sovereignty, and the politics of knowledge that have shaped the 
use of metrics over the past decades in this field suggest that global health strives toward forms 																																																								
151 ISNTD, http://www.isntd.org/#/isntd-conferences/4565830915, Accessed 4/10/16  
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of knowledge that are distinguished from those found in an era of postwar, postcolonial 
international health” (ibid., p. 2)  
 
Measurement and the production of metrics is intended to be an apolitical, politically neutral or 
value-neutral form of evidence, as opposed to practices of self-interested colonial health.  
Adams argues, "...the metrics we rely on to avoid politics often do not avoid politics at all; they 
become a form of politics in their own right, augmenting the political stakes and political 
underpinnings of health projects" (ibid., p. 9).   
 
The political nature of numbers is therefore important to explore, more so because of the 
appearance of neutrality, leading to bias as being hidden.  We should ask, what do metrics do? 
as, "(M)etrics not only enable us to set aside questions of politics; they also turn moral 
questions.... into problems of numbers" (ibid., p. 25).  Speaking to Adams' identification of (1) 
economy, (2) sovereignty and (3) the politics of knowledge in shaping metrics, it is also on 
similar grounds through which measurement has been elevated in importance in public 
discourses.   
 
Firstly, counting health has been closely tied to an economic view of the world.  For Reubi et al, 
it is an underlying health economics perspective that puts greater reliance on evidence-based 
justification and intervention strategies (2015).  This perspective comes out in the metrics used 
in the two examples of RCTs for the worm wars and effectiveness for EA.   
 
Secondly, measurement increasingly is important on a global scale and not only directed toward 
sovereign states.  Measurement is connected with another word that has regained importance: 
'grand'.  As I explored briefly in Chapter 4, 'grand challenges' have gained popularity as a global 
outlook on problems.  Grand or the similar word great, convey something momentous, which 
affects and is important to us all, the whole of humanity.  Interviewing Gates about his work in 
public health Herper refers to a 'grand human problem' (2011).   
 
Thirdly, the metrics used for measurement reflect our ideals and values about knowledge and 
the way we think about problems.  Informed by what we know and what we would like to know, 
metrics are fulfilling this need, they are “...imagined to offer uniform and standardized 
conversations about how best to intervene, how best to conceptualize health and disease, and 
how best to count and be accountable, and how best to pay for it all” (Adams, 2016, p. 6).  
Metrics are part of a wider politics of knowledge, through the means of acquiring and applying 
knowledge, which in turn shapes problem understandings.  When looking at the two public 
discourses of measurement I will be concerned with the underlying ideals and values about 
knowledge. 
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7.1 Counting worms and their treatment 
 
The next section highlights the first public discourse of measurement: the worm wars.  I want to 
begin with some background for the interest in worms and measurement as part of a longer 
history of statistical counting of parasitic worms dating back to post-war America.  This history 
was marked by a 1947 paper in the Journal of Parasitology by Norman Stoll (see Stoll, 1947), a 
renowned parasitologist and epidemiologist based at the Rockefeller Institute.  Stoll played a 
key role in bringing attention to the problem of parasitic worms in humans.  Measurement was 
needed for advocacy of an undetermined problem in scale and importance.  Not being 
outwardly visible in signs or symptoms, measurement conceptualizes and provides some 
certainty about the problem.  Even if it is rhetorical in that purpose, the work of Stoll in 
highlighting the problem of worms showed that measurement matters. 
 
The presentation of his paper was through an address to the American Society of 
Parasitologists reacting to the parasitic worm-infected servicemen returning from the pacific 
battlefields of World War II (Klass, 2015).  Stoll called it “the great infection of mankind” and 
highlighted the need to conquer worms for the common good and raise human capabilities: 
“(F)or only in a society made up of parasite-free individuals will we know of what the human 
being is capable” (quoted by Klass, 2015).  To reach such a state, he posed the crucial question 
at that meeting: "Just how much human helminthiasis is there in the world?" (quoted by Keiser 
and Utzinger in Zhou et al., 2010, p. 198).  The question of measuring the occurrence of worms 
proved difficult, as there existed no central source to access the information needed.  However, 
Stoll was able to provide an estimate of the global numbers of infection with major 
helminthiases, Through an extensive review of the literature and consultation with other 
parasitologists (Utzinger, Bergquist, Olveda, & Zhou, 2010).  The review included the NTDs: 
soil-transmitted helminths (roundworm, hookworm, whipworm, and threadworm) along with 
lymphatic filariasis, schistosomiasis, and food-born trematodiasis (ibid.).  His estimates showed 
a roundworm global prevalence in 1940 of 29.8% (with 644.4 million people infected), while that 
number has now dropped to a 12.4–18.8% global prevalence for 2003–5 but with more people 
infected (807–1221 million) because of population growth (ibid., p. 199).   
 
Over half a century later Stoll's influence is still being felt.  In 2010, taking the title of his highly 
quoted 1947 article 'This wormy world’; an online project led by th London School of Hygiene 
and Tropical Medicine (LSHTM) and 'www.thiswormyworld.org' was launched, providing 
accurate and up-to-date maps of helminth distribution using data from thousands of field 
surveys.152  The concern with worm infections has since expanded from the occurrence of 
worms to the economic and development impact they are having.  The pursuit of this question 																																																								
152 ‘This wormy world’ produced the 'Global Atlas of Helminth Infections' (This Wormy World, 
http://www.thiswormyworld.org/, Accessed 2/4/14). 
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about impact has led to the so called 'worm wars', named because of the epistemological and 
cross-disciplinary debate it has inspired between academics, played out in scientific and popular 
news outlets.  The conflicting views have mainly been with a group of epidemiologists, who 
found they could not replicate the findings of the work of two development economists, in a 
scrutiny of methodology used, including basic statistical practices.  However it went on to 
become a wider discussion about the nature of evidence.  This discussion concerns what 
counts as robust evidence and how it is derived through the validity of the metric used, in this 
case 'cluster controlled' Randomized Control Trials (RCTs), which I will explain shortly.  I also 
argue how the ambition of measurement connection and explanation attempted is of contention.  
The World Bank has produced an anthology of the controversy, which consists of around 50 
links (Evans, 2015).   
 
It is one area where NTDs have entered a public discourse.  While beginning as an academic 
debate it was then picked up upon through various media outlets.  According to the World Bank 
the two high-profile articles that prompted a host of responses were: 'Scientists Are Hoarding 
Data And It’s Ruining Medical Research', BuzzFeed (Goldacre, 2015) and 'New research 
debunks merits of global deworming programmes', The Guardian (Boseley, 2015). 
 
Both UK-based, Ben Goldacre is a popular science author and Sarah Boseley the Health Editor 
for the newspaper The Guardian.  The ensuing debate happened on blogs (across a whole 
range of individuals and organisations) and on twitter (with the hashtag #wormwars).  However, 
instead of being referred to as NTDs, it is 'worms' that have reached some prominence in the 
public arena.  The reason is because the worm wars only refer to part of one NTD sub-group - 
helminths,153 and so a linkage has not been strongly made with NTDs. 
7.1.1 School deworming for development 
 
References to the beneficial effects of school deworming were argued early on in the NTD 
campaign.  The WHO Berlin report (2005) already presented the claim about school deworming 
that sparked the worm wars, stating:  "The package of neglected tropical diseases is a clear 
example of a rapid-impact intervention with a high pay-off at a very low cost. School deworming, 
for example, is highly cost-effective" (ibid., p. 8).  Here a connection is made with de-worming 
as an NTD intervention that can be measured in terms of impact, cost-effectiveness, and quick 
results.  The impact is upon better school attendance translating to economic results, as the 
WHO describes:  
 
																																																								
153 The types of NTD worms that are being referred to in the worm wars (outlined by Miguel and Kramer) 
are much the same as those that concerned Normon Stoll: soil-transmitted helminths (roundworm, 
hookworm whipworm) and schistosomiasis. 
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"From a microeconomic perspective, tackling neglected tropical diseases provides both health 
and economic benefits at low cost. There is ample evidence of significant gains in worker 
productivity as well as impressive effects on school attendance test scores. Externalities also 
apply to children attending schools without deworming activities, given the lower rate of infection 
in the community" (ibid. p. 9).   
 
Therefore, the WHO report relates the lowering of worm infection rates with economic 
development.  The adverse effect of worms begins early in life and carries through to working 
adults.  It is through 'ample evidence' that the argument is made for children suffering 
nutritionally, educationally, and productively. 
 
The year before, in 2004, an economics paper had been published entitled 'Worms: Identifying 
Impacts On Education And Health In The Presence Of Treatment Externalities' (Miguel & 
Kremer, 2004).  The paper pushed the evidence for school deworming into the limelight by 
presenting a correlation between mass deworming with increased school attendance and 
health.  There had been previous papers covering the topic but this paper emphasized the 
positive benefits of deworming through the externalities observed.  Externalities is an economic 
concept capturing the effect of a production or consumption decision that imposes costs or 
benefits on others (see OECD, 1993).  Although it is not completely clear through the paper 
what sort of externalities were at work: was it epidemiological where lower numbers of worms 
interrupted transmission cycles or was it behavioural in that more peers being able to attend 
school influenced others to attend?  Or was it both?  The prestige of the journal 
Econometrica 154  and the reputation of the development economists Michael Kremer and 
Edward Miguel at Harvard and Berkeley respectively, no doubt played a part in raising the 
profile of the paper.  They also presented novel measurement techniques.   
 
Kremer and Miguel conducted a 'cluster controlled trial' to measure the benefit of deworming 
treatment for school absenteeism, with a group of Kenyan schools that had received the 
treatment but also included neighbouring schools that had not.  A cluster-controlled trial is a 
randomized control trial (RCT), which is a scientific experiment to compare an intervention with 
a treated group and a non-treated control group, in school groups using a cluster sample, rather 
than sampling individuals.  The sampling took place through a randomized phasing of 75 
Kenyan primary schools for deworming treatment, to show an impact of possible externalities 
from the deworming treatment on neighbouring schools.  The results presented had been 
sought after in development economics because it appeared to further reaffirm that deworming 
had a positive effect on school attendance and also had positive externalities. The authors 																																																								
154 Econometrica is a well-regarded journal publishing articles in all branches of economics with an impact 
factor of 3.823 but with a leaning perhaps toward quantitative economics, as it is listed the number two 
journal in 'Mathematics, Interdisciplinary Applications' (out of 92) and in 'Social Sciences, Mathematical 
Methods' (out of 44) according to the ISI Journal Citation Reports® Ranking 2012 (The Econometric 
Society, http//:www.theconometricsociety.org, Accessed 2/4/14). 
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contended that previous studies had underestimated the impact of deworming because 
externalities had not been considered.   
 
Controversy began when a group of epidemiologists from the London School of Hygiene and 
Tropical Medicine (LSHTM) tried to replicate the findings.  Aiken, Davey, Hargreaves, and 
Hayes replicated the findings using the original dataset but found a lower and no longer 
statistically significant number of attendances by treated children (2015).  Specifically they found 
that the lines in the program to calculate which schools fell into the 'deworming nearby' category 
had erroneously excluded the majority of schools, meaning that once that key error was 
corrected, the benefit for neighbouring schools 'effectively disappeared' (Goldacre, 2015).  Even 
after re-applying analytical approaches originally used, and correcting for various errors, the 
epidemiologists found little evidence for the previously reported indirect effects of a deworming 
intervention.  Although the evidence varied by method, as shown with another article by some of 
the same LSHTM authors putting forward a more positive analysis: 
 
"The evidence supporting an improvement in school attendance differed by analysis method... 
We find that the study provides some evidence, but with high risk of bias, that a school-based 
drug-treatment and health-education intervention improved school attendance and no evidence 
of effect on examination performance" (Davey et al., 2015).   
 
What followed was a back and forth between commentators about whether the study claims 
were valid.  The worm wars were about evidence – what counts as evidence, how evidence can 
link a health issue to economic development, what sort of evidence is legitimate (such as 
conducting an RCT), and how that is defined.  In an 'author's response' to the controversy 
Hargreaves et al., stated that as HIV epidemiologists they wanted to learn about the evaluation 
methodology guiding economist-led randomized trials of the early 2000s on HIV-risk behaviours, 
as they found, "...appraising these studies challenging because of different approaches to study 
design, reporting and analysis" (2015, p. 1).  Miguel and Kremer in response viewed the 
reanalysis as still supporting their initial findings but with the correction of some errors of 
externality and school participation effects (Kremer & Miguel, 2015).   
 
The message here is not just that measurement is contestable but two key points in how 
measurement is used to provide evidence for understanding policy problems and their 
interventions: (1) a connection is sought between an intervention for a policy problem and 
economic development outcomes; (2) a hierarchy in methods exists for solutions to policy 
problems privileging the quantifiable, statistical measurement that appears objective, scientific, 
and comparable. 
 
Whether a connection between deworming and education (attendance and performance) is 
found is important in order to understand the justification for NTD intervention.  The claim that 
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an intervention – in this case health improvement – leads directly to economic outcomes is a 
tendency that is widely subscribed to, such as with R&D leading to economic growth (despite a 
clear link being unproven and yet we carry on investing).  There appears to be a concerted need 
to connect health with economic benefits and to have straightforwardness in the solution.  
Goldacre acknowledges: "The seductiveness of simple pills, as a solution to complex problems 
in the developing world, is perhaps overwhelming" (2015).  Paul Garner from the Liverpool 
School of Tropical Medicine (LSTM) goes one step further.  As the coordinating editor for the 
Cochrane Infectious Diseases Group, he classes the current promotion of deworming 'a 
panacea' in seeking a “...single solution to multiple problems in low- and middle-income 
countries, and that the belief that deworming will impact substantially on economic development 
seems delusional when you look at the results of reliable controlled trials” (Boseley, 2015).   
 
Perhaps the deeper consequences are in the type of evidence that is supported to make the 
connection between a simple pill and economic benefits.  Goldacre describes this situation as, 
"...an entire movement of people doing proper randomized trials — the most 'fair test' of whether 
an intervention works — throughout the entire community of development work" (2015).  The 
gold standard of RCTs from medicine had been passed onto some social science research but 
the RCT standard is a high bar to pass.  The original Cochrane review in 2000 that inspired 
Kremer and Miguel to react had stated:  
 
"...the evidence of benefit for mass treatment of children related to positive effects on growth 
and cognitive performance is not convincing. In the light of these data, we would be unwilling to 
recommend that countries or regions invest in programmes that routinely treat children with 
anthelmintic drugs to improve their growth or cognitive performance" (Dickson et al., 2000, p. 
1700).  
 
It appears the Cochrane report excluded papers if they were not 'pure' RCTs and historical 
papers that did not incorporate RCTs (Kremer & Miguel, 2015, p. 2).  The measurement is 
placed on a hierarchy of evidence as judged by an 'Evidence-based Medicine' (EBM) approach 
to judge the current 'best evidence' in making decisions in healthcare (Sackett, 1997, p. 3).155  
RCTs are rated to be the highest quality of evidence for unfiltered information, ahead of cohort 
studies and case-controlled studies (for the filtered information, systematic reviews, which 
Cochrane studies carry out are top).  See Figure 12.   
																																																								
155 See Chapter 3 for a wider discussion on 'Evidence-based policymaking’ (EBPM). 
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Figure 12 EBM pyramid  
(Health Sciences Library University of Pittsburgh, 1996) 
Not meeting the rigorous requirements of RCTs in the past meant a recommendation against 
investment in routine schoolchildren deworming because of the lack of evidence for benefit.  
Such a reaction demonstrates how reliable and robust evidence is important for justifying policy 
decisions and actions.  However, the deworming debate and its contentions has not transferred 
so straightforwardly to the NTD community.  Economic development or socio-economic 
arguments for NTD interventions are common, particularly for the worm NTDs.  For example, a 
chapter in the Berlin Report (WHO, 2005) was entitled 'Tropical diseases: impact on people, 
societies, and economies'.156  
 
A more recent trend has been to connect worm prevalence directly with human and economic 
development.  Hotez and Jennifer Herricks at the Baylor College of Medicine have produced a 
'Worm Index' comparing disease burden data from the WHO (indices range from 0-1, with 1 
being the highest) with United Nations Development Programme (UNDP) Human Development 
Index (HDI).157  The index appears to show a connection between low HDI and high worm 
levels. 
																																																								
156 The author David Canning from the Harvard School of Public Health wrote a paper the year after the 
Berlin report.  He made the argument that interventions against NTDs should be thought of as 
"investments in human capital and form an integral part of global poverty reduction" (Canning, 2006, p. 
503).   
157 The HDI measures a country’s achievement in education, standard of living and years of life lived in 
good health (Sabin Institute http://www.sabin.org/updates/blog/%25E2%2580%259Cworm-
index%25E2%2580%259D-reveals-association-between-ntds-and-human-development, 2015, Accessed 
2/4/14).  McGollovray emphasises it is intended to be a comparative measure, as an assessment of 
"...intercountry development levels on the basis of three so-called deprivation indicators: life expectancy, 
adult literacy and the logarithm of purchasing power adjusted per capita GDP" (1991).   
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Figure 13 Worm index showing worm prevalence against HDI by country158  
 
 
Figure 14 Worm Index showing worm prevalence on map159  
The well-used adage may state 'correlation does not imply causation'.  However, it is more 
important to consider what the debate about measuring worms means for NTDs as a policy 
problem.  The worm wars did not seem to enter NTD discussions and may be viewed by some 
as an unwelcome and detracting controversy on some fronts.  Again it has been anthropologists 
Allen and Parker (2016) who have formed an interest, as school deworming is a main vehicle for 
mass drug administration (MDA).  Their weighing into the worm wars has been to further 
emphasize how the evidence for MDA of NTDs is lacking, as I have touched upon in previous 
chapters. 160  
 
																																																								
158 Sabin Institute http://www.sabin.org/updates/blog/%25E2%2580%259Cworm-
index%25E2%2580%259D-reveals-association-between-ntds-and-human-development, 2015, Accessed 
2/4/15  
159 Sabin Institute http://www.sabin.org/updates/blog/%25E2%2580%259Cworm-
index%25E2%2580%259D-reveals-association-between-ntds-and-human-development, 2015, Accessed 
2/4/15  
160 Allen and Parker make an additional point that the use of the term 'deworming' is applied inconsistently 
to refer to different infections and treatment regimes.   
 216 
Some debate has also taken place on RCTs specifically and what other options there might be 
to school deworming interventions that have suited RCT measurement.  At the WHO Antonio 
Montresor has researched RCTs for MDA for parasitic worm NTDs.161  He believes that there is 
some delusion of the benefit of MDA and also RCTs in measuring the effects of the intervention.  
In an interview with Montresor, he recounted how post-war Italy had eradicated NTDs without 
the distribution of drugs but from quality of life improvements as a result of economic 
development and Japan showed a similar if not faster results: 
 
 “I think sanitation is a right of a person but is not the case for 99% of people, to replicate some 
technology that proved to be efficient in Europe – it’s not possible and development like after 
the war is not possible” (Interview with author, Montresor, 2013).   
 
For Montresor the prevalence of worms in poor areas means improving sanitation, not through 
the same technologies of developed countries, but through new, adapted solutions to a different 
environment.  Similarly Simon Croft at the LSHTM has worried about how the good news story 
of MDA does not encompass some of the drawbacks: 
 
“...Mass Drug Administration can lead to drug resistance… doesn’t separate out the fact that 
some worms the ascaris roundworms, 90% sensitive to most of these drugs but trichuris and 
other worms are only about 30% sensitive.162  You classify them altogether…” (Interview with 
author, Croft, 2014). 
 
The negative consequences are ill-considered and the policy treatment of grouping together as 
'worms' or 'NTDs' prevents a tailored approach to interventions. 
7.1.2 Summarizing the worm wars 
 
I argue that the worm wars have shown the importance placed on measurement by various 
actors including academics (economists and epidemiologists in this instance) but also following 
pressure from policymakers, NGOs and international organizations (for example in World Bank 
reporting) to present a policy problem through measurement.  However, differing disciplinary 
approaches have been a cause for debate and to me this debate raises more fundamental 
questions about the difficulty of measuring policy outcomes by making connections between 
intervention and effect.  How does the ability to measure affect which interventions are taken 
and what arguments are used to make the case for intervention?  Likewise what effects are 
sought and how does the intended effect influence the type of intervention and measurement 
sought? 																																																								
161 The worms that Montresor refers to are soil-transmitted helminths, schistosomiasis and lymphatic 
filariasis. 
162 Ascaris and trichuris are types of soil-transmitted helminths, 
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The worm wars have occurred in relative isolation to NTDs as a broad policy grouping.  
Reference has only come in the original presumption of a connection between deworming and 
improved school attendance in the argumentation as to why NTDs have an impact upon 
economic growth and development.  Other interactions with the measurement of worms have 
been in the seemingly straightforward counting of worm infections and seeking more direct 
correlations between worms and the HDI index.  Some pushback can be found in the use of 
RCTs to measure the success of deworming interventions and this became apparent when I 
interviewed the WHO scientist Montresor.  Interventions such as improved sanitation may be 
less easily measured through RCTs, and this may influence whether these types of 
interventions are pursued or not if the RCT is prized so highly as a metric.  
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7.2 Effective altruism 
 
Another discourse of measurement, concerning NTDs can be seen in the case of 'effective 
altruism' (EA) a philosophical approach and social movement about how best to give to charity.  
The EA argument is captured through two defining books by philosophers Peter Singer and 
William MacAskill: The Most Good You Can Do (Singer, 2015) – but with roots in his earlier 
publications including The Life You Can Save: Acting Now to End World Poverty (2009) and 
essay "Famine, Affluence and Morality" (1972) and Doing good Better (MacAskill, 2015). 
 
Singer and MacAskill argue for the need to apply measurement to philanthropic activity, and it is 
through measuring hoq we should donate that NTDs have become a cause worth caring about.  
EA provides an interesting intersection of a group of diseases labeled as neglected on one hand 
and a group of people who are saying we should care about them on the other.   
 
Singer is a moral philosopher and public intellectual.163   He first outlined EA through his book 
'The Most Good You Can Do: How Effective Altruism is Changing Ideas About Living Ethically' 
(2015).  He describes how best to live an ethical life by donating to the most effective causes.   
According to Singer, while the public has sought to find out how efficient a charity is, by looking 
at the amount of money that ends up with recipients, the effectiveness of interventions has not 
been given the same attention.  EA might sound like a strange juxtaposition between a moral 
position of 'altruism' and the measurement value of 'effectiveness'.  A question that arises is to 
whom this new way of giving appeals to?  There is a cachet, as Singer has professed, with 
Silicon Valley: "people who are quantitative types, good with data, they understand the point of 
making a difference, and they have the opportunity to do it" (Cook, 2015).   
 
Applying a similar treatment as the disruptive innovation of technology entrepreneurship,164 
Singer has deemed traditional charitable giving to be ineffective and overly bureaucratic, with 
even the very method of appealing to 'an imperative of the heart' being outdated.  Certainly a 
need for a new type of charitable giving signals a loss of trust and confidence in the old 
mechanisms, including public sector institutions.  To make altruism ‘effective’ is to individually 
make optimal choices guided by rationality and evidence that then have an impact on the 
inequalities and injustices in our world.   
 
																																																								
163 A controversial figure since the late 70s, Singer has made the case for animal rights by arguing against 
a moral distinction between animals and humans, and angered disability advocates by saying that severely 
disabled newborns should be euthanized.		 
164 Disruptive Innovation Theory was popularized by Clay Christensen as a "means of broadening and 
developing new markets and providing new functionality, which, in turn, may disrupt existing market 
linkages" (Yu & Hang, 2010) 
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The ideas of his book and also MacAkill's book are put into action through EA-affiliated 
organizations that I have observed, included below. 
Box 5 EA-affiliated organizations 165 
 
EA-affiliated organizations implicate NTDs through measurement by to be an 'effective' 
philanthropic intervention.  This section will discuss how EA is measuring NTDs in terms of 
effectiveness and furthermore what such a form of measuring means for prioritizing policy 
problems through lists.  
 
The Centre for Effective Altruism describes EA as a "growing social movement founded on the 
desire to make the world as good a place as it can be, the use of evidence and reason to find 
out how to do so, and the audacity to actually try".166  EA-affiliated organizations rank NTDs as 
an issue to be tackled, high up the scale of importance, in a concern for neglected causes.  One 
of the key figures in the movement, the philosopher William MacAskill, describes the factors to 
consider when evaluating a charity or a cause as being:  
 
 
Scale 
Neglect 
Tractability 
 
"how big is the issue in terms of suffering or loss of happiness" 
"how many resources have already been devoted to it" 
"how easy is the problem to solve" 
 
Table 23 Factors to evaluate a charity or cause (derived from Appleton, 2015) 
 
The issue of global public health and especially NTDs tick all these boxes.  Next, the way of 
taking action is prescribed by Singer and MacAskill to be through an existing charity that can 
best direct financial resources toward a quantifiable impact.  They propose firstly a new way of 
giving, by donating a large percentage (one third) of salaries.  Donating a large amount is 
permissible and encouraged within EA whether it be from individuals in seemingly non-altruistic 
careers in developed countries that are highly paid, such as banking, or from those with a very 
modestly paid job, as earnings will still be higher than that of most of the world population.   																																																								
165 www.givewell.org/about; www.centreforeffectivealtruism.org; https://80000hours.org; 
www.givingwhatwecan.org, Accessed 2/4/16. 
166 www.centreforeffectivealtruism.org, Accessed 2/4/16. 
• GiveWell Charity evaluator  
Created 2007 by two former investment analysts Holden Karnofsky and Elie Hassenfeld 
• The Life You Can Save Information and promotes activities to reduce poverty/inequality 
Created 2009 by Peter Singer, Professor of Bioethics, Princeton University 
• Centre for Effective Altruism Grows and maintains the EA movement 
• 80,000 hours Provides help with ethical and high-impact career decisions 
Both created 2011 by William MacAskill, Associate Professor of Philosophy, University of Oxford 
• Giving what we can Charity evaluator, 10% income pledge for most effective charities 
Created in 2009 by Toby Ord, Postdoctoral Fellow in Philosophy, University of Oxford 
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Secondly, the choice must be made to best direct funds toward a quantifiable impact through 
resources such as GiveWell.167  They rank charities according to set criteria – chiefly whether 
they are "proven, cost-effective programs serving the global poor" (ibid.).  The top charities are 
all against tropical disease:  
1. Against Malaria Foundation 
2. Schistosomiasis Control Initiative (SCI)  
3. Deworm the World Initiative 
(ibid.). 
 
The next question that arises is what types of people are providing the guidance to make these 
difficult choices?  What kind of rationale and ideology is behind the EA thinking, that gives it 
authority?  Singer relies upon a utilitarian conception of altruism, where the best possible 
outcome is pursued and so it follows that to make optimal decisions requires assistance from 
sources of knowledge and expertise.  
 
The message of EA is about the obligations of the affluent to people in extreme poverty, to 
make the world better rather than simply not doing harm, and that this can be done easily with 
minimum or no cost.  EA draws on utilitarian ideas of creating the greatest good for the greatest 
number – a maximizing of good (valuable and worthwhile) by reducing suffering and death.  
Singer is also consequentialist in that it does not matter about what the means are as long as 
overall welfare is maximized.  Similarities can be found with philosopher Thomas Pogge (2001) 
in the moral obligation to the poor, which claims that our everyday life violates human rights 
through the rights of the poor.  Also aligned is a commentary on the effectiveness of aid where 
individual giving counters what is seen to be wrong with aid provided by governments and 
international governance organizations (see Easterly, 2014).  Singer's point is that individual 
donors and not just government should be making judgment about what does not work, what 
does and what has an impact.168   
 
What impact is EA having on NTDs?  My contention is that EA uses what Jasanoff (2013) calls 
'technologies of rationality,' such as "behavioral economics, social psychology, risk analysis, 
and public policy," to make rational appeals on a codified basis in order to explain as well as 
justify actions and behaviours.  The guiding principle of technologies of rationality is that 
humans are characterized as irrational but respond to reason found in technical discourses of 
expert scientists or politicians.  The critical stance for this idea builds upon scholarship in STS, 
which has shown that the prestige and power of measurement (a topic explored in depth by 
Theodore Porter in his seminal 1995 book 'Trust in Numbers') and by others since, masks value 																																																								
167 www.givewell.org/about, Accessed 2/4/14. 
168 Singer builds on arguments by the development economist William Easterly (2014) and others 
critiquing aid but where he differs is in assigning individual responsibility. 
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judgments, belief systems, and subjectivity.  Similarly Lupton argues that there is a 'politics of 
measurement' in the perception of neutrality of numbers but the quantification, interpretation of 
phenomena and purpose for measurement is: "...implicated in social relationships, power 
dynamics and ways of seeing" (Lupton, 2013, p. 399).  Therefore, the growing EA movement 
capitalizes on the appeal of effectiveness as a technology of rationality: rationalizing the fuzzy 
idea of charitable giving within a knowable and trustworthy rubric.    
 
Inside the philanthropic sector, the measurement trend was present early on.  As Saunders-
Hastings identifies, 'scientific philanthropy' was a movement at the end of the nineteenth and 
start of the twentieth century (Boston Review Forum, 2015).  This idea was to replace the 
pursuit of what the philanthropist Andrew Carnegie disparagingly described as a 'gratifying 
feeling', with a supervisory approach to monitor unfortunate recipients of charity and assess the 
progress of the intervention (ibid.).  Here blame was squarely placed on the moral deviancy of 
the poor rather than the rich being to blame or held responsible.  A concern for the effectiveness 
of aid was borne out of the presumption that the poor would not make good use of help if it were 
not monitored.  Saunders-Hastings worries that EA, while not directing moral criticism to the 
poor, still adopts a paternalistic role in not conferring agency to the poor, instead preferring the 
route to procure goods, rather than offering beneficiary choice.  She gives the example of 
'goods' being "...insecticide-treated bed nets to prevent malaria and treatments for neglected 
tropical diseases" (e.g. through drugs) over cash payouts, where it is left to beneficiaries to 
decide what is the best course of action (ibid.).   
 
The scientific philanthropy approach today is mostly defunct, although provides intellectual 
underpinnings to EA in a paternalist preference for creating a community via the donating public 
rather than through beneficiaries.  More influential perhaps is the present era of 
'Philanthrocapitalism', also with roots in the philanthropy of businessmen such as Carnegie but 
now heralded for bringing business ideas to giving (e.g. the Gates Foundation and similar 
organizations).  McGoey describes how it "...is the idea that to do good socially, one must do 
well financially" (2012, p. 185).  Therefore, it is the measure of success that has changed from 
the moral outcomes of those helped to now a financial or financially measured outcome.  In the 
past it was morally determined in the perceived changes to the poor through a person's 
character and lifestyle.  Today it is reflected in both the ability to measure and the extent of 
measurable success, drawn from the business world.  EA thus seeks to extend scientific 
knowledge and techniques to philanthropy, with conservative underlying values in a focus on 
the individual using evidence-based hubris.169   
 
The emphasis on individual action rather than systemic change is one of the most common 
critiques leveled at EA.  It is problematic because it negates the need for democratic decision-
making from both the philanthropists and the recipients of EA.  As Economics Nobel Laureate 																																																								
169 Singer in his book uses many case examples of individuals who have adopted the EA way of life. 
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Angus Deaton critiques of EA, the subjects are the actual people helped but they remain 
passive (Boston Review Forum, 2015).  Their opinions and agency are missing from the EA 
narrative, and he also views the problem concerning the effectiveness of altruism itself has 
been misdiagnosed.  The problem of poverty and suffering is neither financial nor technical but 
political.  Furthermore what can be measured or not is a major determining factor of assessing 
effectiveness, arguably the financial and technical is more measurable than the political.   
 
If appeals to philanthropy are made on an individual basis it may also have an individualizing 
effect, further eroding trust in public institutions and political engagement, assigning roles of 
social institutions to individual and groups.  Effectiveness is a measurement value to be revered 
but I question the trust being placed.  This preoccupation can be seen as part of a wider trend in 
the values of modern life, to be determined by the measurability of interventions on a wide 
range of topics in quantifiable and commensurate terms.  Arguably EA is overly reliant on 
effectiveness expertise on subjective concepts such as neglect, where aspects of emotion and 
thought are ignored.  It is thus an uneven relationship between the public of the neglector and 
the public of the neglected.  
 
If we cast an eye to other effectiveness projects, similar to what we have seen with the worm 
wars, the problems of measurement being a dominant discourse becomes apparent in the 
shaping of priorities and moral judgment.  The measurement tools of effectiveness popular in 
the health policy world are RCTs and DALYs, discussed in this chapter.  What they do, points 
out sociologist Rachel Kahn Best (2012) is decontextualize illness and place diseases and 
treatments on a hierarchical scale.  These measures have the appearance of rationality but they 
conceal the complexity and underlying decisions made by the experts who determine the 
parameters of what to measure and what not to.  As Adams also describes health metrics, 
these are "statistical forms of reason" and the on-the-ground reality of metric quantification in 
global health 'metrics work' (ibid., pp. 1-9).   
 
For instance, policy officials have placed an increasing importance on disease categories and 
individual disease severity to ensure effective health spending in the United States Best (2012).  
This ranking is accompanied by moral judgment of blame for the patients, so that particular 
diseases (diabetes, lung cancer, and drug addiction) are stigmatized.  In the same vein, policies 
that do not fit into neat disease categories are easily neglected (e.g. environmental health risks, 
basic research, and equitable access).   
 
Diseases have long-held a moral dimension.  Moralizing can happen when there is a threat to 
social order that transcends body boundaries: "If the body is under threat from a dangerous 
'other', then so is society" (Nettleton, 2006, pp. 63–4).  Nettleton gives the example of HIV/AIDS: 
"Certainly during the 1980s the source of HIV always seemed to be elsewhere: either in different 
countries or in 'different', and often presumed to be 'deviant', social groups" (ibid.).  She re-
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quotes Susan Sontag that a dominant origin story of AIDS is that it came from the 'dark 
continent' and is "understood as a tropical disease: another manifestation from the so-called 
Third World" (ibid., 65).  There are parallels here for NTDs, as these diseases are not only 'the 
other' but the outlook is that they will remain so being mostly confined to poor countries and only 
offering threat through epidemics, international travel and climate change.   
 
7.2.1 Listing problems for humanity 
 
The relevance for NTDs, in measuring effectiveness of philanthropic interventions, is the 
identification of the problems where interventions have most effect.  I return to issue 
competition, as I began to explore with competition between diseases as in Chapter 4, but now 
discuss the listing and prioritization of policy problems more broadly.  I also look at connectivity 
between policy problems through development goals and consensus.  Here, I am interested in 
how and why EA identifies problems, which is different from priorities of the aid and 
development industry.  The identification and prioritization of which problems to care about is 
what drew me to EA in the first place, with NTDs being featured and a high proportion of interest 
through the charities that are suggested.170   
 
Giving What We Can list their criteria as: "Importance, Tractability and Neglectedness".171  As I 
began to discuss in Chapter 3, a problem denotes importance, urgency and solvability.  The 
Giving What We Can criteria is similar: Importance is the benefit of a successful intervention; 
tractability is weighting problems in terms of the progress that can be made to having results 
(thus related to solvability and how results can be measured) and neglectedness is the number 
of people already working on the problem.  This definition of neglect relies on a measurement of 
the degree of neglect by assessing resources already being directed through attention, people 
and funding.  EA is interested in systematically underexplored topics, which will have a high-
benefit-to cost ratio when attention is re-directed. 
 
Similarly 80,000 Hours, another EA-affiliated organization, have a list of the world's biggest 
problems, decided on again similar grounds of "Scale, Neglectedness, and Solvability" – see 
Figure 15.  Scale and solvability refers to how big a problem is, related again to importance and 
how easy it is to solve and neglectedness is again the attention it currently receives.  The figure 
shows their number one world problem as risks from artificial intelligence (AI), rated the highest 
because solvability is low and the neglectedness and scale is high.  Next is promoting EA, 
followed by global priorities research, all work that is closely aligned with the 80,000 Hours 
organization.  Health issues are included with both non-communicable diseases and NTDs 
represented.  Factory farming is there too, animals have been a main topic of concern for a sub-																																																								
170 The EA-affiliated organization 'Giving What We Can' has almost the same list of charities as GiveWell. 
171 Giving What We Can, www.givingwhatwecan.org, Accessed 2/4/14.    
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section of EA supporters.  Others are maybe markedly global in character – security (bio and 
nuclear), climate change, and land use reform.   
  
Problem Recommendation Scale Neglectedness Solvability Total Score  
Risks from artificial 
intelligence Recommended 14 11 2 27 
Promoting effective 
altruism Recommended 13 10 3 26 
Global priorities 
research Recommended 11 11 3 25 
Factory farming Sometimes recommended 11 8 4 23 
Biosecurity Sometimes recommended 12 6 4 22 
Nuclear security Sometimes recommended 14 5 3 22 
Climate change 
(extreme risks) 
Sometimes 
recommended 13 5 3 21 
Land use reform Sometimes recommended 10 9 2 21 
Smoking in the 
developing world 
Sometimes 
recommended 11 7 3 21 
Developing world 
health 
Sometimes 
recommended 13 2 5 20 
Figure 15 80,000 Hours list of the world's biggest problems  
(Adapted from https://80000hours.org, Accessed 2/4/14) 	
I compare this list next to another collection of global problems, in the form of goals – the 
Millennium Development Goals (MDGs) set in 2000 by all countries at the UN (Fig. 16 below).  
These are 'development' goals, they were not global goals or problems but we can still analyze 
where priorities differ in what is determined to be important and why.   
 
 
Figure 16 UN Millennium Development Goals  
(The Millennium Development Goals Report, 2015) 	
The 'goal' description already puts each issue area on a more equal footing than a 'list' and 
even how the goals are presented – not in list-form but in rows – suggest there is less of a 
hierarchy, or at least a degree of connection between issues.  There is no display of 'scores' in 
the MDGs and therefore less appeal to numbers as an authority.  The urgency of need and 
priority of the very worse off comes across, in comparison with the previous list.  The technology 
skew of the 80,000 hours list is also evident.  The risk from AI is still hypothetical, although the 
consequences could be tremendous.  Much of the fears come from the AI community itself and 
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the wider tech community figures like Elon Musk and Bill Gates.172  Some sections of EA have 
also been accused of too much emphasis on animal rights, reflecting chasms in EA priority-
setting with those who either favour a focus on technology orientation, poverty reduction, or 
animal rights.173  These splits are indicative of the publics that are being served; both from the 
side of the EAs and also in the publics intended to be helped.  Is the EA public of those who 
give or public intended to be helped by EA concentrated in developing countries or developed? 
 
The new set of MDGs, the Sustainable Development Goals (SDGs), announced in 2015 (Fig. 28 
below).  The economy, environment, social justice, and security now feature.  These are more 
global, not only focus on developing countries, and possibly more of a tech emphasis (in the 
innovation reference).  
 
 
Figure 17 UN Sustainable Development Goals  
(Sustainable Development Knowledge Platform, https://sustainabledevelopment.un.org/?menu=1300, 
Accessed 2/4/16) 
As I have stated earlier on in the thesis, NTDs crucially were not included in the MDGs, a point 
of contention that led to advocacy for them by activist scientists and NGOS that has led to 
subsequent inclusion in the SDGs.  It is not only through international governance institutions 
that neglect has begun to feature, the idea of neglected problems has made an entry into other 
organizations and initiatives concerned with setting development goals.   
 
An institute called the Copenhagen Consensus was, "...conceived to address a fundamental, 
but overlooked topic in international development: In a world with limited budgets and attention 
spans, we need to find effective ways to do the most good for the most people".174  The institute 
began as an independent body of the Danish government providing economic and 																																																								
172 Fear of AI is a phenomenon that psychologist Stephen Pinker believes is down to how: "...alpha male 
thinking pattern is at the root of our AI fears, and that it is misguided" (2016).   
173 The Effective Altruism Forum also lists 'meta-effective altruism' and 'the far future' as other main focus 
areas (Effective Altruism Forum, http://effective-
altruism.com/ea/4k/four_focus_areas_of_effective_altruism/, Accessed 20/10/16). 
174 Copenhagen Consensus, http://www.copenhagenconsensus.com, Accessed 2/4/14.  
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environmental cost-benefit analyses and evolved to provide a 'scorecard' to prioritize solutions 
to ten of the world’s most pressing issues.  The methodology used is statistical analysis and 
historical economics.175  The scorecard relies on an expert panel of economists to appraise the 
collated data (including Nobel prize winners) who evaluate and rank proposals on being most 
deserving of aid.  Cost is important for the panel to assess the size and pervasiveness of a 
problem.  The biggest global problems listed are:  
  
• Armed conflicts 
• Trade barriers 
• Malnutrition 
• Human health 
• Water and sanitation 
• Gender inequality 
• Education 
• Air pollution 
• Biodiversity 
• Climate change 
 
 
(Copenhagen Consensus, http://www.copenhagenconsensus.com, Accessed 2/4/14) 
 
All problems have since fallen in severity as illustrated in the picture below (It is diagrams such 
as these that Castañeda may refer to when saying "The aesthetics of data contributes 
significantly to its power" (2016).  'A Scorecard from 1900 to 2050' quantifies the damage 
caused by attaching a cost to global problems and is compared on a regional and global level to 
total human wealth (at the given time) so the problem is measured as a percentage of world 
GDP.  When it comes to human health the prognosis is: "Economic terms give the clearest 
summary. The cost of poor health at the outset of the 20th century was a phenomenal 32% of 
global GDP. Today, it is down to about 11%, and by 2050 will have halved again" (ibid.).  Here 
there is a clear reliance on economic expertize to judge and pointedly measure global problems.  
 
 																																																								
175 See Copenhagen Consensus, , http://www.copenhagenconsensus.com, Accessed 2/4/14.     
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Figure 18 Copenhagen Consensus biggest global problems  
(Copenhagen Consensus, http://www.copenhagenconsensus.com, Accessed 4/5/16) 
Economist Jeffrey Sachs is one critic of this methodology and argues that:  
"It failed to mobilize an expert group that could credibly identify and communicate a true 
consensus of expert knowledge on the range of issues under consideration. The panel included 
distinguished economists but no natural scientists or public-health specialists... A panel of 
economists brings an important set of tools to the table, but it cannot accurately assess the 
social costs and benefits of alternative interventions regarding climate, agriculture, disease, 
water and nutrition without the input of natural scientists, engineers and public-health 
practitioners" (2004).  
Even if the results were deemed by some to be skewed for many reasons it is still pertinent that 
through an economic form of measurement NTDs rank highly as a problem worth investing in – 
shown by deworming being ranked fourth in 2012 by the Copenhagen Consensus panel, rising 
from 6th place in 2008 (when it was also combined with nutritional programmes).  See box 
below: 
 
Box 6 Copenhagen Consensus investments to solve global problems 
(Copenhagen Consensus, http://www.copenhagenconsensus.com, Accessed 2/4/14) 
1. Bundled micronutrient interventions to fight hunger and improve education 
2. Expanding the Subsidy for Malaria Combination Treatment  
3. Expanded Childhood Immunization Coverage 
4. Deworming of Schoolchildren, to improve educational and health outcomes  
5. Expanding Tuberculosis Treatment  
6. R&D to Increase Yield Enhancements, to decrease hunger, fight biodiversity destruction, and 
lessen the effects of climate change 
7. Investing in Effective Early Warning Systems to protect populations against natural disaster 
8. Strengthening Surgical Capacity  
9. Hepatitis B Immunization  
10. Using Low‐Cost Drugs in the case of Acute Heart Attacks in poorer nations (these are already 
available in developed countries) 
11. Salt Reduction Campaign to reduce chronic disease 
12. Geo‐Engineering R&D into the feasibility of solar radiation management 
13. Conditional Cash Transfers for School Attendance  
14. Accelerated HIV Vaccine R&D  
15. Extended Field Trial of Information Campaigns on the Benefits From Schooling 
16. Borehole and Public Hand Pump Intervention 
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Neglect could be seen, then, as an additional concern that gets increasingly included in making 
sense of what is a problem.  Neglect in the way it is used by EA considers the people and 
resources dedicated to the problem.  Scholars who have been theorizing the nature of policy 
problems have not typically identified neglect as a characteristic as I have pointed out in 
Chapter 3.  For example Rochefort and Cobb have listed: severity, incidence, novelty, proximity, 
and crisis, which echo other concerns listed before but whether a problem is neglected does not 
factor (1993, p. 62). 
 
The concern with neglect fits within a general measurement discourse – a strategic prioritization 
and cost-efficiency rubric.  However, it is a certain conception of neglect that fits a measurement 
sensibility.  EA has concentrated on neglect in action through people and resources, as well as 
how well allocated these are.  The claim of EA supporters is that a well-discussed problem is 
most likely to attract attention (Todd, 2013; MacAskill, 2015).  Therefore, it does not make sense 
for an individual to also be involved in a problem that already receives attention because of 
diminishing utility176 of the best opportunities being taken first (ibid.).  
 
For other types of neglect, something might be known as a problem but lacks the emotional 
response of care and the thought capacity needed is not applied.  An example might be the 
emotional response to AIDS in its early manifestation as a policy problem.  According to some 
accounts, neglect was centred on emotion, through apathy that it was a self-inflicted disease, 
reflective of morally bad lifestyles and not deserving of problem-solving attention, with the onus 
on ill individuals being deemed ‘responsible’.  As Deborah Gould (2009) reflected, it was 
government neglect and inaction based in part on a lack of compassion, causing activists to 
then undertake 'emotions work' in the mobilizing of some feelings and suppression of others, to 
bring about a change in the government response to the AIDS crisis. 
 
Gould writes of the 'emotional turn' of the late 1990s in the study of social movements as "...a 
response to the excesses of the rationalist paradigms" as emotion had been previously ignored, 
relegated to the arena of protest, with protestors understood as emotional and political actors 
being rational, or all actors being rational (ibid. p. 16).  Rather than drawing dualistic oppositions 
Gould argues that neuroscientific research has influenced an understanding of emotion:  
 
"In short, rather than being a force that interferes with reason that should therefore be 
sequestered from the public, political realm, emotion here is viewed as crucial means by which 
human beings come to know and understand themselves and their contexts, their interests and 
commitments, their needs and their options in securing those needs" (ibid. p. 17).   
 
																																																								
176 Diminishing utility is the economic concept 'law of diminishing marginal returns or utility' where every 
additional input yields lower return than the one before (Funke, 2000). 
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Ignoring the importance of emotion is to reduce advocacy and activism to depoliticized 'acting 
out' (ibid.).177  Claims of reductionism and depoliticization have similarly been made against EA 
(Boston Review Forum, 2015).  While some have argued the political is ignored through EA, 
proponents of EA are keen for it to have the character of a social movement, despite being 
intellectually driven by philosophers. Their conception or social movement may be different to 
what to commonly defined in the literature as touched upon before as a pursuit of social change 
and more akin to activity that is grass-roots, self-reinforcing, and growing in the population.   
 
Regardless of whether EA is a social movement or not, the aspiration to be so is relevant in 
what it says about publics implicated.  In a neglect relationship between two parties (unless we 
are looking only at diseases where the responsibility is more placed with individuals, such as 
with obesity), there are two camps, the neglected and the neglectors.  The neglected lack 
agency to make a difference in their own lives, while the neglectors are given agency and 
character by EA.  They are individualized but they also need to be elevated by EA.  The 
neglectors in the case of EA, are those who have the will and the ability to do something about 
neglect, are constructed as high earners who can contribute in a straightforwardly quantifiable 
way.   
 
The ability of the neglectors to reason and make rational decisions is a quality preferred over 
emotion by EA.  Emotion is an appeal to 'an imperative of the heart', which Singer views to be 
outdated for philanthropy, where action based on information is needed instead.  It appeals to 
the cachet that Singer has talked about as coming from Silicon Valley and young, motivated, 
tech-minded people at elite universities.  Banking is another desirable industry because of the 
consequentialist focus on how much that can be donated rather than the way philanthropy 
happens.178  Therefore, EA legitimizes banking and tech entrepreneurship in relation with 
philanthropy their place in society.  Profitable and even morally dubious careers are permissible 
as long as a sum of money is donated to impactful causes within the EA framework.   
7.2.2 Reacting to measurement in global health  
 
The intention of the EA discussion in this chapter has not been to make a comprehensive 
critique of EA, as others have and continue to do (for an example see this selection of articles 
by the Boston Review Forum, 'The Logic of Effective Altruism', 2015, where academic and 
professionals discuss EA).  I have considered why proponents of EA view NTDs as relevant by 
exploring its underlying philosophy, including under what criteria EA policy problems are 
determined and who the intended audiences are.  I have discussed why neglect is an important 																																																								
177 Depoliticization is invoked in the suggestion that treating an object of analysis politically means to 
render it complex, as a part of larger structural reasons and power relations rather than only individually 
limited behaviour. 
178 The moral argument supporting industries such as banking goes against against criticisms typically 
levelled (e.g. responsibility for the global financial crisis, corruption, greed, sexism and inequality).   
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concern because it has measurement appeal, used to identify policy problems and judge 
whether a problem needs addressing.  
 
Measurement here is a value that is prized, and so the criteria to identify and prioritize problems 
is part persuasive device to convince those donating in philanthropy that their activity is 
worthwhile.  What measurement does for EA is to rationalize emotive decisions and address 
uncertainty about whether philanthropic giving is worthwhile.  By scientizing (Sarewitz, 2006) 
decision-making is to treat philanthrophy with a scientific approach, a trend that has already 
existed but now found a new form through measuring effectiveness of charitable choices.  This 
cause selection and prioritization is a driving force behind many new and already dominant 
organizations not only in the arena of public health but anywhere that is engaged with problems 
and challenges facing the world.  For listing global problems, to rank problems relative to others 
they are transformed to be important and tractable by measurement, certifying importance and 
providing information upon which to advocate and take action.      
 
What the act of measurement does is bring an issue into being, labeling something we want to 
know about and track.  As Alain Desrosières (2002) outlined in 'The Politics of Large Numbers', 
statistical techniques transform social facts into things, shifting the representation of an object of 
study in the process.  The measurement metrics of the 10/90 gap, DALYs and 50 cents per 
person all shaped how NTDs are represented and assisted in characterizing neglect.  
Measurement also has a performative function to the objects of measurement in constituting a 
problem and issue as 'neglected'.  The label attached is type of linguistic performativity is 
Austinian in the use of language and speech to pronounce something into being, as a minister 
does in proclaiming a couple husband and wife, and in a ship being named with a bottle broken 
on the hull (Morris, 2016).   
 
In summary, I have argued that neglect is appearing as an issue of concern in the listing of 
global problems when measurement of the proved effectiveness of an intervention determines 
whether a problem worth caring about.  Neglect provides criteria on which to measure and 
provide evidence that an issue should be prioritized against others, when there is competition 
for care, and NTDs are implicated under the neglect label.  NTDs featured in public 
measurement discourses such as the worm wars and EA because of policy packaging of NTDs 
by activist scientists and NGOs that purport them to be both a symptom of underdevelopment 
and a precursor to economic development.   
 
This packaging lends itself to measuring progress in development, either through a connection 
with health intervention as with the worm wars or in determining what is an effective 
philanthropic intervention with EA in addressing poverty.  The policy packaging of NTDs 
therefore relies on an argument of economic development.  Instead of a concern for proving 
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impact or effectiveness, there are other concerns that could be prioritized but not as easily 
measured, such as social justice.   
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7.3 Other policy packagings: A human rights approach 
 
In the public health field, Powers and Fadden argue that concerns about justice are, 
"...commonly understood as external to the moral purpose of public health" (2006, pp. 9-10).  
Views that justice is an external concern and that health is 'a form of justice' is part of separate-
spheres view of justice (ibid.).  The consequences of separating justice from health ignores, 
"...other public policies and social environments are structured or to how people are faring with 
regard to the rest of their lives" (ibid., p. 9-10).  Therefore the economic development packaging 
may be a too narrow focus for the complex policy problem that is NTDs. 
 
A human rights approach was a policy packaging used early on in the NTD campaign.  In the 
WHO Berlin report a chapter was dedicated to 'Neglected diseases and the right to health' 
(WHO, 2005, p. 11).  From the first WHO meeting on NTDs in 2003 the case was made for 
three perspectives to tackle NTDs: "economic, public goods, and human rights" (ibid., p. iii).  
NTDs were presented by the various stakeholders around the table (from the WHO, donor 
governments to NGOs and scientists) as not gaining international attention because of the 
preoccupation of individual rather than collective health security.  The argument was made that 
focus was limited to HIV/AIDS, malaria, and tuberculosis, and more generally the global health 
security of infectious diseases that easily cross borders (ibid.).   
 
A human rights angle has since appeared to drop off the agenda, proving not to be the most 
effective packaging for NTDs, although some remnants have carried through.  Lorenzo Savioli, 
Director of WHO Department of Control of Neglected Tropical Diseases until 2014, stated in 'A 
Letter from the Director': "Our actions are aimed to promote the common good of every 
individual and are based on a human rights approach, which requires that interventions and 
processes are guided by human rights principles of participation, non-discrimination and 
accountability".179  This view of human rights is somewhat narrow, as the principles appear to 
pertain more to the WHO as an institution upholding human rights in the face of competing 
interest claims among UN members.  As Leslie London sets out, a human rights approach 
consists of three components, two of these are described by Savioli as accountability, 
participation (agency) and the third is related to non-discrimination but is more specifically, 
"...the indivisibility of civil and political rights, and socio-economic rights" (London, 2008, p. 65).  
The final point is more akin to 'health as a right' where rights are transferred directly to health.  
 
Citizens are beginning to expect their government to ensure the 'right to health'.  In Brazil this 
right is enshrined in the constitution and integrated health systems.  As described by the WHO 
constitution: "...the enjoyment of the highest attainable standard of health is one of the 
fundamental rights of every human being" (WHO, 2007, p. 7).  Specifically the 'Office Of The 																																																								
179 WHO, http://www.who.int/neglected_diseases/director/en/, 2011a, Accessed 2/4/14.   
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High Commissioner For Human Rights' (OHCHR) calls NTDs, "a right-to-health issue with many 
faces" with clear links to human rights in the discrimination of poor and marginalized 
populations, where essential drugs are unavailable or inadequate, and health interventions and 
R&D are underfunded (2008, p. 8). 
 
Does it matter that human rights do not form a main packaging anymore?  What could the idea 
of human rights bring to the understanding and dealing with NTDs as a policy problem?  By 
packaging NTDs as a human rights issue, certain aspects of these diseases and the avenues 
explored for intervention would be emphasized.  The right to health brings up the question of 
what type of health intervention constitutes social justice, whether access to health is sufficient, 
or a more directed and purposeful provision is required.  As Davies puts it: "At the heart of the 
debate about health and human rights is a tension between access and provision that mirrors 
the philosophical distinction between negative and positive rights" (2010, p. 64).  Provision 
tends also to be important in the right to health, ahead of simply only granting access. 
 
I contend that two arguments persist in how the right to health can be taken forward as an 
approach.  First, taking a global rights approach, as Oprea et al. (2009) have noted, 
international cooperation on NTDs is delayed because of the promotion of national interests, 
"...rather than social justice at a global level" (ibid., p. 310).  Emergency and the threat of 
epidemic has long been the concentration of efforts within international relations (IR), based on 
an individual rather than collective view of human security.  Recent epidemics have had 
similarities with NTDs as a public health issue, in that they have originated in poverty-struck 
regions or involved a shared vector (an agent carrying an infectious pathogen, such as 
mosquitos) – seen with Ebola and Zika.  However, these diseases have epidemic potential while 
NTDs tend not to.  A consequence is an increase in attention to diseases of poverty or towards 
the shared vector but with the risk of also potentially drawing resources away.180  Value could 
be had then in promoting NTDs as an issue in IR, security and cooperation settings or linking 
the two in policy, media and NGO communication.  Activist scientist Peter Hotez has done some 
promotion and linking as his role as US Science Envoy181 and in his varied media publications.   
 
Second, taking an individual rights approach, interest groups can be effective forms of patient 
activism.  As I demonstrated in Chapter 6, national visions and priorities can mean that a 
globalized NTD policy faces challenge.  However, patient activism at the national level has not 
been a forthcoming for NTDs as I have noted previously, because of the nature of the afflicted 
group being 'voiceless' and 'powerless'.  Two limited examples of patient interest group action 																																																								
180 A rights approach may be a way of directing attention to NTDs on the grounds of equality and justice to 
endemic country governments, countering the arguments of emergency and security threat of individual 
government interests in the international system. 
181 US Science Envoys are eminent scientists who "...develop partnerships, improve collaboration, and 
forge mutually beneficial relationships between other nations and the United States to stimulate increased 
scientific cooperation and foster economic prosperity" (US Department of State, 
http://www.state.gov/r/pa/prs/ps/2014/12/234682.htm, Accessed 4/5/15). 
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are given by Detels and Gulliford (2015, p. 282).  In 1980s Peru patients associations formed to 
successfully contest the government's lack of provision of drugs and financial compensation for 
leishmaniasis (also see Guthmann et al., 1997).  In Uganda, 'Village Health Teams' have 
provided delivery mechanisms for NTD community interventions, with also community 
mobilization to deliver health education measures for the NTD onchocerciasis (Amazigo, et al., 
2012).  These sorts of activities cannot be directed from above but the promotion of values of 
participation and inclusiveness are pertinent. 
 
The two avenues presented are ways in which a human rights approach could be taken forward 
though global rights in IR and patient activism.  It is uncertain how receptive the global health 
community would be, as Adams has described, the human rights approach is seen as a “…bold 
(and some would say naïve) mission " (2016, p. 5).  A perspective of human rights highlights 
interests and ideals that might be sidelined otherwise, and it demonstrates a different means of 
measuring success that could be pursued.  This is a means that is more concerned with how 
health actors take ownership of NTDs as a shared problem and the ways that those affected by 
NTDs make their voices heard by addressing discrimination and inequity.  The outcomes would 
be focused on political and structural change to types of healthcare delivery at the community 
level.  
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7.4 Conclusion: Measuring is caring? 
 
As this chapter has demonstrated, measurement constructs a particular type of problem to be 
solved.  Certain methods and means are taken, and underlying values and ideas privileged, by 
displacing humanitarian goals for economic development measurement.  A self-reinforcing cycle 
moves from measurement supporting NTDs, to NTDs supporting measurement as a rhetorical 
tool.  This chapter has explored two public discourses through the 'worm wars' and EA 'effective 
altruism', and presented an alternative policy packaging of human rights.  Both discourses have 
shown how important measurement has become in defining and advocating for global health 
problems.  The pervasive use of quantitative metrics in global health is having an effect, 
especially in how metrics are deployed by developed countries to represent developing 
countries through setting agendas and priorities.   
 
Canning (2006, p. 499) believes that deciding priorities in global health is not merely the 
question of how best to spend limited resources but with "how to generate increased support for 
health in the poorest countries of the world from more developed".  Thus rather than assuming a 
transfer of funding, resource and knowledge from developed to developing countries, a 
consideration is also needed for what the moral imperative is to do so.  I have shown that moral 
imperative is guided by measurement, whether that is measuring impact of health interventions 
for economic development (with the worm wars) or the effectiveness of philanthropy to do good 
(EA).  In essence, the discussion is not only what should we care about, but why should we 
care.  The morality argument to care is the proposition of why should some people in one place 
and position care about other people in another place and position?  This is assuming from the 
outset that one set are privileged that need to care about others that are not.   
 
Caring about disparities of situation or inequality has had a particular relationship within the 
health realm.  Deaton describes how: "(M)any people who are prepared to accept inequality in 
the allocation of goods as a (possibly) necessary evil are not prepared to accept similar 
inequalities in health outcomes" (1999, p. 6).  Caring about global problems is a different 
proposition when it comes to health but the worm wars show that health alone is not a justifiable 
policy end, it will need to be translated into economic outcomes. 
 
A somewhat paradoxical relationship then exists between health, problem setting, and problem 
solving.  Health can be viewed as an end in itself, however multiple competing problems in the 
global health realm means that making arguments about economic impact strengthens the 
intervention case.  Health inequalities make uncomfortable decision-making that is compounded 
by a hierarchical scale needed to decide between health issues.  Powers and Fadden thus ask 
the question: "Which inequalities matter most"? (2006, p. 9).  This question is still concerning 
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why should we care but caring about one inequality over another, where proof of an economic 
reasoning magnifies the importance of inequality.   
 
There is often a utilitarian basis to this sort of question in public health about prioritization based 
on having "utilitarian commitments to bring about as much health as possible" (2006, p. 9).  EA 
responds in formalizing how developed countries should help developing countries, what is the 
moral argument for doing so, and how inequalities should be addressed in terms of priority.  
With both the worms wars and EA, I have shown how a reliance on metrics helps to make 
difficult decisions, which have a moral, subjective and value-led core.   
 
Here is where the circle reconnects – in Chapter 5 I argued that measurement is used to 
characterize NTDs as a policy problem.  Two metrics measure the source of neglect: the ‘10/90 
gap’ and ‘DALYs’, and the '50 cents per person' to measure the cost-effective solution.  Why 
were these metrics needed and why does measurement extend to how we locate the problem of 
NTDs amongst other problems?  Measurement metrics are needed because when there is care 
for a problem, we are driven by a moral imperative but also want to measure it to assess how 
much we should care and track progress.  Caring happens on the basis of the relationship 
between developed countries towards developing countries – it is caring about the disparity 
between health opportunities and outcomes (but still requires judgment of other possible cares 
and assessing of progress).   
 
Adams, who has written extensively about the role of metrics in global health, begins to suggest 
metrics as being a form of caring.  If metrics are telling stories, they encapsulate certain cares 
and "what those who rely on them care about most... These cares are coded into the naming of 
some variables as important and the exclusion of others" (Adams, 2016, p. 9).  I want to take 
the idea of measurement as caring further.  Cares, to care, and caring should be distinguished, 
as they do not mean the same thing.  The capacity of measurement to reflect cares may be 
somewhat obvious.  To care is a more emotive state; it encompasses the feeling and moral 
imperative, while 'cares' can merely be inherent in measurement decision, and may be 
subconscious or an automatic activity.  I contend that caring therefore, is to bring together 
emotion and action to have an effect.  It is also an activity that is closely related to health and 
wellbeing.   
 
Measurement being a form of caring and as this chapter has demonstrated, becomes crucial in 
solving neglected problems.  Annemarie Mol observed that care is, "...something that contrasts 
with neglect" (2008, p. xi).  She noted that a simplified western view of good care, "...helps to 
hide neglect – a word that risks disappearing from our vocabulary" but that good care can also 
exist alongside neglect and errors (ibid., p. 6).  I have found with NTDs the care and cure 
distinction may matter more in a developing country context.  
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Mol finds interesting the distinction between care and choice as two ways of dealing with 
disease, albeit it is squarely a consideration of what she calls 'clichés of the West' and so may 
be less relevant for developing countries.  However, the point she makes about responsibility is 
pertinent.  In developed countries there is more capacity for choice, which in turn transforms 
treatment into a private concern (the downside is that the mobilizing of the logic of choice can 
lead to poor care).  If an action is deemed a choice, the responsibility and ownership has to be 
transferred, from public to private or doctor to patient.   
 
For care to be assumed by developed countries for the health of those in developing countries, 
responsibility is also implicated.  As shown by the measurement discourses I have analyzed, 
the choice of the 'recipients' or the 'neglected' has not factored.  Responsibility and ownership 
sits with the 'donors' or the 'neglectors'.  Cares, to care, and caring becomes paternalistic, as 
well as the measurement in the service of care.  Looking at human rights as another policy 
packaging, places more agency and priority on the individual and potentially a scope for an 
autonomous path by endemic countries.  The consequences of a change in policy packaging 
will be discussed in the final chapter. 
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Chapter 8. Conclusion: Using evidence and advocacy to 
showcase neglect 
8.1 Summary of NTDs as a policy problem 
 
The preceding chapters have focused on how NTDs have developed as a policy problem and 
the use of evidence and advocacy in the understanding of and response to neglect.  I argue that 
the characterization of advocacy and evidence, shown by this case of NTDs, is markedly 
different in conditions of neglect.  The type of advocacy that responds to neglect is forged out of 
circumstances that differ from more typical social or health movements.  If an issue is neglected 
it is unlikely to have a constituency ready to advocate for it.  Furthermore, advocacy here has 
different objectives with a need to change how that issue is perceived and constructed into a 
policy problem.  Tropical diseases are repackaged using what already existed in a new form 
and commodified as part of a global health brand competing for resource and attention.  These 
circumstances for advocacy are why a policy movement arose in response to NTDs and why it 
was activist scientists that led it.     
 
The type of measurement evidence that provides policy rationale for and in response to neglect 
also differs.  Evidence forms a type of advocacy in itself, as neglect has become a value of 
concern in global health, and this is separate from an instrumental use in advocacy arguments.  
The dominant discourses that help to produce certain types of evidence play a role of providing 
metrics that can direct measurement resources to the disposal of those advocating for NTDs.   
 
DALYs were not developed as an advocacy tool for NTDs but it became evident that an idea of 
neglect drove the reasoning for why that metric was developed.  Similarly, NTDs were only a 
small part of the diseases that made up the preventable conditions outlined by the 10/90 gap 
that were not receiving a proportional share of R&D investment.  However, a connection 
between NTDs and the concept of neglect proved a suitable match.  Lastly, the '50 cents per 
person' measurement of MDA for NTDs was not specifically developed to produce policy appeal 
for MDA, but the wording and phrasing later created policy appeal.  The measure was part of an 
emphasis on measuring cost effectiveness.  Neglect is shown to be even more unacceptable if 
easy, cheap and known solutions are available – it is harder to plead ignorance if measurement 
both spotlights neglect and shows us how to address it.   
 
Understanding the meaning behind the use of evidence and advocacy in policy therefore, has 
also required specific attention to the assumptions, practices and implications of 'neglect' in 
NTD policy.  The last chapter was pre-occupied with contemporary public discourses where I 
have viewed NTDs as a neglected subject matter entering public debate and arenas.  The 
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previous chapters closely analyzed how the NTD concept arose.  In Chapter 1, I began setting 
the background for how NTDs have become a label for a group of diseases, previously called 
tropical diseases.  This included how 'the big three' HIV/AIDS, TB, and malaria have dominated 
in global health. I identified the two defining trends in raising the prominence of NTDs as 
advocacy and evidence, explored throughout this thesis. 
 
Chapter 2 presented the methods and methodology as to how to draw out the relationship 
between NTDs and policy, with three central research aims,  (1) to connect the understanding of 
NTDs with tropical diseases and colonial origins; (2) to explore the policy development of NTDs 
in the constitution of problem-solution in how these diseases have been moved up policy 
agendas through advocacy and evidence; (3) provide examples in which to view the enactment 
of global policies addressing neglect.  I noted how a study about neglect builds on recent 
sociological research into ignorance and absences, but how neglect is differently characterized 
through the addition of implicit blame and responsibility, between a neglector and the neglected.  
I also introduced new terms into the discussion: activist scientists, policy movement, and policy 
packaging.  
 
Chapter 3 presented the theory I drew upon for my research on how policy problems can be 
approached, to make sense of the 'who, what, why, and where' that leads to a topic being 
considered as a problem for policy.  I explored how policy can be understood as discourse, the 
importance of narrative in describing policy problems, and the use of innovation in 
conceptualizing solutions.  I also argued that the disciplinary lens matters in describing policy 
problems and how understanding of neglect also differs.  I was concerned with a dominant 
economic disciplinary discourse shown through measurement.   
 
For Chapter 4 I provided a view of the conceptualization for NTDs with an exploration of two 
early initiatives: the 'Special Programme for Research and Training in Tropical Diseases' (TDR) 
and the 'Great Neglected Diseases of Mankind' (GND).  I identified the key events from the 
'Berlin meeting' to the 'London Declaration' to put forward a timeline for the policy development 
of NTDs.  I have argued that central to these developments were the listing of diseases, politics 
of characterization, global campaigns, and political connections forged, which have led to 
commitments from the Gates Foundation and donations from big pharma.  
 
In Chapter 5 I returned to categorization and took a brief historical look into how NTDs 
transitioned from tropical diseases, through the colonial history legacy and current geography in 
determining 'What is tropical?'.  In determining 'What is neglected?', the answer is shown to be 
largely described through ideas of poverty and underdevelopment.  I interrogated these 
categories of tropical and neglected, arguing why a dominant drug-based strategy for 
intervention has been reached and what this means for understandings of 'neglect'.  Neglect 
imagined through a globalized policy for NTDs, based on an ultimate goal of eradication, differs 
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on a national and local level.  The globalized imaginary arises from a position of 'otherness' and 
does not consider endemic country needs as it should, and neglect understood in mainly 
universal terms becomes problematic. 
 
Chapter 6 presented the repackaging of NTDs as a disease brand and the role of activist 
scientists in creating this re-characterization of what was once tropical diseases.  I explored the 
conceptual beginnings for NTDs: by revisiting the GND, profiling activist scientists in the US and 
UK, and questioning whether Brazilian and Chinese scientists are activists 'by another name'.  I 
have built on the policy frame literature by introducing the idea of policy packaging, to provide 
the policy appeal, rather than a reframing of the contextual discourse.  I showed how a 
neglected characterization was created through the advocacy of activist scientists and the use 
of evidence metrics.  These were: DALYs (measuring disease burdens), the '10/90 gap' 
(measuring R&D investment in relation to disease burden), and the '50 cents per person' (cost 
effectiveness of MDA measure).  
 
Chapter 7 was dedicated to public discourses of measurement.  I analyzed two discourses, the 
'worm wars' and 'effective altruism', to then present an alternative policy packaging taking a 
human rights approach.  Finally, I questioned whether measurement can be seen as a form of 
caring, which I will explore further in this chapter.   
 
In this final chapter, I am compelled to return again to tropical diseases.  The need for 
'otherness' to play a role has been persistent in the tropical medicine project from an early 
stage.  Edmond describes how, "(A)s Europe slowly freed itself from an epidemiological past of 
cholera, malaria, leprosy and plague, these and other diseases were banished to the tropics 
where they became a primary signifier of native otherness" (Edmond, 2006, p. 117–8).  While 
Iris Marion Young (2011) warns against a binary distinction between dominating and dominated 
groups, but she views domination is a structural phenomenon.  Otherness results from fluid and 
complex relations, that may be unconscious and even arbitrary but is a situation of privilege 
produced from an unequal relationship.  The unstable footing of domination to be 'fluid' and 
'even arbitrary' must be acknowledged.  In other social spheres that neglect is seen in, who is 
doing the dominating may be more or less obvious, in the neglect of one responsible party over 
the other.  Examples may be neglect of children by their parents or guardians’, elder neglect of 
the elderly by their carers or family, animal neglect of pets, farming or working animals by their 
owners, and environmental neglect of buildings or nature. 
 
To understand how domination and otherness both causes and results in neglect, it is worth 
recalling the object of enquiry this thesis set out upon.  The WHO outlines 17 'neglected' tropical 
diseases (NTDs) as being in need of attention and deeply affecting health in poor communities.  
Progress is being made: two diseases are targets for eradication (guinea worm and yaws) and 
eight more are marked for regional and global elimination (trachoma, Chagas disease, African 
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sleeping sickness, leishmaniases, lymphatic filariasis, river blindness, rabies, schistosomiasis) 
(see WHO, 2015).  As I noted previously, elimination relates to a defined geographic area where 
disease transmission is interrupted, while eradication requires global cooperation to rid 
humankind of a disease completely (Hopkins, 2011, p. 19).  Elimination and eradication thus 
become closely tied conceptually with neglect, and the very idea is ideological.  The solution for 
neglect of diseases, from this perspective, is to eradicate them as a medical problem and not to 
focus on social, political, and economic circumstances that may be underlying causes.   
 
Stepan argues that eradication has been closely tied historically to an imperial view of tropical 
medicine (2013, p. 7).  Now it carries weight with the technology solutionism of Big Pharma and 
the technocratic Bill and Melinda Gates Foundation.  While NTDs are at various stages on the 
path to eradication, the end point appears close but not yet met.  If this pursuit is ideological, 
from a position of domination, we must ask what might be lost in the process.  An example is 
whether control and surveillance, as well as short-term measures more generally, are de-
prioritized in favour of a long-term goal of eradication?  As I demonstrated in Chapters 4 and 5, 
reviewing the dominant strategies to deal with NTDs suggests that it is not the case long-term 
goals are prioritized.  The availability of cheap drugs to control NTDs – on a short-term basis – 
are central.   
 
However, there are other non-medical factors that also contribute to the persistence of NTDs. 
The social, political, and economic factors that create and perpetuate disease, sometimes 
summarized as the 'social determinants of health' (SDH).  The WHO describes SDH as: 
 
"...Conditions in which people are born, grow, live, work and age, which are key determinants of 
health equity. These conditions of daily life are, in turn, influenced by structural drivers: 
economic arrangements, distribution of power, gender equity, policy frameworks and the values 
of society" (WHO, 2014, p. xvii).   
 
SDH has reached mainstream public health policy as a way to address inequities in health, as 
evidenced by WHO reporting, task groups and commitments, and other regional activities such 
as the 'European policy framework for health and well-being, Health 2020' (ibid.).  However, 
neglect in a policy sense should be understood differently to 'determinants of health'.  This 
thesis has shown the importance of a policy packaging advanced through advocacy and 
evidence.   
 
There is also a difference for global health policy problems.  In solving these problems there is a 
potential to rid the world of some health issues.  While some global problems may appear 
'wicked', unprecedented successes in health have included: smallpox eradication, vaccination, 
sanitation and clean water, antibiotics, better maternal and child health outcomes, and less 
hunger and malnutrition.  Still, disease can fight back, in part because of the social and political 
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dimension of disease, for example: vaccination hesitancy and refusal, unsustainability of 
sanitation and water systems across world, war and conflict, antibiotic overuse and resistance.  
In addition policy choices also play a part; even for model case of smallpox, the virus still exists 
as stocks in two laboratories, one in the US and the other in Russia.  The security and political 
risk, whether as accidental or purposeful as a deliberate act of biological warfare, is persistent.   
 
Smallpox has also been emblematic as a disease defeated by scientific progress but HIV/AIDS, 
Ebola, and Zika, have since emerged as new diseases to challenge scientists.  There has 
similarly been a return of dengue and the persistence of malaria.  Tropical diseases at one point 
seemed a victorious battle won, defeated by some developed countries but they have returned 
as NTDs.  Therefore the tropical medicine history of NTDs has shaped their current emergence, 
de-emergence, and re-emergence in how they are treated in policy, grouped together, defined 
as a policy problem, and the ways in which solutions are sought.   
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8.1.1 Neglected endemic countries  
 
As noted in the introduction I have been concerned with the distinction between advocacy and 
evidence in the development of policy problems across sites of high politics of global health and 
in endemic countries.  Still, there are some aspects that I would have done differently with 
hindsight.  My fieldwork from Brazil and China in this research was not used to the level of detail 
that I had originally intended, in providing endemic country perspectives.  Although I believe that 
these country perspectives are reflected to an extent in the resulting research, I think a more 
fruitful approach would have been to select a very specific case study site in one of these 
countries.  Endemic country involvement in policy formation does appear to be an understudied 
area, especially in the responses to a policy context dominated by developed countries (at least 
from a surface level).  Therefore this is one aspect of research that I will further study in the 
future and believe that should attract attention from more research.  
 
Considering they are the main focus of neglect, the individuals and the endemic countries that 
are affected by NTDs must be central to any policy for addressing the diseases.  However, we 
also need to understand evidence and advocacy from the side of the 'neglectors', which have a 
tremendous impact upon diseases of the poorest and most vulnerable.  This is where my inquiry 
was directed towards and why I also chose not to undertake an ethnographic study of 
individuals affected by NTDs.  Parker and Allen have covered a large amount of ground in 
ethnographic fieldwork focusing on worms and MDA in Tanzania and Uganda.  Certainly more 
ethnographic studies of individual NTDs in specific locations are needed and these are taking 
place: Chagas in Brazil (Armus, 2003; Dell’Arciprete et al., 2014; Stepan, 2011) and dengue in 
Malaysia and other new sites predominantly in Asia (Mulligan et al., 2015; Mulligan, Elliott, & 
Schuster-Wallace, 2012; Stoler et al., 2014).  What is uncommon is the extrapolation of results 
to speak about NTDs more generally.  This is what I have been interested in and my attention 
has been on the actors and circumstances that are directing policy, having drawn upon 
ethnographic work (especially by Parker and Allen) as secondary sources. 
 
The literature I compiled encompassed a variety of sources that would not normally have been 
collated together into one analysis.  This was principally in combining the established and 
expansive social science research on tropical diseases and fledging research on NTDs.  
Advocacy has been central within social movement literature, but I have found that without a 
societal backing for NTDs, this has comes from elite groups, shown by the activist scientists.  I 
have argued that evidence in addition to advocacy is needed to make a case for care.  Evidence 
is needed through measurement metrics to assess the scale of a problem and provide proof for 
economic development outcomes for health.  I have identified with scholars researching metrics 
and measurement (such as Vincanne Adams), concerned with a symmetrical evaluation with 
the “accomplishments, limits, and consequences of using quantitative metrics in global health” 
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(Adams, 2016).  I similarly aimed to highlight what is displaced, sidelined or de-prioritized and 
worth revisiting in the process of measurement.  This eventually led me to address the question 
of what makes human rights and a humanitarian approach a difficult route to take in 
approaching policy problems and why an economic development lens of policy packaging is 
preferable.   
8.1.2 The concept of neglect in policy  
 
What has this study of advocacy and measurement contributed to an understanding of neglect 
in policy?  Where are we left with NTDs?  NTDs are defined first by what they are not, as the 
opposite of attention and care.  A multitude of descriptors point towards the reasons why 
something is neglected.  This is through an absence, a lack of, or not enough attention and 
care.  Having carried out my research, I have assembled these descriptors, which I see as 
responses to a type of neglect into a typology.  In suggesting a typology I did not want to fall into 
the trap of what McGoey describes of in ignorance studies of trying to address "immeasurable 
ways of saying nothing" (2012b, p. 7).  Applying scales of neglect would be a difficult 
undertaking to qualify but types of neglect is something that I did observe. 
 
It became apparent to me that there are different types of neglect in the problem understanding 
and solutions proposed for policy problems.  There are numerous opposites to neglect that exist 
on a scale from acknowledgement, to attention, and to care.  Determining what type of neglect 
is faced will have implications for response to policy problems.  Thus 'neglect' as a policy 
characterization in the case I have looked at has spanned emotional neglect, informational 
neglect, neglect of thought, and neglect to act, as contributions to the understanding of policy 
problems.  
 
This typology has some similarities with four components that Nimmo outlined in his 1974 book 
'Popular images of politics: a taxonomy', in how an image of a policy problem is projected and 
perceived.  He identifies how an image is represented as being: perceptual (through direct 
observation or a processing of information), affective (with feeling or emotion), cognitive (in 
interpretation or thought), and conative (for action potential) (ibid., p. 9).  Nimmo's typology has 
had limited influence outside research on political campaigning and communication but I see 
parallels with how political images are represented and perceived, and how policy problems are 
perceived and responded to.  Figure 19 shows how I view neglect as being grouped across four 
aspects: neglect in information, emotion, thought, and action.  I see emotional neglect and 
neglect in action as being more connected with an advocacy response and informational neglect 
and neglect of thought as closely related to an evidence response.  I go on to consider the four 
aspects of neglect I have identified one by one. 
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ADVOCACY
feeling
justification
interest
care
concern
sympathy/empathy
affect
LACK OF: LACK OF:
LACK OF: LACK OF:
problem-solving
mobilization
prioritization
agenda-setting
funding/ resources
intervention/ 
implementation
knowledge
awareness
recognition
attention
exposure
understanding/ explaining
problematization
debate/discussion
argumentation
questioning
conceptualizing
reason/ rationalization
EVIDENCE
Emotional
neglect
Informational
neglect
Neglect
in action
Neglect of 
thought
 
Figure 19 A typology of neglect in policy 
(a) Information 
Information and informational arguments are used to persuade or rank.  Information can often 
be considered as being the first step to provoke emotion, action and thought (although activity 
might also be spurred through the action of social movements or thought applied to an issue).  If 
information is lacking or what is used to inform policy is not supportive, a policy problem may 
have difficulty in getting traction.  I have explored how information is used through the metrics to 
measure neglect and present evidence on NTDs, as well as interaction of metrics with 
audiences through public discourses of measurement (in Chapter 7).  Informational neglect may 
be uneven, depending upon who is finding and presenting the information.  We take it as given 
that everyone does not possess equal information.  Economists will call this inequality of 
information 'information asymmetry', where some hold more information than others and it is a 
further question as to whether is it the right information (Wankhade & Dabade, 2010).  
(b) Emotion 
I discussed emotion and the relationship with information through the philosophy and social 
movement 'effective altruism' (EA) in Chapter 7.  EA tries to remove the emotion from 
philanthropy or at least not let it play centre stage.  As Warren, the director of the GND, 
described for epidemiology it is, “...compassion with the tears wiped away” (Keating, 2014, p. 
S29), therefore emotion has been viewed in the past to somehow degrade serious thought and 
work.  However, as a topic of study, emotion has seen an entry into STS discussions, as 
response to social issues and as a driving force.  Sympathy or empathy is an emotional 
connection to an issue, which causes attention, interest, awareness, and recognition or more 
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strongly concern and care.  I noted in the previous chapter that emotion has been devalued as a 
persuasion tool and seen to interfere with the measurement of impact and effectiveness, both 
through the earlier trend of 'Scientific Philanthropy' to ‘Philanthrocapitalism‘ and more recently 
EA.  Despite a contentious status it remains closely tied to philanthropy.   
 
Public health is another area where emotion is an important aspect.  Also in the previous 
chapter I showed how emotional neglect played a part in response to the HIV/AIDS crisis 
through the ‘emotions work’ that was needed.  Care, as an emotion of concern or interest is also 
a defining feature of public health.  This spans from micro level caring for the sick to the macro 
of caring for populations and caring about what makes them sick.  I have also shown that 
measurement is a form of caring, further confirming that emotion should not be discounted as a 
response to neglect.  
(c) Action 
Lack of action may appear to be a straightforward form of neglect.  Social movements exemplify 
action but there are also other forms, as with policy movements that I discussed in depth in 
Chapter 6.  Action through policy movements has happened through the repackaging of NTDs, 
where the term 'tropical diseases' became NTDs.  Other ways of describing policy action in the 
literature have been through 'modes of coordination' or 'regimes of action' (Jessop, 1999).  The 
ways in which caring in global health is connected to action through the ability or capacity to 
care is described by Reubi et al.:   
 
"The ability and will to care, in turn, is shaped by the complex, multi-scalar politics and resource 
flows that condition so much of the global health enterprise. Care implies a need for empathy, 
responsibility and duty just as much as it does the fair distribution of medical services and 
resources and the capacity to access and make use of these" (Reubi et al., 2015, p. 4).   
 
Care is not possible without being able to to distribute medical services and resources, and also 
to allow access.  As described in Chapter 6, much of the activity of a policy movement to create 
the NTD brand took place in the UK and US, as places of 'high politics' of global health (Storeng 
& Béhague, 2014, p. 266).  A spotlight on this activity through media attention and the skew 
towards the UK and US in the main events and milestones of the policy movement182 have 
meant that the actions of endemic countries have not been well acknowledged, across media, 
academic and policy circles.  While various societal actors can take action (government, big 
pharma, philanthropy, and international organizations) some actions are more prominent than 
others.   
																																																								
182 The main events and milestones of the policy movement include: The first NTD paper, Global Network, 
London Declaration, Presidential Initiative on NTDs and the DIFID commitment.  
! 
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(d) Thought 
Responding to a global health problem is not only grounded in action, information, and emotion 
but in thought, too.  This is the thoughtful reflection of what problems mean, what is involved, 
and what is at stake.  The theory Chapter 3 began with exploring the literature on policy 
problems and carried this throughout the thesis.  I have understood 'thought' as analytically 
putting information to work, whether it is to present arguments, structure discussions and 
debates, make arguments, or problematize issues.  For NTDs, thought has been the conceptual 
work on the NTD brand and the accompanying policy rationale, discussed in Chapter 6.  
Thought is presumed to put to use reason, rationality, and morality but can also be an 
argumentative activity, involving justification and rationale.  Rationale and incentive can be both 
emotional and thought-based (as explored in the previous chapter).  
 
Some of the responses to neglect clearly cut across type and there may be overlap.  I am aware 
of the danger in perpetuating dualities or dichotomies (for example between emotion and 
information already discussed), and potentially drawing lines where they do not truly exist.  I 
argue that this typology is a heuristic to question what is meant by neglect and also an 
acknowledgement that in sorting meaning we actively place ideas into camps.  More widely, this 
typology seeks an expansion of enquiry for the sociological study of absence and ignorance of 
problems, which pertain in the main to a lack of or suppression of information (and associated 
knowledge). 
8.1.3 Who is responsible? 
 
Responsibility lies behind information, action, emotion, and thought for NTDs.  But where does it 
lie and with whom?  For issues where neglect has become a synonymous characterization, 
responsibility may appear clearer.  For example medical neglect takes place on an individual 
basis with a doctor or hospital's failure of a duty of care to a patient.  Sometimes responsibility 
can also fall on individuals for not caring for their health adequately (e.g. illness related to 
obesity or smoking) (Herrick, 2009) or wider institutional, governmental and societal reasons 
that make medical neglect systematic.  Responsibility can shift, as with drug and alcohol abuse, 
blame can be a moral judgment of behaviour or blamed on being an illness (Martin, 1999).   
 
The agency assigned to the neglected party becomes central.  Child and elder neglect are more 
obvious examples, as the neglected are viewed as weaker and more vulnerable, with a duty of 
care from the parents, guardians or carers.  Child abuse and neglect had to be accepted as a 
concept (Hacking, 1991), before legal protection and recompense was possible.  The first legal 
case of physical child abuse occurred in 1874 but as the concept had not yet found a legal form 
it had to be brought forward by the American Society for the Prevention of Cruelty to Animals 
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(Markel, 2009).183  It is an example of how neglect can also be systemic even on an individual 
basis in legal, policy, political, cultural, or social systems.  Similarly, the label of neglect was 
required for the policy problem of NTDs to be identified and dealt with.  
   
NTDs are a complicated proposition to assign blame because of the many societal actors 
involved.  More generally societal neglect is a failure to care when one should and it may 
include all societal actors, with varying responsibilities.  Responsibility for health can be thought 
of being grouped in the following major areas: personal, governmental, social and 
environmental (Collins, 2004).  The social and environmental perspective has gained ground 
through the rise of epidemiology looking at health of populations and the governmentality of the 
populace with responsibility for health placed with the state.  The balance between personal and 
societal responsibility moves back and forth, such as how now epidemiology is interested in 
individual risk factors of disease and government taxes 'unhealthy' individuals (e.g. sugar, 
alcohol, cigarettes).   
 
If responsibility is spread amongst various actors as with NTDs, this returns to the question of 
how it is divided, whether equally or to varying degrees.  Big pharma is thought to supply the 
drugs and innovation or R&D.  Whether they need incentives or not to do this has been 
debated, as has who pays – the donation of drugs was not straightforwardly arrived at.  
Similarly governments of donor countries and international organizations such as the UN have 
provided most of the funding for NTDs.  Funding has more lately switched to philanthropic 
foundations including the Gates Foundation and endemic countries themselves, especially 
innovative developing countries such as Brazil and China.   
 
The expectations of various actors will also change, as big pharma is expected to have a larger 
corporate social responsibility role, and governments are expected to provide more than access 
and encompass: "...sanitation, pollution control, food and drug safety, health education, disease 
surveillance, urban planning and occupational health" (Resnik, 2007, p. 444).  Although I have 
presented how neglect can be thought of as lacking across four areas (information, emotion, 
action and though), simply identifying types of neglect, does not assign agency, causality or 
answer why neglect occurs.  The next section will look at questions about the role of neglect in 
policy that are broader than the case of NTDs. 
																																																								
183 Child neglect cases are reported as the most frequent form of child abuse (NSPCC, 
https://www.nspcc.org.uk/preventing-abuse/child-abuse-and-neglect/neglect/, Accessed 2/4/14) 
 249 
8.2 New questions raised, recommendations, and implications 
 
What then are the perceived conceptual weaknesses and future research directions for ‘neglect’ 
arising from this thesis, in order to go beyond the case of NTDs?  A first consideration to make 
is that NTDs do not have the monopoly on neglect in global health, despite their name.  Neglect 
can also be part of being a high-profile disease.  The relationship between NTDs and the big 
three has been a constant theme throughout this thesis.  Malaria, the non-neglected tropical 
disease, is exemplary of the continuum of neglect that diseases exist on, until the event of 
control, elimination, or (unlikely) eradication.  As Kelly and Beisel describe: 
 
"Despite that attention, neglect remains central to malaria’s high profile. After the first malaria 
eradication campaign was abandoned in the late 1960s, funding for malaria-specific health 
interventions decreased dramatically, causing case numbers to soar... That narrative of 
abandonment and resurgence, we suggest, is linked to a military industrial concern: an-all-or-
nothing commitment that links health advances to technological innovation and pathogen-
obliteration, constituting malaria anew along untapped markets and neglected fronts" (2011, p. 
72) 
 
What did it mean for malaria to be neglected, un-neglected, and then neglected again, with the 
characterization as such?  Viewing malaria alongside NTDs, I have found that neglect is a part 
of the attention that diseases received in the past, how attention has accelerated, and then 
regressed again.  The way of dealing with neglect in the case of malaria is all-out warfare, either 
everything is thrown in or nothing.  A cycle of neglect and attention is also accompanied by 
memory and amnesia.  These are forgotten events, places, people, a collective amnesia, 
purposeful or accidental, "...cycles of public health amnesia, memory and neglect" (ibid., p. 71).  
As such, neglect is an enigmatic and increasingly used concept in policy to identify global 
problems, which warrants further study. 
8.3 NTDs today: Taking out the 'neglect'  
 
A second consideration provoked by this thesis, is what we are left with when an issue once 
labeled as neglected is no longer (neglected)?  No longer neglected is something that does 
need to be qualified.  Taking the example in Chapter 1, Sudeepa Abeysinghe (2015) saw 
ignorance claims about NTDs as a call to action.  It is not only claims on the grounds of 
information that invokes action.  As I have shown through the typology of neglect, ignorance 
(through lack of knowledge or information) is only one part corrected by addressing neglect.  It 
is possible then for claims to be made on aspects of neglect on the grounds of emotion, thought 
and action, but all may not be addressed equally.  
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However, what if all aspects of neglect are addressed?  I have shown the characterization of 
neglect to be an ongoing process, but what happens when it reaches some sort of desired end?  
This is part paradox of language, as to call something neglected can be reasonable from the 
outset but then become contradictory as it reaches a conclusion, with the term being used more 
and the issue addressed.  The strategic power of the neglect label as a discursive construct can 
be diminished or even become detrimental and if this happened the question would remain what 
would replace it?  My contention is the need for a straightforward and cohesive policy 
transformation of disease is inherently problematic.  NTDs could be no longer be neglected but 
that does not mean the problem is solved.  Action taken could be ineffective, counterproductive 
or even cause unintended adverse consequences.  Therefore the characterization of neglect will 
not necessarily mean that NTDs are dealt with in the best way possible. 
 
Furthermore, truly neglected issues and topics may be those that are not identified as such in 
the first place (as found in the sociological 'absence' and 'ignorance' literature).  Or some policy 
problems are not addressed because they are judged not to be neglected enough but require 
ongoing or new types of support.  This quandary of neglect can be demonstrated further through 
emerging diseases (HIV/AIDS, Ebola), re-emerging diseases (as a threat it was not previously 
seen with dengue and Zika) and persistent diseases (malaria and polio, with polio continuing to 
be elusively close to eradication).  Neglect rarely reaches an end point in global health – we can 
only come close to saying this with smallpox, eradicated from the world.  Even then, there is a 
continued threat (as noted previously) and it can also have uses, for example in research.  
 
'Emergence' and 're-emergence' are related topics to 'neglected' and 'un-neglected' in policy 
problems, pertinent to global health.  Emergence relates to the increase in incidence of a 
disease but also whether it is recognized, while neglect more specifically relates to the policy 
reaction and implies that it is not enough or insufficient in some way.  In how I have criticized the 
way that the term 'politicized' is used in policy, to call something neglected, de-neglected, or re-
neglected should also not be self-evident and it is important to qualify such claims.  The 
compulsion to create categories to place diseases into does not seem to be diminishing.  
According to the WHO an emerging disease is "...one that has appeared in a population for the 
first time, or that may have existed previously but is rapidly increasing in incidence or 
geographic range".184  The fear of emerging diseases and interest in this category does not look 
to decrease soon and this clearly has an intimate relationship with neglect.  Emerging diseases 
(whether newly emerging or re-emerging) exist in a world of already established health 
priorities, disease hierarchies, and competing policy agendas.   
 
A number of outbreaks and epidemics have arisen from diseases originating in poor 
communities in tropical and semi-tropical regions but with global implications.  However, interest 
in these diseases is also connected to how they affect more affluent countries.  Indeed the 																																																								
184 WHO http://www.who.int/topics/emerging_diseases/en/, Accessed 2/4/14.  
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Ebola outbreak has opened a door for dialogue on wider lessons for global health security 
(Heymann et al., 2015).185   Jackson and Stephenson (2014) similarly view a connection 
between NTDs and emerging infectious diseases (EIDs) as both socio-political constructs, 
arguing that the foregrounding of NTDs relates to the prioritization of 'free market, Global North 
interests' through EIDs.  They view the neglect of NTDs is on humanitarian terms, an argument 
that is seldom made for these diseases apart from at the beginning of their construction in the 
early WHO reports discussed in the last chapter stating: "We suggest that ‘neglect’ reflects the 
rise of a secular humanitarian global health moral not only in the Global North but more 
pervasively" (ibid., p. 997).   
 
Therefore neglect materializes when we think of health as being a global moral duty deserving 
of humanitarian intervention.  Instead of repeating the 'right to health' humanitarian approach 
Jackson and Stephenson (2014) invoke action to address neglect as part of the 'right to 
development'.  This approach is a symbiosis of the dominant economic development approach 
and the mostly disregarded humanitarian approach to NTDs on the global stage.  Rather than a 
view of health in times of emergency, the everyday reality of health is employed for the priorities 
of international security, design of global infrastructures, and the practices of global governance.  
 
Critical security studies (CSS) theorists such as Joao Nunes (2013) have been considering how 
health problems can be constructed in certain ways.186  As Nunes argues for Zika: "While the 
world is only now beginning to see Zika as an emergency, the conditions that have enabled the 
spread of the virus and hindered response are “everyday emergencies” for millions of 
Brazilians" (2013).  Nunes with other CSS and International Relations (IR) theorists interested in 
global health have been influenced by STS.  The impact of technical instruments, and scientific 
practices that permeate international affairs, means that the interdisciplinary field of STS and IR 
is challenging existing conceptual approaches, and proving insightful to the global challenge of 
public health (Mayer, et al., 2014).  The combination of STS and IR policy ideas could shed new 
light on neglect in policy across sites of poverty, conflict, and emergency, especially if there 
were to be overlap with 'critical public health'.   
 
It is at the intersection of disciplines that future research on global health policy looks most 
promising and mirrors the fundamental changes afoot.  The global relations, governance, and 
politics of health are one example of the challenge of NTDs that manifests as security and IR 																																																								
185	Heymann has highlighted that attention to collective health security is not enough, we also need to 
acknowledge individual health security: "This is security that comes from access to safe and effective 
health services, products, and technologies" (ibid., p. 1884).  The idea of collective health security has 
dominated in IR, with the focus being on contagion of infectious diseases across countries, where the 
political impact of disease across countries is one of emergency.  Note some tropical diseases do involve 
vectors that travel (e.g. dengue) and people who move with disease (e.g. Chagas) (Hotez, 2014).  
186 Critical security studies consider the intentions of international actors, their relations with one another, 
as well as overarching international policy trends.  The characterization of disease and rationales for 
intervention become spheres of contestation and collaboration between countries, and for the negotiation 
of policy.   
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problems.187  These types of problems involve how countries and international bodies interact 
on global health issues, overlapping between the critical security studies literature and 
sociological approaches to security.  
 
Looking forward, neglect in policy requires policy packaging that can encompass more 
disciplinary lenses than the economic development packaging allows.  This thesis has made a 
first step towards analyzing neglect as an important concept for understanding policy problems, 
both in terms of how actors use neglect to make certain claims about a problem but also for 
unraveling the dynamics that allow policy issues to rise in prominence or not.  I have argued that 
neglect in policy is not to know (information), not to care (emotion), not to think about (thought), 
and not to act on (action).  All social actors in global health are implicated, and responsible to 
varying degrees, but it is under these constraints that advocacy through an activist scientist 
policy movement, and evidence in the production and use of measurement metrics has come 
about. 
 
As an in-depth study of NTDs, drawing mostly on STS and public policy theory, this research 
does stand somewhat in isolation.  However, if the sociology of absences and ignorance 
literature and also critical security studies can be further incorporated, it would make for a more 
encompassing view of neglect in policy.  This would be part of a future agenda in the critical 
consideration of how policy problems compete, rise in prominence, and coincide. 
 
 
																																																								
187  NTD specialists Hotez and Pecoul have explored how NTDs destabilize poor societies and contribute 
to civil or international conflict, affecting agricultural productivity and food security (Hotez & Pecoul, 2010, 
p. 5).  
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Appendix 1 Source type cited more than once in thesis 
 
 Type Organisation Location 
1. Universities University of Sussex Phone 
2. Universities LSHTM London 
3. Universities LSHTM London 
4. Universities LSHTM London 
5. Universities LSHTM Skype 
6. Universities LSHTM London 
7. Universities LSHTM London 
8. Universities LSHTM London 
9. Universities LSHTM London 
10. Universities LSTM Phone 
11. Universities University of Johannesburg Phone 
12. Universities University of Oxford  London 
13. Universities Universidade de São Paulo São Paulo 
14. Universities Universidade de São Paulo São Paulo 
15. Pharma companies Novo Nordisk Phone 
16. Pharma companies Novartis Phone 
17. Pharma companies Medicines Australia Phone 
18. Pharma companies Novartis Foundation  Phone 
19. NGO FIND Diagnostics Phone 
20. NGO DNDi Phone 
21. NGO The End Fund Skype 
22. NGO Link2China Phone 
23. NGO Policy Cures Phone 
24. NGO Global Network for Neglected Tropical Diseases Phone 
25. NGO Helen Keller International Phone 
26. Governance Institutions WHO TDR Phone 
27. Governance Institutions WHO Geneva 
28. Governance Institutions WHO Regional Office Phone 
29. Governance Institutions APPMG London 
30. Governance Institutions ECDC Stockholm 
31. Governance Institutions World Bank London 
32. Activist Scientists Cambia Skype 
33. Activist Scientists The Synaptic Leap Sydney 
34. Activist Scientists SCI London 
35. Activist Scientists Sabin Vaccine Institute Phone 
36. Activist Scientists LSTM 1x Phone  
News BBC (5), Financial Times (3), The Guardian (10), The New York 
Times (6) 
Blogs BMJ (3), Wellcome Trust (4) 
High-profile science journals Lancet (18), Nature (12), Science (3) 
Reports WHO (11), Uniting to Combat NTDs (2) 
Websites WHO (12), CDC Website (7) 
PLoS Journals PLOS Medicine (4), PLOS Neglected tropical diseases (20) 
Health and social science journals Health & place (2), Health research policy and systems / BioMed 
Central (4), História, Ciências, Saúde-Manguinhos (2), International 
journal of epidemiology (3), Research Policy (4), Social 
Epistemology (3), Social Studies of Science (7), Minerva (2) 
Books Robert Desowitz (6) 	
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1x London 
37. Research Institutes Swiss TPH Basel 
38. Research Institutes Institute of Tropical Medicine  São Paulo 
39. Research Institutes Fiocruz São Paulo 
40. Research Institutes National Institute of Parasitic Diseases Shanghai 
41. Research Institutes Drug Discovery Centre for Tuberculosis Shanghai 
42. Research Institutes Drug Discovery Centre for Tuberculosis Shanghai 
43. Research Institutes Tsinghua University Beijing 
44. Research Institutes NOKC London 
45. Research Institutes CDTS Rio de 
Janeiro 
46. Research Institutes 
(Group Interview) 
 
National Institute of Parasitic Diseases Shanghai 
Appendix 2 Interviews by organizational type and location 
 
 
 
Information Sheet for Interviewees in Research Fieldwork 
'The policy development of neglected tropical diseases' 
Samantha Vanderslott, University College London, 22 Gordon Sq. London s.vanderslott.12@ucl.ac.uk 
You will be given a copy of this information sheet. This study has been approved by the UCL Research Ethics 
Committee  
We would like to invite ............................ to participate in this research project.  You should only participate if you 
want to; choosing not to take part will not disadvantage you in any way. Ask us if there is anything that is not clear or 
if you would like more information. 
 
Details of Study: 
This research aims to explore how have policy understandings and strategies towards NTDs changed over time.  
This involves asking: What has happened in the change of term and corresponding characterization of the disease 
group of tropical diseases to be renamed NTDs? As a policy idea, disease grouping, how are NTDs are 
characterized in terms of problem and solution? 
To build case studies interviews have been arranged with individuals that have been involved in addressing NTDs, 
e.g. from research institutes, NGOS, pharma companies, universities, international organizations and government. 
Participants will be interviewed following a semi-structured interview guide and recorded if necessary.   
Participants can also remain anonymous if they prefer and confidentiality of participant contact details will be 
maintained.  
 
This research will be published in my thesis and any corresponding research papers or presentations.  Participants 
are able to have access to the final research if requested. 
 It is up to you to decide whether to take part or not. If you decide to take part you are still free to withdraw at any time 
and without giving a reason.  
 
 
Informed Consent Form for ................................................ in Research Studies  
Please complete this form after you have read the Information Sheet and/or listened to an explanation about the 
research. 
 
'The policy development of neglected tropical diseases' 
This study has been approved by the UCL Research Ethics Committee  
Thank you for your interest in taking part in this research. Before you agree to take part the person organising the 
research must explain the project to you. 
If you have any questions arising from the Information Sheet or explanation already given to you, please ask the 
researcher before you to decide whether to join in. You will be given a copy of this Consent Form to keep and refer 
to at any time. 
 
Participant’s Statement 
I ...................................................................... 
  ·  have read the notes written above and the Information Sheet, and understand what the study involves.  
  ·  understand that if I decide at any time that I no longer wish to take part in this project, I can notify the 
researchers involved and withdraw immediately.  
  ·  consent to the processing of my personal information for the purposes of this research study.  
  ·  understand that such information will be treated as strictly confidential and handled in accordance  with the 
provisions of the Data Protection Act 1998.  
  ·  agree that the research project named above has been explained to me to my satisfaction and I agree to 
take part in this study.  
  ·  I understand that my participation will be taped/video recorded and I am aware of and consent to, any use 
you intend to make of the recordings after the end of the project.  
  ·  I agree to be contacted in the future by UCL researchers who would like to invite me to participate in 
follow­up  studies.  
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Signed:                                  Date: 
 
 
Interview Guide 
Research question: How have policy understandings and strategies towards NTDs changed over time?   
What has happened in the change of term and corresponding characterisation of the disease group tropical diseases 
to be renamed NTDs? As a policy idea and disease grouping how are NTDs characterised in terms of 
problem/solution? 
1. To begin with can you tell me a little about your background?  What drew you to NTDs or your disease more 
specifically? 
2. What is your account of how tropical diseases were given the label neglected?  Who were the key actors?  What 
was the timeline of events?  
 
Brand 
1. Do you think there is an NTD brand?  What is it?  What are the positives and negatives?  What do you think of 
health branding generally?  Are there any changes/clarifications you would like to make to the brand (e.g do you use 
some terms interchangeably like Neglected Parasitic Diseases)?  What will happen after NTDs receive more 
attention (and the neglected becomes contested or redundant)?  
2. Have a group of scientists or public health advocates been instrumental in creating the NTD brand?  
3. What were your intentions, aims, strategies and methods?  Was the basic intention to drive NTDs up policy 
agendas?  How did you go about doing this and did you change your aims, strategies or methods along the way? 
 
Characteristics, criteria, individual diseases 
4. What are the defining features of an NTD?  Does this follow the original 6 criteria of the WHO in the first report? 
5. Are the any diseases you think should be included that aren't or should be taken away?  Why do you think zoonic 
diseases have been more neglected and what can be done about this?  Do you think other diseases of poverty 
should be included - diarrheal/waterborne diseases?  Should the foodborne diseases be included? 
6. Why did the WHO list change from 13, to 17?  Any reflections on other lists/ There appears to be outliers (dengue 
and rabies high mortality if ill, dengue affect middle class, dengue, Chagas, sleeping sickness limited strategy for 
intervention?) 
7. What has been the interaction of individual campaigns for diseases?: guinea worm, worms, leprosy, dengue, 
Chagas, trachoma, sleeping sickness historical intervention?  Your disease? 
 
Key policy events 
8. How important do you think the London Declaration was?  Who was responsible to the lead up for Gates and big 
pharma involvement?  Why were other actors not so prominent (governments)?  How does emphasis on drug 
donation and development relate to the need for say vector control?   
 
Appendix 3 Information sheet with informed consent and interview guide 
 
Free Nodes Tree Nodes 
(1) MDA 
(2) Big three 
(3) Malaria 
(4) Government 
(5) NGO 
(6) Gates Foundation 
(7) Epidemiology 
(8) Funding 
(9) Sanitation/water/hygiene 
(10) Awareness/acknowledgement 
(11) Neglect (concept) 
(12) Problem 
(13) WHO 
(14) MDGs 
(15) SDGs 
(16) Policy 
(17) Care/caring 
 
 
(1) Evidence 
(1.1) Evidence-based medicine 
(1.2) Measurement 
(1.3) Metrics 
(1.4) 50 cents per person 
(1.5) DALY 
(1.6) 10/90 gap 
(1.7) RCTs 
(2) Innovation in solutions 
(2.1) R&D 
(2.2) IP 
(2.3) Pharma 
(3) NTD term 
(3.1) Branding 
(3.2) History 
(3.3) Classification 
(3.4) Categorization 
(4) Endemic countries 
(4.1) Global 
(4.2) Local 
(4.3) Brazil 
(4.4) China 
(5) Advocacy 
(5.1) Scientist advocates/ Activists 
(5.2) Media 
(5.3) Public 
 
Appendix 4 NVivo coding scheme node listing 
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Appendix 5 List of technical conferences for participant observation 
 
 
Disease 
specific reports 
and factsheets 
 
• Report of the Eighth Meeting of the WHO Alliance for the Global Elimination of Blinding 
Trachoma (2004) 
• Making Progress Toward the Global Elimination of Blinding Trachoma (2006); and 
Trypanosomiasis, human African (sleeping sickness) (Factsheet N°259, 2015). 
 
 
Special topic 
reports  
 
• Global public-private partnerships: Part I--A new development in health? (Buse & Walt, 2000) 
• Neglected diseases: A human rights analysis (Hunt, 2007) 
• Guidelines For Assuring Safety of Preventive Chemotherapy (First Edition) (2012b) 
• Health Product Research and Development Fund: A Proposal for Financing and Operation 
(WHO/TDR, 2016) 
 
 
Material on 
specific 
diseases, the 
resolutions on 
NTDs as a 
grouping and 
recommended 
strategies, 
updated on 
WHO NTD 
webpages 
 
• Immunization, Vaccines and Biologicals: Dengue (WHO Programmes 
http://www.who.int/immunization/diseases/dengue/en/, 2015, Accessed 2/4/14) 
• World Health Assembly adopts resolution on all 17 neglected tropical diseases (WHO, 
http://www.who.int/neglected_diseases/WHA_66_seventh_day_resolution_adopted/en/, 2013, 
Accessed 2/4/14) 
• Why are some tropical diseases called "neglected"? (WHO Features 
http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/, 2012, Accessed 2/4/14) 
• The 17 neglected tropical diseases (WHO, 
http://apps.who.int/iris/bitstream/10665/152781/1/9789241564861_eng.pdf, 2015, Accessed 
2/4/14) 
• Metrics: Disability-Adjusted Life Year (DALY) (WHO Programmes 
http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/, 2015b, Accessed 
2/4/14). 
 
Appendix 6 Key WHO reports 
 
 
Appendix 7 Frickel study of absences and relevance for neglect (Adapted from Frickel, 2014, p. 89-90)  
Methodological consideration to study 
absences 
Use in thesis 
1) Develop causal analyses  Explanations over description and look for structural conditions 
2) Extend and challenge explanatory symmetry 'Otherness' of tropical disease and NTDs  
3) Specify the type or form of absence under 
investigation  
What does neglect mean and to whom? What sort of thing, 
condition, process and outcome?  Who are the actors, sets of 
knowledge, discourses, infrastructures and techniques? 
4) Define the subject  Set scope using concise and conceptually bounded definitions 
5) Identify case parameters  Consider history, culture and organizational contexts 
6) Measure the shapes of absence  Characterize the environment, place and institution to measure 
temporal or spatial terms; their status, flow over time in an 
area, organisational domain and cultural terrain 
7) Measure the relations of absences  I primarily do this spatially, geographically and historically 
8) Measure densities of absences  Draw upon existing statistics and network analyses (e.g. 
GFINDER for NTDs) 
9) Pursue strategic comparison  Comparative studies to understand processes and outcomes  
10) Nurture a modest reflexive awareness Reflect my terms, understanding and why I use them 	
• 'Drugs for Neglected Diseases (DNDi) 10-year anniversary event', 4 & 5 December 2013 at Institut Pasteur, Paris, 
France  
• 'Schistosomiasis Control Initiative Open Day' 2014, at Imperial College London, 26th June 2014 in London, UK 
• 'Newton Fund ECR Workshop on Neglected Diseases' hosted by the University of Sussex, and the British council, 
17 - 20th November 2015 Belo Horizonte, Brazil 
• 'Advances in scientific research for NTD control' hosted by London Centre for Neglected Tropical Disease 
Research, 27 January 2016, London, UK 
• 'ISNTD Coinfections & Comorbidities', Institute of Child Health, 29th April 2016, London, UK 
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Disease Description Is it an NTD? 
Fevers 
1. Malaria One of the 'big three' not a neglected tropical disease. not neglected 
2. Yellow Fever Has a vaccine so now not a neglected tropical disease. not neglected 
3. Plague Disease caused by bacterium yersinia pestis, usually transmitted 
from bite of rodent flea carrying bacterium or handling infected 
animal. Treated by antibiotics. Cases occur in Africa and Asia.  
not neglected 
4. Dengue Dengue (grouped with chikungunya by the WHO). yes 
5. Mediterranean Fever Familial Mediterranean fever a genetic disorder causing recurrent 
febrile polyserositis prevalent in individuals of Mediterranean 
descent. Also known as Armenian disease (Zadeh, Getzug, & 
Grody, 2011). Disease associated with 'tropical people' but would 
be likely called a genetic disease today. 
not tropical  
6. Japanese River Fever Japanese Encephalitis. not neglected 
7. Kala-azar Kala-azar or visceral leishmaniasis one of three forms of 
leishmaniasis, caused by protozoan organism, transmitted by sand 
fly bites (also called Assam fever, black fever, dumdum fever). 
yes 
8. Tropical typhoid Infectious bacterial fever treated by antibiotics and a vaccination 
exists. 
not neglected 
9. Heat-stroke Fever when exposed to excessively high temperatures. not neglected 
10. Unclassed Fever (today there is an argument that malaria is over-diagnosed leading 
to the category of unknown febrile illness). 
not neglected 
General diseases of undetermined nature 
11. Beriberi Nutritional deficit of thiamine (vitamin B1). not tropical 
12. Endemic Dropsy Results from cooking with mustard oil, especially N. India (Purnell, 
2012). 
not neglected 
13. Negro Lethargy or 
Sleeping Sickness 
African trypanosomiasis or sleeping sickness.  yes 
Abdominal diseases 
14. Cholera Varyingly understood as an imported disease to L. America. not tropical 
15. Dysentery Type of gastroenteritis caused by a number of types of infection 
(bacteria, viruses, helminths or protozoa). 
not tropical 
16. Endemic 
Gangrenous Rectitis 
Disease affecting children in S. America).  Also called epidemic 
gangrenous proctitis, Caribi, Indian Sickness, El Becho. 
not neglected 
17. Hill Diarrhea Hill diarrhea or tropical diarrhea are symptoms of tropical sprue.  not neglected 
18. Sprue Tropical Sprue syndrome characterized by acute/chronic diarrhea, 
weight loss, and malabsorption of nutrients. Exact causative factor 
unknown, but thought to be intestinal microbial infection (Clarke, 
Katz, Adediji, & Ozick, 2014). 
not neglected 
19. Tropical Liver Hepatitis A, B, C, E (See Beeching & Dassanayake, 2011). not tropical 
20. Abscess of the Liver Amebic liver abscess is a collection of pus in liver in response to 
intestinal parasite. Infection occurs worldwide, but is most common 
in tropical areas where crowded living conditions and poor 
sanitation exist (U.S. National Library of Medicine, 2013). 
not tropical 
21. Infantile Biliary 
Cirrhosis 
Linked to copper exposure in Indian families possible through 
water supply, cooking materials or storage containers (Nayak & 
Chitale, 2013).  Also known as Indian childhood cirrhosis (ICC). 
not neglected 
22. Ponos Same as kala-azar or visceral leishmaniasis, however could more 
specifically refer to disease occurring in young children in Greek 
islands, possibly infantile form of visceral leishmaniasis (Kontos & 
Spais, 1989; Macpherson, Meslin, Wandeler, Eds., 2000). 
not neglected 
Infective granulomatous diseases 
23. Leprosy Leprosy or Hansen disease. x 
24. Yaws Yaws or Endemic treponematoses.  x 
25. Verruga Peruana Vector-borne disease found in Andean Valleys of Peru, where 
severe form is 'Oroya fever', followed by chronic stage verruga 
peruana and treated with antibiotics (Rothe, 2014, p. 211). 
not neglected 
26. Ulcerating 
Granuloma of the 
Pudenda 
Also know as granuloma inguinale or donovanosis a bacterial 
disease treated by antibiotics. 
not neglected 
27. Oriental sore Cutaneous leishmaniasis, a second form of leishmaniasis. x 
Animal parasites and associated diseases  
28. Filaria Nocturna  Elephantiasis or lymphatic filariasis. x 
29. Filaria Diurna Type of filaria parasite (Clemow, 2011; Hindle, 2011). unknown 
30. Filaria Demarquaii 
31. Filaria Ozzardi 
32. Filaria Perstans 
33. Filaria Magalhaesi 
34. Bilharzia 
Haematobia & 
Endemic 
Haematuria 
Schistosomiasis or snail fever. yes 
35. Filaria Medinensis Guinea worm or dracunculus.  yes 
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36. Filaria Loa Loiasis caused by Loa Loa eye worm, occurs in rainforest and 
swamp areas of W. and C. Africa, transmitted by bites of mango or 
deer fly and can cause localized swellings (DNDi, 2015). 
not neglected 
37. Filaria Volvus Onchocerciasis or River Blindness. yes 
38. Craw-craw Skin disease occurring in West Africa, some cases caused by 
Onchocerca. 
unknown 
39. Distomum Ringeri & 
Endemic 
Haemoptysis 
Foodborne parasites.  not tropical 
40. Distomum 
Conjunctum 
41. Distomum Sinense 
42. Pentastomum 
Constrictum 
Intestinal infection of larvae through contact with animals. unknown 
43. Trichocephalus 
Dispar 
Whipworm or trichuris trichiura is a soil-transmitted helminth. yes 
44. Ascaris 
Lumbricoides 
Roundworm or ascaris lumbricoides is a soil-transmitted helminth. yes 
45. Ankylostomum 
Duodenale and 
Ankylostomiasis 
Hookworm or Ancylostoma duodenale and necator americanus, 
are types of soil-transmitted helminths. 
yes 
46. Strongylus Subtilis Disease caused by roundworm and found in the small intestine in 
native Egyptians and in intestine of the camel (F. E. G. Cox, 2002). 
unknown 
47. Amphistomum 
Hominis 
Gastrodiscoides hominis is a large fluke - type of flatworm found in 
pigs and humans, constituting important parasite of humans in 
Assam, Indian, the Philippines and Southeast Asia (Dada-
Adegbola, Falade, Oluwatoba, & Abiodun, 2004).  
48. Distomum 
Heterophytes 
Type of tapeworm, found in dogs. 
49. Taenia Nana Now called dwarf tapeworm/ hymenolepis nana. Most common in 
temperate zones. One of most common intestinal worm/helminth 
infecting humans, especially children (CDC 
http://www.cdc.gov/parasites/hymenolepis/, 2012, Accessed 
14/416). 
not tropical 
50. Taenis 
Madagascariensis 
Type of tapeworm. unknown 
51. Bothriocephalus 
Mansoni 
Former name for Spirometra mansoni a tapeworm of wild and feral 
cats, larval form of which (sparganum) may survive in human 
tissues with few human cases mostly southeast Asian countries 
(CDC http://www.cdc.gov/dpdx/sparganosis/, Accessed 14/416). 
52. Larvae of Diptera Filamentous fungi associated with mosquito larvae (Pereira, 
Sarquis, Ferreira-Keppler, Hamada, & Alencar, 2009). 
Animal parasites and associated diseases 
53. Prickly Heat Also known as miliaria rubra is a rash of small red bumps caused 
by blockage of sweat glands. 
not neglected 
54. Sloughing 
Phagedaena 
Also called tropical ulcer, it is a lesion rapidly spreading and 
associated with clouging or gangreen. 
not neglected 
55. Boils A bacterial or fungal infection that affects groups of hair follicles 
and nearby skin tissue (U.S. National Library of Medicine, 2014a). 
not tropical 
56. Pemphigus 
Contagiosus 
Rare, autoimmune disease affecting skin and mucous membranes 
insmall percentage of population (NIH, 2015). 
not tropical 
Skin diseases 
57. Mycetomia or 
Madura Foot 
Also known as eumycetoma, a fungal or bacterial skin infection 
common in tropical and sub-tropical regions. 
not neglected 
58. Dhobie Itch Also known as tinea cruris, a fungal infection on the skin of the 
groin region treated by antifungal medication. 
59. Tinea Imbricata Superficial fungal infection of skin, endemic in some islands of S. 
Pacific (Polynesia), SE Asia, Central and S America, and Mexico 
(Bonifaz, Archer-Dubon, & Saúl, 2004). 
60. Pinta Skin disease in Mexico, Central America, and South America. 
61. Piedra Hair disease caused by fungus. 
62. Chigger Chiggers are a mite whose bite causes severe itching (U.S. 
National Library of Medicine, 2014b). 
63. Myiais Infection with a fly larva, usually in tropical/subtropical areas (CDC 
http://www.cdc.gov/parasites/myiasis/faqs.html, Accessed 14/5/16) 
Local diseases of uncertain nature 
64. Goundou or Anakhre A historical form of yaws that has now disappeared (Mafart, 2002). not neglected 
65. Ainhum Also called dactylolysis spontanea, condition involving a 
constriction of base of fifth toe, affects black patients in tropical 
regions and etiology may be genetic (Selden & Elston, 2015). 
Appendix 8 Manson list of 65 tropical diseases with detail 
(Adapted from Manson, 1898). 
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NTD  Status  Type of control Strategy 
Diseases controllable by 
preventative 
chemotherapy 
 MDA control 
Soil transmitted helminths 
(STH)  
Over 1 billion infected globally  Annual treatment with albendazole 
or mebendazole 
Schistosomiasis (Bilharzia)  200 million infected – mostly in Africa from 
water contact 
Treatment with praziquantel, 
improved water supplies, 
Lymphatic filariasis 
(elephantiasis)  
120 million infected in Africa and the Indian 
sub continent, but elimination is possible 
Administrations with albendazole + 
Mectizan (in Africa) or albendazole + 
DEC (elsewhere) 
Trachoma (preventable 
blindness)  
80 million infected, 8 million visually impaired – 
eliminated from Morocco 
Annual treatment with Zithromax, as 
part of a “SAFE” strategy 
 
Onchocerciasis (River 
blindness)  
50 million infections in Africa  Control of symptoms by annual 
treatment with Mectizan 
 
  Provision of filtered water 
Dracunculiasis (Guinea 
worm)  
Close to eradication Individual case finding 
and case containment 
 
Diseases requiring 
individual treatment  
 Case control 
Leprosy  Close to elimination  Case finding followed by multi drug 
therapy (Novartis) 
Buruli Ulcer  Endemic in 30 countries in the Americas, 
Africa and SE Asia 
Early diagnosis, treatment with 
antibiotics or surgery 
Chagas disease  Limited distribution in South America – a 
disease of poor housing 
Control of the bed bugs which carry 
the disease 
Human African 
Trypanosomiasis  
Narrow distribution in Africa dictated by Tsetse 
fly distribution 
Case finding and treatment; vector 
control where appropriate 
Cutaneous Leishmaniasis  1.5 million new cases for CL are considered to 
occur annually, with an estimated 12 million 
people occur annually, with an estimated 12 
million people presently infected worldwide. 
90% of cutaneous leishmaniasis cases occur 
in Afghanistan, Brazil, Iran, Peru, Saudi Arabia 
and Syria. 
Early diagnosis and prompt 
treatment; control of sandfly 
populations through residual 
insecticide spraying of houses and 
through the use of insecticide-
impregnated bednets; 
Visceral Leishmaniasis  500,000 cases per year. 90% of all visceral 
leishmaniasis cases occur in Bangladesh, 
Brazil, India, Nepal and Sudan; fatal if 
untreated. 
Case finding and treatment with 
meglumine antimoniate (Glucantime) 
or sodium 
stibogluconate (Pentostam). 
Dengue 250 million at risk and 50 million cases 
per year in over 100 countries 
Effective clinical management. 
Fluids and possibly transfusions 
Vector control 
  Animal zoonosis 
Neuro-Cysticercosis Up to 20% infections in rural Africa and South 
America 
Tape worm control and strict pig 
meat inspection 
Echinococcus Unknown numbers with cysts in liver Tape worm control in dogs and 
careful surgery 
plus albendazole to remove 
unbroken cysts 
  Animal reservoir 
Brucellosis  Pasteurisation of milk 
Rabies Transmitted by dog bites Vaccination 
Appendix 9 List of NTDs and control strategies for the All-Party Parliamentary Group on Malaria and Neglected 
Tropical Diseases  
(Adapted from APPMG, 2009) 
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(Shading shows 
preferred strategy) 
Environmental-based strategy Drug-based strategy  
1. (blinding) trachoma SAFE strategy of control.  Facial 
cleanliness and environmental 
improvement by improving access to 
water and sanitation (WASH). 
Antibiotics to treat infection and surgery to 
treat the blinding stage of disease. *MDA 
*targeted for global elimination by 2020. 
2. buruli ulcer  Early detection. Antibiotics used (rifampicin/streptomycin) 
but larger lesions require surgery.  Trials for 
oral drugs. 
3. Chagas disease Vector control most effective method of 
preventing transmission through 
improved housing and spraying 
insecticide inside housing to eliminate 
triatomine bugs. Also blood screening to 
prevent infection through transfusion and 
organ transplantation. 
*targeted for control & elimination 
(regional in the Americas, 
transmission interrupted by 2020)  
No vaccine is available. Antiparasitic 
treatment nifurtimox and benznidazole is 
used but pediatric drugs needed to cure 
patients early and a new drug for chronic 
disease.  For both drugs, side effects are 
fairly common, and tend to be more 
frequent and more severe with increasing 
age. 
4. cysticercosis/ 
taeniasis 
Strict meat inspection, health education, 
thorough cooking of pork, sound hygiene, 
adequate water/sanitation, improved pig 
husbandry practices and easy treatment 
access 
Anthelmintics oxfendazole and praziquantel 
administer through large-scale preventive 
chemotherapy in humans, and treatment 
and vaccination of pigs. 
5. dengue and 
chikungunya 
Dengue and chikungunya prevention and 
control solely depends on effective vector 
control measures, including management 
of household water storage that can 
create breeding places for mosquitoes 
(WASH). 
For dengue early detection/access to 
proper medical care lowers fatality rates 
below 1% but several vaccine candidates 
are in clinical/pre-clinical development.  For 
both diseases there is no cure.  Treatment 
is focused on relieving symptoms.   
6. dracunculiasis 
(guinea-worm 
disease) 
Endemic countries (Chad, Ethiopia, Mali 
and South Sudan) where surveillance 
systems working but need awareness 
among affected/at-risk populations 
(WASH) *targeted & close to 
eradication (the first of the parasitic 
diseases). 
No drug and no vaccine to prevent infection 
but can be prevented through safe drinking 
water. 
 
7. echinococcosis Prevention through deworming dogs, 
improved food inspection, slaughterhouse 
hygiene, public education campaigns, 
(vaccination of lambs being evaluated). 
Often expensive and complicated to treat, 
and may require extensive surgery and/or 
prolonged drug therapy. 
8. foodborne 
trematodiases  
Veterinary public health measures and 
food safety practices are recommended 
to reduce the risk of infection through 
faecal contamination: transmission is 
linked to human behaviour patterns 
related to sanitation, hygiene, cooking 
habits, methods of producing, processing 
and preparing foods (WASH). 
Safe and effective anthelminthic medicines 
prevent and treat foodborne trematodiases: 
triclabendazole for fascioliasis and 
paragonimiasis, praziquantel for 
clonorchiasis, pisthorchiasis, 
paragonimiasis (can be administered 
through preventative chemotherapy where 
large numbers of individuals are infected).  
9. human african 
trypanosomiasis 
(sleeping 
sickness) 
No universal control methodology. 
Control/surveillance inc. active/passive 
case finding, diagnosis, treatment, patient 
follow-up, vector control, control animal 
reservoir.  New rapid diagnostic test/ 
vector control needed  * targeted for 
country elimination in 80% of foci and 
global by 2020. 
Eflornithine (hard to administer), 
melarsoprol (for late stage, hard to 
administer, toxic and kills) and pentamidine 
(only for early stage).  In 2009, NECT 
(Nifurtimox and Eflornithine Combination 
Therapy) introduced as first new, improved 
treatment option in 25yrs for stage 2 of 
disease.  
10. leishmaniases 
(cutaneous 
leishmaniasis, 
visceral 
leishmaniasis or 
kala-azar, and 
mucocutaneous  
A combination of intervention strategies 
because transmission occurs in a 
complex biological system 
(diagnosis/case management, vector 
control, disease surveillance, control of 
reservoir hosts, social mobilization and 
strengthening partnerships) 
Highly effective and safe anti-leishmanial 
medicines (particularly for VL - AmBisome).  
Need easy to apply treatments for CL and 
better treatment for ML.  Access to 
medicines a problem but has significantly 
improved.  *VL targeted for elimination in 
Indian subcontinent by 2020 
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11. leprosy (hansen 
disease - 
paucibacillary & 
multibacillary) 
Information campaigns about leprosy in 
high-risk areas crucial so that patients 
and families historically ostracized from 
their communities, are encouraged to 
come forward and receive treatment. 
Multi Drug Therapy (MDT) of antibiotics 
rifampicin and dapsone for PB leprosy 
patients as well as clofazimine an 
antimycobacterial for MB leprosy is bringing 
the disease to elimination.  *targeted for 
global elimination by 2020 and close.  
12. lymphatic filariasis 
(elephantiasis) 
Alternative/equally effective community-
wide regimen use of table salt/ cooking 
salt fortified with DEC for 1 year and 
improved wastewater management as 
vectors prefer breeding in organically 
polluted water and faecal matter found in 
poorly-constructed pit latrines (WASH). 
Antiparasitic drug ivermectin used but need 
new medicines to kill/sterilize adult worms 
(also drugs to reverse or halt lymphedema). 
*MDA *targeted for global elimination by 
2020. 
13. onchocerciasis 
(river blindness) 
Vector control is not considered feasible 
or cost-effective in the remaining APOC 
countries. 
Antiparasitic drug ivermectin but no vaccine 
or medication to prevent infection with O. 
volvulus. *MDA, targeted for regional 
elimination in L. America & selected 
countries in Africa by 2020. 
14. rabies Elimination of dog-mediates feasible 
given political will, adequate resources 
and diligent programme management - 
mass vaccination most efficacious to 
reduce incidence. Targeted for regional 
elimination in Latin America, SE Asia, 
W Pacific regions. 
Vaccine and post-infection vaccine. 
15. schistosomiasis 
(snail fever) 
Preventive measures are avoiding 
wading, swimming, or other contact with 
freshwater in disease-endemic countries 
(WASH). 
No vaccine or drugs for preventing infection 
but anthelmintic drug praziquantel effective.  
Need lower dose/ less bitter taste to make 
child-friendly.   *MDA, targeted for 
elimination selected African countries, 
regional elimination in E. Mediterranean, 
Caribbean, Indonesia, Mekong River 
Basin and by 2020 Americas/ W. Pacific. 
16. soil-transmitted 
helminthiases 
(roundworm, 
hookworm, 
whipworm) 
Education on health/hygiene to reduce 
transmission and reinfection by 
encouraging healthy behaviours; p (not 
always possible in resource-constrained 
settings) (WASH). 
Mass deworming using anthelminthic 
medicines, including albendazole.  *MDA. 
17. Endemic 
treponematoses 
(yaws) 
Can be controlled and possibly 
eradicated as disease occurs only in 
humans. Information, education and 
communication (IEC), advocacy and 
social mobilization needed. 
Antibiotic azithromycin (API) available but 
need development of non-treponemal 
luminex assay.  *targeted for eradication 
in 2020 
 
Appendix 10 Environment-based and drug-based NTD strategies 
(Compiled from information on CDC http://www.cdc.gov/globalhealth/ntd/; DNDi, http://www.dndi.org; WHO 
http://www.who.int/topics/emerging_diseases/en/; 2015)  
 
 
 
 
 
1. Diseases that require a mainly 
drug-based strategy  
Trachoma, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted 
helmithiasis, trachoma, buruli ulcer, leprosy, yaws, and leishmaniasis. 
2. Difficulty developing vaccines/ 
drugs for mosquito vector 
Dengue, chikungunya, and lymphatic filariasis.   
3. Food and animal related 
disease 
Cysticercosis/taeniasis, rabies, echinococcosis, and foodborne trematodiases. 
4. Diseases near elimination or 
eradication 
Especially dracunculiasis and leprosy. 
5. Diseases with limited 
strategies of control 
Human African trypanosomiasis has no universal control methodology but is 
targeted for elimination, with recent improvements in diagnosis and treatment.  
Dengue has had no cure or treatment but now a vaccine is being developed.  
Finally Chagas does not have effective drugs for chronic disease, although vector 
management is typically recommended for control. 
Appendix 11 List of diseases and their group characteristics 
